Response:

In 2017, the Editor-in-Chief (Roger O. McClellan) and Managing Editor (Charles Whalley) of Critical Reviews in Toxicology received two communications containing allegations with regard to the five papers included in the Special Supplement to Volume 46 (2016) and requesting that the papers be “retracted.” In view of the seriousness of the allegations a special investigation was initiated and coordinated by me, in my role as Editor-in-Chief, and Charles Whalley in his role as Managing Editor of Critical Review in Toxicology. The investigation was very thorough and comprehensive including how the manuscripts were prepared, edited, reviewed, accepted for publication and published.

The review was completed in August 2018 with a joint decision made by me, as Editor-in-Chief, and the Publisher, Taylor and Francis, to publish an “Expression of Concern” and Corrigenda for each of the five papers included in the Special Supplement to Volume 46 (2016) of Critical Reviews in Toxicology. These items have been published on-line in the Journal (September and November 2018).

Communications among the key participants (the Editor-in-Chief, the Managing Editor and the authors) is reproduced below.
Roger McClellan

From: Whalley, Charles @tandf.co.uk
Sent: Thursday, March 16, 2017 3:51 AM
To: Roger McClellan
Cc: mbmorgan@
Subject: RE: Journalist for Science trying to reach you

Dear Roger,

Thanks for forwarding this on. I need to discuss with my colleagues. Lovely to catch up in person once again in Baltimore. I've just got home safe and sound; hope you do too.

All best wishes,
Charles

From: Roger McClellan [mailto:Roger McClellan@att.net]
Sent: 16 March 2017 01:04
To: Whalley, Charles @tandf.co.uk
Cc: Roger McClellan; Mildred B. Morgan <mbmorgan@
Subject: Fw: Journalist for Science trying to reach you

Charles:
When it rains it pours. Let's discuss.
I hope you had a safe journey back to the UK.
Roger

On Wednesday, March 15, 2017 7:10 PM, Warren Cornwall <warcorn@gmail.com> wrote:

Hello Mr. McClellan,

I'm a correspondent for Science magazine.

I'm writing a story about glyphosate. Some documents were unsealed recently in a lawsuit between Monsanto and some people who claim their cancer is associated with exposure to Roundup.

I would like to talk with you before my story deadline on Friday. Is there a time when you are available to talk?

Here are some more details about my questions:

The unsealed documents include 2015 e-mails between Monsanto executives about the possibility of publishing a paper related to glyphosate in the journal Critical Reviews in Toxicology.

When discussing options, one official, William Heydens, writes that "A less expensive/more palatable approach might be to involve experts only for the areas of contention, epidemiology and possibly MOA (depending on what comes out of the IARC meeting), and we ghost-write the Exposure Tox & Genetox sections. An option would be to add Greim and Kier
or Kirkland to have their names on the publication, but we would be keeping the cost down by us doing the writing and they would just edit & sign their names so to speak. Recall that is how we handled Williams Kroes & Munro, 2000."

I have a few questions about that:

1. Does the journal Critical Reviews in Toxicology have any policy about papers where portions are "ghost written" by undisclosed authors or companies?

2. The journal published a 2016 paper in which Kirkland is one of the authors. Here is the link: [http://www.tandfonline.com/doi/full/10.1080/10408444.2016.1214680](http://www.tandfonline.com/doi/full/10.1080/10408444.2016.1214680)
   - Do you know whether any portion of that paper was written by Monsanto officials?
   - Are you looking into whether this is the case?

Those are my main questions at this point. You can reach me any time via e-mail, or on my cell phone at [redacted]

Thanks for your time. I look forward to talking.

Best,

Warren

Warren Cornwall

C: [redacted]

O: [redacted]

Encrypted, confidential correspondence: Signal texting app to [redacted] on [http://www.english.wordpress.com](http://www.english.wordpress.com)

Twitter: [redacted]
Dear Roger,

In Charles' absence, as he is having a much deserved day off today, I am writing with our suggested response to the journalist from Science. Based on feedback from our communications and legal department, we suggest the following:

Our Instructions for authors submitting to Critical Reviews in Toxicology require all authors to conform to the International Committee of Medical Journal Editors (ICME)'s Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals. These Recommendations stipulate that all those meeting certain criteria for authorship should be identified as authors and should take responsibility and be accountable for what is published, and that any other contributors should be acknowledged. We expect all authors to adhere to these instructions when submitting to the journal.

In respect of the 2016 paper, the authors have declared their employment affiliations and previous positions in the paper. Further, the Declaration of Interest states that, 'Neither any Monsanto company employees nor any attorney reviewed any of the Expert Panels manuscripts prior to submission to the journal'.

For more information on this, please refer to my Editorial, and in particular the paragraph which states: “Each of the five papers was rigorously reviewed by 5-10 independent reviewers selected by the CRT Editor and anonymous to the authors. A total of 27 different reviewers participated with several of the individuals reviewing all five papers. The authors of each paper were provided the review comments on their paper and asked to make appropriate revisions. The final papers, published here, represented the work product of the authors. Each paper includes an Acknowledgements section and an extensive Declaration of Interest section.”

I hope this wording is ok with you. Please let me know any comments.

Many thanks

Deborah

Deborah Kahn
Publishing Director, Medicine and Open Access
Taylor & Francis Ltd

Taylor & Francis Group

4 Park Square, Milton Park, Abingdon, Oxon. OX14 4RN, UK

Direct line: [phone number]
Email: deborah.kahn@tandf.com

Taylor & Francis is a trading name of Informa UK Limited.
FYI

On Thursday, March 16, 2017 4:30 AM, American Council on Science and Health <morning@acsh.org> wrote:

Today's Dispatch

- Why Worms Are Cornerstones of Scientific Research
- "This" Corporate Shill is Living In His Altima
- Glyphosate: NYT's Danny Hakim Is Lying To You
- Wild Pitch: Osteopathic Study on Protecting Shoulders Unpopular
- Academic Medical Centers at Risk of Not Being Academic or Medical

Why Worms Are Cornerstones of Scientific Research

It may seem strange that many important, scientific questions are being answered using the roundworm, which is roughly the size of the next comma you see here. But it is, indeed, an incredibly powerful experimental system. READ MORE
"This Corporate Shill is Living In His Altima
When people disagree with us, that's fine. But when they start accusing us that we write what we do because some secret company is funding us, that's not fine -- because it's a lie. For those too stupid or blind to realize this, Dr. Josh Bloom offers this little refresher course on the reality behind the research. READ MORE

Glyphosate: NYT's Danny Hakim Is Lying To You
When it comes to feeding the world, there's no more room for being nice. This New York Times writing is hoping to gain a Pulitzer prize by lying to Americans. READ MORE

Wild Pitch: Osteopathic Study on Protecting Shoulders Unconvincing
A new study, which claimed that a training method to improve shoulder flexibility among pitchers was effective, had all the accuracy of an errant curveball in the dirt. The Spencer technique might actually be useful, but researchers here overreached based, in part, on the very small size of the study. READ MORE

Academic Medical Centers at Risk of Not Being Academic or Medical
Our academic medical centers are offering treatments that its officials know come from flawed randomized controlled studies, or observational/case studies. While they follow the money, they harm medicine as a science. The shamans have returned. READ MORE

support us by making a tax-deductible DONATION
Roger McClellan

From: Roger McClellan <ait.net>
Sent: Tuesday, June 6, 2017 12:26 PM
To: Whalley, Charles
Cc: Roger McClellan, Mildred B. Morgan
Subject: Re: CONFIDENTIAL -- CRT peer review

Scholar One changes
Charles:
I enjoyed our telephone conversation this AM. As we discussed please proceed with the change in Scholar One, the same as currently used by Current Medical Research and Opinion, to assist in identifying potential conflicts of interest on the part of prospective reviewers. We can try this for a period of time and dependent on our experience determine if further changes are needed. One possible addition is to ask prospective reviewers if they have been involved during the past 5 years in any legal or regulatory proceedings related to the subject of the paper being reviewed.

I am continuing to explore potential changes to the Editorial Advisory Board for implementation over the coming months.

Best regards,
Roger

On Tuesday, June 6, 2017 2:17 AM, "Whalley, Charles" <tandf.co.uk> wrote:

Dear Roger,

I'm not sure I've heard from you on this yet. I'm eager to make the changes to the ScholarOne site, so please let me know if you're happy with this improvement.

Similarly, I'd like to make some progress on refreshing the Editorial Board. First, can I assume that David Warheit has indeed stepped down, as we discussed in Baltimore? If so, we can work on replacing him (as well as adding an additional member). As I mentioned below, I'd prefer it at least one of these members was from an academic background.

Let me know your thoughts. I hope all is well with you. The sunny weather we've been having in England for the last few weeks has finally broken for the old familiar rain.

All best wishes,
Charles

From: Whalley, Charles
Sent: 19 May 2017 12:38
To: 'Roger McClellan' <ait.net>
Subject: RE: CONFIDENTIAL -- CRT peer review

Dear Roger,
Thanks for your voicemail last week, and sorry that I’ve missed you. I’m currently in Switzerland for a clinical toxicology meeting.

Regarding your question of how the reviewer declarations of interest could be achieved, we do indeed have such a system on another journal, *Current Medical Research & Opinion*: http://www.tandfonline.com/teclomo20/current. In the online form in which reviewers input their recommendation and comments, there is a question above asking them to supply any conflicts of interest. This is then visible to the EiC and recorded in the system. I suggest we implement the same. What do you think?

Best wishes,
Charles

From: Whalley, Charles
Sent: 12 May 2017 13:54
To: Roger McClellan@tandf.net
Subject: CONFIDENTIAL -- CRT peer review

Dear Roger,

I’ve completed our investigation into the review of the Pierce et al paper, as you will have seen. In this investigation, I’ve also looked at our processes and policies more broadly. As you know well, we have an obligation to the journal, its readers and the wider community to be as transparent and thorough as possible in these matters. I’m grateful for your understanding and support as usual, and hope you understand that in all this I fully appreciate the seriousness and integrity that you’ve always applied to the same purpose.

Re Pierce et al, thanks for your comments lately and indeed in Baltimore last month. As we’ve advised externally, I’m satisfied that the review process met the journal’s standards for rigour and independence. At this point, I can see nothing of great concern, so we consider the matter raised by Christian Hartley closed. My focus, even so, is on improving our processes, as ever. There are points to address under that aim.

I have noticed, both here and with other examples, that although we often receive an above average number of reviews, the backgrounds of most reviewers tend to be in industry or consultancy. For Pierce et al, for example, I note that ¾ reviewers have industry backgrounds. I also note that this wasn’t necessarily for lack of trying; those invited to review were from a range of backgrounds, across academia and industry. It’s just that we were limited by those who accepted the invitation.

Similarly, this comes back to a point I raised in our discussions in Baltimore about Editorial Board recruitment. Alongside broadening the Board in areas we’ve already begun working on, such as including more women and members from new geographic areas, it’s important that we have strong voices from perspectives outside of industry. Currently, it mostly falls to Gunnar to push that viewpoint, as with the glyphosate supplement. (In fact, the discussion we had with the Board around the glyphosate supplement is a good example of how this should work, as that healthy debate improved the transparency we demonstrated.)

Due to the regulatory implications of much of the journal’s content, we must incorporate a range of perspectives in our decision-making, be that in editorial policy or in the review of individual articles. We should also be able to feel confident that you, as Editor-in-Chief, are as informed as possible about potential Conflicts of Interest amongst reviewers, as much as we are about authors. I don’t doubt the good sense of your or of our current Board members, but I want to make it easier for you to feel comfortable that all bases have been covered.

With all this in mind, I’ve 3 proposals:
• We ensure that the peer review of all manuscripts incorporates the input of reviewers from academic and industry backgrounds, even if that means actively seeking reviews from those potentially hostile to a manuscript's authors or aims. We require at least 2 reviews from reviewers outside of industry/consultancy on each manuscript, where possible.
• We request a Declaration of Interest statement from reviewers, alongside their submitted review. This would be saved in ScholarOne and visible to you when receiving each review, but of course would remain confidential. We remind reviewers that conflicts of interest extend to relationships beyond the purely financial.
• We appoint an additional Editorial Board member this year with an academic background. We can do this a part of our ongoing project of updating the Board.

Please let me know your thoughts.

Very best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: Switchboard:  
charles.whalley@tandf.co.uk
www.tandfonline.com

Taylor & Francis is a trading name of Informa UK Limited, registered in England under no. 1072954
https://www.bloomberg.com/news/articles/2017-08-09/monsanto-was-its-own-ghostwriter-for-some-safety-reviews

Dear Roger

Thanks for your messages, and apologies for missing your calls. I've been travelling for meetings in the UK, which isn't the best timing...

First, in terms of our plans here, there is a lot of work that I need to do first, in consultation with legal counsel here, to get on top of all of this. The released documents on which these journalists are basing their enquiries have caught us on the back foot. As you'll have seen from the Bloomberg article (above), this extends to Taylor & Francis journals beyond CRT. I'll update you on our next steps once decided. In the meantime, please can you forward me any response you get from Ashley or any other authors, and avoid any further comment once or if a response comes? Equally, it would be much better if we have all correspondence regarding this matter in writing via email.

Second, I'll be in the office and pleased to speak with you on the 14th. I am working from now until the 16th, and likely spending much of my time working on this! From the 17th until the 24th, I'm on holiday in France with no access to email.

I appreciate your patience and good sense here, as ever.

All best wishes,
Charles
Dear Roger,

Thanks for this. It was nice catching up with you too. I’ll pass on and let you know as soon as I can.

Best wishes.
Charles

---

Charles:

It was a pleasure visiting with you today concerning the CRT Special Issue on Glyphosate. Shown below is a rough draft of the beginning of a memo as part of the T and F investigation of the articles in the special issue with regard to conforming to the canons of scientific publishing. In my opinion, the Declarations of Interest are the linch pin. Did the authors accurately and completely describe in the Declaration of Interest how the articles were prepared and the role of the financial sponsor of the review and related papers submitted to CRT. Please excuse the typing and any errors, this is a personal work product.

DRAFT E-MAIL

Dear Dr. Roberts, authors and co-authors of Review Papers:

This e-mail is being sent to you in view of your role in the review and preparation of five papers that were published on line in a Special Supplemental Issue of Critical Reviews in Toxicology entitled, “An Independent Review Of The Carcinogenic Potential of Glyphosate”, Volume 46, 2016. The five papers and an Introductory Article prepared by Roger O. McClellan, Editor of Critical Reviews in Toxicology, are available electronically at XXXXXXXXXXX.

It was known by McClellan and Taylor and Francis, the publisher of CRT, personnel from their earliest communications on the Special issue that the review of Glyphosate and preparation of the papers was sponsored financially by Monsanto Co., a producer and marketer of Glyphosate. It was fully anticipated that the specific role of Monsanto would be related in the Declaration of Interest for each article. The need for a Declaration of Interest (DOI) is clearly spelled out in the Publishers Instruction’s to Authors. Moreover, McClellan gave explicit instructions on multiple occasions on the need for each article to have an accurate, comprehensive and transparent DOI.

Recently, as part of legal proceedings in California both internal and external communications by Monsanto personnel have been made public. An overview of what has been revealed is reported in...
an article, "Guess Who's Ghostwriting Monsanto's Safety Reviews" that appeared in Bloomberg's Businessweek, August 14, 2017. (You may wish to attach the Bloomberg article.)

Certain of the Monsanto communications raise serious accusation to whether the DOIs for the five articles are complete and accurate as to the role of Monsanto in selecting panel members to participate in the reviews and in the preparation of each of the five papers. This in turn raises questions as to whether well established canons of scientific publishing have been followed by the authors of the papers and the financial sponsor, Monsanto.

This issue is sufficiently serious that Taylor and Francis, as the Publisher, with the assistance of McClellan, as Editor, have initiated an investigation as to whether the author's completely and accurately described in each of the DOIs the role of Monsanto in selection of Panel members, in the conduct of the reviews and in preparation of each of the five papers. One source of information for conducting the investigation is the publically available disclosures. In addition, we seek your assistance.

Dependent upon the findings of the investigation several outcomes may be envisioned. One outcome is to publish revised DOIs for each paper with a commentary describing the differences between the original and revised DOIs. Another option is to retract the papers based on flawed and incomplete DOIs with a commentary as to the basis for retraction.

[At this juncture, I need input from legal counsel as to what to request. One possibility is to ask each author to report if they were independently compensated by Monsanto at any time in the past as an employee or consultant and/or during conduct of the review and preparation of the papers. A second question is if they received compensation from Intertek for conduct of the review and preparation of the papers. A third question is whether any of the individuals received input directly or via others related to the preparation on the papers as submitted. A fourth question might relate to whether they received any input from Monsanto directly or via others as the papers were revised.]

I am uncertain who should send the E-mail, perhaps, it is best if it comes from T and F with a request for responses by a date certain. Another question is whether the E-mail should also go to Monsanto.

Please do not hesitate to contact me by E-mail or phone (USA 888-888-8888) if you need further input.

Regards,
Roger O. McClellan

PS Attached to this e-mail is a copy of my biography for the benefit of T and F personnel who may not be familiar with my background.

On Wednesday, August 9, 2017 8:42 AM, "Whalley. Charles" <2333333@tandf.co.uk> wrote:

https://www.bloomberg.com/news/articles/2017-08-09/monsanto-was-its-own-ghostwriter-for-some-safety-reviews
Dear Roger,

Thanks for your messages, and apologies for missing your calls. I've been travelling for meetings in the UK, which isn't the best timing...

First, in terms of our plans here, there is a lot of work that I need to do first, in consultation with legal counsel here, to get on top of all of this. The released documents on which these journalists are basing their enquiries have caught us on the back foot. As you'll have seen from the Bloomberg article (above), this extends to Taylor & Francis journals beyond CRT. I'll update you on our next steps once decided. In the meantime, please can you forward me any response you get from Ashley or any other authors, and avoid any further comment once or if a response comes? Equally, it would be much better if we have all correspondence regarding this matter in writing via email.

Second, I'll be in the office and pleased to speak with you on the 14th. I am working from now until the 16th, and likely spending much of my time working on this! From the 17th until the 24th, I'm on holiday in France with no access to email.

I appreciate your patience and good sense here, as ever.

All best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line Switchboard
www.tandfonline.com

Taylor & Francis is a trading name of Informa UK Limited, registered in England under no. 1072954
Charles:

See attached letter. I called Dr. Donley and spoke to him concerning his proposed Letter. He indicated it was related to the Special Glyphosate issue. In response to my questioning he indicated his prospective Letter was NOT concerned with the specific science but ethical issues concerned with the Declaration of Interest published in the several papers. I related that this matter was under investigation by the publisher with my cooperation. I indicated I would be pleased to receive a Letter from him which I would share with the Publisher. I further noted that I did not anticipate his Letter being shared with the authors and did not anticipate his or similar Letters being published in the Journal. It will be interesting to see if he sends a Letter to me.

I will keep you posted as to any further similar developments.

Regards,

Roger

On Tuesday, August 15, 2017 12:46 PM, Nathan Donley <[redacted]@biologicaldiversity.org> wrote:

Hi Roger, my name is Nathan Donley and I’m a senior scientist at the Center for Biological Diversity. I am hoping to submit a letter to the editor to Critical Reviews in Toxicology. I’m not seeing a place for an LTE on the author submission portal.

Would I be able to email it to you directly or is there a more formal process I should go through?

Thank you very much,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity
[biologicaldiversity.org]
Roger McClellan

From: Roger McClellan <redacted>@att.net>
Sent: Tuesday, August 15, 2017 5:03 PM
To: Samuel M. Cohen; Vicki Dellarco; David Dorman; David Dorman; Russell Cattley; Frederick P. Guengerich; Gunner Johanson; Herman Bolt; Hermann Bolt; Shuji Tsuda; David Warheit; Charles Whalley; Roger McClellan; Mildred B. Morgan
Cc: Charles Whalley; Roger McClellan; Mildred B. Morgan
Subject: Issues Related to Special Supplement of CRT on Glyphosate Carcinogenicity.

To all:
The purpose of this e-mail is to bring you up to date on issues related to the Special CRT Supplement on Glyphosate published in 2016. A number of you reviewed one or more of the five papers published in the Supplement. An electronic copy of the Supplement is attached.

As you will recall, special care was taken to have these papers critically reviewed and revised prior to publication. Moreover, special care was taken to attempt to secure Declarations of Interest for each article that were complete, accurate and transparent. Recently, a substantial number of Monsanto documents concerning Glyphosate were released related to on-going litigation in California. The attached news article published in Bloomberg Businessweek provides a summary of some of the issues, especially related to the papers published in Critical Reviews in Toxicology.

Taylor and Francis, publisher of Critical Reviews in Toxicology, with my involvement as Editor, is conducting an investigation of this matter. The outcome of that investigation will be the basis for further action by Taylor and Francis. If you should receive an inquiries concerning these papers and their publication in Critical Reviews in Toxicology I suggest you refer the inquiry via an E-mail to Charles Whalley, the Managing Editor of CRT for Taylor and Francis and also keep me in the loop.

I will keep you informed of further developments. In the meantime, if you have any questions on any matters related to CRT please do not hesitate to contact me by E-mail or call (redacted).

Best regards,
Roger
Dear Roger,

Sorry I’ve missed your calls; I’ve been in meetings for much of this week so far.

To update you quickly, we’re still waiting on legal counsel in the US on our proposed email from you to the authors. I don’t think they will ask for major changes but I’d like to be assured that they are comfortable with wording. I’ll let you know as soon as I can.

I’m about to leave the office but perhaps we can speak tomorrow.

Very best wishes,
Charles
Mildred:
Let's discuss.
Roger

On Friday, September 15, 2017 7:29 AM, "Whalley, Charles" wrote:

Dear Roger,

Sorry to keep you waiting on this. Following our review, please see my suggested email below my signature. I have made only minor changes to your initial draft. You'll note that it asks for a response by the end of next week.

The email addresses of all authors on all manuscripts (taken from ScholarOne) are below. I suggest the email is sent to all of them, with me in CC, that you indicate that the matter is confidential in the subject line, and that you mark it as high importance.

<table>
<thead>
<tr>
<th>Name</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gary Williams</td>
<td>nymc.edu</td>
</tr>
<tr>
<td>Marilyn Aardema</td>
<td>ame.com</td>
</tr>
<tr>
<td>John Acquavella</td>
<td>gmail.com</td>
</tr>
<tr>
<td>Colin Berry</td>
<td>acolinberry.co.uk</td>
</tr>
<tr>
<td>David Brusick</td>
<td>aol.com</td>
</tr>
<tr>
<td>Michele Burns</td>
<td>childrens.harvard.edu</td>
</tr>
<tr>
<td>Joao Lauro Viana de Camargo</td>
<td>uol.com.br</td>
</tr>
<tr>
<td>David Garabrant</td>
<td>comcast.net</td>
</tr>
<tr>
<td>Helmut Greim</td>
<td>lrz.tum.de</td>
</tr>
<tr>
<td>Larry Kier</td>
<td>ac.com</td>
</tr>
<tr>
<td>David Kirkland</td>
<td>genetoxconsulting.co.uk</td>
</tr>
<tr>
<td>Gary Marsh</td>
<td>comcast.net</td>
</tr>
<tr>
<td>Keith Solomon</td>
<td>uoguelph.ca</td>
</tr>
<tr>
<td>Tom Sorahan</td>
<td>bham.ac.uk</td>
</tr>
<tr>
<td>Ashley Roberts</td>
<td>intertek.com</td>
</tr>
<tr>
<td>Douglas Weed</td>
<td>acl.com</td>
</tr>
</tbody>
</table>

Please let me know as soon as you can if you'd like to make any changes. If you're happy to send it as it is, please go ahead.

Very best wishes,
Dear Dr Roberts, authors and co-authors of Review Papers:

This e-mail is being sent to you in view of your role in the preparation of five papers that were published on line in a Special Supplemental Issue of Critical Reviews in Toxicology entitled, "An Independent Review Of The Carcinogenic Potential of Glyphosate", Volume 46, 2016. The five papers and an Introductory Article prepared by Roger O. McClellan, Editor of Critical Reviews in Toxicology, are available electronically at http://tandfonline.com/toc/itxc20/46/sup1.

It was known by McClellan and Taylor and Francis, the publisher of CRT, from their earliest communications on the supplemental issue that the review of glyphosate and preparation of the papers was sponsored financially by the Monsanto Company, a producer of glyphosate. It was fully anticipated that the specific role of Monsanto would be related in the Declaration of Interest for each article, and that the authorship attributed to each article would reflect all contributions made. The need for a Declaration of Interest (DOI) is clearly spelled out in the Instructions for Authors at http://tandfonline.com/action/authorSubmission?journalCode=itxc20&page=instructions#Disclosure_statement. Moreover, McClellan gave explicit instructions on multiple occasions on the need for each article to have an accurate, comprehensive and transparent DOI.

On submission, you confirmed that the authorship attributions, any declarations of funding and any DOIs were accurate and complete in the journal’s peer review system. On publication, you made warranties in the Author Publishing Agreements again confirming this, and that you had understood and complied with the journal’s ethical policies. You will understand that compliance with the journal and Taylor & Francis’ policies here, which are in line with COPE and ICMJE guidelines, is paramount for maintaining the integrity of our published research.

Recently, as part of legal proceedings in California both internal and external communications by Monsanto personnel have been made public. These communications have been reported upon in Bloomberg Businessweek and the New York Times, as well as elsewhere. The documents released raise serious questions as to whether the warranties made for all articles in the supplement were accurate. Specifically, the documents suggest that employees of Monsanto were involved in the drafting of articles in the supplement without being acknowledged as authors, and that the relationship between some authors on the supplement and Monsanto was not fully described in the DOIs. Overall, the documents suggest that the warranties made and DOIs provided with these articles do not accurately reflect the extent of Monsanto’s involvement in their preparation.

This issue is sufficiently serious that Taylor and Francis, as the Publisher, with the assistance of McClellan, as Editor, have initiated an investigation. To assist in this investigation, at this stage I ask you to comment on the questions raised. Specifically, I’d be grateful for your explanation as to the extent of any contributions to the
drafting of articles in the supplement from authors not currently listed as authors and the accuracy of all
Declarations of Interest. I ask you respond by September 22\textsuperscript{nd}.

I am CCing Charles Whalley, Managing Editor at Taylor & Francis, in this e-mail. I hope to receive a response
from you soon.

Regards,
Roger O. McClellan
Roger McClellan

From: Marilyn Aardema <mara@me.com>
Sent: Sunday, September 17, 2017 9:19 AM
To: Fwd: Glyogisae Papers Published in CRT

Roger-I received an error message indicating the email below was not delivered. Please confirm when you receive this.

Marilyn
Marilyn Aardema Consulting

Begin forwarded message:

From: Marilyn Aardema <mara@me.com>
Date: September 17, 2017 at 10:44:08 AM EDT
To: Roger McClellan <mara@att.net>
Cc: "gary_williamsed3"<gary_williamsed3@att.net>, "acquaiohned"<acquaiohned@att.net>, "brusick41@att.net", "brusick41@att.net", "Michele.Burns@att.net", "decam@att.net", "hdx3@att.net", "helmut.greim@gmail.com", "idkier@att.net", "rootfa@att.net", "smash911@att.net", "T.M.Soraham@att.net", "ashley.roberts@att.net", "douglasweed@att.net", "Charles Whalley <charlesw@tanaf.co.uk>, "Roger O. McClellan" <rogerm@hararav.com>

Subject: Re: Glyogisae Papers Published in CRT

Roger-I am not aware of any writing by anyone not listed as a coauthor on the papers I was involved in. I did not have any contact or relationship with Monsanto, or any influence from them during the writing of these papers. We undertook an independent review following scientific and professional standards.

Marilyn
Marilyn Aardema Consulting

On Sep 15, 2017, at 5:36 PM. Roger McClellan <mara@att.net> wrote:

Roger O. McClellan, DVM, MMS, DSc (Honorary)
Diplomate-ABT and ABVT
Fellow-ATS, SRA, AAAR, HPS, and AAAS
Member-National Academy of Medicine
Editor, Critical Reviews in Toxicology
Advisor, Toxicology and Human Health Risk Analysis
September 15, 2017

Dear Dr. Roberts, authors and co-authors of Review Papers:

This e-mail is being sent to you in view of your role in the preparation of five papers that were published online in a Special Supplemental Issue of Critical Reviews in Toxicology entitled, "An Independent Review of the Carcinogenic Potential of Glyphosate," Volume 46, 2016. The five papers and an Introductory Article prepared by me as Editor of Critical Reviews in Toxicology are available electronically at http://tandfonline.com/toc/critx20/46/sup1.

It was known by me and Taylor and Francis, the publisher of CRT, from the earliest communications on the supplemental issue that the review of glyphosate and preparation of the papers was sponsored financially by the Monsanto Company, a producer of glyphosate. It was fully anticipated that the specific role of Monsanto would be related in the Declaration of Interest for each article, and that the authorship attributed to each article would reflect all contributions made. The need for a Declaration of Interest (DOI) is clearly spelled out in the Instructions for Authors at http://tandfonline.com/action/authorSubmission?journalCode=itxc20&page=instructions#Disclosure_statement. Moreover, I gave explicit instructions on multiple occasions on the need for each article to have an accurate, comprehensive and transparent DOI.

On submission, you confirmed that the authorship attributions, any declarations of funding and any DOIs were accurate and complete in the journal’s peer review system. On publication, you made warranties in the Author Publishing Agreements again confirming this, and that you had understood and complied with the journal’s ethical policies. You will understand that compliance with the journal and Taylor & Francis’ policies here, which are in line with COPE and ICMJE guidelines, is paramount for maintaining the integrity of our published research.

Recently, as part of legal proceedings in California both internal and external communications by Monsanto personnel have been made public. These communications have been reported upon in Bloomberg Businessweek and the New York Times as well as elsewhere. The documents released raise serious questions as to whether the warranties made for all articles in the supplement were accurate. Specifically, the documents suggest that employees of Monsanto were involved in the drafting of articles in the supplement without being acknowledged as authors, and that the relationship between some authors on the supplement and Monsanto was not fully described in the DOIs. Overall, the documents suggest that the warranties made and DOIs provided with these articles do not accurately reflect the extent of Monsanto’s involvement in their preparation.
This issue is sufficiently serious that Taylor and Francis, as the Publisher, with my assistance as Editor, have initiated an investigation. To assist in this investigation, at this stage I ask you to comment on the questions raised. Specifically, I would be grateful for your explanation as to the extent of any affixing of articles in the supplement from authors not currently listed as authors and the accuracy of all Declarations of Interest. I ask that you respond by September 22nd.

I am CCing Charles Whalley, Managing Editor at Taylor & Francis, in this e-mail. I hope to receive a response from you soon.

Regards,

Roger O. McClellan
Editor, CRT
Dear Dr. McClellan,

I am not aware of any contribution to the manuscripts by anyone not listed as coauthor of the published papers. I understand that the section on animal tumors—which I did participate—was drafted and finalized solely by the panel members. I believe that the declaration of interests that appeared at the end of the articles accurately reflects my participation. During the panel activities and writing of these papers I did not have contact with anyone from Monsanto regarding the contents of the manuscripts. The published papers convey my own independent expert opinion.

J.L.V. de Camargo, MD, PhD, FIATP
Professor of Pathology
Botucatu Medical School
18618-000 Botucatu SP Brazil
@uol.com.br
@lmb.unesp.br

PS – A copy of this email was sent to the other coauthors.

September 15, 2017

Dear Dr. Roberts, authors and co-authors of Review Papers:
This e-mail is being sent to you in view of your role in the preparation of five papers that were published on line in a Special Supplemental Issue of Critical Reviews in Toxicology entitled, "An Independent Review of the Carcinogenic Potential of Glyphosate," Volume 46, 2016. The five papers and an Introductory Article prepared by me as Editor of Critical Reviews in Toxicology are available electronically at http:// tandfonline.com/toc/ttxe20/46/sup1.

It was known by me and Taylor and Francis, the publisher of CRT, from the earliest communications on the supplemental issue that the review of glyphosate and preparation of the papers was sponsored financially by the Monsanto Company, a producer of glyphosate. It was fully anticipated that the specific role of Monsanto would be related in the Declaration of Interest for each article, and that the authorship attributed to each article would reflect all contributions made. The need for a Declaration of Interest (DOI) is clearly spelled out in the Instructions for Authors at http:// tandfonline.com/action/authorSubmission?journalCode=ttxe20&page=instructions#Disclosure_statement. Moreover, I gave explicit instructions on multiple occasions on the need for each article to have an accurate, comprehensive and transparent DOI.

On submission, you confirmed that the authorship attributions, any declarations of funding and any DOIs were accurate and complete in the journal’s peer review system. On publication, you made warranties in the Author Publishing Agreements again confirming this, and that you had understood and complied with the journal’s ethical policies. You will understand that compliance with the journal and Taylor & Francis’ policies here, which are in line with COPE and ICMJE guidelines, is paramount for maintaining the integrity of our published research.

Recently, as part of legal proceedings in California both internal and external communications by Monsanto personnel have been made public. These communications have been reported upon in Bloomberg Businessweek and the New York Times as well as elsewhere. The documents released raise serious questions as to whether the warranties made for all articles in the supplement were accurate. Specifically, the documents suggest that employees of Monsanto were involved in the drafting of articles in the supplement without being acknowledged as authors, and that the relationship between some authors on the supplement and Monsanto was not fully described in the DOIs. Overall, the documents suggest that the warranties made and DOIs provided with these articles do not accurately reflect the extent of Monsanto’s involvement in their preparation.

This issue is sufficiently serious that Taylor and Francis, as the Publisher, with my assistance as Editor, have initiated an investigation. To assist in this investigation, at this stage I ask you to comment on the questions raised. Specifically, I would be grateful for your explanation as to the extent of any contributions to the drafting of articles in the supplement from authors not currently listed as authors and the accuracy of all Declarations of Interest. I ask that you respond by September 22nd.

I am CCing Charles Whalley, Managing Editor at Taylor & Francis, in this e-mail. I hope to receive a response from you soon.

Regards,

Roger O. McClellan
Editor, CRT
September 20, 2017

TO: Dear Dr Roberts, authors and co-authors of Review Papers:

FROM: Roger O. McClellan

SUBJECT: Glyphosate Special Issue – CONFIDENTIAL

Attached is a copy of the memo I sent you on April 15, 2017 concerning the Special Issue of Critical Reviews in Toxicology that contained 5 papers you authored or co-authored. I am pleased to note that many of you have responded. The purpose of this memo is to ask those of you who have not responded to provide me a response with a copy to Charles Whalley, Taylor and Francis, at your earliest convenience. It is important that each of you respond, not just the corresponding or first author of each paper. Your individual responses are critical to our completing our investigation of this matter in a timely manner. If you have any questions please feel free to contact me. Thank you for your assistance.

If you are not able to respond by Friday, September 22, 2017, please acknowledge receipt of this memo and let me know when I can expect your response.

Attachment: Letter of April 15, 2017

Cc: Charles Whalley (Charles.Whalley@tandf.co.uk)
    Mildred Morgan (M.Morgan@harvey.com)
Summary of Responses from Authors and Co-Authors on 5 Glyphosate Papers

Marilyn Aardema

9/17/17

Roger-I am not aware of any writing by anyone not listed as a coauthor on the papers I was involved in. I did not have any contact or relationship with Monsanto, or any influence from them during the writing of these papers. We undertook an independent review following scientific and professional standards.

Marilyn
Marilyn Aardema Consulting

John Acquavella

9/15/17

Roger:

Thank you for the chance to respond. The epidemiology manuscript was authored jointly by the 5 listed (epidemiologist/biostatistician) authors and each author met every one of the ICJME authorship guidelines. No one from Monsanto had any role in the writing of the epidemiology manuscript, nor did anyone from Monsanto attend our in person expert panel meeting where the approach to our systematic review was decided and each article was critiqued according to standard criteria. The epidemiology section of the summary article also had no input from Monsanto.

Regards,

John

John Acquavella, PhD FACE FISPE
Professor, Dept Clinical Epidemiology
Aarhus University, Denmark
+1 [phone number] (office)
+1 [phone number] (mobile)
Aarhus University email: @clin.au.dk
9/20/17

Thank you Roger for the chance to provide additional information. I’ll begin by drawing a distinction between the epidemiology paper per se, the epidemiology sections of the summary paper, and the other sections of summary paper. Bill Heydens didn’t offer any input on the epidemiology paper or the epidemiology section of the summary paper. With regard to other sections of the summary paper, the gist of the suggested edits by the epidemiologists concerned the tone toward IARC, not the scientific assessment re exposure, genotox or chronic tox. We epidemiologists pushed for sticking to a scientific assessment of the available evidence with very limited explicit or implied criticism of IARC. We left it to Gary Williams, the primary author, to adjudicate where there were differing suggestions re tone and I didn’t keep track of whose comments prevailed where there was disagreement. However, we 5 epidemiologists all read the final version of the summary paper and were satisfied with the tone. As far as I know, the edits in question concerned tone only.

Regards,
John

9/20/17

Roger:

Thank you again for the chance to respond. I’ve included the published DOI below for reference.

I did not receive any compensation from Intertek. I already had a consulting contract in place with Monsanto prior to the initiation of the review, so there was no need for a contract with Intertek or payment from Intertek for my efforts on the review article. I charged Monsanto my usual hourly rate for my time spent on the review, just as the other panelists charged Intertek their usual hourly rate (for them, paid by Monsanto through Intertek). I thought that the important issue regarding compensation for the DOI was that we were all paid by Monsanto, not the contracting or invoicing/payment details.

I believe the DOI is very comprehensive. It notes: that Monsanto funded our work, my previous employment with Monsanto more than 10 years ago, and even the fact that I consulted on a legal case unrelated to glyphosate involving a former Monsanto chemical plant. I tried to include everything possible in the DOI that you might want to be disclosed.
As I noted in my previous email, the glyphosate epidemiology review was conducted according to the highest standards of my profession. The work was conducted totally independent of the sponsor. All five authors contributed actual written sections to the manuscript and met every one of the ICJME authorship criteria. Monsanto did not contribute to or influence the writing at all. I and my co-authors had sole responsibility for the content of the paper, and the interpretations and opinions expressed in the paper were ours.

Regards,
John

Sir Colin Berry

On Sunday, September 17, 2017 2:21 AM, Colin Berry <sircolinberry.co.uk> wrote:

Dear Mr McClelland,

Thank you for your mail.
As a former Chairman of the UK Advisory Committee on Pesticides and a Chairman of Section four Committee of the Medicines Act, I have, for many years, dealt with information concerning toxicity of xenobiotics in a consistent manner. Since retirement from those duties I have seen no reason to change my procedures. Information may come from any source but is used to provide the basis of my independent opinion.

In this instance, the members of the panel dealing with carcinogenicity produced text on the various issues before us in this field and considered the database identified in the document. We then met, or discussed electronically the various sections, about which we harmonised our views. At no stage was anyone from Monsanto involved in any of the discussions. Our opinion and the resultant document was arrived at in the manner which has been used by many regulatory authorities, as for example, the WHO/FAO joint panels.

Drafting was carried out by regular exchanges by members of the panel alone.

Your sincerely,
Professor Sir Colin Berry
These questions have been asked of me on more than one occasion. As the individual who assembled the manuscript describing the genetic toxicology results and interpretation, I can assure you that the entire manuscript content was drafted, reviewed and finalized only by the members of the genetic toxicology panel. I can assure Critical Reviews in Toxicology that there were no other authors directly or indirectly involved in preparing its content.

David Brusick

Michele M. Burns

From: Burns, Michele [mailto:burnm@childrens.harvard.edu]
Sent: 16 September 2017 13:07
To: Roger McClellan
Subject: RE: Glyphosateae Papers Published in CRT [EXTERNAL]

Dear Roger,

I had no communication with Monsanto staff about the content of the papers listed below, nor know of anyone who did. The meetings and scientific discussions were conducted in a highly professional, ethical manner.


Thanks,
Michele

Michele M. Burns, MD, MPH
Joao Lauro Viana de Camargo

On Monday, September 18, 2017 1:52 PM, Joao Lauro <vtol.com.br> wrote:

Dear Dr. McClellan,

I am not aware of any contribution to the manuscripts by someone not listed as coauthor of the published papers. I understand that the section on animal tumors - in which I did participate - was drafted and finalized solely by the panel members. I believe that the declaration of interests that appeared at the end of the articles accurately reflects my participation. During the panel activities and writing of these papers I did not have contact with anyone from Monsanto regarding the contents of the manuscripts. The published papers convey my own independent expert opinion.

J.L.V. de Camargo, MD, PhD, FIATP
Professor of Pathology
Botucatu Medical School
18618-000 Botucatu SP Brazil
vtol.com.br
vtol.com.br

PS - A copy of this email was sent to the other coauthors.

David Garabrant

9/22/17

Dear Dr. McClellan.


As far as I am aware, no employees of Monsanto were involved in the drafting of the two articles that I co-authored. I had no contact with any employees of Monsanto at any time during the drafting of these articles. As far as I am aware, no one other than the listed authors was involved in the drafting of the two articles that I co-authored.

The Declarations of Interest (DOI) that I provided for the two articles that I co-authored were accurate to the best of my knowledge at the time I wrote them. In both articles I wrote, "DG serves on a scientific advisory board to Dow Agro Sciences, which markets pesticides including..."
 glyphosate, and has consulted on behalf of Bayer Corp. on litigation matters concerning 
glyphosate and leukemia."

In November 2016 after the publication of the five papers, in the course of responding to 
subpoenas from the plaintiffs’ attorneys in the California litigation, two events occurred:

1. I was reminded by the attorney for Bayer Corporation, who retained me to act as an 
expert in that litigation, that I was also retained to act as a joint expert for several 
defendants in the *Walsh v BASF Corp, et al.* case. Those defendants are: Bayer 
Corporation; Bayer CropScience LP; Bayer CropScience Holding, Inc.; Dow 
AgroSciences, L.L.C.; BASF Corporation; Syngenta Crop Protection, Inc., Deere & 
Company, Lesco, Inc.; and Monsanto. My point of contact for the group of *Walsh* 
defendants was the attorney for Bayer, which led to the statement I made in the DOI that 
I had consulted on behalf of Bayer Corporation on litigation matters concerning 
glyphosate and leukemia. When I wrote my DOI, I did not list the other defendants in that 
litigation because I did not recall (or did not know at that time) that they had jointly 
retained me.

2. I reviewed my consulting engagements and found that in February 2016 I had been 
retained by a law firm on behalf of Pharmacia LLC (formerly known as Monsanto) 
regarding litigation involving leukemia and benzene exposure, but not involving 
glyphosate. I spent a total of 0.3 hours on that case on 2/16/2016 and never did any 
further work. My company, EpidStat Institute, Inc. was paid $187.50 for my work. I did 
not recall this engagement at the time I wrote my DOI later in 2016.

To the best of my knowledge, I have had no other relationships with Monsanto at any time prior 
to co-authoring the two articles, and I have never spoken with any Monsanto scientist about 
glyphosate or any other scientific issue. Subsequent to the publication of the two glyphosate 
reviews I have had contact with attorneys representing Monsanto, for the purposes of responding 
to subpoenas from the plaintiffs’ attorneys in the California litigation.

I hope these clarifications assist you in your inquiry. I will be pleased to provide any further 
assistance you may need.

Sincerely,

David H. Garabrant, MD, MPH

Ann Arbor, MI

e-mail: [email protected]

phone:
Dear Roger,
in my response to you and all other participants of our exercise the mail to you bounced back.
I am sending my statement to you separately.
Best
Helmut

Dear Roger,
I only can support all the previous statements. There was no interaction or interference with Monsanto people before, during or after the meeting, the evaluation of data or preparation of the manuscripts I have been involved.
Best regress
Helmut Greim

Larry D. Kier

9/22/17
Dear Dr. McClellan:

Thank you for your communication providing the opportunity to respond to concerns.

With respect to the specific question of authorship I fully concur with my fellow authors that the genotoxicity expert panel report was the product of the listed authors. Neither Monsanto employees nor attorneys were “ghost-writers.”

I was initially hired by Monsanto to serve as a consultant to support the Intertek genotoxicity expert panel. In this capacity I was in contact with Monsanto to facilitate providing the panel members with complete and accurate information, including supplemental information on regulatory genetic toxicology studies.

Subsequent to development of the genotoxicity expert panel manuscript I agreed to be added as a co-author subject to the approval of the panel members.

Please note that my employment with Monsanto began in 1974 and not 1979.

Thanks.

Larry Kier
David J. Kirkland

From: David Kirkland [mailto:genetoxconsulting.co.uk]
Sent: 16 September 2017 17:55
Subject: RE: Glyphosate Papers Published in CRT

Dear Dr McClellan,

I am aware of the accusations of "ghostwriting" by Monsanto employees, and I can appreciate the need for an investigation. Because my name was mentioned in one or more of the released emails, I have been contacted on this issue by several journalists, and have given them the same assurance as I will now give you. As far as I am aware, there was no "ghostwriting", and the papers of which I was co-author were written entirely by the authors. Certainly from my side there was no contact with or influence by Monsanto, and I believe that to be the case for the other co-authors. I would never let my name be used on an article ghostwritten by others.

I hope this is helpful.

Kind regards,

David Kirkland.

Gary Marsh

On Tuesday, September 19, 2017 3:22 PM, "Marsh, Gary M" <pitt.edu> wrote:

Dear Roger,

In response to your email of September 15, 2017, this is to confirm that I had no contact whatsoever with Monsanto staff about the contents of the glyphosate review articles. The members of the epidemiology panel on which I served had absolute control, at all stages of the effort, over the contents of the epidemiology review article as well as the epidemiology section of the comprehensive review article. The opinions and conclusions expressed in these epidemiology components of the project were exclusively those of the panel members.

Sincerely,

Gary
Ashley Roberts

9/27/17

Dear Roger:

In response to your enquiries, I can confirm that Monsanto did not participate in the preparation of the 4 critical subject evaluations. The summary paper required clarification on the history and regulatory processes for glyphosate and I shared that summary with Dr. Heydens to ensure the accuracy of this information once the underlying evaluations had been finalized. Dr. Heydens' comments on the summary had no impact on the viewpoints/interpretation or the independent conclusions that had already been reached and set out by the 4 expert panel groups in their evaluations. As such, Monsanto was not involved in the drafting of any of the evaluations and did not have any input into the evaluations or conclusions regarding the safety of glyphosate that was provided to the journal.

Ashley

Ashley Roberts, Ph.D.

---

Keith R. Solomon

9/21/17

Dear Dr. McClellan et al.,

I have finally received computer (back from repair). I have checked the paper and the DOI. The DOI is completely correct in the statement that "Neither any Monsanto company employees nor any attorney reviewed any of the Expert Panel's manuscripts prior to submission to the journal"

As noted in the Acknowledgments "I thank Monsanto Inc. for providing access to reports from exposure studies for glyphosate in applicators". Obviously, to obtain those reports, I communicated with people at Monsanto and might have asked for clarification of material in the reports. The data from the reports that were used are part of the paper and are reported in the supplemental information.

The opinions expressed in this paper and mine only.

Keith
Dear Roger, i had no communications with Monsanto staff about the content of the reviews. Tom Sorahan

Douglas L. Weed

9/19/17

Dr. McClellan,

I appreciate the opportunity to respond to your questions. I can assure you that the manuscript on epidemiology was authored only by those listed as the co-authors, including myself. Similarly, the epidemiology section in the summary article was authored only by the co-authors. Monsanto had no role in writing either of these manuscripts. Furthermore, no one from Monsanto attended the meetings prior to submission of these manuscripts. Finally, my declaration of interests was correct.

Sincerely,
Doug Weed

Douglas L. Weed, M.D., M.P.H., Ph.D.
Founder and Managing Member
DLW Consulting Services, LLC
Salt Lake City, UT

Gary Williams

9/20/17

Dear Roger,

I will respond to your request at this time because the College is closed for the next two days by which you requested a response. I would have wanted to discuss some items with Dr. Roberts, but he is travelling.

My responses cover the three sections of the publication of which I am a co-author.

For the carcinogenicity section, I was assisted in pathology review by my colleague Dr. Michael Iatropoulos. He confirms that all materials provided to us came from intertek.

Likewise, for other sections, source documents came from intertek.

Any materials provided to one member of a working group were provided to all members.
In the many exchanges of drafts I saw no material changes that did not come from a member of the Panel. In other words, I saw no changes that could have come from Monsanto.

From the time of my recruitment to the Panel up to the present, I have had no contact with any Monsanto representative.

In summary, the DOI accurately reflects the absence of input from Monsanto.

In reviewing the DOI, however, I have found a couple of inaccuracies. In referring to the previous review of glyphosate supported by Monsanto (Williams et al, 2000), acknowledgement is made to the contribution of Barry Lynch of Cantox. In the paper, we actually thank Douglas W. Bryant. Also, in several places it is stated that I consulted for Monsanto on litigation matters involving glyphosate. I have consulted for Monsanto on other matters, but I have no recollection of consulting on glyphosate.

I hope that these responses are helpful.

Yours sincerely,

Gary M. Williams, MD
Professor of Pathology
Patricia Borror;

Please acknowledge receipt of this e-mail and the attachment. I will appreciate your making a special effort to seeing that this material reaches Dr Ashley Roberts ASAP. I would also appreciate your advising me as to when Dr Roberts will be returning to Canada and if he will be able to respond to my request for him to respond to the request I made on September 15 which is reiterated in the attached e-mail.

I am very pleased with the prompt responses received from many of the authors and co-authors of the five papers in the Special Glyphosate issue. However, Dr Robert's response is key to our completing the investigation in a timely manner and deciding on a future course of action.

Thank you for your attention to this matter.
Roger O. McClellan, Editor
Critical Reviews in Toxicology

On Wednesday, September 20, 2017 2:18 PM, Mildred Morgan <morgand@hargray.com> wrote:

FYI

Roger O. McClellan, DVM, MMS, DSc (Honorary)
Diplomate-ABT and ABVT
Fellow-ATS, SRA, AAAR, HPS, and AAAS
Member-National Academy of Medicine
Editor, Critical Reviews in Toxicology
Advisor, Toxicology and Human Health Risk Analysis

Albuquerque, NM

September 20, 2017

TO: Ashley Roberts et al.
FROM: Roger O. McClellan
SUBJECT: Glyphosate Special Issue – CONFIDENTIAL

Attached is a copy of the memo I sent you on April 15, 2017 concerning the Special Issue of Critical Reviews in Toxicology that contained 5 papers you authored or co-authored. I am pleased to note that many of you have responded. The purpose of this memo is to ask those of you who have not responded to provide me a response with a copy to Charles Whalley, Taylor and Francis, at your earliest convenience. It is important that each of you respond, not just the corresponding or first author or each paper. Your individual responses are critical to our completing our investigation of this matter in a timely manner. If you have any questions please feel free to contact me. Thank you for your assistance.

If you are not able to respond by Friday, September 22, 2017, please acknowledge receipt of this memo and let me know when I can expect your response.

Attachment: Letter of April 15, 2017

Cc: Charles Whalley (charles.whalley@tandf.co.uk)
Mildred Morgan (m.morgan@chargray.com)
Dear Roger,

I will respond to your request at this time because the College is closed for the next two days by which you requested a response. I would have wanted to discuss some items with Dr. Roberts, but he is travelling.

My responses cover the three sections of the publication of which I am a co-author.

For the carcinogenicity section, I was assisted in pathology review by my colleague Dr. Michael Latropoulos. He confirms that all materials provided to us came from Intertek.

Likewise, for other sections, source documents came from Intertek.

Any materials provided to one member of a working group were provided to all members.

In the many exchanges of drafts I saw no material changes that did not come from a member of the Panel. In other words, I saw no changes that could have come from Monsanto.

From the time of my recruitment to the Panel up to the present, I have had no contact with any Monsanto representative.

In summary, the DOI accurately reflects the absence of input from Monsanto.

In reviewing the DOI, however, I have found a couple of inaccuracies. In referring to the previous review of glyphosate supported by Monsanto (Williams et al, 2000), acknowledgement is made to the contribution of Barry Lynch of Cantox. In the paper, we actually thank Douglas W. Bryant. Also, in several places it is stated that I consulted for Monsanto on litigation matters in involving glyphosate. I have consulted for Monsanto on other matters, but I have no recollection of consulting on glyphosate.

I hope that these responses are helpful.

Yours sincerely,

Gary M. Williams, MD
Professor of Pathology
Dear Roger,

I will respond to your request at this time because the College is closed for the next two days by which you requested a response. I would have wanted to discuss some items with Dr. Roberts, but he is travelling.

My responses cover the three sections of the publication of which I am a co-author.

For the carcinogenicity section, I was assisted in pathology review by my colleague Dr. Michael Latropoulos. He confirms that all materials provided to us came from Intertek.

Likewise, for other sections, source documents came from Intertek.

Any materials provided to one member of a working group were provided to all members.

In the many exchanges of drafts I saw no material changes that did not come from a member of the Panel. In other words, I saw no changes that could have come from Monsanto.

From the time of my recruitment to the Panel up to the present, I have had no contact with any Monsanto representative.

In summary, the DOI accurately reflects the absence of input from Monsanto.

In reviewing the DOI, however, I have found a couple of inaccuracies. In referring to the previous review of glyphosate supported by Monsanto (Williams et al., 2000), acknowledgement is made to the contribution of Barry Lynch of Cantox. In the paper, we actually thank Douglas W. Bryant. Also, in several places it is stated that I consulted for Monsanto on litigation matters in involving glyphosate. I have consulted for Monsanto on other matters, but I have no recollection of consulting on glyphosate.
I hope that these responses are helpful.

Yours sincerely,

Gary M. Williams, MD
Professor of Pathology
Roger McClellan

From: Roger McClellan <att.net>
Sent: Thursday, September 21, 2017 2:11 PM
To: Mildred B. Morgan
Subject: Fw: Response

Hold

On Friday, September 15, 2017 4:08 PM, David Brusick <aol.com> wrote:

I am not sure that you received my response to your letter so I am sending again just to you. David

Roger

These questions have been asked of me on more than one occasion. As the individual who assembled the manuscript describing the genetic toxicology results and interpretation, I can assure you that the entire manuscript content was drafted, reviewed and finalized only by the members of the genetic toxicology panel. I can assure Critical Reviews in Toxicology that there were no other authors directly or indirectly involved in preparing its content.

David Brusick
Roger McClellan

From: Mildred Morgan <mildred_morgan@hargray.com>
Sent: Friday, September 22, 2017 9:34 AM
To: roger.o.mcclellan@
Subject: FW: Glyogisae Papers Published in CRT

FYI

From: David Kirkland [mailto@genetoxconsulting.co.uk]
Sent: Thursday, September 21, 2017 3:54 PM
To: 'Roger McClellan'
Cc: 'Mildred B. Morgan'
Subject: FW: Glyogisae Papers Published in CRT
Importance: High

Resent. Please confirm receipt.

David Kirkland.

From: David Kirkland [mailto@genetoxconsulting.co.uk]
Sent: 16 September 2017 17:55
To: 'Roger McClellan'; 'gary_williams@att.net'; 'mjaardema@att.net'; 'acqua约翰@att.net'; 'colin@att.net'; 'brusick41@att.net'; 'michael_burns@att.net'; 'tmg3@att.net'; 'douglasweeds@douglasweeds.com'; 'T.M.Sorahang@att.net'; 'ashley_roberts@att.net'; 'ksolomon@att.net'
Cc: 'Charles Whalley'; 'Roger O. Mcclellan'; 'Mildred B. Morgan'
Subject: RE: Glyogisae Papers Published in CRT

Dear Dr McClellan,

I am aware of the accusations of “ghostwriting” by Monsanto employees, and I can appreciate the need for an investigation. Because my name was mentioned in one or more of the released emails, I have been contacted on this issue by several journalists, and have given them the same assurance as I will now give you. As far as I am aware, there was no “ghostwriting”, and the papers of which I was co-author were written entirely by the authors. Certainly from my side there was no contact with or influence by Monsanto, and I believe that to be the case for the other co-authors. I would never let my name be used on an article ghostwritten by others.

I hope this is helpful.

Kind regards,

David Kirkland.

From: Roger McClellan [mailto@att.net]
Sent: 15 September 2017 22:37
To: gary_williams@att.net; mjaardema@att.net; acqua约翰@att.net; colin@att.net;
September 15, 2017

Dear Dr. Roberts, authors and co-authors of Review Papers:

This e-mail is being sent to you in view of your role in the preparation of five papers that were published on line in a Special Supplemental Issue of Critical Reviews in Toxicology entitled, ”An Independent Review of the Carcinogenic Potential of Glyphosate,” Volume 46, 2016. The five papers and an Introductory Article prepared by me as Editor of Critical Reviews in Toxicology are available electronically at http://tandfonline.com/toc/itxc20/46/sup1.

It was known by me and Taylor and Francis, the publisher of CRT, from the earliest communications on the supplemental issue that the review of glyphosate and preparation of the papers was sponsored financially by the Monsanto Company, a producer of glyphosate. It was fully anticipated that the specific role of Monsanto would be related in the Declaration of Interest for each article, and that the authorship attributed to each article would reflect all contributions made. The need for a Declaration of Interest (DOI) is clearly spelled out in the Instructions for Authors at http://tandfonline.com/action/authorSubmission?journalCode=itxc20&page=instructions#Disclosure_statement. Moreover, I gave explicit instructions on multiple occasions on the need for each article to have an accurate, comprehensive and transparent DOI.

On submission, you confirmed that the authorship attributions, any declarations of funding and any DOIs were accurate and complete in the journal’s peer review system. On publication, you made warranties in the Author Publishing Agreements again confirming this, and that you had understood and complied with the journal’s ethical policies. You will understand that compliance with the journal and Taylor & Francis’ policies here, which are in line with COPE and ICMJE guidelines, is paramount for maintaining the integrity of our published research.

Recently, as part of legal proceedings in California both internal and external communications by Monsanto personnel have been made public. These communications have been reported upon in Bloomberg Businessweek and the New York Times as well as elsewhere. The documents released raise serious questions as to whether the warranties made for all articles in the supplement were accurate. Specifically, the documents suggest that employees of Monsanto were involved in the drafting of articles in the supplement without being acknowledged as authors, and that the relationship between some authors on the supplement and Monsanto was not fully described in the
DOIs. Overall, the documents suggest that the warranties made and DOIs provided with these articles do not accurately reflect the extent of Monsanto's involvement in their preparation.

This issue is sufficiently serious that Taylor and Francis, as the Publisher, with my assistance as Editor, have initiated an investigation. To assist in this investigation, at this stage I ask you to comment on the questions raised. Specifically, I would be grateful for your explanation as to the extent of any contributions to the drafting of articles in the supplement from authors not currently listed as authors and the accuracy of all Declarations of Interest. I ask that you respond by September 22nd.

I am CCing Charles Whalley, Managing Editor at Taylor & Francis, in this e-mail. I hope to receive a response from you soon.

Regards,

Roger O. McClellan
Editor, CRT
Roger McClellan

From: Roger McClellan <Roger.McClellan@att.net>
Sent: Friday, September 22, 2017 9:49 AM
To: David Garabrant
Cc: Charles Whalley; Mildred B. Morgan; Roger McClellan
Subject: Re: Glyphosate Paper

David:
Thank you for your thorough response. It is helpful.
Best regards, Roger

On Friday, September 22, 2017 9:22 AM, David Garabrant <David.Garabrant@comcast.net> wrote:

Dear Dr. McClellan,

As far as I am aware, no employees of Monsanto were involved in the drafting of the two articles that I co-authored. I had no contact with any employees of Monsanto at any time during the drafting of these articles. As far as I am aware, no one other than the listed authors was involved in the drafting of the two articles that I co-authored.

The Declarations of Interest (DOI) that I provided for the two articles that I co-authored were accurate to the best of my knowledge at the time I wrote them. In both articles I wrote, “DG serves on a scientific advisory board to Dow AgroSciences, which markets pesticides including glyphosate, and has consulted on behalf of Bayer Corporation on litigation matters concerning glyphosate and leukemia.” In November 2016 after the publication of the five papers, in the course of responding to subpoenas from the plaintiffs’ attorneys in the California litigation, two events occurred:

1. I was reminded by the attorney for Bayer Corporation, who retained me to act as an expert in that litigation, that I was also retained to act as a joint expert for several defendants in the Walsh v BASF Corp. et al., case. Those defendants are: Bayer Corporation; Bayer CropScience LP; Bayer CropScience Holding, Inc.; Dow AgroSciences, L.L.C.; BASF Corporation; Syngenta Crop Protection, Inc., Deere & Company, Lesco, Inc.; and Monsanto. My point of contact for the group of Walsh defendants was the attorney for Bayer, which led to the statement I made in the DOI that I had consulted on behalf of Bayer Corporation on litigation matters concerning glyphosate and leukemia. When I wrote my DOI, I did not list the other defendants in that litigation because I did not recall (or did not know at that time) that they had jointly retained me.

2. I reviewed my consulting engagements and found that in February 2016 I had been retained by a law firm on behalf of Pharmacia LLC (formerly known as Monsanto) regarding litigation involving leukemia and benzene exposure, but not involving glyphosate. I spent a total of 0.3 hours on that case on 2/16/2016 and never did any further work. My company, EpidStat Institute, Inc., was paid $187.50 for my work. I did not recall this engagement at the time I wrote my DOI later in 2016.

RM 000504
To the best of my knowledge, I have had no other relationships with Monsanto at any time prior to co-authoring the two articles, and I have never spoken with any Monsanto scientist about glyphosate or any other scientific issue. Subsequent to the publication of the two glyphosate reviews I have had contact with attorneys representing Monsanto, for the purposes of responding to subpoenas from the plaintiffs' attorneys in the California litigation.

I hope these clarifications assist you in your inquiry. I will be pleased to provide any further assistance you may need.

Sincerely,

David H. Garabrant, MD, MPH
Ann Arbor, MI

e-mail: [removed]
phone: [removed]

www.cpidstat.com

CONFIDENTIALITY NOTE: The information transmitted in this electronic communication, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential and/or privileged materials. Any review, transmission, dissemination or other use of this information, or taking any action in reliance upon this information, by person or entities other than the intended recipient is strictly prohibited. If you have received this message in error, please contact the sender and destroy any copies of this information.

On September 16, 2017 at 10:46 AM Roger McClellan <[removed]@att.net> wrote:

Roger O. McClellan, DVM, MMS, DSc (Honorary)
Diplomate-ABT and ABVT
Fellow-ATS, SRA, AAAR, HPS, and AAAS
Member-National Academy of Medicine
Editor, Critical Reviews in Toxicology
Advisor, Toxicology and Human Health Risk Analysis

Albuquerque, NM
Tel: [removed] Cell: [removed] Fax: [removed]
E-mail: [removed]@att.net

September 15, 2017

Dear Dr Roberts, authors and co-authors of Review Papers:

This e-mail is being sent to you in view of your role in the preparation of five papers that were published online in a Special Supplimental Issue of Critical Reviews in Toxicology entitled, "An Independent Review of the Carcinogenic Potential of Glyphosate," Volume 46, 2016. The five papers and an Introductory Article prepared by me as Editor of Critical Reviews in Toxicology are available electronically at http://tandfonline.com/toc/itxc20/46/sup1.

It was known by me and Taylor and Francis, the publisher of CRT, from the earliest communications on the supplemental issue that the review of glyphosate and preparation of the papers was sponsored financially by the Monsanto Company, a producer of glyphosate. It was fully anticipated that the specific role of Monsanto would be related in the Declaration of Interest for each article, and that the authorship attributed to each article would reflect all contributions made. The need for a Declaration of Interest (DOI) is clearly spelled out in the Instructions for Authors at http://tandfonline.com/action/authorSubmission?journalCode=itxc20&page=instructions#DisclosureStatement. Moreover, I gave explicit instructions on multiple occasions on the need for each article to have an accurate, comprehensive and transparent DOI.
On submission, you confirmed that the authorship attributions, any declarations of funding and any DOIs were accurate and complete in the journal’s peer review system. On publication, you made warranties in the Author Publishing Agreements again confirming this, and that you had understood and complied with the journal’s ethical policies. You will understand that compliance with the journal and Taylor & Francis’ policies here, which are in line with COPE and ICMJE guidelines, is paramount for maintaining the integrity of our published research.

Recently, as part of legal proceedings in California both internal and external communications by Monsanto personnel have been made public. These communications have been reported upon in Bloomberg Businessweek and the New York Times as well as elsewhere. The documents released raise serious questions as to whether the warranties made for all articles in the supplement were accurate. Specifically, the documents suggest that employees of Monsanto were involved in the drafting of articles in the supplement without being acknowledged as authors, and that the relationship between some authors on the supplement and Monsanto was not fully described in the DOIs. Overall, the documents suggest that the warranties made and DOIs provided with these articles do not accurately reflect the extent of Monsanto’s involvement in their preparation.

This issue is sufficiently serious that Taylor and Francis, as the Publisher, with my assistance as Editor, have initiated an investigation. To assist in this investigation, at this stage I ask you to comment on the questions raised. Specifically, I would be grateful for your explanation as to the extent of any contributions to the drafting of articles in the supplement from authors not currently listed as authors and the accuracy of all Declarations of Interest. I ask that you respond by September 22nd.

I am CCing Charles Whalley, Managing Editor at Taylor & Francis, in this e-mail. I hope to receive a response from you soon.

Regards,

Roger O. McClellan
Editor, CRT
Roger McClellan

From: Mildred Morgan <bridget@hargray.com>
Sent: Friday, September 22, 2017 11:11 AM
To: roger.o.mcclellan@
Subject: FW: Glyogisae Papers Published in CRT [EXTERNAL]

Fyi

From: David Kirkland [mailtoHB@genetoxconsulting.co.uk]
Sent: Friday, September 22, 2017 11:46 AM
To: 'Mildred B. Morgan'
Subject: FW: G yogisae Papers Published in CRT [EXTERNAL]

From: Burns, Michele [mailto]
Sent: 16 September 2017 13:07
To: Roger McClellan; gary williams@ppi; miaardema@; acquavella@; berry@; brusick41@; de camargo@; garabrant@; greim@; kier@; marsh@; solomon@; sorahan@; roberts@; weed@. cc: Charles Whalley; Roger O. McClellan; Mildred B. Morgan
Subject: RE: Glyogisae Papers Published in CRT [EXTERNAL]

Dear Roger,

I had no communication with Monsanto staff about the content of the papers listed below, nor know of anyone who did. The meetings and scientific discussions were conducted in a highly professional, ethical manner.


Thanks,
Michele

Michele M. Burns, MD, MPH
Fellowship Director: Harvard Medical Toxicology
Medical Director: Regional Center for Poison Control & Prevention serving MA & RI
Staff Physician: Emergency Medicine
Boston Children’s Hospital

Boston, MA
Phone:
Fax:
Thank you.

Michele:
I have now retrieved the e-mail you sent me on September 16th. It is helpful. Best regards, Roger

Roger, Yes, I will provide a response by tomorrow. I knew you meant September 15. Best wishes,
David H. Garabrant, MD, MPH

On Thursday, September 21, 2017 12:44 PM, David Garabrant «^Biacomcasl.net» wrote:

David:
I apologize for the error in the attached memo, it should be September 15th not April 15th. Please acknowledge receipt and indicate if you can provide response by tomorrow. Thanks for your assistance.
Roger

On Wednesday, September 20, 2017 2:05 PM, Roger McClellan <[redacted]@att.net> wrote:
September 20, 2017

TO: Ashley Roberts et al.

FROM: Roger O. McClellan

SUBJECT: Glyphosate Special Issue – CONFIDENTIAL

Attached is a copy of the memo I sent you on April 15, 2017 concerning the Special Issue of Critical Reviews in Toxicology that contained 5 papers you authored or co-authored. I am pleased to note that many of you have responded. The purpose of this memo is to ask those of you who have not responded to provide me a response with a copy to Charles Whalley, Taylor and Francis, at your earliest convenience. It is important that each of you respond, not just the corresponding or first author or each paper. Your individual responses are critical to our completing our investigation of this matter in a timely manner. If you have any questions please feel free to contact me. Thank you for your assistance.

If you are not able to respond by Friday, September 22, 2017, please acknowledge receipt of this memo and let me know when I can expect your response.

Attachment: Letter of April 15, 2017

Cc: Charles Whalley (tandf.co.uk)
Mildred Morgan (whargray.com)
Larry:

Thanks. Your message has been received. I appreciate your efforts.
Best wishes to your wife for a speedy recovery. Roger

On Friday, September 22, 2017 6:57 PM, Forrest Mann wrote:

Roger,

This email response to you has bounced twice when sent from my q.com (address unknown) so I'm forwarding from my other account.

Thanks.

Larry Kier

From: Larry Kier <Larry.Kier@q.com>
Sent: Saturday, September 23, 2017 1:47 PM
To: Roger McClellan
Subject: RE: Glyogisae Papers Published in CRT

Dear Dr. McClellan:

Thank you for your communication providing the opportunity to respond to concerns.
With respect to the specific question of authorship I fully concur with my fellow authors that the genotoxicity expert panel report was the product of the listed authors. Neither Monsanto employees nor attorneys were “ghost-writers.”

I was initially hired by Monsanto to serve as a consultant to support the Intertek genotoxicity expert panel. In this capacity I was in contact with Monsanto to facilitate providing the panel members with complete and accurate information, including supplemental information on regulatory genetic toxicology studies.

Subsequent to development of the genotoxicity export panel manuscript I agreed to be added as a co-author subject to the approval of the panel members.

Please note that my employment with Monsanto began in 1974 and not 1979.

Thanks.

Larry Kier

From: Roger McClellan [mailto:RogerMcClellan@att.net]
Sent: Friday, September 15, 2017 3:37 PM
To: gary_williams@acquajohn(i>gosha
Michele.Burns@acquajohn(i>gosha
acquajohn(i>gosha
role@acquajohn(i>gosha
gmarsh9116@acquajohn(i>gosha
helmut.greim@acquajohn(i>gosha
brusick41@acquajohn(i>gosha
T.M.Sorahan@acquajohn(i>gosha
ashley.roberts@acquajohn(i>gosha
douglaswedeking@acquajohn(i>gosha
Charles Whalley; RogerO.Mccclellan; Mildred B. Morgan
Cc: Charles Whalley; RogerO.Mccclellan; Mildred B. Morgan
Subject: Glyogisae Papers Published in CRT

Roger O. McClellan, DVM, MMS, DSc (Honorary)
Diplomate-ABT and ABVT
Fellow-ATS, SRA, AAAR, HPS, and AAAS
Member-National Academy of Medicine
Editor, Critical Reviews in Toxicology
Advisor, Toxicology and Human Health Risk Analysis

Albuquerque, NM
Tel: Cell: Fax:
E-mail: RogerMcClellan@att.net

September 15, 2017

Dear Dr Roberts, authors and co-authors of Review Papers:

This e-mail is being sent to you in view of your role in the preparation of five papers that were published on line in a Special Supplemental Issue of Critical Reviews in Toxicology entitled, "An Independent Review of the Carcinogenic Potential of Glyphosate," Volume 46, 2016. The five papers and an Introductory Article prepared by me as Editor of Critical Reviews in Toxicology are available electronically at http://tandfonline.com/toc/itxc20/46/sup1.

It was known by me and Taylor and Francis, the publisher of CRT, from the earliest communications on the supplemental issue that the review of glyphosate and preparation of the papers was sponsored financially by the Monsanto Company, a producer of glyphosate. It was fully anticipated that the specific role of Monsanto would be related in the Declaration of Interest for each article, and that the authorship attributed to each
article would reflect all contributions made. The need for a Declaration of Interest (DOI) is clearly spelled out in the Instructions for Authors at http://tandfonline.com/action/authorSubmission?journalCode=itxc20&page=instructions#Disclosure_statement. Moreover, I gave explicit instructions on multiple occasions on the need for each article to have an accurate, comprehensive and transparent DOI.

On submission, you confirmed that the authorship attributions, any declarations of funding and any DOIs were accurate and complete in the journal’s peer review system. On publication, you made warranties in the Author Publishing Agreements again confirming this, and that you had understood and complied with the journal’s ethical policies. You will understand that compliance with the journal and Taylor & Francis’ policies here, which are in line with COPE and ICMJE guidelines, is paramount for maintaining the integrity of our published research.

Recently, as part of legal proceedings in California both internal and external communications by Monsanto personnel have been made public. These communications have been reported upon in Bloomberg Businessweek and the New York Times as well as elsewhere. The documents released raise serious questions as to whether the warranties made for all articles in the supplement were accurate. Specifically, the documents suggest that employees of Monsanto were involved in the drafting of articles in the supplement without being acknowledged as authors, and that the relationship between some authors on the supplement and Monsanto was not fully described in the DOIs. Overall, the documents suggest that the warranties made and DOIs provided with these articles do not accurately reflect the extent of Monsanto’s involvement in their preparation.

This issue is sufficiently serious that Taylor and Francis, as the Publisher, with my assistance as Editor, have initiated an investigation. To assist in this investigation, at this stage I ask you to comment on the questions raised. Specifically, I would be grateful for your explanation as to the extent of any contributions to the drafting of articles in the supplement from authors not currently listed as authors and the accuracy of all Declarations of Interest. I ask that you respond by September 22nd.

I am CCing Charles Whalley, Managing Editor at Taylor & Francis, in this e-mail. I hope to receive a response from you soon.

Regards,

Roger O. McClellan
Editor, CRT
Dr. Ashley Roberts:

Attached are copies of the responses I have received from the authors and co-authors of the five papers published in the 2016 Special Issue containing five papers related to the evaluation of the carcinogenicity of glyphosate published in Critical Reviews in Toxicology. You will recall these papers were submitted in April, 2016, accepted July, 2016 and published online on September 28, 2016. I look forward to receiving your response to my earlier e-mails on this matter at the earliest possible date. Of all the authors and co-authors you are the only individual who has not responded.

Your response is needed to allow us (Taylor and Francis, the publisher of CRT and me) to complete our investigation of the manner in which the papers were prepared and, in particular, the accuracy and completeness of the Declarations of Interest published with these papers. It has been alleged that these DOIs are not accurate and complete and, specifically, that Monsanto personnel participated in the preparation of the paper. I would like you to specifically address the accuracy and completeness of the contents of paragraph 2 of the paper by Williams et al including the statement the Monsanto personnel did not review the paper prior to its submission to CRT. In responding it is important that you reconcile the apparent discrepancy between the contents of this DOI and widely reproduced copies of e-mail correspondence between you and Mr. Heyden of Monsanto relating to the papers published in CRT.

Again, it is our goal to complete the investigation at the earliest possible date. Please provide me your response by close of business on Monday, September 25th or provide me your best estimate of when I can expect to receive your response.

Thank you for your assistance on this important matter.

Roger O. McClellan, Editor
Critical Reviews in Toxicology

On Saturday, September 23, 2017 12:43 PM, Mildred Morgan <m.morgan@hargray.com> wrote:

Dear Charles and Dr. Roberts:

Dr. Roger McClellan asked me to send you the attached Summary of the Authors and Co-Authors responses to the 5 Glyphosate papers. More information will be sent later.

Mildred Morgan
Assistant to Roger McClellan
Tel: 
Fax: 
Email: m.morgan@hargray.com
Dear Roger,

We have responded, in very similar terms to how we have to similar queries. Let me know if you hear anything else.

All best wishes.
Charles

---

On Sunday, September 24, 2017 11:28 AM, "FOUCART, Stéphane" wrote:

Dear Mr McClellan,

I hope this message finds you well. The French daily Le Monde will publish in the coming days an article dealing w/ the internal Monsanto documents recently released. It appears that the articles published in 2016 were reviewed and edited by Monsanto employees prior to their submission to the journal. The acknowledgements published state, on the contrary, that "neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel’s manuscripts prior to submission to the journal."

Would you accept to answer a few questions ? If yes, please find below a few of them below : Were you aware of such a situation ? Were you in contact w/ Monsanto employees to prepare the publication of this special issue ? Will CRT publish an errata or an editorial to correct the statements of the journal regarding this special issue ?

Many thanks for your time & help,
Best regards,

Stéphane Foucart

---

Stéphane Foucart
Le Monde
service Planète/Science - Environment/Science desk
80 boulevard Auguste Blanqui
Roger McClellan

From: Roger McClellan <rjor@att.net>
Sent: Tuesday, September 27, 2016 9:57 AM
To: hank@*
Cc: Ashley Roberts; Charles.Whalley@
Subject: Re: Articles for our next Priorities magazine/Glyphosate

Hank:
Thank you for the invitation. I will give the matter some thought. I will be in contact if I come up with a topic (and some time to prepare an article). In the meantime, I am forwarding your e-mail to Dr Ashley Roberts of Intertek. He has coordinated an independent review of the carcinogenic potential of Glyphosate which will be reported in five papers in a Special Issue of Critical Reviews in Toxicology, published by Taylor and Francis. That Special Issue should be posted online with open access in the next few days. As soon as it is posted you will want to note it in one of your regular media releases. In addition, the topic might be an excellent one for Priorities. As an aside, I prepared a brief forward to the Special Issue. In it I note the five papers were peer reviewed by a total of 27 experts in the field.
I will send you a link to the Special issue as soon as it is posted on-line. Please feel free to contact Dr Roberts.
Best regards,
Roger

On Mon, 9/26/16, Hank Campbell <hank@...> wrote:

Subject: Articles for our next Priorities magazine
To: roger.o.mcclellan@
Date: Monday, September 26, 2016, 12:54 PM
Please help us make the public smarter about science and health.
Or at least ask awkward questions about junk science or scaremongering groups.
We're looking for articles for our next issue of Priorities magazine.

Our Priorities magazine has been a huge success and we have you to thank for it. We send them out to you, our advisory board, along with every donor, media representatives, and anyone who requests one, all free of charge.

We're looking for expert insight on just about any topic related to science and health for October, so if you have an idea and can put fingers to keys, please do so. We can help with editing and graphics, we just need smart people who want to educate the public.

Interested? Please let me know!
Dear Roger:

In response to your enquiries, I can confirm that Monsanto did not participate in the preparation of the 4 critical subject evaluations. The summary paper required clarification on the history and regulatory processes for glyphosate and I shared that summary with Dr. Heydens to ensure the accuracy of this information once the underlying evaluations had been finalized. Dr. Heydens' comments on the summary had no impact on the viewpoints/interpretation or the independent conclusions that had already been reached and set out by the 4 expert panel groups in their evaluations. As such, Monsanto was not involved in the drafting of any of the evaluations and did not have any input into the evaluations or conclusions regarding the safety of glyphosate that was provided to the journal.

Ashley

Ashley Roberts, Ph.D.
Subject: Re: CONFIDENTIAL - Summary of Authors/Co-Authors Responses

Ashley:
Thanks for the note. It would be helpful if in your response you are able to indicate your response was not reviewed with Monsanto personnel, if that will be a true statement.
I look forward to receiving your response.
Roger

On Tuesday, September 26, 2017 3:12 PM, Ashley Roberts Intertek <a1@att.net> wrote:

Dear Roger,

I do apologise for my delay in responding due to unforeseen circumstances and I will have something to you definitely tomorrow.

Best Wishes
Ashley.

Ashley Roberts, Ph.D.
Senior Vice President - Food & Nutrition
Health, Environmental & Regulatory Services (HERS)

Direct +1
Office +1
Skype www.intertek.com

Intertek
Total Quality Assured.

Intertek, 2233 Argentia Rd., Suite 201, Mississauga, ON L5N 2X7

WE ARE EXHIBITING AT:
SUPPLYSIDE WEST

September 27-28, 2017 | Mandalay Bay, Las Vegas

From: Ashley Roberts Intertek
Sent: September-25-17 7:49 PM
To: Roger McClellan <r@att.net>
Cc: Charles Whalley <t@lande.co.uk>; Mildred B. Morgan <m@hargray.com>
Subject: RE: CONFIDENTIAL - Summary of Authors/Co-Authors Responses

Dear Roger,
I will be able to respond tomorrow morning.

Best Wishes

Ashley

From: Roger McClellan [mailto:Roger.McClellan@taylorandfrancis.com]
Sent: September-24-17 7:17 PM
To: Ashley Roberts
Cc: Charles Whalley; Mildred B. Morgan; Roger McClellan
Subject: Fw: CONFIDENTIAL - Summary of Authors/Co-Authors Responses

Dr. Ashley Roberts:

Attached are copies of the responses I have received from the authors and co-authors of the five papers published in the 2016 Special Issue containing five papers related to the evaluation of the carcinogenicity of glyphosate published in Critical Reviews in Toxicology. You will recall these papers were submitted in April, 2016, accepted July, 2016 and published online on September 28, 2016. I look forward to receiving your response to my earlier e-mails on this matter at the earliest possible date. Of all the authors and co-authors you are the only individual who has not responded.

Your response is needed to allow us (Taylor and Francis, the publisher of CRT and me) to complete our investigation of the manner in which the papers were prepared and, in particular, the accuracy and completeness of the Declarations of Interest published with these papers. It has been alleged that these DOIs are not accurate and complete and, specifically, that Monsanto personnel participated in the preparation of the paper. I would like you to specifically address the accuracy and completeness of the contents of paragraph 2 of the paper by Williams et al including the statement the Monsanto personnel did not review the paper prior to its submission to CRT. In responding it is important that you reconcile the apparent discrepancy between the contents of this DOI and widely reproduced copies of e-mail correspondence between you and Mr. Heyden of Monsanto relating to the papers published in CRT.

Again, it is our goal to complete the investigation at the earliest possible date. Please provide me your response by close of business on Monday, September 25th or provide me your best estimate of when I can expect to receive your response.

Thank you for your assistance on this important matter.

Roger O. McClellan, Editor
Critical Reviews in Toxicology

On Saturday, September 23, 2017 12:43 PM, Mildred Morgan <hargray.com> wrote:

Dear Charles and Dr. Roberts:

Dr. Roger McClellan asked me to send you the attached Summary of the Authors and Co-Authors responses to the 5 Glyphosate papers. More information will be sent later.

Mildred Morgan
Assistant to Roger McClellan
Tel: [redacted]
Fax: [redacted]
Charles:
Are you available for a call on Wednesday? Note that the DOI indicate to papers were not reviewed by Monsanto PRIOR to submission. This leads to a question as to when Monsanto personnel were involved. Let’s discuss. Best regards, Roger

On Monday, October 2, 2017 1:28 PM. "Whalley, Charles" <tandf.co.uk> wrote:

Dear Roger and Mildred,

I hope this finds you both well today.

I owe you an update. Many thanks to you both for compiling the author responses for me. I note that Ashley Roberts acknowledges that Monsanto employees were involved in revising the summary article. Based on their responses, I will review with legal counsel. We anticipate considerable scrutiny on our next steps here.

I will let you know if we have any other questions or concerns for now.

Very best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: 
Switchboard: 
charles.whalley@tandf.co.uk
www.tandf.co.uk

Taylor & Francis is a trading name of Informa UK Limited, registered in England under no. 1072954
Dear Gary, fine with me. Tom Sorahan

On 5 Oct 2018 15:33, "Williams, Gary" wrote:

Dear Colleagues,

Attached is the proposed final draft of the corrigendum for the summary paper.

I hope to submit this on Monday, Oct 8. Therefore, please send any essential corrections before noon Monday.

Thanks, Gary
Dear Roger,

The Monsanto correspondence is still available at the following address:
http://baumhedlundlaw.com/pdf/monsanto-documents/. It appears to show Bill Heydens at Monsanto discussing edits to manuscripts in January 2016, prior to submission to CRT.

The review from legal counsel is primarily limited to the contractual basis of the articles and the supplement, and our redress in situations of ethical misconduct. They have also advised on the extent to which we can rely upon the leaked correspondence in our investigation. They have not reviewed the content of the correspondence, or how it relates to the scientific contents of the supplement. That remains an Editorial responsibility, that thus far I have been doing with the help of my colleagues in Oxford.

We're not expecting you to perform any additional analysis of the scientific content just yet. I only asked you to summarise your thoughts when we spoke on the phone because your interpretation, as you related on the phone, would be useful for us. It is by no means essential at this point, so don't feel the need to take a lot of time over it. I asked in case you felt you could type up your thoughts quickly; if not, no matter.

I hope this clarifies. As ever, I appreciate your support and patience here.

All best wishes.
Charles

Charles:
The August 21, 2017 letter from Guyton at IARC that I forwarded to you contained electronic references to Monsanto communications concerning the glyphosate papers. Unfortunately, I did not retain copies and I am no longer able to access and download them. I assume the legal counsel at Tand F downloaded and reviewed them. If you can forward copies of the material to me to me.

I am especially interested in the dates of the various communications so they can be compared to the dates the papers were returned to the authors for revision and when I received the revised papers. I am also interested in learning if anyone at Tand F has done any analysis of the changes made in the five papers between original submission and the final revised papers to determine if any material changes were made in the scientific content. Most importantly, are any of these changes related to comments from Monsanto to Intertek.

If these kinds of analyses have been done by Tand F legal personnel then there is no need for me to repeat what they have already done. It will be helpful for me to know what kind of review, if any has been done by T and F legal counsel, so I can best determine how to use my limited time. Perhaps, they are expecting me to do all the analyses of scientific content. If so, I will need to make time in my schedule.
In short, we need to make certain our efforts are well-coordinated and our resources are used effectively. I hope this memo does not sound intemperate. However, I just realized I have had no feedback on these important matters from T and F legal counsel.
Best regards, Roger.
The purpose of this memo is to thank you for your prompt response to the McClellan e-mail query of September 15, 2017 and to ask for further clarifying information. As noted in the September 15th memo, the Special Supplement to Critical Reviews in Toxicology entitled – “An Independent Review of the Carcinogenic Potential of Glyphosate,” Vol. 46, S1, 2016, has attracted considerable attention. Indeed, the summary paper on which all of you are co-authors has been viewed on-line open access over 9000 times. There has also been substantial interest from the media. This interest has been stimulated in part by the public availability of some 70 documents released by Monsanto in the course of discovery related to litigation in California on alleged health effects related to exposure to glyphosate. Those documents can be accessed at – http://bsumberdlundlaw.com/pdf/monsanto-documents/. As you will note, some of those documents relate to the papers published in the special issue. It is noteworthy that the publicly available documents reveal communications in January 2016 between Ashley Roberts of Intertek and Monsanto personnel concerning the papers in the special supplement.
The communication with Monsanto personnel directly contradicts the Declaration of Interest statement in the Williams et al paper in which you are all co-authors. The DOI states – “Neither any Monsanto company employees nor any attorneys reviewed any of the Panel’s manuscripts prior to submission to the journal.” The Williams et al paper on which you are all co-authors was submitted April 8, 2016, revised June 20, 2016, accepted July 15, 2016 and published online open access on September 28, 2016.

A formal complaint letter from Kathryn Guyton, International Agency for Research on Cancer, was received on August 15, 2017 and subsequently posted online on the IARC web site. A copy of the letter is attached. This letter and other considerations prompted the investigation of charges concerning the preparation of the five papers published in the special supplement. The two of us have the lead responsibility for conducting the investigation. In broad terms, the investigation focuses on whether the preparation and submission of the five papers conformed with current scientific publishing canons, the guidelines published by Taylor and Francis for Critical Reviews in Toxicology and my guidance to Ashley Roberts and the corresponding authors. A specific charge relates to the involvement of Monsanto Company personnel in the preparation and editing of the paper and whether any such involvement is accurately and fully disclosed in the Acknowledgments and Declaration of Interest sections of each of the five papers.

Your individual responses to the email of September 15, 2017 from McClellan have been very helpful in our conduct of the investigation. However, your collective responses still leave several issues unresolved.
As I am sure you appreciate, the charges leveled are very serious. The information we have already received is sufficient that it is apparent that the Declarations of Interest on one or more papers is not accurate and fully complete. Thus, we are turning to you for additional input.

We are asking for the following input: (1) we ask that the corresponding authors of each paper provide a revised Declaration of Interest for the paper unless they and all the co-authors are of the opinion that the published version is accurate and complete; (2) we also ask that the Acknowledgments section of each paper be reviewed and revised as necessary. In particular, the Acknowledgments section should identify any individuals, including colleagues, who may have assisted in assembling material, reviewing drafts or otherwise assisted in preparing each paper; (3) we are also asking each corresponding author and Ashley Roberts to provide a chronological accounting of any communications (letters, e-mails or telephone calls) by them or their co-authors with Monsanto Company personnel concerning the contents of the papers. If such communications did not occur, a statement to that effect will suffice; (4) we are also asking the corresponding author for each final published paper to identify any statements (i.e., phrases, sentences, etc.) that were contributed by Monsanto personnel or others in response to input from Monsanto personnel. This should specifically include changes that involved text written by John Acquavella and commented on by Monsanto personnel. If Monsanto offered no comments on a specific paper, a statement to that effect will suffice; and (5) if you have other information you think will be helpful to us as we proceed with our investigation we will be pleased to receive it.

We are optimistic that the information you provide will allow us to reach a decision to either (a) retract the papers en bloc because of undisclosed involvement and influence of Monsanto personnel prior to when the papers were submitted after submission (not sure where you wanted these two words to go), or (b) Taylor and Francis to publish revised
Acknowledgments and Declarations of Interest for each paper if the published
Acknowledgments and Declaration of Interest were not accurate and complete.

Thank you for your assistance.

Attachment: Kathryn Guyton Letter
Gary,

I have no further comments.

Thank you.

David H. Garabrant, MD, MPH
Ann Arbor, MI
e-mail: [[[email redacted]]]
phone: [[[phone number redacted]]]
www.epidstat.com

On October 5, 2018 at 9:32 AM "Williams, Gary" <[[email redacted]]> wrote:

Dear Colleagues,

Attached is the proposed final draft of the corrigendum for the summary paper.

I hope to submit this on Monday, Oct 8. Therefore, please send any essential corrections before noon Monday.

Thanks, Gary
Gary,
fine with me as well.
Best
Helmut

Am 05.10.2018 19:23, schrieb Marilyn Aardema:
> Ok with me
> Marilyn
> Marilyn Aardema Consulting
> On Oct 5, 2018, at 1:16 PM, David Kirkland
> Marilyn Aardema Consulting wrote:
> >> Gary,
> >> Also OK with me.
> >> David Kirkland.
> >> FROM: Larry Kier <dkirkland@gmail.com>
> >> SENT: 05 October 2018 16:38
> >> TO: Williams Gary <gmganetoxconsulting.co.uk>
> >> CC: ksolomon@nymc.edu; Roberts Intertek Ashley
> >> Acquavella John <john.aquavella@gmail.com>; colin@ac.l.com;
> >> Brusick David <jbrusick@bham.ac.uk>; \[email]@gmail.com;\[email]@bham.ac.uk>
> >> Garabrant David <dgarabrant@comcast.net>; jdecam@lrz.tum.de; Larry Kier
> >> Tom Sorahan <tomas@bham.ac.uk>; douglas weed
> >> SUBJECT: Re: Summary corrigendum.
> >> Gary,
> >> OK with me and thanks very much for your good and patient work with
> >> this.
On Fri. Oct 5, 2018 at 8:35 AM Williams, Gary wrote:

Dear Colleagues,

Attached is the proposed final draft of the corrigendum for the summary paper.

I hope to submit this on Monday, Oct 8. Therefore, please send any essential corrections before noon Monday.

Thanks, Gary

__________ESET NOD32 Antivirus__________

This email was scanned, no threats were found.

Detection engine version: 18166 (20181005)

http://www.eset.com
Gary,
fine with me as well.
Best
Helmut

Am 05.10.2018 19:23, schrieb Marilyn Aardema:
> Ok with me
>
> Marilyn
> Marilyn Aardema Consulting
>
> On Oct 5, 2018, at 1:16 PM, David Kirkland
> <^J^^^@genetoxconsulting.co.uk> wrote:
> 
> >> Gary,
> >>
> >> Also OK with me.
> >>
> >> David Kirkland.
> >>
> >> FROM: Larry Kier <^^^^^@gmail.com>
> >> SENT: 05 October 2018 15:38
> >> TO: Williams Gary <^^^^^@nycmc.edu>
> >> CC: ksolomon@intertek.com; Aardema Marilyn<^^^^^@me.com>; 
> >> Acquavella John <^^^^^@gmail.com>; colin@intertek.com; 
> >> Brusick David <^^^^^@aol.com>; 
> >> Michele.Burns@intertek.com, jdcom@intertek.com; David 
> >> Garabrant<^^^^^@comcast.net>; helmut.greim@lrz.tu-muenchen.de; Larry Kier 
> >> <^^^^^@q.com>; root@lrz.tu-muenchen.de; gmarsh911@google.com; 
> >> Tom Sorahan<^^^^^@bham.ac.uk>; douglas weed 
> >> <^^^^^@aol.com>; McClellan Roger <^^^^^@att.net>
> >> SUBJECT: Re: Summary corrigendum.
> >>
> >> Gary,
> >>
> >> OK with me and thanks very much for your good and patient work with 
> >> this.
Dear Colleagues,

Attached is the proposed final draft of the corrigendum for the summary paper.

I hope to submit this on Monday, Oct 8. Therefore, please send any essential corrections before noon Monday.

Thanks, Gary

This email was scanned, no threats were found.

Detection engine version: 18166 (20181005)

http://www.eset.com
Charles:
Please acknowledge receipt.

Roger

On Sunday, October 8, 2017 4:55 PM, Roger McClellan wrote:

Charles:
Attached is a proposed memo from you and to the 16 authors of the papers in the special glyphosate supplement. As I note in my summary status report memo to you I think we need to acquire additional information from the authors, including revised Acknowledgements and Declaration of Interest sections, at least for several of the papers, to conclude our investigation of the possible influence of Monsanto personnel on the contents of the papers.

I think the memo needs to go to all the authors since they all share some responsibility for the contents of the papers. I think it is critical that we obtain a better understanding of when Roberts, and possibly Williams, communicated with Heyden at Monsanto. We also need increased clarity on when Acquavela communicated with Monsanto on key changes in the epidemiology paper that have been widely cited. We also need increased clarity on when Acquavela and Kier received compensation directly from Monsanto as employees or consultants.

I also think it is very desirable to compare the final revised papers as published with the original submissions. Taking this step will hopefully allow us to conclude that no material changes were made in the papers between the time they were originally submitted and accepted for publication. This extra step of due diligence will strengthen our final decision, assuming it our final decision, that the critical scientific contents, interpretations and conclusions were those of the authors without influence from Monsanto personnel.

We also need to begin discussions as to how the results of our investigation will be communicated to the public and the scientific and publishing communities. A related issue is the extent to which the results of this investigation suggest changes in T and F and CRT policies and procedures.

Best regards, Roger
Roger McClellan

From: Whalley, Charles - [REDACTED]@tandf.co.uk
Sent: Monday, October 30, 2017 3:07 PM
To: Roger McClellan
Cc: Mildred B. Morgan
Subject: Re: Contact_ Resolution of Glyphosate Issue Issues

Dear Roger,

Apologies for going silent, as I've been in travelling and in meetings.

I'm afraid there is no further progress on the supplement. The consultation between editorial and legal colleagues has become quite extensive, as the company is being particularly careful over the implications. I can't advise any move until this is resolved.

I'll be in the office tomorrow and Wednesday if you'd like to speak.

Best wishes,
Charles

From: Roger McClellan <[REDACTED]@att.net>
Sent: 27 October 2017 04:01:50
To: Whalley, Charles
Cc: Mildred B. Morgan; Roger McClellan
Subject: Contact_ Resolution of Glyphosate Issue Issues

Charles:
It has been some time since we spoke about the path forward on resolution of the issues around the special Glyphosate Issue. Are you available for a call on Friday, October 27? If so what number will be best for me to call? Best regards,
Roger
Roger McClellan

From: Roger McClellan <Roger.McClellan@att.net>
Sent: Tuesday, October 31, 2017 5:40 AM
To: Charles Whalley
Cc: Mildred B. Morgan; Roger McClellan
Subject: Fw: Glyqogisae Papers Published in CRT

FYI

On Tuesday, October 31, 2017 6:20 AM, Thomas Sorahan <thomas.sorahan@bham.ac.uk> wrote:

Dear Roger

I need to add to my earlier statement to you. It has been brought to my attention that I did in fact receive an email from John Acquavella months before submission indicating that some very minor comments had been received from Monsanto staff about the epidemiology draft paper. If corrections are to be made to the DOI’s then this should be noted, I think. I will bring this to the attention of Gary Williams and Ashley Roberts, with a copy of this email.

Tom Sorahan

From: Thomas Sorahan
Sent: Saturday, September 16, 2017 10:47 AM
To: Roger McClellan
Cc: Charles Whalley; root@vax1; lkierc@vax1; ashley.roberts@bham.ac.uk; ...
Subject: Re: Glyqogisae Papers Published in CRT

Dear Roger,

I had no communications with Monsanto staff about the content of the reviews. Tom Sorahan

On 15 Sep 2017 10:36 pm, Roger.O.McClellan@att.net wrote:

September 15, 2017

Dear Dr Roberts, authors and co-authors of Review Papers:

This e-mail is being sent to you in view of your role in the preparation of five papers that were published online in a Special Supplemental Issue of Critical Reviews in Toxicology entitled, “An Independent Review of
the Carcinogenic Potential of Glyphosate," Volume 46, 2016. The five papers and an Introductory Article prepared by me as Editor of Critical Reviews in Toxicology are available electronically at http://tandfonline.com/toct/critx20/46_sup1.

It was known by me and Taylor and Francis, the publisher of CRT, from the earliest communications on the supplemental issue that the review of glyphosate and preparation of the papers was sponsored financially by the Monsanto Company, a producer of glyphosate. It was fully anticipated that the specific role of Monsanto would be related in the Declaration of Interest for each article, and that the authorship attributed to each article would reflect all contributions made. The need for a Declaration of Interest (DOI) is clearly spelled out in the Instructions for Authors at http://tandfonline.com/action/authorSubmission?journalCode=txc20&page=instructions=Disclosure_statement . Moreover, I gave explicit instructions on multiple occasions on the need for each article to have an accurate, comprehensive and transparent DOI.

On submission, you confirmed that the authorship attributions, any declarations of funding and any DOIs were accurate and complete in the journal’s peer review system. On publication, you made warranties in the Author Publishing Agreements again confirming this, and that you had understood and complied with the journal’s ethical policies. You will understand that compliance with the journal and Taylor & Francis’ policies here, which are in line with COPE and ICMJE guidelines, is paramount for maintaining the integrity of our published research.

Recently, as part of legal proceedings in California both internal and external communications by Monsanto personnel have been made public. These communications have been reported upon in Bloomberg Businessweek and the New York Times as well as elsewhere. The documents released raise serious questions as to whether the warranties made for all articles in the supplement were accurate. Specifically, the documents suggest that employees of Monsanto were involved in the drafting of articles in the supplement without being acknowledged as authors, and that the relationship between some authors on the supplement and Monsanto was not fully described in the DOIs. Overall, the documents suggest that the warranties made and DOIs provided with these articles do not accurately reflect the extent of Monsanto’s involvement in their preparation.

This issue is sufficiently serious that Taylor and Francis, as the Publisher, with my assistance as Editor, have initiated an investigation. To assist in this investigation, at this stage I ask you to comment on the questions raised. Specifically, I would be grateful for your explanation as to the extent of any contributions to the drafting of articles in the supplement from authors not currently listed as authors and the accuracy of all Declarations of Interest. I ask that you respond by September 22nd.

I am CCing Charles Whalley, Managing Editor at Taylor & Francis, in this e-mail. I hope to receive a response from you soon.

Regards,

Roger O. McClellan
Editor, CRT
Charles:
I look forward to speaking to you on Friday.
Best regards, Roger

On Wednesday, November 1, 2017 4:41 AM, "Whalley, Charles" <whalley@tandf.co.uk> wrote:

Dear Roger,

I hope your meetings in Washington went well.

As we discussed, I will be in my home office in Leeds this Friday but happy to talk to you. I trust 9:30am Albuquerque (3:30pm London) suits you. Please can you connect to the call using the details below?

CRT Editorial Call, Fri 3rd Nov
Fri, Nov 3, 2017 3:30 PM - 4:30 PM GMT
Please join my meeting from your computer, tablet or smartphone.
https://global.gotomeeting.com/join/781743581
You can also dial in using your phone.
United States (Toll Free): __________
Access Code: __________
More phone numbers
United Kingdom (Toll Free): 0 800 169 0432
First GoToMeeting? Let's do a quick system check: https://link.gotomeeting.com/system-check

Best wishes,
Charles
Charles:

Thank you for your communications on the Glyphosate Supplement. I now have a better understanding of the role of legal counsel, you and me in this matter.

Attached is the summary status memo you and I discussed. A second e-mail will contain a proposed memo from you and I to the authors of the papers in the Glyphosate Supplement. When will you be available to discuss these memos?

Best regards,
Roger
Dear Roger,

Thanks for this. I forget if I mentioned already, but you may be interested to learn that our Publishing Director, Deborah Kahn, - who has been involved in discussions around the supplement - sits on COPE Council. As we’ve discussed, I understand your frustration with the time this is taking. The consultation here involves senior colleagues across the company, which doesn’t lend itself to rapid decision-making. If you have any specific concerns or questions you’d like me to take to legal counsel, I’d be happy to do so.

Best wishes,
Charles

---

From: Roger McClellan
Sent: 23 November 2017 18:30
To: Whalley, Charles
Cc: Mildred B. Morgan; Roger McClellan
Subject: Fw: COPE Core Practices |Code of Conduct

Charles:

Please verify that you have shared the attached material and linkage with the T and F attorneys and other parties involved in resolving the issues around the Special Glyphosate Issue published in Critical Reviews in Toxicology. One of the linkages of interest is on "Retractions: Guidance from the Committee on Publication Ethics (COPE)".

I am eager to resume our discussion of the handling of the issues surrounding the Special Glyphosate Issue. Quite frankly, I am disappointed that I have not been involved in ANY discussions with the legal personnel. In my opinion, any decision on how to proceed with the handling of this matter should involve you as the Managing Editor, myself as the Scientific Editor, and legal counsel. In my opinion, this is clearly not just a legal matter. Their counsel is certainly crucial, however, in my opinion, their role is that of providing counsel not dictating a specific course of action.

I will be sending you an additional e-mail on this matter. I do wish to emphasize that I am concerned that this matter has not been resolved in a more timely manner. In my opinion, I have acted appropriately in interacting with the Authors of the papers in the special issue and provide those responses in a timely manner to you. If there is additional information the legal personnel have obtained that is relevant to resolution of the matter I would appreciate receiving copies of the material.

Thank you for your assistance. Best regards.
Roger

On Friday, November 17, 2017 5:07 AM, COPE <cope_administrator@publicationethics.org> wrote:
COPE Core Practices

Background
A Code of Conduct for Editors has been in place at COPE since 2004, its purpose to provide guidance on current thinking in the practice of publication ethics. Subsequent editions and versions have evolved since their first introduction. Though they have been immensely valuable in guiding how COPE works and supporting how editors, journals and publishers function, they have also been criticised as being overly specific in some areas and not specific enough in others.

What are the Core Practices?
Firstly, COPE has radically simplified the description of its expectations for everyone involved in publishing the scholarly literature, with a particular focus on editors and their journals, publishers, and also institutions.

Secondly, the expectations laid out in the core practices are a framework. Each core practice has links to the detailed documents and resources COPE has already published on its website. These documents and resources will continue to build into a comprehensive and, most importantly, continually revised library. Within COPE's core practices is a suite of documents including over 500 cases, 20 flowcharts (in multiple languages), 11 guidance documents, and much more.
The ten core practices are:

1. Allegations of misconduct
2. Authorship and contributorship
3. Complaints and appeals
4. Conflicts of interest / Competing interests
5. Data and reproducibility
6. Ethical oversight
7. Intellectual property
8. Journal management
9. Peer review processes
10. Post-publication discussions and corrections

Download a pdf poster of the core practices

Why did we do this?
The phrase “Code of Conduct” has been misinterpreted as being quasi legal. COPE is a membership organisation with no statutory or regulatory powers. COPE’s remit is to support and advise editors of scholarly journals and publishers/owners.

The core practices include the core tenets of the Code of Conduct, but have been simplified and better reflect current practice. Additionally, the new framework will make it easier for members and the wider community to find COPE’s continuously updated resources as new issues arise.

The COPE website contains a wealth of information and resources but user feedback tells us that it is difficult to find guidance or advice related to a specific issue. The core practices now groups all resources, including cases, flowcharts, guidelines, presentations, news and events under each topic making those connections automatically.

The Core Practices are relevant to (and expected of) all bodies: Editors, Journals, Publishers, Institutions, etc. (unless otherwise noted) which means just one document and linked resources being maintained to avoid confusion about what applies to whom. Our hope is that COPE is also helpful to the broader academic and publishing community.

How should you implement the Core Practices in your policies and procedures?
• Take each core practice individually and think about what that practice means for your discipline or organisation and how best to achieve it
• Use the COPE resources to understand how best to create a policy and practice that sets a good standard for your discipline or organisation
• Add to your policy documents and put into practice, for example, in your journal guidelines, editorial office software and contracts

The ten core practices will remain the same, but the way we describe them will change over time. For example, data publishing is evolving rapidly and it’s certain to be reflected in our guidance.

What we expect from our members
COPE still expects that high standards are met by our members and the communities we serve. Therefore, in parallel with the launch of the core practices, we have also made changes to our Complaints subcommittee, now renamed the Facilitation and Integrity subcommittee (more details here).

The changes clarify that COPE’s role is to facilitate between a complainant and a COPE member where a concern or issue has been raised. However, crucially, the changes in remit of the subcommittee also enable COPE to reach out to our members in cases where they may need guidance which has not been raised to COPE’s attention, either as a complaint or a Forum case. Furthermore, we have implemented a formal sanctions policy which clarifies the expectations we have of our members and allows COPE to further support the ethical standards of those members.

Best regards
COPE Officers and Executive Officer, 16 November 2017
Dear Roger and Mildred,

I can confirm that this has been received. This is indeed useful. I have already shared it with my colleagues. I'll get back to you on this matter soon.

Thanks and best wishes,
Charles

---

From: Roger McClellan [mailto:Roger.McClellan@att.net]
Sent: 28 November 2017 04:48
To: Whalley, Charles <Charles.Whalley@tandf.co.uk>
Cc: Mildred B. Morgan <Mildred.B.Morgan@hargray.com>, Roger McClellan
Subject: Re: Follow-up on Actions Related to Glyphosate Papers

Charles:

Please acknowledge receipt of the material sent by Mildred Morgan. Please let me know when we can discuss the material including my proposed e-mail to the authors of the papers. I feel strongly we have been remiss in not informing the authors of the e-mail letter from Nathan Donley. In my opinion, I as the Scientific Editor of CRT and T and F as the publisher of CRT have an ethical responsibility to the authors to inform them of the serious charges level against them. If you and/or others at T and F have a different view of this issue I would appreciate being informed of it and the rationale for the alternative opinion.

I do hope my updated assessment is useful to you and your colleagues and provides a basis for moving forward in an expeditious manner.

Thanks again for your assistance in resolving this very complex matter.
Roger

---

On Monday, November 27, 2017 4:36 PM, Mildred Morgan <Mildred.B.Morgan@hargray.com> wrote:

Dear Charles:

Attached is a memo from Dr. McClellan related to following up on actions related to investigation of issues related to publication of the five papers on the Carcinogenic Potential of Glyphosate.
Roger McClellan

From: Roger McClellan <persona1@att.net>
Sent: Tuesday, November 28, 2017 11:05 AM
To: Whalley, Charles
Cc: Mildred B. Morgan; Roger McClellan
Subject: Re: COPE Core Practices | Code of Conduct

Charles:

I am uncertain as to the extent the EU discussions on renewal of the registration of Glyphosate was influencing T and F lack of action, however, I note the EU on November 27th approved renewal of the registration of Glyphosate for another 5 years. I do hope we can stay focused on what needs to be done with regard to the papers in the special issue of CRT and avoid being excessively concerned about the implications of our actions. The issues around use of Glyphosate and its use with GMO crop seeds most assuredly will continue for decades. I note that France is "threatening" to go it alone and move to ban Glyphosate use. I did note with interest the NGOs that were lobbying for cancelation of the registration of Glyphosate. I urge that we work together to decide on our criterion for examining the issues at play in the case of the papers in the special Glyphosate issue of CRT, assemble the relevant information, proceed to make a decision, take the appropriate action and then move on.

We are fortunate that CRT publishes review papers on scientific issues that are of concern to Society at Large. In that regard, have we ever had a paper published in CRT, or in any T and F journal that has been accessed over 10,500 times in the first year after posting on line as has been the case for the summary Glyphosate review paper. That is about 30 times a day, rather remarkable.

Best regards,
Roger

On Monday, November 27, 2017 1:38 AM, "Whalley, Charles"<persona2@tandf.co.uk> wrote:

Dear Roger,

I understand entirely. The added dimensions of media interest and legal ramifications, which have implications for the business beyond just CRT, have necessitated the input of these additional cooks. I look forward to your status report and will take this forward to my colleagues to ensure they understand your position.

All best wishes,
Charles

From: Roger McClellan [mailto:persona1@att.net]
Sent: 25 November 2017 19:14
To: Whalley, Charles <persona2@tandf.co.uk>
Cc: Mildred B. Morgan <persona3@hargray.com>; Roger McClellan <persona1@att.net>
Subject: Re: COPE Core Practices | Code of Conduct

Special Issue -- Frustration with lack of feedback and progress in achieving resolution

Charles:
You are correct in your assessment — I am very frustrated by the continued delays in resolving the issues surrounding the Special Glyphosate Issue.

In my opinion, there are an "excess number of cooks in the kitchen". A part of my frustration is I do not know who these individuals are and their areas of responsibility. In particular, I am concerned that some of these individuals do not understand my central role, in accord with the COPE Guidance, as the Scientific Editor of Critical Reviews in Toxicology in resolution of this matter. I take the failure to respond to my earlier suggested approach to acquiring critical information that could lead to resolution of the matter to be one of "placing road blocks in the way of my exercising my responsibilities as the Scientific Editor of CRT".

I did note the role of Debra Kahn in COPE and was pleased that you have affirmed her role. Perhaps, it would be useful if I could speak to her and you about the matter and how we can best move forward.

In the meantime, I am preparing a "status report" memo to you that details my understanding of where the matter stands and my proposed approach to resolving this matter. As you know, my reputation as a scientist and Scientific Editor is potentially impacted by how this matter is handled. I also understand that the reputation of the journal, CRT, and of T and F is potentially impacted. As I will also note in the memo I am drafting, the reputations of the 16 scientists who are authors of the five papers are also potentially impacted and any actions by me and T and F needs to take that aspect of the matter into consideration.

I am frustrated in part because, other than you, I do not know the other participants in this drama with regard to their expertise and responsibilities and their concerns or viewpoints. The lack of any feedback on my previous communications, which I prepared with considerable thought, is extremely frustrating.

I look forward to our conversations next week on this matter.

With best regards,
Roger

Dear Roger,

Thanks for this. I forget if I mentioned already, but you may be interested to learn that our Publishing Director, Deborah Kahn, - who has been involved in discussions around the supplement - sits on COPE Council. As we've discussed, I understand your frustration with the time this is taking. The consultation here involves senior colleagues across the company, which doesn't lend itself to rapid decision-making. If you have any specific concerns or questions you'd like me to take to legal counsel, I'd be happy to do so.

Best wishes.
Charles

From: Roger McClellan [mailto:Roger.McClellan@tanef.co.uk]
Sent: 23 November 2017 18:30
To: Whalley, Charles <Charles.Whalley@tanef.co.uk>
Cc: Mildred B. Morgan <margray.com>; Roger McClellan <Roger.McClellan@tanef.co.uk>
Subject: Fw: COPE Core Practices Code of Conduct

Charles:
Please verify that you have shared the attached material and linkage with the T and F attorneys and other parties involved in resolving the issues around the Special Glyphosate Issue published in Critical Reviews in

527

RM 000551
Toxicology. One of the linkages of interest is on "Retractions: Guidance from the Committee on Publication Ethics (COPE)"

I am eager to resume our discussion of the handling of the issues surrounding the Special Glyphosate Issue. Quite frankly, I am disappointed that I have not been involved in ANY discussions with the legal personnel. In my opinion, any decision on how to proceed with the handling of this matter should involve you as the Managing Editor, myself as the Scientific Editor, and legal counsel. In my opinion, this is clearly not just a legal matter. Their counsel is certainly crucial, however, in my opinion, their role is that of providing counsel not dictating a specific course of action.

I will be sending you an additional e-mail on this matter. I do wish to emphasize that I am concerned that this matter has not been resolved in a more timely manner. In my opinion, I have acted appropriately in interacting with the Authors of the papers in the special issue and provide those responses in a timely manner to you. If there is additional information the legal personnel have obtained that is relevant to resolution of the matter I would appreciate receiving copies of the material.

Thank you for your assistance. Best regards.
Roger

On Friday, November 17, 2017 5:07 AM, COPE wrote:
supporting how editors, journals and publishers function, they have also been criticised as being overly specific in some areas and not specific enough in others.

What are the Core Practices?
Firstly, COPE has radically simplified the description of its expectations for everyone involved in publishing the scholarly literature, with a particular focus on editors and their journals, publishers, and also institutions.

Secondly, the expectations laid out in the core practices are a framework. Each core practice has links to the detailed documents and resources COPE has already published on its website. These documents and resources will continue to build into a comprehensive and, most importantly, continually revised library. Within COPE’s core practices is a suite of documents including over 500 cases, 20 flowcharts (in multiple languages), 11 guidance documents, and much more.

The ten core practices are:

1. Allegations of misconduct
2. Authorship and contributorship
3. Complaints and appeals
4. Conflicts of interest / Competing interests
5. Data and reproducibility
6. Ethical oversight
7. Intellectual property
8. Journal management
9. Peer review processes
10. Post-publication discussions and corrections

Download a pdf poster of the core practices

Why did we do this?
The phrase “Code of Conduct” has been misinterpreted as being quasi legal. COPE is a membership organisation with no statutory or regulatory powers. COPE’s remit is to support and advise editors of scholarly journals and publishers/owners.

The core practices include the core tenets of the Code of Conduct, but have been simplified and better reflect current practice. Additionally, the new framework will make it easier for members and the wider community to find COPE’s continuously updated resources as new issues arise.
The COPE website contains a wealth of information and resources but user feedback tells us that it is difficult to find guidance or advice related to a specific issue. The core practices now groups all resources, including cases, flowcharts, guidelines, presentations, news and events under each topic making those connections automatically.

The Core Practices are relevant to (and expected of) all bodies: Editors, Journals, Publishers, Institutions, etc. (unless otherwise noted) which means just one document and linked resources being maintained to avoid confusion about what applies to whom. Our hope is that COPE is also helpful to the broader academic and publishing community.

How should you implement the Core Practices in your policies and procedures?

- Take each core practice individually and think about what that practice means for your discipline or organisation and how best to achieve it
- Use the COPE resources to understand how best to create a policy and practice that sets a good standard for your discipline or organisation
- Add to your policy documents and put into practice, for example, in your journal guidelines, editorial office software and contracts

The ten core practices will remain the same, but the way we describe them will change over time. For example, data publishing is evolving rapidly and it’s certain to be reflected in our guidance.

What we expect from our members
COPE still expects that high standards are met by our members and the communities we serve. Therefore, in parallel with the launch of the core practices, we have also made changes to our Complaints subcommittee, now renamed the Facilitation and Integrity subcommittee (more details here).

The changes clarify that COPE’s role is to facilitate between a complainant and a COPE member where a concern or issue has been raised. However, crucially, the changes in remit of the subcommittee also enable COPE to reach out to our members in cases where they may need guidance which has not been raised to COPE’s attention, either as a complaint or a Forum case. Furthermore, we have implemented a formal sanctions policy which clarifies the expectations we have of our members and allows COPE to further support the ethical standards of those members.
Best regards
COPE Officers and Executive Office, 16 November 2017
Dear Roger,

After a considerable delay, please find attached my revised draft of your memo. For the most part I have attempted to respect your tone and purpose. You’ll note one significant change: I have altered the focus of the memo away from the letters we have received and towards the initial responses from the authors. As I hope the memo makes clear, the comments from Drs Acquavella, Kier and Roberts provide evidence that the Declarations of Interest and possibly the Acknowledgements were incorrect or incomplete. Whilst it may seem tedious of us to quote their comments back to them, I think it is clearer and fairer to do so, rather than quote accusations arising from elsewhere or from leaked internal correspondence. There is nothing in the latter that we haven’t also learnt from the initial responses quoted in the memo.

Please let me know if you have any questions. If not, I propose that we send this, as is, on to the authors without further delay.

All best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon. OX14 4RN, UK
Direct line: 02352 000556
Switchboard: 020 7017 5000
www.tandfonline.com

Taylor & Francis is a trading name of Informa UK Limited, registered in England under no. 1072954.
Roger McClellan

| From: | Marilyn Aardema <m@me.com> |
| Sent: | Thursday December 7, 2017 9:27 PM |
| To: | Roger McClellan |
| Cc: | gary_williams@brusick41, acquajohn@colin@ashley.robert@gmarsh911@helmut.greim@jdecam@dhg3@Michele.Burns@t.M.Sorahan@ashley.roberts@dougla@Charles.Whalley |
| Subject: | Re: BUSINESS CONFIDENTIAL |

Roger, not sure if you still wanted each of us to reply, but I’m acknowledging receipt of your email.

Marilyn
Marilyn Aardema Consulting LLC

On Dec 7, 2017, at 2:42 PM, Roger McClellan <m@att.net> wrote:

TO ALL:

Attached is the correct memo relating to the glyphosate papers. As I indicated earlier, please ignore and destroy the memo I sent earlier.

Roger McClellan

<Glyphosate Authors Memo from McClellan and Whalley 12 7 17.docx>
TO ALL:

Please ignore the memo I sent you a few minutes ago regarding the investigation of the glyphosate papers. Please ignore and delete from your system.

The correct memo will follow shortly.

Roger
David Kirkland

December 8, 2017

Dear Roger,

I had a consulting contract with Monsanto (on behalf of the glyphosate task force) from July 2012 in order to work with Larry Kier to publish the Kier & Kirkland review of the genotoxicity of glyphosate in 2013. This contract terminated when the paper was published, and therefore was not active when the expert panel work through Intertek took place.

Therefore, when I was approached by Intertek in 2015 to join the genotoxicity panel to review the IARC opinion on glyphosate I did not have an “active” contract with Monsanto. Through the preparation of the genotoxicity panel paper and the summary paper all of my communications were with other panel members (Brusick, Aardema, Kier and Williams) or with Ashley Roberts at Intertek. I had no contact with anyone at Monsanto during the writing and revision of the papers for the Special Supplement to Critical Reviews in Toxicology entitled – “An Independent Review of the Carcinogenic Potential of Glyphosate,” Vol. 46, 51, 2016

Therefore, I believe the statements in the Declaration of Interests that apply to me, were accurate. However, if one wanted to be more precise the Declaration could say:

David Kirkland had previously served as an independent consultant for the Monsanto Company on the European Glyphosate Task Force, but the contract had expired by the time these papers were being written.

David Kirkland was engaged by, and acted as a consultant to, Intertek, and there was no direct contact or communication with the Monsanto Company during the preparation and revision of these papers.

In terms of acknowledgements, there is nothing to add. I did not have any help from any colleagues (other than the co-authors) in the preparation of these papers, so there is no-one to acknowledge.

I repeat, I (personally) had no contact or communication with Monsanto during the preparation and revision of these papers, so to my knowledge no phrases or sentences were contributed by Monsanto personnel. However, I do not know if any of my co-authors were in correspondence with Monsanto. Since (it now appears) Dr Kier was hired by Monsanto and not be Intertek, he may have been in direct contact with Monsanto. However, I am not aware that Dr Kier tried to “force” any specific phrases or sentences into the paper. Dr Kier was primarily involved in tabulating the data from the various studies.

Kind regards,

David Kirkland.
Keith Solomon

December 8, 2017

Roger,

Thanks for the quick reply. This new URL is not functioning.

I did have correspondence with Monsanto regarding their internal reports that I used (and acknowledged) in my paper. However, I might not have all my emails related to that correspondence and would like to see them. At that time, I was on satellite-internet and needed to remove emails etc. that were slowing my connection.

Keith

On 2017-12-08 11:32 AM, Roger McClellan wrote:

Keith:
Baum Hedlund Aristei Goldman is the law firm that obtained the internal Monsanto correspondence including correspondence about the special issue of CRT.

Best regards, Roger
December 10, 2017

Dear all,

After various emails I am very confused to whom I should send the response below, so I am sending it to you all. Please confirm receipt.

I had a consulting contract with Monsanto (on behalf of the glyphosate task force) from July 2012 in order to work with Larry Kier to publish the Kier & Kirkland review of the genotoxicity of glyphosate in 2013. This contract terminated when the paper was published, and therefore was not active when the expert panel work through Intertek took place.

Therefore, when I was approached by Intertek in 2015 to join the genotoxicity panel to review the IARC opinion on glyphosate I did not have an "active" contract with Monsanto. Through the preparation of the genotoxicity panel paper and the summary paper all of my communications were with other panel members (Brusick, Aardema, Kier and Williams) or with Ashley Roberts at Intertek. I had no contact with anyone at Monsanto during the writing and revision of the papers for the Special Supplement to Critical Reviews in Toxicology entitled – "An Independent Review of the Carcinogenic Potential of Glyphosate," Vol. 46, S1, 2016

Therefore, I believe the statements in the Declaration of Interests that apply to me, were accurate. However, if we want to be more precise the Declaration could say:

David Kirkland had previously served as an independent consultant for the Monsanto Company on the European Glyphosate Task Force, but the contract had expired by the time these papers were being written.

David Kirkland was engaged by, and acted as a consultant to, Intertek, and there was no direct contact or communication with the Monsanto Company during the preparation and revision of these papers.

In terms of acknowledgements, there is nothing to add. I did not have any help from any colleagues (other than the co-authors) in the preparation of these papers, so there is no-one to acknowledge.

I repeat, I (personally) had no contact or communication with Monsanto during the preparation and revision of these papers, so to my knowledge no phrases or sentences were contributed by Monsanto personnel. However, I do not know if any of my co-authors were in correspondence with Monsanto. Since (it now appears) Dr Kier was hired by Monsanto and not be Intertek, he may have been in direct contact with Monsanto. However, I am not aware that Dr Kier tried to "force" any specific phrases or sentences into the paper. Dr Kier was primarily involved in tabulating the data from the various studies.

Kind regards,

David Kirkland.
Michele Burns

December 12, 2017

Dear All,

I acknowledge receipt of the memo and did not have any communication with Monsanto staff about the content of the 2 papers listed below on which I am an author.

I will review any changes for the Declaration of Interest/Acknowledgement sections that my co-authors feel are necessary.


Thank you.
Michele

Michele M. Burns, MD, MPH

December 12, 2017

Dear All,

I acknowledge receipt of the memo and did not have any communication with Monsanto staff about the content of the 2 papers listed below on which I am an author.

I will review any changes for the Declaration of Interest/Acknowledgement sections that my co-authors feel are necessary.


Thank you.
Michele
Keith Solomon

December 12, 2017

Roger and Mildred,

Just to officially respond to this email and the two memos. I have made some corrections in the DOIs and made them consistent between the two papers where I was listed as an author. How to we communicate these, via Intercen as they prepared and consolidated the original DOIs?

Keith

On 2017-12-07 2:20 PM, Roger McClellan wrote:

Dear All:

Attached is a memo from me and Charles Whalley on the investigation of Issues Related to publication of Five papers on the Carcinogenic potential of Glyphosate.

I would appreciate your confirmation of this memo and your response no later than January 5, 2018.

Thanks.

Roger O. McClellan

Keith R Solomon, Fellow ATS, Fellow SETAC, Prof. Emeritus (U of G)

January 5, 2018

Dear Dr. McClellan,

Attached are edits and corrections to the DOI for the Exposure Paper and the Overview Paper. These are shown in track-changes in the attached file. I had copied the one for the Overview Paper to Gary Williams but have not heard back from him. I also spoke to Ashley about consolidation of the DOIs but that is apparently not being done. If you need further information, please get back to me.

Keith
Response of Keith Solomon (Corresponding Author) to 12/7/2017 request for information from Roger McClellan

I was the sole author of the exposure paper and the opinions expressed therein are mine only and were not commented on or edited by Monsanto. My communications with Monsanto were only related to provision of unpublished reports on exposure-studies and clarifications of the scientific methods used in these.

The original DOIs were consolidated by Intertek and I missed an error in the galley proofs. I did not serve as a consultant to the European Glyphosate Task Force. After reviewing my records, I have added an independent consultation that I provided to Monsanto on the deregulation of RR alfalfa and two other activities involving glyphosate, a paper coordinated by Cantox in 1999 and my serving on an advisory board to Dow AgroSciences (as also mentioned by David Garbrant) but not related to Monsanto.

My revisions to the Acknowledgments and the DOIs are shown in “Track Changes below” with comments as appropriate.


Acknowledgments
The author gratefully acknowledges the extensive comments offered by five reviewers selected by the Editor and presented anonymously to the author. These comments were useful in revising the paper. I thank Monsanto Inc. for providing access to reports from exposure studies for glyphosate in applicators and for providing clarification of the methods used in these studies. I wish to thank the authors of the other papers in this series for their constructive suggestions and comments.

Declaration of interest
The employment affiliation of the author is shown on the cover page. However, it should be recognized that the author participated in the review process and preparation of this paper as an independent professional and not as a representative of his employer. Keith R. Solomon previously served as an independent consultant for the Monsanto Company on the European Glyphosate Task Force (2012-2014). In collaboration with Cantox, KRS contributed to an ecotoxicological risk assessment for Roundup® herbicide, which was published (Giesy et al. 2000). In addition, between 2014 and 2016, he served on a scientific advisory board to Dow AgroSciences, which markets pesticides including glyphosate. KRS has not been involved in any litigation procedures involving Monsanto Company and glyphosate. KRS’s recruitment and evaluation of the data was organized and conducted by Intertek.

Commented [KS1]: Unfortunately, I have no records of these efforts on communication but they were likely with Dow or Farmers or Monsanto.

Commented [KS2]: I have never served on the European Glyphosate Task Force. This must be a cut and paste error that happened when Intertek was consolidating DOI statements for the papers. Unfortunately, not spotted when the galley was corrected. In 2011, I served as an independent consultant for the Monsanto Company on the deregulation of RR alfalfa in the US. The work of this work was on effects in the environment, not human health, however, I have included this. The one paper on Roundup as coordinated by Cantox in 1999 (Williams et al. 1999) is mentioned in the DOI of the Williams et al. 2016 paper and, for consistency, the other paper prepared at the same time (Giesy et al. 2000) should be mentioned here. I had forgotten about the advisory committee for Dow AgroSciences in this, as this was not a Monsanto activity but, as IG mentioned it, for consistency, it should be.
Scientific & Regulatory Consultancy (Intertek). KRS acted as a consultant for Intertek. Intertek (previously Cantox) is a consultancy firm that provides scientific and regulatory advice, as well as safety and efficacy evaluations for the chemical, food and pharmaceutical industries.

While Intertek Scientific & Regulatory Consultancy has not previously worked on glyphosate related matters for the Monsanto Company, previous employees of Cantox had worked in this capacity. Funding for this evaluation was provided by the Monsanto Company which is a primary producer of glyphosate and products containing this active ingredient. Neither any Monsanto company employees nor any attorney reviewed any of the Expert Panel's manuscripts prior to submission to the journal.

This article is part of a supplement, sponsored and supported by Intertek Scientific & Regulatory Consultancy. Funding for the sponsorship of this supplement was provided to Intertek by the Monsanto Company, which is a primary producer of glyphosate and products containing this active ingredient.

I am a co-author on the Overview Paper with Gary Williams as a lead author. For consistency, the DOI should be consistent with my paper (above).


Declaration of interest
The employment affiliation of the authors is as shown on the cover page. However, it should be recognized that each individual participated in the review process and preparation of this paper as an independent professional and not as a representative of their employer.

The Expert Panel Members recruitment and evaluation of the data was organized and conducted by Intertek Scientific & Regulatory Consultancy (Intertek). The Expert Panels were engaged by, and acted as consultants to, Intertek, and were not directly contacted by the Monsanto Company. Funding for this evaluation was provided to Intertek by the Monsanto Company which is a primary producer of glyphosate and products containing this active ingredient. Neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel's manuscripts prior to submission to the journal. Intertek (previously Cantox) is a consultancy firm that provides scientific and regulatory advice, as well as safety and efficacy evaluations for the chemical, food, and pharmaceutical industries. While Intertek has not previously worked on glyphosate-related matters for the Monsanto Company, previous employees (Ian Munro, Barry Lynch) of Cantox, have worked in this capacity. These employees of Cantox, and Gary M. Williams, prepared a safety and risk assessment, including the carcinogenicity, of Roundup herbicide (glyphosate), which was published in 2000 (Williams et al. 2000).

Gary M. Williams, Sir Colin Berry, David Brusick, Joao Lauro Viana de Camargo,
Helmut A. Greim, David J. Kirkland, Keith R. Solomon, and Tom Sorahan have previously served as independent consultants for the Monsanto Company on the European Glyphosate Task Force. Keith R. Solomon, previously served as an independent consultant for the Monsanto Company on the deregulation of RR alfalfa in the US (2012-2014). In collaboration with Cantox, KRS contributed to an ecotoxicological risk assessment for Roundup® herbicide which was published (Giesy et al. 2000). In addition, between 2014 and 2016, he served on a scientific advisory board to Dow AgroSciences, which markets pesticides, including glyphosate. John Acquavella and Larry D. Kier have also served as independent consultants and were previously employees of the Monsanto Company. John Acquavella was employed by Monsanto between the years 1989 and 2004 while Larry D. Kier was employed between 1979 and 2000. David Garabrant serves on a scientific advisory board to Dow AgroSciences, which markets pesticides including glyphosate, and has consulted on behalf of Bayer Corp. on litigation matters concerning glyphosate and leukemia. Gary Williams and Tom Sorahan have consulted for Monsanto on litigation matters involving glyphosate. Tom Sorahan has received consultancy fees and travel grants from Monsanto Europe SA/NV as a member of the European Glyphosate Toxicology Advisory Panel and participated in the IARC Monograph Meeting for volume 112, as an Observer for the Monsanto Company. Douglas L. Weed has consulted on litigation matters concerning Monsanto that did not involve glyphosate and as such declare no potential conflicts of interest. Furthermore, other than David Garabrandt, Gary Williams and Tom Sorahan, none of the aforementioned authors have been involved in any litigation procedures involving glyphosate.

This article is part of a supplement, sponsored and supported by Intertek Scientific & Regulatory Consultancy. Funding for the sponsorship of this supplement was provided to Intertek by the Monsanto Company, which is a primary producer of glyphosate and products containing this active ingredient.
Dear Mildred,
I had received the memo and had declared that for our publication there was no contact with monsanto whatsoever.
Best
Helmut
Attached are the responses to the memo points with respect to the glyphosate genetic effects manuscript. The revised DOI was a collaborative effort with the other panel members. The responses to points 2-5 were prepared by me but reviewed by the other panel members.

If you have any questions or concerns about the DOI or other responses, please feel free to contact me.

David

(1) We ask that the corresponding authors of each paper provide a revised Declaration of Interest for the paper unless they and all the co-authors are of the opinion that the published version is accurate and complete. One point the Declarations of Interest should address is the specific contractual engagement of all authors at the time the manuscripts were prepared;

(1) Response: Revised Draft Declaration of Interest for the Genetic Toxicology Paper

The employment affiliation of the authors is as shown on the cover page. Each individual participated in the review process and preparation of this paper as an independent professional. No individuals other than the cited authors were involved in developing the analysis and conclusions of the manuscript prior to its submission to the journal.

The Expert Panel Member recruitment was organized and conducted by Intertek Scientific & Regulatory Consultancy (Intertek) and the initial Expert Panelists worked under individual consulting contracts with Intertek. Intertek (previously Cantox) is a consultancy firm that provides scientific and regulatory advice, as well as safety and efficacy evaluations for the chemical, food, and pharmaceutical industries. While Intertek Scientific & Regulatory Consultancy has not previously worked on glyphosate related matters for the Monsanto Company, previous employees of Cantox had worked in this capacity.

Larry Kier did not have a consulting contract with Intertek; he was employed as a consultant by Monsanto to provide support for the Glyphosate Expert Panel in the areas of genotoxicity and oxidative stress. Larry did review the report as it was being written and provided his expertise when requested by the panel members. After the final draft of the report was written Larry was added as a co-author and genotoxicity Expert Panel member with the consent of the genotoxicity Expert Panel Members.

Gary Williams, David Brusick, and David Kirkland have previously served as independent consultants for the Monsanto Company, some on the European Glyphosate Task Force. Larry Kier was previously an employee of the Monsanto Company and has also served as an independent consultant for Monsanto Company. Marilyn Aardema has not previously been employed at the Monsanto Company or previously been involved in any activity involving glyphosate and as such declares no potential conflicts of interest. Ian Munro, Douglass W.
Bryant, and Gary Williams prepared a safety and risk assessment paper of Roundup herbicide (glyphosate) (Williams G.M. et al., 2000).

Except for assistance with final formatting, neither any Monsanto company employees nor any attorney provided any review of the Expert Panel's manuscript analysis and conclusions prior to submission to the Journal. This article is part of a supplement, sponsored and supported by Intertek Scientific & Regulatory Consultancy. Funding for the sponsorship of this supplement was provided to Intertek by the Monsanto Company, which is a primary producer of glyphosate and products containing this active ingredient.

Response:

The original version is fine. The only addition may be an acknowledgement to Anna Bickel: a Monsanto employee provided clerical assistance in formatting the final report before sending it to the Journal. However, that may be taking the acknowledgment a little too far.

Response:

There were no communications of any type between me and any Monsanto Company personnel during the course of analysis, report preparation or submission of the manuscript on genetic effects. I had no contact with any person at Monsanto during any aspect of the glyphosate IARC assessment program.

Response:

I was responsible for producing the initial draft and updating the content of the manuscript as it evolved during the course of its development. The manuscript on genetic effects of glyphosate was written entirely by the authors listed on the publication. No statements were offered or contributed by Monsanto employees. All additions, deletions, and changes to the initial draft that I prepared were made only by the authors, with unanimous agreement.
If you have other information you think will be helpful to us as we proceed with our investigation, we will be pleased to receive it.

Response:

The individuals involved with preparation of the genetic effects manuscript have all worked together on other programs and projects and have a high regard for each other's skills and objectivity. I think I speak for our group by stating that there is no merit to allegations of being influenced by anyone at Monsanto or any other organization to prepare anything other than an objective assessment of the data.

As for the overview summary manuscript and meeting presentations, our panel members were all given the opportunity to review and comment on their content in advance. I believe that the statements in those publications and presentations were lifted virtually intact from the genetic effects manuscript and did not alter or change the original conclusions or opinions of the genetic effects panel report.
Gary Williams

January 3, 2018

Gary:

Thanks for the update on the response to our request related to the Special CRT Issue containing the 5 papers on Glyphosate. I look forward to receiving your response and that of the other first authors on the five papers. I have also received an update from Dave Brusick. I assume that all of the responses will be coordinated with Ashley so the revised Declarations of Interest on all 5 papers will accurately document any communications with any Monsanto personnel or other interested parties concerning the manuscripts.

Best wishes for peace, prosperity and good health in 2018.

Roger

---

On Wednesday, January 3, 2018 12:51 PM, "Williams, Gary" <NYMC.EDU> wrote:

Dear Roger,

We are working diligently on the responses that you requested. However, holidays and weather produced delays. I anticipate that we should finish next week.

Yours kindly,

Gary

Gary M. Williams, M.D.
Professor of Pathology
New York Medical College

---

On Wednesday, January 10, 2018 4:42 AM, Roger McCollan <Alt.net> wrote:

Gary:

Thanks for the update and question. In the communication to you and the other authors concerning the papers in the Special Glyphosate Issue we asked (1) a series of questions and (2) asked for proposed revised Declarations of Interest. Attention should be given to both.

You are correct that the focus is on providing information that will assist me, Charles Whalley and Taylor and Francis, as the Publisher in obtaining a complete and accurate view of all interactions with parties, other than the authors, up to the time the 5 papers were published online. We requested this information because it appears the original
Declarations of interest and Acknowledgements sections were not fully complete and accurate, especially as regards interactions with Monsanto personnel.

As I note, the focus is on interactions with Monsanto personnel and their potential influence on the contents of the 5 papers as published online. However, if there were any interactions by the authors with any other individuals or corporate representatives that the authors believe would be of interest to me, as the Editor, or Charles, as the T and F representative, as regards the preparation and contents of the papers that should be provided to us.

If there are any interactions that occurred after the papers were published online those interactions should also be revealed now. If in doubt, provide more rather than less information. This most certainly would include any interactions with representatives of Monsanto or Bayer or other corporate entities involved in the production and marketing of Glyphosate containing products or agencies such as IARC.

To restate the obvious, the central issue is the need for complete and accurate disclosures related to the contents of the 5 papers and how those papers were prepared. This information will assist Charles and me in determining how best to deal with this matter.

This inquiry is not intended to address new scientific information that may have been published after the 5 original reviews were published, that is a separate issue.

I hope this response is helpful to you. Again, if in doubt as to the relevance of any information please provide it to me and Charles so we can evaluate the information. We are eager to bring this matter to closure.

Thank you for your assistance.

Roger McClellan, Editor - Critical Reviews in Toxicology

Dr. Tuesday, January 9, 2018 12:48 PM, "Williams, Gary" wrote

Roger,

An issue has come up. Some authors want to disclose events after publication of the papers, whereas I thought we were revising the original declarations to capture all relevant facts at the time of preparation of the papers. I need your guidance.

Thanks and kind regards,

Gary

Gary M. Williams, M.D.,
Thank you for your communication on behalf of Drs. Garabrant, Tom Sorahan, Marsh, Weed and yourself. I have just begun to review the material you have provided. The material provided is clearly very helpful. Charles Whalley and I will likely have some questions as we review your response and the responses on the other papers.

To expand on the material provided with regard to point #2, Acknowledgements, it would be helpful if you could provide the date you sent a draft of the paper to Bill Heydens at Monsanto and the date of his response to you. This request is consistent with the details requested in the original point 3.

Based on the involvement of Bill Heydens, Monsanto, in reviewing the paper, it is my initial reaction is that a revised Acknowledgements should be provided that explicitly identifies Heydens as a reviewer. It will be important to make clear which version of the paper he reviewed and when, i.e., a pre-submission draft or a post-submission version. Did you provide a copy of the paper to Heydens or was it provided by Ashley Roberts to Heydens? Were the Heydens comments shared with all the co-authors of the paper? In a revised Acknowledgements section, it will be important to also identify any other non-author reviewers of the paper.

I look forward to your response.

Best regards and best wishes to all for peace, prosperity and good health in 2018.

Roger McClellan, Editor, CRT

On Thursday, January 4, 2018 9:45 AM, John Acquavella wrote:

Dear Roger:

On behalf of Drs. Sorahan, Garabrant, Marsh, Weed, and myself, please find attached the information you requested in your email of December 7 as concerns the glyphosate epidemiology expert panel paper.

Sincerely,

John
Response of the Epidemiology Panel (John Acquavella, Corresponding Author) to 12/7/2017 request for information by Roger McClellan

(1) We ask that the corresponding authors of each paper provide a revised Declaration of Interest for the paper unless they and all the co-authors are of the opinion that the published version is accurate and complete. One point the Declarations of Interest should address is the specific contractual engagement of all authors at the time the manuscripts were prepared.

(1) Response: Revised Draft Declaration of Interest for the Epidemiology Paper

The employment affiliation of the authors is as shown on the cover page. However, it should be recognized that each individual participated in the review process and preparation of this paper as an independent professional and not as a representative of their employer. This expert panel evaluation was organized and conducted by Intertek Scientific & Regulatory Consultancy. Funding for this evaluation was provided by Monsanto Company, which is a primary producer of glyphosate and products containing this active ingredient. The authors had sole responsibility for the content of the paper, and the interpretations and opinions expressed in the paper are those of the authors.

JA worked for Monsanto from 1989 through 2004 and is a consultant on a legal case unrelated to glyphosate that involves a former Monsanto industrial chemical plant. DG serves on a scientific advisory board to Dow Agro Sciences, which markets pesticides including glyphosate. He was jointly retained by Buyer Corporation: Bayer CropScience LP; Buyer CropScience Holding, Inc.; Dow AgroSciences, L.L.C.; BASF Corporation; Syngenta Crop Protection, Inc., Deere & Company, L.P.; and Monsanto in litigation matters concerning glyphosate and leukemia. He also provided consultation in February 2016 to an attorney representing Pharmacia (formerly Monsanto) in litigation that did not involve glyphosate. That consultation consisted of 0.3 hours of professional services, after which he did no further work on the litigation. GM has no additional declarations. TS has received consultancy fees and travel grants from Monsanto Europe SA/NV as a member of the European Glyphosate Toxicology Advisory Panel and participated in the IARC Monograph Meeting for volume 112, as an Observer for the Monsanto Company. In addition, TS has consulted for Monsanto on litigation matters involving glyphosate. DW has consulted on litigation matters concerning Monsanto that did not involve glyphosate. This article is part of a supplement, sponsored and supported by Intertek Scientific & Regulatory Consultancy. Funding for the sponsorship of this supplement was provided to Intertek by the Monsanto Company, which is a primary producer of glyphosate and products containing this active ingredient. JA was paid directly by Monsanto for his work on this expert panel. The other authors (DG, GM, TS, DW) were paid by Intertek, which was funded by Monsanto.

(2) We also ask that the Acknowledgments section of each paper be reviewed and revised as necessary. In particular, the Acknowledgments section should identify any individuals, including colleagues, who may have assisted in assembling material, reviewing drafts or otherwise assisted in preparing each paper. We encourage all co-authors to review the guidance on authorship, and particularly on "Non-Author Contributors", in the ICMJE Recommendations.
(2) *Response:* Monsanto staff were provided a draft of the epidemiology manuscript for review. Based on comments received subsequently from Bill Heydens, we revised our section on analytic selection bias to be more understandable for a general scientific audience and corrected a few typographical errors. We did not include any text written by Monsanto employees or attorneys in the published paper. Intertek provided clerical assistance in formatting the final report per Critical Reviews in Toxicology’s author instructions.

(3) We are also asking each corresponding author and Ashley Roberts to provide a chronological accounting of any communications (letters, e-mails or telephone calls) by them or their co-authors with Monsanto Company personnel concerning the contents of the papers. If such communications did not occur, a statement to that effect will suffice.

(3) *Response:* JA received email comments on the draft epidemiology manuscript as described in #2 above.

(4) We are also asking the corresponding author for each final published paper to identify any statements (i.e., phrases, sentences, etc.) that were contributed by Monsanto personnel or others in response to input from Monsanto personnel. If Monsanto offered no comments on a specific paper, a statement to that effect will suffice.

(4) *Response:* The manuscript on epidemiology was written entirely by the authors listed on the publication. No statements were contributed by Monsanto employees. All additions, deletions, and changes to the draft manuscript were made only by the authors, with unanimous agreement.

(5) if you have other information you think will be helpful to us as we proceed with our investigation we will be pleased to receive it.

(5) *Response:* We have no additional information. We would like the readers of Critical Reviews in Toxicology to be aware of these revisions to our disclosures. We regret any inconvenience to the journal or its readers as a result of these revisions.

January 3, 2018
FROM: John Acquavella

Roger:

As you’ve requested, we’ve expanded the response to #3 to include the timeline. Please use this version of our response.

Sincerely,

John
Date: Thursday, January 4, 2018 at 10:33 AM
To: John Aquavella

Subject: Re: BUSINESS CONFIDENTIAL

John:

Thank you for your communication on behalf of Drs Garabrant, Tom Sorahan, Marsh, Weed and yourself. I have just begun to review the material you have provided. The material provided is clearly very helpful. Charles Whalley and I will likely have some questions as we review your response and the responses on the other papers.

To expand on the material provided with regard to point #2, Acknowledgements, it would be helpful if you could provide the date you sent a draft of the paper to Bill Heyden at Monsanto and the date of his response to you. This request is consistent with the details requested in the original point 3.

Based on the involvement of Bill Heyden at Monsanto, in reviewing the paper it is my initial reaction is that a revised Acknowledgements should be provided that explicitly identifies Heyden as a reviewer. It will be important to make clear which version of the paper he reviewed and when, i.e., a pre-submission draft or a post-submission version. Did you provide a copy of the paper to Heyden or was it provided by Ashley Roberts to Heyden? Were the Heyden comments shared with all the co-authors of the paper? In a revised Acknowledgements section, it will be important to also identify any other non-author reviewers of the paper.

I look forward to your response.

Best regards and best wishes to all for peace, prosperity and good health in 2018.

Roger McClellan, Editor, CRT
Dear Roger:

On behalf of Drs. Surahan, Garabrant, Marsh, Weed, and myself, please find attached the information you requested in your email of December 7 as concerns the glyphosate epidemiology expert panel paper.

Sincerely,

John
Dear Roger,

Thank you for your email. I respond to your request I will put together a chronology of events which I will try to get to you next week.

Regarding the DOI's for the individual papers I believe several of these have been provided by the lead authors and only the carcinogenicity paper remains outstanding. Please could you confirm?

Best Wishes

Ashley

Ashley Roberts, Ph.D.
Ashley Roberts  
January 11, 2018  

Ashley:

I intended that you receive a copy of my response to the e-mail I had received from Gary Williams. In reviewing my e-mails I realized a copy was not sent to you. Attached is the communication from Gary and my response. In addition, I have summarized some key points that require your attention.

Charles and I are eager to receive the responses to our e-mail from the first authors concerning the papers in the special issue of CRT. I assume you are working with the authors. As will have noted we asked a series of questions and requested revised Declarations of Interest that are complete and accurate to potentially be published as replacements / supplements to the original DOIs. Since each original paper had its own DOI it is important that each original DOI be critically reviewed and a proposed revision be provided that is complete and accurate. Those proposed revised DOIs and the responses to the questions we proposed will hopefully allow us to conclude our investigation of this matter and decide on a course of action, dependent on the facts we are presented with, that will resolve the issues that have been raised. Dependent on the facts we are presented with one potential course of action may include publication of the revised DOIs and an over-arching piece authored by myself, as Editor, and Charles, as the representative of the publisher.

It is apparent that you had contacts with Monsanto personnel concerning the papers, thus, it is important that you respond to the questions that Charles and I have posed. This response from you goes beyond your role as a co-author of one of the papers. It is especially important that you provide a chronology of all your interactions with Monsanto personnel and any other parties with regard to the contents of the multiple papers included in the Special Supplement to CRT.

Please let me and Charles know, preferable by end of the business day on January 12, 2018, when we can expect to receive your response and that of the first authors as well as responses from any other authors that are germane.

Your timely assistance on this serious matter is greatly appreciated.

Roger

Roger O. McClellan  
Editor, Critical Reviews in Toxicology
January 11, 2018

Dear Roger,

Thank you for your email. In response to your request I will put together a chronology of events which I will try to get to you next week.

Regarding the DOI’s for the individual papers I believe several of these have been provided by the lead authors and only the carcinogenicity paper remains outstanding. Please could you confirm?

Best Wishes

Ashley

Ashley Roberts, Ph.D.

Intertek, 2233 Argenta Rd., Suite 201, Mississauga ON L5N 1X7

From: Roger McClellan <mailto:Roger McClellan@att.net>
Sent: January-11-18 12:02 AM
To: Ashley Roberts intertek@intertek.com>
Subject: Fw: glyphosate

January 19, 2018

Dear Roger,

I am still working on this so it will take a little time longer.

Best Wishes

Ashley

Ashley Roberts, Ph.D.
January 11, 2018

Gary:

I would like to understand the nature of the events post publication of the papers that some of the authors desire to disclose. Perhaps, you can provide additional information including examples so Charles and I can better understand the situation.

Thank you for your assistance.

Roger

Gary:

Thanks for the update and question. In the communication to you and the other authors concerning the papers in the Special Glyphosate Issue we asked (1) a series of questions and (2) asked for proposed revised Declarations of Interest. Attention should be given to both.

You are correct that the focus is on providing information that will assist me, Charles Whalley and Taylor and Francis, as the Publisher in obtaining a complete and accurate view of all interactions with parties, other than the authors, up to the time the 5 papers were published online. We requested this information because it appears the original Declarations of Interest and Acknowledgements sections were not fully complete and accurate, especially as regards interactions with Monsanto personnel.

As I note, the focus is on interactions with Monsanto personnel and their potential influence on the contents of the 5 papers as published online. However, if there were any interactions by the authors with any other individuals or corporate representatives that the authors believe would be of interest to me, as the Editor, or Charles, as the T and F representative, as regards the preparation and contents of the papers that should be provided to us.

If there were any interactions that occurred after the papers were published online those interactions should also be revealed now. If in doubt, provide more rather than less information. This most certainly would include any interactions with representatives of Monsanto or Bayer or other corporate entities involved in the production and marketing of Glyphosate containing products or agencies such as IARC.

To restate the obvious, the central issue is the need for complete and accurate disclosures related to the contents of the 5 papers and how those papers were prepared. This information will assist Charles and me in determining how best to deal with this matter.

This inquiry is not intended to address new scientific information that may have been published after the 5 original reviews were published, that is a separate issue.
I hope this response is helpful to you. Again, if in doubt as to the relevance of any information please provide it to me and Charles so we can evaluate the information. We are eager to bring this matter to closure.

Thank you for your assistance.

Roger McClellan, Editor - Critical Reviews in Toxicology

On Wednesday, January 10, 2018 4:42 AM, Roger McClellan wrote:

Gary:

Thanks for the update and question. In the communication to you and the other authors concerning the papers in the Special Glyphosate Issue we asked (1) a series of questions and (2) asked for proposed revised Declarations of Interest. Attention should be given to both.

You are correct that the focus is on providing information that will assist me, Charles Whalley and Taylor and Francis, as the Publisher in obtaining a complete and accurate view of all interactions with parties, other than the authors, up to the time the 5 papers were published online. We requested this information because it appears the original Declarations of Interest and Acknowledgements sections were not fully complete and accurate, especially as regards interactions with Monsanto personnel.

As I note, the focus is on interactions with Monsanto personnel and their potential influence on the contents of the 5 papers as published online. However, if there were any interactions by the authors with any other individuals or corporate representatives that the authors believe would be of interest to me, as the Editor, or Charles, as the T and F representative, as regards the preparation and contents of the papers that should be provided to us.

If there are any interactions that occurred after the papers were published online those interactions should also be revealed now. If in doubt, provide more rather than less information. This most certainly would include any interactions with representatives of Monsanto or Bayer or other corporate entities involved in the production and marketing of Glyphosate containing products or agencies such as IARC.

To restate the obvious, the central issue is the need for complete and accurate disclosures related to the contents of the 5 papers and how those papers were prepared. This information will assist Charles and me in determining how best to deal with this matter.

This inquiry is not intended to address new scientific information that may have been published after the 5 original reviews were published, that is a separate issue.
I hope this response is helpful to you. Again, if in doubt as to the relevance of any information please provide it to me and Charles so we can evaluate the information. We are eager to bring this matter to closure.

Thank you for your assistance.

Roger McClellan, Editor • Critical Reviews in Toxicology
From: ROM
January 23, 1918

Ashley:
Thanks for the update on your response on this important matter. I and Charles Whalley are eager to receive the material from you concerning the Special Glyphosate issue of CRT so we can review it relative to the material provided by the other first authors. We do not think it appropriate to prematurely conclude a review of the other proposed revised Declarations of Interest since the information you provide could impact on the contents of any revised Declarations of Interest.

As you will recall it was your contact and the timing of that contact, with Monsanto personnel that was not disclosed when the original papers were published that is at the heart of the controversy. Thus, it is important as we bring our investigation to a close and explore options for a final disposition that we have the information from you that we previously requested. It is important that we have complete and accurate disclosures from all the corresponding authors and you to conclude our investigation and resolution of the matter.

Please keep me informed as to your progress.

Thank you for your assistance on this very important matter. And best wishes for the New Year.

Regards.
Roger
Roger O. McClellan
Editor, Critical Reviews in Toxicology

On Friday, January 19, 2018 5:54 AM, Ashley Roberts <ar@interTek.com> wrote:

Dear Roger,

I am still working on this so it will take a little time longer.

Best Wishes

Ashley
Roger McClellan

From: Keith Solomon <ksolomon@uoguelph.ca>
Sent: Friday, December 8, 2017 9:53 AM
To: Roger McClellan
Cc: Mildred B. Morgan
Subject: Re: BUSINESS CONFIDENTIAL

Roger,

Thanks for the quick reply. This new URL is not functioning.

I did have correspondence with Monsanto regarding their internal reports that I used (and acknowledged) in my paper. However, I might not have all my emails related to that correspondence and would like to see them. At that time, I was on satellite-internet and needed to remove emails etc. that were slowing my connection.

Keith

On 2017-12-08 11:32 AM, Roger McClellan wrote:

Keith:
Try <www.baumhedlundlaw.com/toxic-tort-law/monsanto-courtpapers>,
Baum Hedlund Aristei Goldman is the law firm that obtained the internal Monsanto correspondence including correspondence about the special issue of CRT.
Best regards, Roger

On Friday, December 8, 2017 6:07 AM, Keith Solomon <ksolomon@uoguelph.ca> wrote:

Roger,
Thanks for the memo.
I have tried to access the site mentioned in your memo < http://baumhedlundlaw.com/pdf/monsanto-documents/ >
However, the link does not work. Could you please send me the correct link.
Keith

On 2017-12-07 2:42 PM, Roger McClellan wrote:
TO ALL:

Attached is the correct memo relating to the glyphosate papers. As I indicated earlier, please ignore and destroy the memo I sent earlier.

Roger McClellan
Roger,  
Many thanks, this worked.  
Keith  

On 2017-12-08 3:04 PM, Roger McClellan wrote:  
TO ALL:  
Some individuals have indicated that they were unable to reach the website used in the memo sent to you yesterday regarding the glyphosate papers. An alternative website is as follows:  
Roger McClellan
TO ALL:

Some individuals have indicated that they were unable to reach the website used in the memo sent to you yesterday regarding the glyphosate papers. An alternative website is as follows:


Roger McClellan
Dear Dr. McClellan,

I did receive your and Whalley memo and took notice of the deadline to provide the requested information.

Thank you,

João Lauro Viana de Camargo

---

Dear All:

Some of you have responded confirming your receipt of McClellan and Whalley memo on the Investigation of Issues Related to Publication of Five Papers on the Carcinogenic Potential of Glyphosate. It would be appreciated if those of you who have not confirmed receipt of this memo to please respond to me or Dr. McClellan (e-mail address redacted) as soon as possible.

Thanks.
Mildred Morgan
Assistant to Roger McClellan
Tel: [redacted]
Fax: [redacted]
Email: [redacted]@hargray.com
Roger McClellan

From: Thomas Sorahan <thomas.sorahan@bham.ac.uk>
Sent: Monday, December 11, 2017 2:10 AM
To: mbmorgan@mcclellan
Cc: roger.o.mcclellan@gmail.com
Subject: RE: Confirmation of Receipt of Glyphosate Memorandum

Dear Mildred

I confirm receipt of the email from Roger McClellan requesting further information on the glyphosate review papers. I also note the timelines.

Tom Sorahan

---

From: mbmorgan@mcclellan
Sent: 08 December 2017 22:56
To: gary.williams@brusick41
mjaardema@brusick41
acquajohn@brusick41
colin@brusick41
brusick41
michelle.burns@brusick41
jdecamo@brusick41
dhs@brusick41
helmut.gremel@brusick41
didier.rob@brusick41
ksolomon@brusick41
thomas.sorahan@brusick41
ashley.roberts@douglasweeds
roger.o.mcclellan@gmail.com
Subject: Confirmation of Receipt of Glyphosate Memorandum

Dear All:

Some of you have responded confirming your receipt of McClellan and Whalley memo on the Investigation of Issues Related to Publication of Five Papers on the Carcinogenic Potential of Glyphosate. It would be appreciated if those of you who have not confirmed receipt of this memo to please respond to me or Dr. McClellan (roger.o.mcclellan@gmail.com) as soon as possible.

Thanks.

Mildred Morgan
Assistant to Roger McClellan
Tel: 
Fax: 
Email: mbmorgan@mcclellan@gmail.com
Trying again. I keep getting undeliverable messages.

Dear all,

After various emails I am very confused to whom I should send the response below, so I am sending it to you all. Please confirm receipt.

I had a consulting contract with Monsanto (on behalf of the glyphosate task force) from July 2012 in order to work with Larry Kier to publish the Kier & Kirkland review of the genotoxicity of glyphosate in 2013. This contract terminated when the paper was published, and therefore was not active when the expert panel work through Intertek took place.

Therefore, when I was approached by Intertek in 2015 to join the genotoxicity panel to review the IARC opinion on glyphosate I did not have an “active” contract with Monsanto. Through the preparation of the genotoxicity panel paper and the summary paper all of my communications were with other panel members (Brusick, Aardema, Kier and Williams) or with Ashley Roberts at Intertek. I had no contact with anyone at Monsanto during the writing and revision of the papers for the Special Supplement to Critical Reviews in Toxicology entitled – “An Independent Review of the Carcinogenic Potential of Glyphosate,” Vol 46, SI, 2016

Therefore, I believe the statements in the Declaration of Interests that apply to me, were accurate. However, if we want to be more precise the Declaration could say:

David Kirkland had previously served as an independent consultant for the Monsanto Company on the European Glyphosate Task Force, but the contract had expired by the time these papers were being written.

David Kirkland was engaged by, and acted as a consultant to, Intertek, and there was no direct contact or communication with the Monsanto Company during the preparation and revision of these papers.

In terms of acknowledgements, there is nothing to add. I did not have any help from any colleagues (other than the co-authors) in the preparation of these papers, so there is no one to acknowledge.

I repeat, I (personally) had no contact or communication with Monsanto during the preparation and revision of these papers, so to my knowledge no phrases or sentences were contributed by Monsanto personnel. However, I do not know if any of my co-authors were in correspondence with Monsanto. Since (it now appears) Dr Kier was hired by Monsanto.
and not be Intertek, he may have been in direct contact with Monsanto. However, I am not aware that Dr Kier tried to “force” any specific phrases or sentences into the paper. Dr Kier was primarily involved in tabulating the data from the various studies.

Kind regards.

David Kirkland.

From: Roger McClellan [mailto:Roger.McClellan@att.net]
Sent: 07 December 2017 19:43
To: gary.williams@...; mjardema@...; acquajohn@...; colin@...; brusick41@...; Michele.Burns@...; idcami@...; dhg3@...;helmut.greim@...; idkier@...; rootie@...; ashd@...; gmash911@...; charles.whalley@...; ashley.roberts@...; douglasweerd@...;
Cc: Charles Whalley; Roger McClellan
Subject: BUSINESS CONFIDENTIAL

TO ALL:

Attached is the correct memo relating to the glyphosate papers. As I indicated earlier, please ignore and destroy the memo I sent earlier.

Roger McClellan
The message was checked by ESET NOD32 Antivirus.

http://www.eset.com

__________ Information from ESET NOD32 Antivirus, version of detection engine 16548 (20171210)

The message was checked by ESET NOD32 Antivirus.

http://www.eset.com

__________ Information from ESET NOD32 Antivirus, version of detection engine 16548 (20171210)

The message was checked by ESET NOD32 Antivirus.

http://www.eset.com

__________ Information from ESET NOD32 Antivirus, version of detection engine 16548 (20171210)

The message was checked by ESET NOD32 Antivirus.

http://www.eset.com
Roger McClellan

From: Ashley Roberts Intertek <intertek.com>
Sent: Monday, December 11, 2017 5:30 AM
To: Roger McClellan
Cc: Mildred B. Morgan; Charles Whalley
Subject: RE: BUSINESS CONFIDENTIAL - Glyphosate

Dear Roger,

This is to confirm that I have received your message.

Kind Regards

Ashley

From: Roger McClellan [mailto:@att.net]
Sent: December-08-17 11:39
To: Ashley Roberts Intertek
Cc: Mildred B. Morgan; Roger McClellan; Charles Whalley
Subject: Fw: BUSINESS CONFIDENTIAL - Glyphosate

Ashley:

Attached is the memo from Roger McClellan and Charles Whalley regarding the Investigation of Issues Related to Publication of Five Papers on the Carcinogenic Potential of Glyphosate. Although the first named author of each of the individual papers has the ultimate responsibility, along with the co-authors for preparing, as needed a revised Acknowledgements and Declaration of Interest sections for their papers I and Charles are assuming that you will be working with them to make certain these statements are absolutely complete and accurate. This should include documentation in the DOI of any communications concerning the paper that you or any authors may have had with Monsanto personnel or other personnel concerning the contents of each specific paper from the time of initial discussions through drafting and submission of the paper through copy editing. If any personnel other than the authors or you were present during any of the discussions leading to drafting of the papers they should be identified by name and affiliation. This should also include any participants in any reviews or editing of drafts of the papers. This should obviously include, but not be limited, to any individuals compensated by Intertek and/or Monsanto or affiliated organization.

If you or any of the authors have been deposed in any legal matters related to the preparation or contents of the papers published in CRT please make that known to us.

I would appreciate it if you would confirm receipt of this memo to me-Mildred Morgan <morgat@haugray.com> and Charles Whalley <whalleystandl.co.uk>

Thank you for your assistance with this important matter.
I did reply initially. This email is my formal notice that I have received the memo and will work on the responses.

David Brusick

--- Original message ---

TO ALL:

Dr. Roger McClellan and I are still waiting for several authors of the 5 glyphosate papers to confirm receipt of the memo from him and Charles Whalley on the Investigation of Issues Related to Publication of Five Papers on the Carcinogenic Potential of Glyphosate dated 12/7/2017.

So far, we have received confirmation of the memo from the following authors:

Ashley Roberts

Keith Solomon
I would appreciate it if the other 10 authors would confirm receipt of this memo to Roger McClellan (dickie@stf.net), me (mille@harrgray.com) and Charles Whalley (charles@tandf.co.uk) as soon as possible.

Thank you for your assistance with this important matter.

Mildred Morgan
Assistant to Roger McClellan
Tel: 
Fax: 
Email: milly@harrgray.com
Roger McClellan

From: Keith Solomon <[redacted]@uoguelph.ca>
Sent: Tuesday, December 12, 2017 7:58 PM
To: Roger McClellan
Cc: Mildred B. Morgan
Subject: Re: BUSINESS CONFIDENTIAL

Roger and Mildred,

Just to officially respond to this email and the two memos. I have made some corrections in the DOIs and made them consistent between the two papers where I was listed as an author. How do we communicate these, via Intertec as they prepared and consolidated the original DOIs?

Keith

On 2017-12-07 2:20 PM, Roger McClellan wrote:

Dear All:

Attached is a memo from me and Charles Whalley on the investigation of Issues Related to publication of Five papers on the Carcinogenic potential of Glyphosate.

I would appreciate your confirmation of this memo and your response no later than January 5, 2018.

Thanks.

Roger O. McClellan
Mildred, 
I replied last week when your email came. I confirm that I received it.

David H. Garabrant, MD
Ann Arbor, MI
www.epidstat.com

On Dec 12, 2017, at 6:36 PM, brusick41 <brusick41@comcast.net> wrote:

I did reply initially. This email is my formal notice that I have received the memo and will work on the responses.
David Brusick

TO ALL:
Dr. Roger McClellan and I are still waiting for several authors of the 5 glyphosate papers to confirm receipt of the memo from him and Charles Whalley on the Investigation of Issues Related to Publication of Five Papers on the Carcinogenic Potential of Glyphosate dated 12/7/2017.

So far, we have received confirmation of the memo from the following authors:

Ashley Roberts
Keith Solomon
Sir Colin Berry
Joao Lauro Viana de Camargo
David Kirkland
Tom Sorahan

I would appreciate it if the other 10 authors would confirm receipt of this memo to Roger McClellan (_________@att.net), me (_________@hargray.com) and Charles Whalley (_________@tandf.co.uk) as soon as possible.

Thank you for your assistance with this important matter.

Mildred Morgan
Assistant to Roger McClellan

Tel: [redacted]
Fax: [redacted]
Email: [redacted]@hargray.com
Mildred:

I replied last week as well. I confirm that I received it and am cognizant of the requested timeline.

Regards,

John

John Acquavella, PhD FACE FISPE
Professor, Dept Clinical Epidemiology
Aarhus University, Denmark
+1 (office)
+1 (mobile)
Aarhus University email:clin.au.dk

From: David Garabrant <dhg3@au.dk>
Date: Wednesday, December 13, 2017 at 7:09 AM
To: brusick41@au.dk
Cc: Mildred Morgan <hargray.com>, <gary_williams@au.dk>, <mjaardema@au.dk>, <acquavella@au.dk>, <coing@au.dk>, <Michele.Burns@au.dk>, <jdecam@au.dk>, <helmut.greim@au.dk>, <ldkier@au.dk>, <root@au.dk>, <ksolomon@au.dk>, <T.M.Sorahan@au.dk>, <ashley.roberts@au.dk>, <douglasweed@au.dk>, <roger.o.mcclellan@au.dk>
Subject: Re: CONFIRMATION OF RECEIPT FOR McClellan & Whalley Memo dated 12/7/2017

Mildred,

I replied last week when your email came. I confirm that I received it.

David H. Garabrant, MD
Ann Arbor, MI
comcast.net
www.epidstat.com
On Dec 12, 2017, at 6:36 PM, brusick41 <brusick41@...> wrote:

I did reply initially. This e-mail is my formal notice that I have received the memo and will work on the responses.
David Brusick

Sent from my Verizon, Samsung Galaxy smartphone

-------- Original message --------
From: Mildred Morgan <mbmorgan@...>
Date: 12/12/17 4:40 PM (GMT-05:00)
To: carly will...mjaarderra
brusick41@...michele burns@...; helmut greim@...; ksolomon@...; douglasweed@...
Cc: roeer.o.mcclellan@...
Subject: CONFIRMATION OF RECEIPT FOR McClellan & Whalley Memo dated 12/7/2017

TO ALL:

Dr. Roger McClellan and I are still waiting for several authors of the 5 glyphosate papers to confirm receipt of the memo from him and Charles Whalley on the Investigation of issues Related to Publication of Five Papers on the Carcinogenic Potential of Glyphosate dated 12/7/2017.

So far, we have received confirmation of the memo from the following authors:

Ashley Roberts
Keith Solomon
Sir Colin Berry
Jooao Lauro Viana de Camargo
David Kirkland
Tom Sorahan
I would appreciate it if the other 10 authors would confirm receipt of this memo to Roger McClellan (rmcclella@att.net), me (rmorg@hargray.com) and Charles Whalley (chwh@landf.co.uk) as soon as possible.

Thank you for your assistance with this important matter.

Mildred Morgan
Assistant to Roger McClellan
Tel: [Redacted]
Fax: [Redacted]
Email: [Redacted]@hargray.com
Dear Roger, this is to acknowledge receipt of your memo and the response deadline. Gary Marsh

On December 7, 2017 at 2:42 PM Roger McClellan <Roger.McClellan@att.net> wrote:

TO ALL:

Attached is the correct memo relating to the glyphosate papers. As I indicated earlier, please ignore and destroy the memo I sent earlier.

Roger McClellan
Roger McClellan

From: Mildred Morgan <[redacted]@hargray.com>
Sent: Friday, December 22, 2017 8:18 AM
To: 'Charles Whalley'
Cc: roger.o.mcclellan
Subject: Responses from Glyphosate Authors

Dear Charles:

Dr. McClellan asked me to send you a note to inform you that we have now received acknowledgment of the memo from all of the 16 authors of the glyphosate papers. I didn’t receive an acknowledgment from Larry Kier, but Dr. McClellan spoke with him by telephone.

Mildred
David:

Thanks for your prompt response. Charles and I will be reviewing early in the New Year all of the responses concerning the papers in the special Glyphosate issue of CRT. If we require any additional information we will be in contact with you.

I extend best wishes for a Happy Holiday Season and peace, prosperity and good health in the New Year.

Best regards,
Roger

On Friday, December 22, 2017 2:02 PM, David Brusick <[EMAIL]@aol.com> wrote:

Roger

Attached are the responses to the memo points with respect to the glyphosate genetic effects manuscript. The revised DOI was a collaborative effort with the other panel members. The responses to points 2-5 were prepared by me but reviewed by the other panel members.

If you have any questions or concerns about the DOI or other responses, please feel free to contact me.

David
Gary:

Thanks for the update on the response to our request related to the Special CRT Issue containing the 5 papers on Glyphosate. I look forward to receiving your response and that of the other first authors on the five papers. I have also received an update from Dave Brusick. I assume that all of the responses will be coordinated with Ashley so the revised Declarations of Interest on all 5 papers will accurately document any communications with any Monsanto personnel or other interested parties concerning the manuscripts.

Best wishes for peace, prosperity and good health in 2018.

Roger

On Wednesday, January 3, 2018 12:51 PM, “Williams, Gary” <[redacted]@nymc.edu> wrote:

Dear Roger,

We are working diligently on the responses that you requested. However, holidays and weather produced delays. I anticipate that we should finish next week.

Yours kindly,

Gary

Gary M. Williams, M.D.
Professor of Pathology.
New York Medical College
Dear Dr. McClellan,

Please find attached my return to your message/memo as below.

Thank you very much.

J.L.V. de Camargo, MD, PhD, FIATP
Professor of Pathology
Botucatu Medical School
18618-000 Botucatu SP Brazil

From: Roger McClellan
Sent: Thursday, December 07, 2017 5:42 PM
To: gary_williams@...; mjaardema@...; acquajohn@...; colin@...; brusick41@...; Michele.Burns@...; dhg3@...; helmut.greim@...; ldkier@...; root@...; ksolomon@...; T.M.Sorahan@...; marsh911@...; douglasweedd@...; charles.whalley@...;
Cc: Charles Whalley; Roger McClellan
Subject: BUSINESS CONFIDENTIAL

TO ALL:

Attached is the correct memo relating to the glyphosate papers. As I indicated earlier, please ignore and destroy the memo I sent earlier.

Roger McClellan
Dear Dr. McClellan,

Attached are edits and corrections to the DOI for the Exposure Paper and the Overview Paper. These are shown in track-changes in the attached file. I had copied the one for the Overview Paper to Gary Williams but have not heard back from him. I also spoke to Ashley about consolidation of the DOIs but that is apparently not being done. If you need further information, please get back to me.

Keith
Roger McClellan

From: Roger McClellan <roger.mcclellan@att.net>
Sent: Wednesday, January 10, 2018 10:06 PM
To: Williams, Gary
Cc: Charles Whalley; Roger McClellan; Mildred B. Morgan; Ashley Roberts Intertek
Subject: Re: glyphosate

Gary:

I would like to understand the nature of the events post publication of the papers that some of the authors desire to disclose. Perhaps, you can provide additional information including examples so Charles and I can better understand the situation.

Thank you for your assistance.

Roger

On Tuesday, January 9, 2018 12:49 PM, "Williams, Gary" <g-williams@nymc.edu> wrote:

Roger,

An issue has come up. Some authors want to disclose events after publication of the papers, whereas I thought we were revising the original declarations to capture all relevant facts at the time of preparation of the papers. I need your guidance.

Thanks and kind regards,

Gary

Gary M. Williams, M.D.,
Professor of Pathology,
New York Medical College
From: Williams, Gary @NYMC.EDU>
Sent: Thursday, January 11, 2018 7:13 AM
To: 'Roger McClellan'
Subject: RE: glyphosate

Roger,

After publication, several of the Panelists, including myself, were subpoenaed by plaintiffs’ attorneys. The question arose whether this should be included under “involvement in litigation”. Based on your response to my query, presently I think not, but I am open to your recommendation.

With the amount of back and forth, I do not expect completion until next.

With kind regards,

Gary

From: Roger McClellan [mailto:Roger McClellan]@att.net]
Sent: Thursday, January 11, 2018 12:06 AM
To: Williams, Gary
Cc: Charles Whalley; Roger McClellan; Mildrec B. Morgan; Ashley Roberts Intertek
Subject: Re: glyphosate

Gary:

I would like to understand the nature of the events post publication of the papers that some of the authors desire to disclose. Perhaps, you can provide additional information including examples so Charles and I can better understand the situation.

Thank you for your assistance.

Roger

On Tuesday, January 9, 2018 12:49 PM, "Williams, Gary" @NYMC.EDU> wrote:

Roger,

An issue has come up. Some authors want to disclose events after publication of the papers, whereas I thought we were revising the original declarations to capture all relevant facts at the time of preparation of the papers. I need your guidance.

Thanks and kind regards,

Gary

Gary M. Williams, M.D.,
Professor of Pathology,
Roger McClellan

From: Williams, Gary <NYMC.EDU>
Sent: Tuesday, January 23, 2018 8:53 AM
To: Roger McClellan
Cc: Ashley Roberts Intertek
Subject: RE: glyphosate

Roger,

I have today produced draft final responses and sent to Ashley for approval. Once I have his agreement I will circulate it to the Panel, finalize it and send to you and others.

All the best,

Gary

From: Roger McClellan [mailto:Roger.McClellan@att.net]
Sent: Tuesday, January 23, 2018 6:30 AM
To: Ashley Roberts Intertek
Cc: Williams, Gary; Charles Whalley; Mildred B. Morgan; David Brusick; John Acquavella; Keith Solomon; mbmorgan@intertek.com; Roger McClellan
Subject: Re: glyphosate

Ashley:

Thanks for the update on your response on this important matter. I and Charles Whalley are eager to receive the material from you concerning the Special Glyphosate issue of CRT so we can review it relative to the material provided by the other first authors. We do not think it appropriate to prematurely conclude a review of the other proposed revised Declarations of Interest since the information you provide could impact on the contents of any revised Declarations of Interest.

As you will recall it was your contact, and the timing of that contact, with Monsanto personnel that was not disclosed when the original papers were published that is at the heart of the controversy. Thus, it is important as we bring our investigation to a close and explore options for a final disposition that we have the information from you that we previously requested. It is important that we have complete and accurate disclosures from all the corresponding authors and you to conclude our investigation and resolution of the matter.

Please keep me informed as to your progress.

Thank you for your assistance on this very important matter. And best wishes for the New Year.

Regards,

Roger

Roger O. McClellan
Editor, Critical Reviews in Toxicology

On Friday, January 19, 2018 5:54 AM, Ashley Roberts Intertek <intertek.com> wrote:
Dear Roger,

I am still working on this so it will take a little time longer.

Best Wishes

Ashley

Ashley Roberts, Ph.D.
Senior Vice President – Food & Nutrition
Health, Environmental & Regulatory Services (HERS)

From: Ashley Roberts Intertek
Sent: January-11-18 8:32 AM
To: 'Roger McClellan'@att.net>
Cc: Gary Williams <wack@nymc.edu>; Charles Whalley <tan@tan-lf.co.uk>; Mildred B. Morgan <gray@hargray.com>
Subject: Re: glyphosate

Dear Roger,

Thank you for your email. I response to your request I will put together a chronology of events which I will try to get to you next week.

Regarding the DOI's for the individual papers I believe several of these have been provided by the lead authors and only the carcinogenicity paper remains outstanding. Please could you confirm?

Best Wishes

Ashley

Ashley Roberts, Ph.D.
Senior Vice President – Food & Nutrition
Health, Environmental & Regulatory Services (HERS)
Ashley:

I intended that you receive a copy of my response to the e-mail I had received from Gary Williams. In reviewing my e-mails I realized a copy was not sent to you. Attached is the communication from Gary and my response. In addition, I have summarized some key points that require your attention.

Charles and I are eager to receive the responses to our e-mail from the first authors concerning the papers in the special issue of CRT. I assume you are working with the authors. As will have noted we asked a series of questions and requested revised Declarations of Interest that are complete and accurate to potentially be published as replacements / supplements to the original DOIs. Since each original paper had its own DOI it is important that each original DOI be critically reviewed and a proposed revision be provided that is complete and accurate. Those proposed revised DOIs and the responses to the questions we proposed will hopefully allow us to conclude our investigation of this matter and decide on a course of action, dependent on the facts we are presented with, that will resolve the issues that have been raised. Dependent on the facts we are presented with one potential course of action may include publication of the revised DOIs and an over-arching piece authored by myself, as Editor, and Charles, as the representative of the publisher.

It is apparent that you had contacts with Monsanto personnel concerning the papers, thus, it is important that you respond to the questions that Charles and I have posed. This response from you goes beyond your role as a co-author of one of the papers. It is especially important that you provide a chronology of all your interactions with Monsanto personnel and any other parties with regard to the contents of the multiple papers included in the Special Supplement to CRT.

Please let me and Charles know, preferable by end of the business day on January 12, 2018, when we can expect to receive your response and that of the first authors as well as responses from any other authors that are germane.

Your timely assistance on this serious matter is greatly appreciated.

Roger

Roger O. McClellan
Editor, Critical Reviews in Toxicology

On Wednesday, January 10, 2018 4:42 AM, Roger McClellan wrote:
Gary:
Thanks for the update and question. In the communication to you and the other authors concerning the papers in the Special Glyphosate Issue we asked (1) a series of questions and (2) asked for proposed revised Declarations of Interest. Attention should be given to both.

You are correct that the focus is on providing information that will assist me, Charles Whalley and Taylor and Francis, as the Publisher in obtaining a complete and accurate view of all interactions with parties, other than the authors, up to the time the 5 papers were published online. We requested this information because it appears the original Declarations of Interest and Acknowledgements sections were not fully complete and accurate, especially as regards interactions with Monsanto personnel.

As I note, the focus is on interactions with Monsanto personnel and their potential influence on the contents of the 5 papers as published online. However, if there were any interactions by the authors with any other individuals or corporate representatives that the authors believe would be of interest to me, as the Editor, or Charles, as the T and F representative, as regards the preparation and contents of the papers that should be provided to us.

If there are any interactions that occurred after the papers were published online those interactions should also be revealed now. If in doubt, provide more rather than less information. This most certainly would include any interactions with representatives of Monsanto or Bayer or other corporate entities involved in the production and marketing of Glyphosate containing products or agencies such as IARC.

To restate the obvious, the central issue is the need for complete and accurate disclosures related to the contents of the 5 papers and how those papers were prepared. This information will assist Charles and me in determining how best to deal with this matter.

This inquiry is not intended to address new scientific information that may have been published after the 5 original reviews were published; that is a separate issue.

I hope this response is helpful to you. Again, if in doubt as to the relevance of any information please provide it to me and Charles so we can evaluate the information. We are eager to bring this matter to closure.

Thank you for your assistance.

Roger McClellan, Editor - Critical Reviews in Toxicology

On Tuesday, January 9, 2018 12:49 PM, "Williams, Gary" wrote.

Roger,

An issue has come up. Some authors want to disclose events after publication of the papers, whereas I thought we were revising the original declarations to capture all relevant facts at the time of preparation of the papers. I need your guidance.
Thanks and kind regards,

Gary

Gary M. Williams, M.D.,
Professor of Pathology,
New York Medical College
Ashley:

Charles and I are eager to resolve the issue of inadequacies in the Acknowledgements and Declaration of Interest sections of the papers in the Special Glyphosate issue. However, to do so I need a communication from you that fully informs us of your involvement with Monsanto prior to publication of the papers and assures us that the proposed, revised Acknowledgments and Declaration of Interest statements are completely accurate and complete. Each of the revised statements must reflect any communications you had with Monsanto concerning the papers.

When can I expect to receive the requested material from you?

Best regards, Roger

On Friday, February 2, 2018 11:05 AM, "Williams, Gary"@NYMC.EDU wrote:

Dear Roger,

On behalf of the Glyphosate Expert Panel, I am pleased to submit responses to your questions of September 15, 2017 concerning the Summary paper.

We found errors, which have been addressed in the revised Acknowledgement and DOI. I apologize for these.

If I can be of any further assistance, I am most willing to do so.

With kind regards,

Gary

Gary M. Williams, M.D.,
Professor of Pathology,
New York Medical College
Dear Roger,

Regarding the response that Dr. Williams provided to you earlier today regarding the summary publication, I can attest to these being accurate.

Regarding the preparation of the 4 expert panel manuscripts including the exposure paper, the animal cancer paper, the genotoxicity paper and the epidemiology paper, I concur with the declarations of interest that were provided by each of the lead authors. During my involvement in the program I was not aware of any changes or any edits conducted by Monsanto personnel to any of the individual manuscripts and therefore confirm that the evaluations and conclusions of the 4 Expert Panel groups, were those of the listed authors and no one else.

Best Wishes

Ashley

Ashley Roberts, Ph.D.

---

From: Roger McClellan [mailto:RM 000620]
Sent: February-02-18 1:59 PM
To: Ashley Roberts Intertek
Cc: Charles Whalley; Mildred B. Morgan; Gary Williams; David Brusick; Keith Solomon; John Acquavella
Subject: Fw: Responses to questions regarding Williams et al CRT, 2016
Ashley:
Charles and I are eager to resolve the issue of inadequacies in the Acknowledgements and Declaration of Interest sections of the papers in the Special Glyphosate issue. However, to do so I need a communication from you that fully informs us of your involvement with Monsanto prior to publication of the papers and assures us that the proposed, revised Acknowledgments and Declaration of Interest statements are completely accurate and complete. Each of the revised statements must reflect any communications you had with Monsanto concerning the papers.

When can I expect to receive the requested material from you?

Best regards, Roger

On Friday, February 2, 2018 11:05 AM, "Williams, Gary" <@NYMC.EDU> wrote:

Dear Roger,

On behalf of the Glyphosate Expert Panel, I am pleased to submit responses to your questions of September 15, 2017 concerning the Summary paper.

We found errors, which have been addressed in the revised Acknowledgement and DOI. I apologize for these.

If I can be of any further assistance, I am most willing to do so.

With kind regards,

Gary

Gary M. Williams, M.D.
Professor of Pathology,
New York Medical College

Total Quality Assured.

CONFIDENTIALITY NOTICE

This email may contain confidential or privileged information, if you are not the intended recipient, or the person responsible for delivering the message to the intended recipient then please notify us by return email immediately. Should you have received this email in error then you should not copy this for any purpose nor disclose its contents to any other person.

http://www.intertek.com
Dear Roger,

Please find attached the responses from the carcinogenicity group.

Kind regards,

Gary
Dear Roger,

I hope this finds you well today. I’ve had a busy month, so apologies for being quiet.

I have been reviewing the status of the glyphosate supplement. According to my emails, we have responses to our questions from all lead authors on each of the five articles, apart from the carcinogenicity paper. Gary Williams, lead author on that and on the summary paper, has provided a lengthy response regarding the summary paper but not, as far as I can see, for the carcinogenicity paper. Have I missed an email?

Ashley Roberts has confirmed that he is happy with the information provided by Gary Williams for the summary paper, the only paper on which Ashley is an author. Is there further information you’d like from Ashley?

Assuming we receive (or have already received) the revised Declarations of Interest and Acknowledgements from each lead author, as far as I can see the next step would be to use these responses to draft corrigenda for each article, and then send to the authors for their approval before publishing.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line [redacted]
Switchboard [redacted]
charles.whalley@tandf.co.uk
www.tandfonline.com

Taylor & Francis is a trading name of Informa UK Limited, registered in England under no. 1072954
Dear Roger,

Thanks for this. We will most likely publish each corrigendum separately, so they can be linked appropriately to their corresponding article; however, as this is a little unusual, I've sought the views of a few of my colleagues. We'll work out the best way to present this.

Best wishes,
Charles

Confidential and Private

Charles:
Attached is a draft Corrigenda for your review and comment. I have not yet decided how best to add the several references that are noted in several of the DOIs.

I have not shared this version with any of the authors. However, the material was all provided by the lead authors. I took the approach of providing a few paragraphs of context before presenting my original Acknowledgements and DOI sections for my Introductory Commentary and then the revised Acknowledgements and DOIs for each paper. There is considerable redundancy in the material. However, I think this is necessary so each article and related Acknowledgements and DOI section stands on its own.

I look forward to learning of your views.
Best regards,
Roger
Dr. Donley,
Thank you for bringing this matter to our attention. I trust that you and Messrs. Walley and McClellan will notify our news staff as soon as there is a decision concerning the request to retract the 2016 supplement.

Regards,
Peter Waldman
Bloomberg Businessweek
Tel. 

---

Hello Charles and Roger,

I am inquiring once again about the status of the investigation into scientific misconduct that occurred in the 2016 supplemental issue of Critical Reviews in Toxicology entitled "An Independent Review of the Carcinogenic Potential of Glyphosate."

It has been more than six months since this investigation began. I have attached the letter that was sent to you both on October 12th, 2017 by scientists from four national environmental-health organizations. I have also CC'd the 3 reporters who broke this story and whose initial inquiries sparked your investigation.
https://www.bloomberg.com/news/articles/2017-08-09/monsanto-was-its-own-ghostwriter-for-some-safety-reviews

Please let us know at your earliest convenience the status of your investigation.

Thank you,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

donley@centerforbiologicaldiversity.org

From: Nathan Donley
Sent: Wednesday, November 1, 2017 9:04 AM
To: Whalley, Charles; roger.o.mcclellan@whalley.com
Subject: RE: Retraction request

Great, thanks Charles

Nathan

From: Whalley, Charles [mailto:Charles.Whalley@whalley.com]
Sent: Wednesday, November 1, 2017 12:49 AM
To: Nathan Donley; roger.o.mcclellan@whalley.com
Subject: RE: Retraction request

Dear Nathan,
Thanks for your email. I can confirm that we have received your letter. Our investigation into these matters is still ongoing. I’ll be happy to update you in due course.

All best wishes,

Charles

---

From: Nathan Donley [mailto:NDonley[REDACTED]]
Sent: 31 October 2017 23:53
To: Whalley, Charles <Charles.Whalley[REDACTED]>
; roger.o.mcclellan[REDACTED]
Subject: Retraction request

Hello Charles and Roger,

Just checking in to make sure you got our retraction request. I want to thank you both for looking into this issue.

Nathan

---

From: Nathan Donley
Sent: Thursday, October 12, 2017 7:56 AM
To: 'Whalley, Charles'
Subject: Retraction request

Hello Charles,

Please find the attached letter from scientists from four national environmental-health organizations calling for a retraction of the summary review article that was published in the 2016 supplemental issue of Critical Reviews in Toxicology entitled "An Independent Review of the Carcinogenic Potential of Glyphosate."

Please feel free to contact me if you have any questions and please keep me updated on your investigation.
This letter was also sent to Roger McClellan and this matter forwarded to the Committee on Publication Ethics (COPE)

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity
ndonley@centerforbiologicaldiversity.org

RM 000628
Roger McClellan

From: Roger McClellan <roger.mcclellan@att.net>
Sent: Tuesday, February 27, 2018 4:12 PM
To: Charles Whalley
Cc: Mildred B. Morgan, Roger McClellan
Subject: Fw: Retraction request
Attachments: Retraction_letter_to_Critical_Reviews_in_Toxicology.pdf

Charles:
Are you available on Wednesday or Thursday to discuss how we should proceed in dealing with the glyphosate issue? What is the best number to call?
Best regards, Roger

Dr. Donley,
Thank you for bringing this matter to our attention. I trust that you and Messrs. Whalley and McClellan will notify our news staff as soon as there is a decision concerning the request to retract the 2016 supplement.

Regards,
Peter Waldman
Bloomberg Businessweek
Tel. 


From: NDonley At: 02/26/18 11:49:33
To: Charles Whalley, roger.mcclellan@att.net
Cc: Joel Rosenblatt (BLOOMBERG NEWSROOM: ), Peter Waldman (BLOOMBERG NEWSROOM: ), BFreese@, Caroline@, emilva

Hello Charles and Roger,

I am inquiring once again about the status of the investigation into scientific misconduct that occurred in the 2016 supplemental issue of Critical Reviews in Toxicology entitled “An Independent Review of the Carcinogenic Potential of Glyphosate.”

It has been more than six months since this investigation began. I have attached the letter that was sent to you both on October 12th, 2017 by scientists from four national environmental-health organizations. I have also CC’d the 3 reporters who broke this story and whose initial inquiries sparked your investigation.

https://www.bloomberg.com/news/articles/2017-08-09/monsanto-was-its-own-ghostwriter-for-some-safety-reviews

Please let us know at your earliest convenience the status of your investigation.
Thank you.

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity
ndonley@cbdnature.org

From: Nathan Donley
Sent: Wednesday, November 1, 2017 9:44 AM
To: Whalley, Charles, roger.o.mcclellan@,...
Subject: RE: Retraction request

Great, thanks Charles

Nathan

From: Whalley, Charles [mailto:cmcclellan@...]
Sent: Wednesday, November 1, 2017 12:49 AM
To: Nathan Donley; roger.o.mcclellan@...;
Subject: RE: Retraction request

Dear Nathan,

Thanks for your email. I can confirm that we have received your letter. Our investigation into these matters is still ongoing. I’ll be happy to update you in due course.

All best wishes,
Charles

From: Nathan Donley [mailto:NDonley@...]  
Sent: Thursday, October 12, 2017 7:56 AM  
To: Whalley, Charles; roger.o.mcclellan@...; roger.o.mcclellan@...  
Subject: Retraction request  

Hello Charles and Roger,

Just checking in to make sure you got our retraction request. I want to thank you both for looking into this issue.

Nathan

From: Nathan Donley  
Sent: Thursday, October 12, 2017 7:56 AM  
To: 'Whalley, Charles'  
Subject: Retraction request  

Hello Charles,

Please find the attached letter from scientists from four national environmental-health organizations calling for a retraction of the summary review article that was published in the

Please feel free to contact me if you have any questions and please keep me updated on your investigation.

This letter was also sent to Roger McClellan and this matter forwarded to the Committee on Publication Ethics (COPE)

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

On Monday, February 26, 2018 3:22 PM, Peter Waldman (BLOOMBERG NEWSROOM) wrote:
Dear Nathan,

Thanks for your email. I'm pleased to confirm that we are near the end of the investigation and hope to have concluded in the coming weeks. I'll be sure to notify you and any other interested parties at that time.

Best wishes from a chilly Oxfordshire,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: ☏
Switchboard: ☏
www.tandfonline.com
Taylor & Francis is a trading name of Informa UK Limited, registered in England under no. 1072954
It has been more than six months since this investigation began. I have attached the letter that was sent to you both on October 12th, 2017 by scientists from four national environmental-health organizations. I have also CC’d the 3 reporters who broke this story and whose initial inquiries sparked your investigation.

https://www.bloomberg.com/news/articles/2017-08-09/monsanto-was-its-own-ghostwriter-for-some-safety-reviews

Please let us know at your earliest convenience the status of your investigation.

Thank you,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity
[biologicaldiversity.org]

From: Nathan Donley
Sent: Wednesday, November 1, 2017 9:04AM
To: Whalley, Charles; roger.o.mcclellan
Subject: RE: Retraction request

Great, thanks Charles

Nathan

From: Whalley, Charles [mailto:]
Sent: Wednesday, November 1, 2017 12:49AM
To: Nathan Donley; roger.o.mcclellan
Subject: RE: Retraction request

Dear Nathan,

Thanks for your email. I can confirm that we have received your letter. Our investigation into these matters is still ongoing. I’ll be happy to update you in due course.

All best wishes,
Charles

From: Nathan Donley
Sent: Thursday, October 12, 2017 7:56 AM
To: Whalley, Charles; roger.o.mcclellan; [mailto]
Subject: Retraction request

Hello Charles and Roger,

Just checking in to make sure you got our retraction request. I want to thank you both for looking into this issue.

Nathan
To: 'Whalley, Charles'
Subject: Retraction request

Hello Charles,

Please find the attached letter from scientists from four national environmental health organizations calling for a retraction of the summary review article that was published in the 2016 supplemental issue of Critical Reviews in Toxicology entitled “An Independent Review of the Carcinogenic Potential of Glyphosate.”

Please feel free to contact me if you have any questions and please keep me updated on your investigation.

This letter was also sent to Roger McClellan and this matter forwarded to the Committee on Publication Ethics (COPE)

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity
@biologicaldiversity.org
Charles:

Thanks for the note. As I have conveyed to you, I cannot agree to the proposal for retraction you have offered in your memo of May 18th.

Alternatively, I am in the process of finalizing a memo entitled "Context for Decision-Making on Papers Published in Special Supplemental Issue on Potential Carcinogenic Hazard of Glyphosate". It has taken me some what longer to prepare this document and the attachments then I originally anticipated. I will get it to as soon as possible. I hope review of my memo and the attachments will provide you and your advisors a broader context for considering this very complex matter and the ramifications of two alternative courses of action.

By way of background I am interested in learning of any actions involving retraction of papers from Taylor and Francis journals that have occurred in the last 10 years. If you could share that information with me it will be useful to me in considering the context for your retraction proposal and the proposed course of action.

Best regards,
Roger

On Wednesday, May 30, 2018 2:25 AM, "Whalley, Charles" wrote:

Dear Roger,

I hope this finds you well today. We had a tremendous weekend of thunderstorms here.

Have you had time yet to review the information and policies that I sent on to you last week? In return, am I still expecting some additional notes and correspondence from you and Mildred?

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Millen Park, Abingdon, Oxon. OX14 4RN, UK
Direct line: [Redacted]
Switchboard: [Redacted]
www.tandf.co.uk

Taylor & Francis is a trading name of Informa UK Limited,
registered in England under no. 1072954
Charles:

I want you to have the attached papers in your files since they are relevant to our current and on-going discussions on the five Glyphosate papers and the question of who knew what and when.

My professional association with both Drs Larry Kier and Kirkland goes back decades since they are accomplished scientists in fields that I have followed for decades. Key facts as to their past employment and consulting activities are spelled out in the Declarations of Interest for both papers.

The point I am making is their professional and compensated relationships with Monsanto were well known to me before I received the five papers on Glyphosate ultimately published in the Special Supplement. There is no hidden or secret science involved and it very clear who paid the bills for the prior publications published before the IARC review or the five papers published in the CRT Special Supplement published after the IARC review.

I pride myself on my circle of acquaintances going back decades. I am rarely deceived by unknown and unrevealed relationships.

I wish other journals adhered to the standards used by CRT, it would make it easier to maintain our standards. I hope you appreciate how different the standards are for CRT compared to those used by most journals including those published by Taylor and Francis.

Best regards,
Roger

On Friday, June 1, 2018 11:51 AM, Mildred Morgan <hargray.com> wrote:

Attached are copies of Larry Kier’s published papers in CRT and both are on Glyphosate.
6/1/18

TO: Charles Whalley

FROM: Roger McClellan

SUBJECT: Context Memo

Charles:

Attached is a memo I have prepared to help guide my own decisions and, hopefully yours and your advisors, on handling the controversy around the five papers in the Glyphosate Supplement to Volume 46 of Critical Reviews in Toxicology. I hope that after you read this memo you will agree the best approach to handling the controversy is the approach we had mutually agreed on in March 2018—publish Revised Acknowledgements and Revised Declarations of Interest for each of the five papers.

I do not think retraction of any of the papers is appropriate. The papers were prepared in a scientifically sound manner without external influence from the Monsanto Corporation as attested to by all 16 authors and the papers report valuable conclusions. I acknowledge that the original Acknowledgements and Declarations of Interest were not fully adequate, however, I do not believe the flaws warrant retraction of the scientifically sound papers that draw conclusions of broad interest and global importance. It is also clear that the policies and procedures of Taylor and Francis were not adequate for handling complex authorship issues such as encountered with these papers. All of us can learn from this situation and take steps to improving our handling of review papers such as the Glyphosate papers that address important Societal issues at the interface of science and public policy. Retractions of the papers would do irreparable harm to multiple parties including, most of all, the authors, the Journal, the publisher and key employees such as you and, in addition, me in my role as the Scientific Editor of CRT. Moreover, retraction of the papers would remove from the public domain the scientific analysis and conclusions published in the papers.

As I have previously indicated, I am willing to travel to England for discussions with you and senior Taylor and Francis about these matters and their resolution and to also discuss strategies and actions to minimize the occurrence of future problems related to preparation, submission, review and publication of other papers on complex scientific matters at the interface of science and public policy. The need for thinking strategically on these matters is of vital importance because this is the niche that CRT fills in the scientific publication arena.

Respectfully,

Roger

On Thursday, May 31, 2018 3:35 PM, Mildred Morgan <mmpgray.com> wrote:

Final Context memo attached.

RM 000637
Context for Decision-Making on Papers Published in Special Supplemental Issue on Potential Carcinogenic Hazard of Glyphosate

"An Independent Review of the Carcinogenic Potential of Glyphosate," a supplement to Volume 46 (2016) of Critical Reviews in Toxicology (CRT) was published online on September 28, 2016. The Supplement contained a foreword (McClellan, 2016), a summary paper (Williams et al., 2016) and four detailed papers with evaluations undergirding the summary paper. The detailed papers addressed exposure evidence (Solomon, 2016), genotoxicity evidence (Brusick et al., 2016), animal carcinogenicity evidence (Williams et al., 2016), and epidemiological evidence (Acquavella et al., 2016).

The five papers were prepared by 16 internationally-recognized scientists whose efforts were coordinated by Ashley Roberts of Intertek with financial support from the Monsanto Company, a producer and marketer of products containing Glyphosate. Monsanto also produces and markets seeds for plants that are resistant to Glyphosate. Convening of the experts followed publication of an International Agency for Research on Cancer (IARC) Monograph in 2015 that reviewed the potential carcinogenic hazard of a group of herbicides, including Glyphosate. The IARC Panel (IARC, 2015; Guyton et al., 2015) concluded that Glyphosate was a probable human carcinogen (Class 2A).

The review of the Intertek Advisory group published in Critical Reviews in Toxicology, Supplemental Issue 1, Volume 46 (2016) concluded that Glyphosate exposure did not pose a carcinogenic risk to humans. As an aside, similar conclusions have been reached by other expert
groups such as JMPR, ECHA, EPA, EFSA, Brazil ANVISA and others. However, that is not
the subject of this overview.

The conflicting conclusions drawn by IARC and the Intertek advisors/authors have
received widespread media attention. The controversy over the human carcinogenic potential for
Glyphosate exposure has also been stimulated by regulatory debates around the world over
continued use of Glyphosate and Glyphosate-ready seeds and litigation in the United States over
the role of Glyphosate exposure in causing specific cases of human cancer. More recently, the
U.S. Congress has expressed interest in the activities of IARC and funding of IARC by U.S.
Agencies.

In the late summer of 2017, Taylor & Francis, the publisher of Critical Reviews in
Toxicology, initiated a review of the circumstances related to the formation and activities of the
Intertek Advisory Panel and preparation and publication of the five papers included in the
Special Supplement to Volume 46. The review was triggered by a letter from IARC over the
signature of Kathryn Z. Guyton raising questions about the preparation of the papers published in
Volume 46. This is the same Kathryn Z. Guyton who organized the IARC review of Glyphosate.
Although not revealed in her letter, it is apparent she has a vested interest in the Volume 46
papers that reach a different conclusion than the IARC review she managed (IARC, 2015;
Guyton et al., 2015). The Taylor & Francis review of the publication of the supplement
containing five inter-related papers has specifically involved Roger O. McClellan, Scientific
Editor of CRT, Charles Whatley, Managing Editor of CRT and other Taylor & Francis
personnel. A range of actions to conclude the Taylor & Francis review have been discussed,
focusing on the potential for (a) publishing corrected Declarations of Interest for five articles or
(b) retraction of one or more of the articles published on-line on September 28, 2016 as a Special
Supplement to Volume 46.

The purpose of this memo is to provide some context for decisions and future actions
with regard to the five papers prepared by the Intertek Advisors and published in Volume 46.
The author, Roger McClellan, Scientific Editor of Critical Reviews in Toxicology, has been
motivated to prepare this memo because of the perceived ad hoc manner in which tentative
decisions with regard to potential actions have been and are being made by Taylor & Francis
with regard to the five papers. Such ad hoc actions may lead to certain affected parties, such as
the authors, charging that the decisions made and actions taken are "arbitrary and capricious" and will cause irreparable harm to their professional and personal reputations.

**Specific Context**

The five papers in question are not original research papers typical of the vast majority of papers published in Taylor & Francis journals; they are in a broad sense review papers. However, it should be emphasized that these are not typical review papers. These papers specifically address the gathering and synthesis of scientific evidence related to evaluating the potential carcinogenic human health risks of exposure to Glyphosate. This is a highly specialized area of scientific activity in a field now generally referred to as "human health risk assessment or analysis." The author was invited to review this developing field in two addresses given at the U.S. National Academy of Science, Washington, DC in May and December 1997. The contents of the two addresses were published as a single paper — "Human Health Risk Assessment: A Historical Overview and Alternative Path Forward" in Inhalation Toxicology (McClellan, 1999), a Taylor & Francis publication. This important field at the interface of science and public policy started to emerge post-World War II and has continued to evolve and have substantial use and impact around the world.

A key component of risk-based decision-making is hazard identification — Does the agent cause an adverse effect such as cancer in humans? One of the first organizations to become involved in cancer hazard identification was the International Agency for Research on Cancer (IARC), a sub-unit of the World Health Organization located in Lyon, France, beginning in the early 1970s. IARC carries out its cancer hazard characterization activities in its Monograph Section by periodically assembling Panels of Experts to review and classify a group of closely related agents as to their carcinogenic potential. The review process is highly structured. For each agent being reviewed multiple lines of evidence are considered; sources, animal evidence, epidemiological evidence and mode of action (such as genotoxicity) to arrive at a summary conclusion. The summary conclusions are stated in a very straightforward manner without qualification; human carcinogen, probable human carcinogen, possible human carcinogen, probably not a carcinogen (only one compound has ever been placed in this category over the decades) or insufficient evidence to classify. This is the approach IARC used to classify Glyphosate as a probable human carcinogen (IARC, 2015; Guyton et al., 2015). The Intertek
Advisory Panel in the five papers in Volume 46 supplement of CRT reached a different conclusion; exposure to Glyphosate did not pose a human carcinogenic hazard.

The author of this memo is very familiar with IARC and, specifically, the Monograph program. He has served on advisory panels to the IARC Monograph Program recommending priorities for review of agents within the program, served on IARC monograph review panels and as an observer at IARC Monograph reviews.

**Advisory Panels**

As already noted, the IARC Monograph Program regularly uses Advisory Panels consisting of scientists drawn from multiple disciplines and residing around the globe to classify agents as to their carcinogenic potential. Similar approaches are used by many other international and national governmental agencies. Increasingly, private sector organizations are using similar Panels or Advisory bodies to address scientific issues, frequently those at the interface of science and public policy. In many cases, a private sector firm such as Monsanto will engage a consulting firm, such as Intertek, to manage the formation of a group of advisors and guide their activities. The composition of such Panels is quite variable and may include former or current employees of the firm requesting advice. Such individuals are of special value since they are aware of, and have access to, material not published in the open literature. The final product of the advisors may be a report of variable length from a few pages to a report identifiable as a scientific manuscript or a set of manuscripts.

CRT is frequently approached by individuals with regard to publishing such manuscripts. When asked why they have approached CRT, prospective authors usually respond; it is the high quality and rigor of the journal’s external review process. It is worthy of note that the five papers in Volume 46 were reviewed by 27 different reviewers selected by the CRT Scientific Editor. Because the papers were very inter-related some reviewers reviewed more than one paper. Indeed, several reviewers from the CRT Editorial Advisory Board reviewed all five papers. All reviewers were made aware of availability of the ensemble of five papers and given the opportunity to review copies for reference or review purposes. The papers were given rigorous review and the authors used the reviewers’ suggestions to improve the papers. This is a hallmark of CRT.

Copies of the reviews are attached. The review given the five papers was the most extensive ever given to papers published in Critical Reviews in Toxicology. I doubt that any
other five inter-related papers published in a Taylor & Francis journal in the last decade have received a similar level of review.

**Critical Reviews in Toxicology**

The Taylor & Francis Journal, Critical Reviews in Toxicology, is a unique journal and has been so since publication of the first issue in 1971-1972. The founding Editor, Leon Golberg, was a Scientist/Physician, educated in South Africa and the United Kingdom, who had a brief association with Albany Medical College in Albany, NY and then became the founding President of the Chemical Industry Institute of Toxicology (CIIT) in the 1970s. As a leading scientist in the emerging field of toxicology, he was aware of the need for a publishing venue for review papers that assembled and synthesized what was known, and the associated uncertainties about the toxicity and health risks of chemicals. This need gave rise to the creation of CRT. I suspect if CRT had originated slightly later, it would have been titled – "Critical Reviews in Toxicology and Human Risk Analysis." Dr. Golberg recruited me to the CRT Editorial Advisory Board based on my experience as a comparative toxicologist and risk analyst. I was trained in Veterinary Medicine, experienced in conducting research on radiation and chemicals in multiple species and recognized as one of the founders of the field of risk analysis. After Dr. Golberg’s retirement from CIIT and untimely death, I was asked by CRC Press to become Editor of CRT. Later, I would again follow in Golberg’s footsteps and become the third President of CIIT (1988-1999).

The unique nature of CRT has been reflected in its wide readership and impact. CRT is consistently ranked in the top 10th percentile of competing journals and its impact factor is among the highest of journals published by Taylor & Francis.

Readers and authors frequently note the timely nature and global interest in the topics covered in CRT articles. They also frequently note that the authors of articles published in CRT are drawn from all sectors of Society: academe, government, industry and consulting firms. This contrasts sharply with some journals viewed as having an anti-industry bias.

CRT has been a leader in attempting to create robust "Declarations of Interest" that go beyond the very typical Conflict of Interest statements published in many journals – "The authors have no conflicts of interest to declare." These bland, and sometimes meaningless statements, are rooted in the tradition of most journals publishing primarily, or exclusively, papers reporting original research findings. Indeed, a review of the Taylor & Francis guidance to
authors for most journals, including CRT, is focused on this kind of content. It is fair to note that Taylor & Francis has been slow to tailor the unique kind of guidance that is probably needed for authors who are going to publish in CRT. In the absence of well-developed guidance for authors, in my role as Editor of CRT, I have provided written guidance to authors. The nature of these communications is apparent from my now well-known communication to Ashley Roberts concerning the papers published in the Glyphosate supplement. Moreover, to the best of my knowledge, Taylor & Francis provides no specific published or written guidance to individuals, such as Ashley Roberts, who are functioning in a coordinating role assembling multiple, cross-linked papers for publication in a single Supplemental Issue. Such guidance needs to be developed.

Interactions with Monsanto and Intertek

As referenced in several papers included in the Volume 46 supplement, other papers on Glyphosate have been published in CRT. In some cases these papers were authored by Monsanto employees. It is my understanding that copies of those papers were provided to IARC and are referenced in the IARC Monograph (IARC, 2015).

It is not surprising that as Editor of CRT, I would be contacted with regard to potentially publishing a special supplemental issue on the potential human carcinogenicity of exposure to Glyphosate. My response was the same as I give to all prospective authors. The papers need to already identify how the papers were prepared and who funded their preparation. The paper or papers will be given careful consideration and rigorous review. If the papers are of appropriate quality they will be published post-revision. When dealing with the potential submission of closely related papers, I emphasize that all the papers in the group need to be submitted at close to the same date. This is essential since several papers may be sent to the same reviewer as in the case of some of the papers in Volume 46. Moreover, in some cases, as with the Glyphosate supplement, reviewers were made aware that multiple closely-related papers were under consideration and were available to the reviewers. I also note to potential authors that in the case of an ensemble of papers, a decision to publish each of the papers will require favorable review and acceptance of all the papers. It is important to note the CRT review process is rigorous and interactive. I recall the need in a past communication to an Informa employee that the CRT approach involved more than two reviewers checking the box – Accept. That Informa employee
could not understand why I was waiting for a third set of review comments and the paper would likely require revision.

Most importantly, in situations involved multiple papers to be published in a special supplement, I note the need for contact with the CRT Managing Editor, Charles Whalley, to handle all the business details related to the publication of any supplemental issue.

It is important to note I have no knowledge of the amount paid by Intertek/Monsanto to publish the special Glyphosate issue included in Volume 46. It should also be noted that as the Scientific Editor I receive no additional compensation for editing supplemental issues. In my opinion, Charles and I, in the past, have had an effective and appropriate working relationship with my handling of scientific editorial matters and his handling of the business details of CRT and serving as my primary contact at Taylor & Francis.

**Policies Versus Decision-Making Process**

As we have moved forward during the past 9 months addressing issues raised by external parties concerning the Glyphosate supplement to Volume 46 Taylor & Francis policies that could be identified were considered. However, I must quickly note that it was soon apparent these policies were not always current or relevant. On close examination, it was apparent that most of the policies did not recognize CRT’s role as a review journal versus other journals publishing original research findings. Most importantly, it appears the policies have rarely, if ever, been tested by the need to address concerns raised by external parties, especially when the external parties have strongly held and vested interests in achieving a particular outcome.

During the past 9 months, it has become increasingly apparent to me that policies alone are not sufficient to address the complex issues of concern relative to the Glyphosate issue contained in Volume 46. What is apparently missing is a documented structured decision tree for bridging from the written policies to their use in addressing specific issues. It is my impression that well-documented policies and procedures detailing who has the authority and responsibility for initiating various activities such as collecting information, evaluating and synthesizing the information, and offering alternative interpretations and proposed future actions with likely ramifications identified do not exist. If they exist they have never been shared with me. Such processes need to identify who has the ultimate authority to make various decisions and who has the secondary authority to review and approve the proposed decision. In some organizations this is called a decision-tree. To be effective it must be well documented,
including identification of all individuals participating in the decision-making process. If Taylor & Francis has such a system it has not been revealed to me. Some decision-tree structures frequently identify an “appeals step” for various parties that may be impacted by decisions. In the present situation, the 16 authors will clearly be impacted by some potential decisions that could be made. To date, I have not been included in any discussions that would consider the use of an “appeals step” prior to rendering of a final decision. Specifically, will the authors be notified of a proposed course of action before it is taken and given the opportunity to offer an appeal?

In the absence of a documented approach to decision-making, an ad hoc approach is likely to prevail. An ad hoc approach has a high likelihood of yielding some decisions and actions that will be identified by affected parties as being made in an “arbitrary and capricious manner.” This is a very serious outcome since it may result in inappropriate and irreparable harm to the reputation of some interested parties. It may also serve to trigger litigation.

**Affected Parties**

There are multiple parties that may be impacted by publication of any paper or ensemble of papers published in a scientific journal such as CRT. First and foremost, scientific journals exist to serve as a communication link between individual scientists or groups of scientists and the readers, other scientists, policy makers and the public. The publisher provides that bridge – journals. The publisher desires to maintain a positive reputation which, in turn, is impacted by the reputation of each of the journals it publishes. The authors of individual papers and their employers desire positive reputations. Reviewers also consider the reputation of journals when accepting time-consuming review assignments. Journal editors, such as myself, take pride in the reputation of the journal they edit. Finally, readers are attracted to journals that are held in high regard.

The inter-relationships between the multiple parties identified above are very complex. The situation is not without some vested interests. This includes certain parties that have special interests in promoting or degrading a particular paper or one of the parties identified. In the United States, special vested interests frequently become apparent in the course of litigation and regulatory activities.

As noted earlier, there are numerous law suits currently underway in the United States concerning alleged health effects of Glyphosate exposure. Also as noted earlier, regulatory
activities related to the use of Glyphosate are in play around the world. In all of these situations, there are parties that are pleased with the contents and conclusions presented on the five papers in the Glyphosate supplement. Likewise, there are parties that would like to undermine the credibility of the papers and the authors, including having the papers retracted.

Within this complex arena, publishers and journals have used a variety of approaches to help ensure the credibility of papers published in journals. One particular approach has been the use of “conflict of interest” policies. These policies have evolved over the past several decades with substantial emphasis on financial conflicts of interest. A major challenge is that conflicts of interest are in the eye of the beholder, not the declaree. Critical Reviews in Toxicology has attempted to go a step further by publishing “Declarations of Interest” (DOI) for all papers published in the journals. Some of these DOIs are quite lengthy. The goal is for the authors to declare their interests and let the reader decide as to any conflicts of interest. In my opinion, the DOI approach for Critical Reviews in Toxicology is on the right track and we need to work to continue to improve it.

Current Status

In my opinion, the approach used to date in addressing the concerns raised by external parties, including parties with a strong vested interest in the outcome, has been an ad hoc approach. Although the approach has been well intentioned and implemented in good faith by myself and Charles, it has been very ad hoc. I have read the concerns of outside parties and requested, with concurrence by Charles, clarifying information from the authors. This material has been provided to Charles Whalley. Charles has apparently conferred with other Taylor & Francis personnel, individuals who have not been identified to me.

Based on the feedback from the authors, I have identified serious shortcomings in both Taylor & Francis policies and procedures for handling review manuscripts, especially those involving multiple authors and those involving a coordinator for multiple manuscripts. As an aside, a process needs to be created and implemented to address these deficiencies. It is also apparent that the authors did not always carry out and document actions and interactions on their part that in retrospect should have been documented. In some cases, the attention of individual authors to details was sloppy. As a scientist, I can only assume their focus was on getting the science right, making certain the papers considered all the relevant scientific information and integrated and synthesized it and draw defensible conclusions.
However, I am mindful that all 16 authors, in individual statements, stated the five manuscripts were the work product of their independent review without any influence by Monsanto. A copy of the individual comments provided to me in September 2017, forwarded to Charles Whalley, is attached.

The comments of one of the Intertek advisors/authors, Sir Colin Berry, are shown below:

"As a former Chairman of the UK Advisory Committee on Pesticides and as Chairman of Section for Committee of the Medicines Act, I have, for many years, dealt with information concerning toxicity of xenobiotics in a consistent manner. Since retirement from those duties I have seen no reason to change my procedures. Information may come from any source but is used to provide the basis of my independent opinion.

In this instance, the members of the panel dealing with carcinogenicity produced text on the various issues before us in this field and considered the database identified in the document. We then met, or discussed electronically the various sections, about which we harmonized our views. At no stage was anyone from Monsanto involved in any of the discussions. Our opinion and the resultant document was arrived at in the manner which has been used by many regulatory authorities, as for example, the WHO/FAQ.

Drafting was carried out by regular exchanges by members of the panel alone."

Comments similar to those of Sir Berry were received from the other authors. The bottom line conclusion was that the papers accurately reflected the independent views of the authors and were not influenced by Monsanto.

Beyond the comments of the individual authors, I give substantial weight to the comments of 27 independent scientific reviewers of the five papers, my own reading of the published manuscripts and the clarity with which the papers make known that Monsanto paid for the advisory services provided and documented in the five papers and paid for publication of the special Glyphosate issue. It is up to the reader to form their own opinion as to whether there were any conflicts of interest.

Based on the foregoing information, it was and remains my personal and professional conclusion that the five papers are scientifically sound. However, I do think that some details of how the papers were prepared, submitted and edited could be clarified for the readers by publishing "Corrected Declaration of Interests" for each of the papers. In addition, there is probably a need for Taylor & Francis to acknowledge that its guidance to authors and its editorial
and production processes could be improved. I reached this conclusion in November 2017 and attempted to bring the process to closure at that time so corrections could be published in the printed copy of Volume 47 (2017). I was never given a clear explanation as to why delays from within Taylor & Francis prevented closure on these matters in 2017.

A set of Revised Acknowledgments and Revised Declarations of Interest for the five papers, dated February 8, 2018, are attached. These revised statements were developed by the authors and are considered to be accurate and complete. To be as complete as possible, they are longer than the typical Declarations of Interest published in Critical Reviews in Toxicology. Indeed, they may be viewed as setting a new standard for scientific publishing. I welcome a comparison to the Declarations of Interest or Conflict of Interest statements published for papers in other Taylor & Francis journals or those of other scientific publishers.

Just before the March 2018 Society of Toxicology meeting, Charles informed me that he had reached the same conclusion as I did - it would be appropriate to publish “Corrected Declarations of Interest.” This position was briefly discussed at the CRT Editorial Advisory Board meeting on March 14, 2018. Charles indicated at that time he had a few details that needed to be worked out regarding finalizing the publication of the corrected DOIs.

On May 18, 2018, Charles revealed to me that a different conclusion had been advanced that would involve retraction of three papers; the summary (Williams et al., 2016), the genotoxicity (Brusick et al., 2016) and the epidemiology (Acquavella et al., 2016) papers. This proposed decision involves all 16 authors because the summary paper includes all of the scientists involved with the Intertek coordinated advisory activities and preparation of the final submitted papers. It is not clear to me that the conclusions in the Charles Whalley e-mail of May 18, 2018, are fully supported by the information I obtained from the authors.

In my opinion, the retraction decision proposed in the e-mail of May 18, 2018 appears to be very narrowly crafted when viewed in the broad context of how the five papers were prepared, submitted, reviewed, revised and published. In the field of risk analysis some parties would call the approach taken in reaching a recommendation to retract would be called a “box-checking” exercise absent any exercise of professional judgment.

I submit that a broader approach is essential in view of the complexity of the situation. In the field of risk analysis the approach I am advocating is referred to as a “weight of the
evidence” approach. With this approach all of the facts must be gathered and synthesized and, then, alternative options considered and advanced as to possible paths forward.

I do not support a decision to retract the three papers based on my consideration of all the facts on this matter. The proposal to retract the three papers, in my professional opinion, appears to be “arbitrary and capricious” and not supported by consideration of all the relevant information. In particular, this decision goes counter to the information provided by the 16 individual authors.

In my telephone conversation with Charles Whalley on May 24, 2018, he indicated a decision as to how to proceed “could go either way.” In view of that conclusion I ask Charles to review the contextual information I have provided in this memo and respectfully ask him to agree to publish “Revised Declarations of Interest” for each of the papers published in the Glyphosate issue of Volume 46 based on the feedback we obtained from the authors. Ultimately, any material published will need to receive final approval from all the authors. The Declaration of Interest published with my Foreword (McClellan, 2016) will also need to be reviewed, and if deemed incomplete or inaccurate, revised. In addition to publication of the Revised Declarations of Interest, I suggest Ashley Roberts and other Intertek employees be excluded for 5 years from publishing in Critical Reviews in Toxicology. I take this position recognizing his critical role in coordinating the preparation of the five papers and their submission. I recognize this is a harsh penalty in view of the lack of written guidance from Taylor & Francis on filling his coordinating role.

In addition, I urge Taylor & Francis to initiate, at the earliest possible date, a critical review of all of the policies and procedures related to publishing review papers, such as those in the special Glyphosate issue, in Critical Reviews in Toxicology. I will be pleased to assist, as requested, drawing on my experience as Editor of Critical Reviews in Toxicology and other editorial experience gained over my career. It is quite possible some of our recent experience with this journal will be applicable to other Taylor & Francis journals.

As I have noted on several occasions, I am quite willing to travel to the Taylor & Francis offices in England for discussions if it will be useful in resolving this matter. I am embarrassed at being a participant in a matter that has been drawn out since September 2017. At that time I requested, with concurrence from Charles, clarifying information from the authors. That information was provided in a very prompt manner by the authors. The basis for the subsequent
delays all rest with Taylor & Francis staff. The “flip-flopping” that has occurred on potential
decisions and published corrections versus retractions, is especially troubling.

I am confident that working together, with input from the authors, this matter can be
brought to an orderly conclusion. The five papers are scientifically sound and of wide interest as
attested to by the frequency with which they have been accessed on-line. All 16 authors have
attested to the independence of their professional actions in preparing the papers; this position
needs to be recognized. The points raised in Charles’ retraction proposal need to be addressed in
“Revised Declarations of Interest.” In my opinion, the course of action I have proposed will
further enhance the reputation of Critical Reviews in Toxicology and further encourage the
submission of review manuscripts by accomplished authors on controversial topics important to
Society.

Respectfully,

Roger O. McClellan
Scientific Editor, Critical Reviews in Toxicology

Attachments:
1. Summary of Authors’ individual comments
2. Comments of Reviewers for the 5 Papers
3. Proposed Revised Acknowledgments and Revised
   Declarations of Interest Statements for Five
   Glyphosate Papers (February 8, 2018)

References

Glyphosate Epidemiology Expert Panel Review: A Weight of Evidence Systematic Review of
the Relationship Between Glyphosate Exposure and non-Hodgkin’s Lymphoma of Multiple

Brusick, David, Aardema, Kier, Larry, Kirkland, David and Williams, Gary. 2016. Genotoxicity
Expert Panel Review: Weight of Evidence Evaluation of the Genotoxicity of Glyphosate,
Glyphosate-Based Formulations, and Aminomethylphosphonic Acid. Crit. Rev. Toxicol. 46(S1):
56-74.


Charles,


Your positive comment on "how seriously you take matters like this" was greatly appreciated. My basic nature throughout my life and professional career has been, and remains, to be serious in critically analyzing situations and in making decisions. I might add that I expect the same of others. I view all the decisions I make as Editor of Critical Reviews in Toxicology (CRT) as serious matters. The decisions that must be made around the five papers in the special supplement are probably the most contentious in my decades of service as Editor of CRT.

Your memo identified a specific case from COPE’s archives as representing a precedent setting case. Did you or someone else select the case? In my professional opinion, whoever selected the case very likely does not have an in-depth understanding of the issues surrounding publication of the five Glyphosate papers. They certainly had not read my memo on "context." Let me explain.

(1) The author of the drug review did not reveal he had been a paid consultant to the company producing the drug. This is a central issue in the case. In contrast in the Glyphosate case, the fact that the critical review of the potential carcinogenic hazard of Glyphosate was being paid for by Monsanto Corporation, the company that originally discovered and marketed Glyphosate, was made known to me, the Editor of CRT, in my earliest conversations concerning the potential publication of the five papers. The prior employment and consulting relationships of key participants in the prospective review were also known to me.

(2) In my initial conversation with you concerning the potential for publishing the special supplement, I am confident I made known to you the role of Monsanto in paying for the conduct of the critical review and preparation of the multiple papers. It was very clear Monsanto would be paying directly, or through a third party, for publication of the special supplemental issue.
(3) Since its inception, I have followed the activities of the International Agency for Research on Cancer (IARC). Thus, I was aware for several years that IARC would be reviewing the carcinogenic hazard of Glyphosate. I was also aware that Monsanto would have a vested interest in the outcome of the IARC review.

(4) After I learned that a Panel of independent experts would be assembled to critique the IARC decision that “Glyphosate was a probable human carcinogen,” with financial support from Monsanto, I made it known to Monsanto representatives that CRT would be pleased to publish the Panel’s critique. I made clear that acceptance of the papers would be conditioned on the papers undergoing critical review and revision. Further, I made it known that rather than having the critique published in a single paper, I would recommend preparing several linked papers that would parallel the IARC review process. I also noted that use of a multi-author approach would allow clear recognition of the individuals carrying out various portions of the critique. My response to the inquiry on this matter was no different than that I regularly give to many individuals concerning prospective papers. CRT is in the business of publishing critical reviews! CRT competes with other journals to receive high-quality reviews on topics of global interest!

(5) When the review papers were completed and submitted, I became aware of the names and affiliations of all of the authors. This immediately confirmed, as I expected, that two individual authors, Drs. John Acquavella and Larry Kier, were previously full-time employees of Monsanto. This confirmed what I already knew. Indeed, Dr. Kier had published an earlier paper in CRT on Glyphosate, a paper prepared as a consultant to Monsanto post-employment by Monsanto. I was also confident that the peer members of the Glyphosate Panel whose work was funded by Monsanto were aware of the past and current funding status of Drs. Kier and Acquavella.

(6) As soon as I read the five papers and the summary conclusions that were counter to those reached by IARC, I anticipated that IARC would be very unhappy with the results of the Monsanto sponsored critique. I also speculated that various other parties, and especially those opposed to licensing and regulatory approval of Glyphosate for continued use, would be unhappy with the results presented in the Panel’s papers. Further, I recognized that various parties representing plaintiffs alleging health effects attributable to Glyphosate exposure were also going to be displeased with the Panel’s papers and conclusions. However, I recognize my role as Editor is to not select “Winners and Losers;” it is to publish papers of high-scientific quality.

(7) My approach to the anticipated controversy was to make certain the five papers were subjected to as rigorous an external review as that given any paper published in CRT. This was accomplished by engaging, without compensation, 27 experts from around the world who provided 36 sets of review comments. Several members of the CRT Editor’s Advisory Board reviewed all five papers. Recall the drug review paper you sent and proposed as setting precedent was reviewed by two individuals!
I have carefully reviewed the COPE documentation on the drug review paper your memo advances as a precedent for action on the five Glyphosate papers. I respectfully disagree that this paper serving in any way to set precedent for the handling of the five Glyphosate papers.

In my professional opinion, the five Glyphosate papers are scholarly pieces of work clearly documenting the process used to critique the IARC report and provide an alternative hazard characterization. The statements of the 16 individual authors testify to the independence of their work. The independent process used in preparing the critique is clearly captured in the statement of Sir Colin Berry quoted in my context memo. The five papers are scientifically sound.

Review of the alleged precedent only serves to strengthen my conviction that it would be a breach of scientific ethics and my own standards of scientific integrity to agree to retraction of any or all of the Glyphosate papers published in the special supplemental issue of CRT. I agree that certain aspects of the process by which the five papers were prepared and published could have been improved, especially documentation. I do recommend publishing “Revised Acknowledgments and Revised Declarations of Interest Statements” for all five papers.

Beyond bringing actions on the five Glyphosate papers to closure, it is critically important that a rigorous review be initiated of the Taylor and Francis process for preparation and submission of papers, especially when the journal, such as CRT, uses a “Declaration of Interest.” The current on-line documentation is out of date. In part, this situation has developed as CRT has put in place much more rigorous processes to minimize perceived and real conflicts of interest than used by most Taylor and Francis journals.

Respectfully,

Roger
Hi Peter,

My colleague, Charles, has passed your email on to me and you may also have seen his email yesterday to Nathan Donley on this, which you were also copied in to (both to the original query and Charles' reply) and which answers your question below.

We are presuming that you would also like to be informed as soon as our investigation has completed and a decision has been reached, and so we will ensure we contact you as soon as we reach that point.

Best wishes, Elaine

Elaine Devine | Associate Communications Director (Content and Communications)
Taylor & Francis Group

Mr. Whalley and Dr. McClellan,

Dr. Donley's note below reminds me that you said in February that a conclusion to your investigation of this matter was weeks away. Can you please let me know what's taking so long?

Thanks,

Peter Waldman
Bloomberg News

Hello Charles and Roger,

I am writing to inquire a third time on the status of our request for retraction of the article entitled "An Independent Review of the Carcinogenic Potential of Glyphosate." It has been 10 months since Dr. McClellan indicated in an interview that this investigation had...
begun and eight months since Taylor and Francis received our request for retraction laying out definitive evidence of ethical misconduct in the publishing of this review article. *Critical Reviews in Toxicology* has had similar requests for retraction by concerned scientists that have received no response and had no corrective action taken (2013 letter regarding false conflict of interest disclosures in asbestos safety review [here](#)). It is my sincere hope that this is not becoming a pattern or practice for this journal.

In response to allegations of favoritism towards industry-funded studies ([here](#) and [here](#)), *Critical Reviews in Toxicology* often touts its “Declaration of Interest” section as an effective and transparent cataloguing of potential conflicts that the authors possess. However, if the conflict of interest disclosure contains false statements or significant omissions (or both, as in this case), it is no longer effective or transparent – it is meaningless.

In the last couple of weeks, two peer-reviewed papers have been published that have detailed this issue in the scientific literature. I have attached both in this email. The reason this case has received, and will continue to receive, so much attention is because these ethical violations are so blatant and so egregious.

I ask you both to please consider the standards to which you are willing to hold scientists who publish in your journal, if not for the reputation of the journal itself, then for the regard of science in general. When the public keeps reading of instances where industry manipulates “independent” scientific research, it erodes trust in the scientific process at a time when that trust is needed more than ever. Bad actions must have consequences or else those actions will keep occurring.

It is Taylor and Francis’s policy to issue retractions for misconduct “when there has been an infringement of publishing ethics....” A corrigendum is not appropriate in this instance because this was not the result of an author’s error or mistake. As outlined in our retraction request, public records show that Dr. McClellan told the corresponding author specifically what information should be included in the Declaration of Interest and at least some of the authors were aware or should have been aware that information contained in that declaration was false. Retraction is the appropriate course of action in this case.

Please let us know at your earliest convenience the status of your investigation and your plans for action regarding this matter.
Thank you,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

Dear Nathan,

Thanks for your email. I’m pleased to confirm that we are near the end of the investigation, and hope to have concluded in the coming weeks. I’ll be sure to notify you and any other interested parties at that time.

Best wishes from a chilly Oxfordshire,

Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK

Direct line: [Redacted]
Switchboard: [Redacted]
@tandf.co.uk
Hello Charles and Roger,

I am inquiring once again about the status of the investigation into scientific misconduct that occurred in the 2016 supplemental issue of Critical Reviews in Toxicology entitled "An Independent Review of the Carcinogenic Potential of Glyphosate."

It has been more than six months since this investigation began. I have attached the letter that was sent to you both on October 12th, 2017 by scientists from four national environmental-health organizations. I have also CC'd the 3 reporters who broke this story and whose initial inquiries sparked your investigation.

https://www.bloomberg.com/news/articles/2017-08-09/monsanto-was-its-own-ghostwriter-for-some-safety-reviews

Please let us know at your earliest convenience the status of your investigation.
Thank you,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity
971-717-6406
@biologicaldiversity.org

From: Nathan Donley
Sent: Wednesday, November 1, 2017 9:04 AM
To: Whalley, Charles; roger.o.mcclellan@...<redacted>
Subject: RE: Retraction request

Great, thanks Charles

Nathan

---

From: Whalley, Charles [mailto:...@tandf.co.uk]
Sent: Wednesday, November 1, 2017 12:49 AM
To: Nathan Donley; roger.o.mcclellan@...<redacted>
Subject: RE: Retraction request

Dear Nathan,

Thanks for your email. I can confirm that we have received your letter. Our investigation into these matters is still ongoing. I’ll be happy to update you in due course.

All best wishes.

Charles
Hello Charles and Roger,

Just checking in to make sure you got our retraction request. I want to thank you both for looking into this issue.

Nathan

Hello Charles,

Please find the attached letter from scientists from four national environmental-health organizations calling for a retraction of the summary review article that was published in the 2016 supplemental issue of Critical Reviews in Toxicology entitled “An Independent Review of the Carcinogenic Potential of Glyphosate.”

Please feel free to contact me if you have any questions and please keep me updated on your investigation.

This letter was also sent to Roger McClellan and this matter forwarded to the Committee on Publication Ethics (COPE)

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

@biologicaldiversity.org
Yes, thank you.

----- Original Message ----- 
From: Elaine Devine <elaine.devine@tandf.co.uk>
At: 27-Jun-2018 00:44:00

Hi Peter,

My colleague, Charles, has passed your email on to me and you may also have seen his email yesterday to Nathan Donley on this, which you were also copied in to (both to the original query and Charles’ reply) and which answers your question below.

We are presuming that you would also like to be informed as soon as our investigation has completed and a decision has been reached, and so we will ensure we contact you as soon as we reach that point.

Best wishes, Elaine

Elaine Devine | Associate Communications Director (Content and Communications)
Taylor & Francis Group
Mr. Whalley and Dr. McClellan,

Dr. Donley’s note below reminds me that you said in February that a conclusion to your investigation of this matter was weeks away. Can you please let me know what’s taking so long?

Thanks,

Peter Waldman

Bloomberg News

From: NDonlev@blo... At: 06/25/18 07:22:17
To: Charles.Whalley@blo..., roger.o.mcclellan@blo...
Cc: Joel.Rosenblatt@BL... , Peter.Waldman@BL... , BFreese@BL..., Carolinger@BL..., emilyB@BL..., carey@BL..., sheldon.Krisny@BL..., leemon.mchenry@BL..., Lisa.Song@BL..., hakim@BL...
Subject: Glyphosate Review Retraction Request

Hello Charles and Roger,

I am writing to inquire a third time on the status of our request for retraction of the article entitled “An Independent Review of the Carcinogenic Potential of Glyphosate.” It has been 10 months since Dr. McClellan indicated in an interview that this investigation had begun and eight months since Taylor and Francis received our request for retraction laying out definitive evidence of ethical misconduct in the publishing of this review article. Critical Reviews in Toxicology has had similar requests for retraction by concerned scientists that have received no response and had no corrective action taken (2013 letter regarding false conflict of interest disclosures in asbestos safety review here). It is my sincere hope that this is not becoming a pattern or practice for this journal.

In response to allegations of favoritism towards industry-funded studies (here and here), Critical Reviews in Toxicology often touts its “Declaration of Interest” section as an effective and transparent cataloguing of potential conflicts that the authors possess. However, if the conflict of interest disclosure contains false statements or significant omissions (or both, as in this case), it is no longer effective or transparent – it is meaningless.
In the last couple of weeks, two peer-reviewed papers have been published that have detailed this issue in the scientific literature. I have attached both in this email. The reason this case has received, and will continue to receive, so much attention is because these ethical violations are so blatant and so egregious.

I ask you both to please consider the standards to which you are willing to hold scientists who publish in your journal, if not for the reputation of the journal itself, then for the regard of science in general. When the public keeps reading of instances where industry manipulates “independent” scientific research, it erodes trust in the scientific process at a time when that trust is needed more than ever. Bad actions must have consequences or else those actions will keep occurring.

It is Taylor and Francis’s policy to issue retractions for misconduct “when there has been an infringement of publishing ethics...” A corrigendum is not appropriate in this instance because this was not the result of an author’s error or mistake. As outlined in our retraction request, public records show that Dr. McClellan told the corresponding author specifically what information should be included in the Declaration of Interest and at least some of the authors were aware or should have been aware that information contained in that declaration was false. Retraction is the appropriate course of action in this case.

Please let us know at your earliest convenience the status of your investigation and your plans for action regarding this matter.

Thank you,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

[Redacted email address]
Dear Nathan,

Thanks for your email. I’m pleased to confirm that we are near the end of the investigation and hope to have concluded in the coming weeks. I’ll be sure to notify you and any other interested parties at that time.

Best wishes from a chilly Oxfordshire,

Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK

www.tandfonline.com
Hello Charles and Roger,

I am inquiring once again about the status of the investigation into scientific misconduct that occurred in the 2016 supplemental issue of Critical Reviews in Toxicology entitled "An Independent Review of the Carcinogenic Potential of Glyphosate."

It has been more than six months since this investigation began. I have attached the letter that was sent to you both on October 12th, 2017 by scientists from four national environmental-health organizations. I have also CC'd the 3 reporters who broke this story and whose initial inquiries sparked your investigation.

https://www.bloomberg.com/news/articles/2017-08-09/monsanto-was-its-own-ghostwriter-for-some-safety-reviews

Please let us know at your earliest convenience the status of your investigation.

Thank you,

Nathan Donley, Ph.D

Senior Scientist, Center for Biological Diversity
Great, thanks Charles

Nathan

Dear Nathan,

Thanks for your email. I can confirm that we have received your letter. Our investigation into these matters is still ongoing. I'll be happy to update you in due course.

All best wishes,

Charles

From: Nathan Donley
Sent: Wednesday, November 1, 2017 9:04AM
To: Whalley, Charles; roger.o.mcclellan@...}
Subject: RE: Retraction request
Hello Charles and Roger,

Just checking in to make sure you got our retraction request. I want to thank you both for looking into this issue.

Nathan

From: Nathan Donley  
Sent: Thursday, October 12, 2017 7:56 AM  
To: 'Whalley, Charles'  
Subject: Retraction request

Hello Charles,

Please find the attached letter from scientists from four national environmental-health organizations calling for a retraction of the summary review article that was published in the 2016 supplemental issue of Critical Reviews in Toxicology entitled "An Independent Review of the Carcinogenic Potential of Glyphosate."

Please feel free to contact me if you have any questions and please keep me updated on your investigation.

This letter was also sent to Roger McClellan and this matter forwarded to the Committee on Publication Ethics (COPE)

Nathan Donley, Ph.D  
Senior Scientist, Center for Biological Diversity  

@biologicaldiversity.org
Dear Roger,

Thanks for your email. Please don’t interpret Elaine’s response as anything other than a holding message. You’ll have seen, I hope, my other email to you about a teleconference between you, me and two of my colleagues (including our Editorial Director) to discuss precisely these next steps. I’m eager to get this in the diary as soon as possible, so once you’ve had time to read through, please let me know when we can talk all together.

Best wishes as ever.
Charles

Charles:

I am uncertain of the nature of your contact with Elaine Devine in the T and F PR unit. I am curious as to why she feels it necessary to contact and provide a promissory note to Bloomberg. It is my understanding that no firm decision has yet been made concerning a very complicated matter. I have certainly not agreed to your proposal and remain optimistic that we can reach a more equitable agreement for all parties.

If she is “thirsty” for something to do she should start creating a broad based list of media contacts for use when a press release is appropriate. I can assure you that the contacts provided by Nathan Donley are not broadly representative of US media. He is certainly not main stream US science, indeed, to call him a scientist is a stretch. I urge you to check out all four of the organizations he presumes to represent.

If she feels compelled to start writing now she can prepare one under the title of “Taylor and Francis over-rides long time scientific editor”. I hope we do not have to use this one, I am willing to keep the discussions open.

I remain open to coming to England to meet with you and senior officials of T and F/Informa to attempt to reach a resolution equitable to all parties on a very complicated issue. I hope you and your colleagues are open to considering various levels of “punishment”, not just a “life in prison” term for the scientists including a “knighthed English scientist”

Best regards,
Roger
Roger McClellan

From: Cohen, Samuel M. <sam.1@unmc.edu>
Sent: Friday, June 29, 2018 10:00 AM
To: Roger McClellan <mcmcc@att.net>
Subject: FW: McClellan Memo on Glyphosate Papers

Roger, I did not get the memo referred to in this email.
For your information, I have consulted for Monsanto and Bayer in the past and have done research in my laboratory
supported by them, although that was more than a decade ago.
I do not currently consult for either of them.

Sam

From: Gunnar Johanson <gjohanson@ki.se>
Sent: Thursday, June 28, 2018 10:46 AM
To: Charles Whatley <l@hargray.com>; bolti@kcl.ac.uk; roger.o.mcclellan@unmc.edu; mildred.morgan@hargray.com;
david_dorman@unmc.edu; f.guengerich@unmc.edu; Cohen, Samuel M <sam.1@unmc.edu>; shuji.tsuda@iwate-u.ac.jp
Subject: RE: McClellan Memo on Glyphosate Papers

Non-UNMC email

Dear Roger and all,
This is just to state that I have no, and have never had, any involvement with Monsanto, nor with Bayer. Further, I did
not review any of the glyphosate papers. My only involvement in this matter was my advice that the sponsorship by
Monsanto of the special issue as well as all the authors’ funding and potential conflicts of interest should be made very
clear in print as well as in online versions. His was also done as far as I could see.
Best summer wishes,
Gunnar

Gunnar Johanson  |  Ph D  |  Senior Professor
Unit of Work Environment Toxicology
Institute of Environmental Medicine
Karolinska Institutet
Nobel vagen 13 | P.O. Box 210 | SE-171 77 Stockholm, Sweden
Tel: +46-8-443 9000  |  Fax: +46-8-443 9001  |  M: +46-70-597 91 71  |  E: gjohanson@ki.se
http://www.ki.se/unit-of-work-environment-toxicology
https://www.nordicemex.org

656

RM 000670
TO ALL:

Attached is a memo from Dr. Roger O. McClellan on "Issues Related to CRT Volume 46 Supplement: An Independent Review of the Carcinogenic Potential of Glyphosate." Also attached is a file which has all of the five papers and Dr. McClellan's Foreword published on-line in on September 28, 2016.

Mildred Morgan
Assistant to Roger McClellan
Tel: [redacted]
Fax: [redacted]
Email: [redacted]@hargray.com

The information in this e-mail may be privileged and confidential, intended only for the use of the addressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you have received this e-mail by mistake, please delete it and immediately contact the sender.
Charles:

In reviewing correspondence between you and Nathan Donley I have observed a situation that is extremely disturbing to me. Nathan Donley on his e-mails to you has regularly included by cc copy a number of individuals from the media. I have been informed by individuals more knowledgeable of these matters than I that this is an approach regularly used by individuals very knowledgeable and savy of interactions with the media.

It is quite clear to me that Mr Donley and his organization have a vested interest in having the five papers published in the 2016 Special Supplement of CRT removed from public view and access. Part of their campaign is to undermine the credibility of the Journal and me as the Editor. This is not a particularly well veiled attempt if you carefully read his e-mail which are filled with innuendos. He has also skillfully made use of e-mails that were released related to litigation in California on alleged health effects related to exposure to Glyphosate. I suspect the validity of the statements made in many of those e-mails will ultimately be challenged in the court. For now, in my opinion they are hearsay.

By responding to Mr Donley and including all his addresses you are assisting him in raising concerns as to my scientific and editorial abilities and the credibility of Critical Reviews in Toxicology as a reliable source of scientific information. I am sure you have responded in good faith to Mr Donley and may not have recognized how you were being used by him to achieve his goals. Ms Devine fell in to the same trap. I am surprised because she is in the T an F PR group and those individuals should be aware of this common ploy.

In any event, I am asking you to NOT include any cc recipients when you respond to Mr Nathan when the e-mail contains any reference to me or Critical Reviews in Toxicology. I have invested thousands of hours over the last 30 years in advancing CRT as a leading scientific journal in the field of toxicology and risk analysis. Moreover, my hard earned scientific credibility and reputation is at stake. I am confident you and the senior most personnel at Informa and Taylor and Francis understand this symbiotic relationship and do not want to see any party damaged by Mr Donley's skillful manipulation of these issues. That includes the scientific authors of the Glyphosate papers and any other papers published in CRT. I am confident I need not remind you that without those authors CRT can not exist to serve the public interest by communicating sound science.

On a related matter, I request that you and other Taylor and Francis personnel share with me in advance of their release any proposed media releases related to my foreword and the five papers in the special Glyphosate supplement to CRT.

I would appreciate your sharing this memo with Boyd and more senior individuals at Informa and with the T and F PR personnel.

Please acknowledge in writing that you have received this e-mail and understand my concerns.

Best regard,
On Thursday, July 5, 2018 1:21 AM, "Whalley, Charles" wrote:

Dear Nathan,

I'm not able to give you a timeline on this as our emphasis is always to complete any investigation thoroughly and to the highest standard, ensuring we have gathered all relevant information. This does mean timelines can and do change as we move through any case, as I'm sure you can appreciate.

Best wishes,
Charles

Thank you for your response Charles. Do you have an idea of when this investigation might conclude? About four months ago you had mentioned that it would be “concluded in the coming weeks.” I’m curious as to the sudden change in timeline.

Nathan


As you know, the ethical investigation into this supplement has been on-going since 2017. We are fully aware of the number of months this has taken but this is a complex case with a number of authors and papers. It is our responsibility as the publisher to ensure we have been thorough in our review, following both Committee on Publication Ethics guidance and our own corrections and retractions policy in our approach and decisions (which you have also referenced).

As the publisher, we take this responsibility very seriously and while the investigation is on-going we cannot provide you with more detailed updates, which we appreciate is frustrating. We will however be in touch with
you as soon as this process has reached its conclusion, so you are fully aware of the outcome and the ultimate decisions reached. Thank you for your on-going interest in this case.

All best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: [redacted]
Switzerland: +41 61 306 12 34

*This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or anything in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately and notify the sender.*

Informa Group plc: Registered in England & Wales No. 3699067 | 5 Hewitt Place | London | SW1P 1WG

---

**From:** Nathan Donley (mailto: [redacted]@biological/versity.org)

**Sent:** 25 June 2018 15:22

**To:** Whalley, Charles (<mailto: Charles.Whalley@tandf.co.uk>); roger.o.mcclellan@usda.gov; mlwhalley@tamu.edu; Bill Freese (<mailto: Bill.Freese@CenterforFoodSafety.org>); Caroline Cox (<mailto: Caroline.Cox@nrc.org>); Emily Marquez (<mailto: Emily.Marquez@propublica.org>); John Kriensky, Sheldon. (<mailto: sheldon.sheerson@tufts.edu>); McHenry, Leemon B (<mailto: leemonb@csun.edu>); Lisa Song (<mailto: Lisa.Song@propublica.org>); hakim@

**Subject:** Glyphosate Review Retraction Request

Hello Charles and Roger,

I am writing to inquire a third time on the status of our request for retraction of the article entitled “An Independent Review of the Carcinogenic Potential of Glyphosate.” It has been 10 months since Dr. McClellan indicated in an interview that this investigation had begun and eight months since Taylor and Francis received our request for retraction laying out definitive evidence of ethical misconduct in the publishing of this review article. *Critical Reviews in Toxicology* has had similar requests for retraction by concerned scientists that have received no response and had no corrective action taken (2013 letter regarding false conflict of interest disclosures in asbestos safety review here). It is my sincere hope that this is not becoming a pattern or practice for this journal.

In response to allegations of favoritism towards industry-funded studies (here and here), *Critical Reviews in Toxicology* often touts its “Declaration of Interest” section as an effective and transparent cataloguing of potential conflicts that the authors possess. However, if the conflict of interest disclosure contains false statements or significant omissions (or both, as in this case), it is no longer effective or transparent – it is meaningless.

In the last couple of weeks, two peer-reviewed papers have been published that have detailed this issue in the scientific literature. I have attached both in this email. The reason this case has received, and will continue to receive, so much attention is because these ethical violations are so blatant and so egregious.

I ask you both to please consider the standards to which you are willing to hold scientists who publish in your journal, if not for the reputation of the journal itself, then for the regard of science in general. When the public keeps reading of instances where industry manipulates “independent” scientific research, it erodes trust in the
scientific process at a time when that trust is needed more than ever. Bad actions must have consequences or else those actions will keep occurring.

It is Taylor and Francis’s policy to issue retractions for misconduct “when there has been an infringement of publishing ethics....” A corrigendum is not appropriate in this instance because this was not the result of an author’s error or mistake. As outlined in our retraction request, public records show that Dr. McClellan told the corresponding author specifically what information should be included in the Declaration of Interest and at least some of the authors were aware or should have been aware that information contained in that declaration was false. Retraction is the appropriate course of action in this case.

Please let us know at your earliest convenience the status of your investigation and your plans for action regarding this matter.

Thank you,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

Please let us know at your earliest convenience the status of your investigation and your plans for action regarding this matter.

Thank you,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

Dear Nathan,

Thanks for your email. I’m pleased to confirm that we are near the end of the investigation, and hope to have concluded in the coming weeks. I’ll be sure to notify you and any other interested parties at that time.

Best wishes from a chilly Oxfordshire,

Charles
Hello Charles and Roger,

I am inquiring once again about the status of the investigation into scientific misconduct that occurred in the 2016 supplemental issue of Critical Reviews in Toxicology entitled “An Independent Review of the Carcinogenic Potential of Glyphosate.”

It has been more than six months since this investigation began. I have attached the letter that was sent to you both on October 12th, 2017 by scientists from four national environmental-health organizations. I have also CC’d the 3 reporters who broke this story and whose initial inquiries sparked your investigation.

https://www.bloomberg.com/news/articles/2017-08-09/monsanto-was-its-own-ghostwriter-for-some-safety-reviews

Please let us know at your earliest convenience the status of your investigation.

Thank you,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity
biodiversity.org

From: Nathan Donley
Sent: Wednesday, November 1, 2017 9:04 AM
To: Whatley, Charles; roger.o.mcclelland@umich.edu
Subject: RE: Retraction request

Great, thanks Charles

Nathan

From: Whatley, Charles [mailto:charles.whelley@umich.edu]
Sent: Wednesday, November 1, 2017 10:40 AM
To: Nathan Donley; roger.o.mcclelland@umich.edu
Subject: RE: Retraction request

Dear Nathan,

Thanks for your email. I can confirm that we have received your letter. Our investigation into these matters is still ongoing. I’ll be happy to update you in due course.

All best wishes,
Charles

From: Nathan Donley [mailto:nathan@biologicaldiversity.org]
Sent: 31 October 2017 23:53
Hello Charles and Roger,

Just checking in to make sure you got our retraction request. I want to thank you both for looking into this issue.

Nathan

From: Nathan Donley
Sent: Thursday, October 12, 2017 7:56 AM
To: Whalley, Charles
Subject: Retraction request

Hello Charles,

Please find the attached letter from scientists from four national environmental-health organizations calling for a retraction of the summary review article that was published in the 2016 supplemental issue of Critical Reviews in Toxicology entitled “An Independent Review of the Carcinogenic Potential of Glyphosate.”

Please feel free to contact me if you have any questions and please keep me updated on your investigation.

This letter was also sent to Roger McClellan and this matter forwarded to the Committee on Publication Ethics (COPE)

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

protect@biologicaldiversity.org
Dear Nathan,

I think Mr. Whalley is lying. There is really no basis for the delay, other than the very likely strategy that has been imposed by Taylor & Francis lawyers. This is very common — delay, delay, delay, and it will all go away.

In the meantime, this is playing out with big stakes in a courtroom in San Francisco starting today. The opening statement by the plaintiff's lawyer, Brent Wisner, focused on one of the Monsanto sponsored fraudulent articles and introduced the jury to the concept of ghostwriting.

Best,

Leemon
As you know, the ethical investigation into this supplement has been on-going since 2017. We are fully aware of the number of months this has taken but this is a complex case with a number of authors and papers. It is our responsibility as the publisher to ensure we have been thorough in our review, following both Committee on Publication Ethics guidance and our own corrections and retractions policy in our approach and decisions (which you have also referenced).

As the publisher, we take this responsibility very seriously and while the investigation is on-going we cannot provide you with more detailed updates, which we appreciate is frustrating. We will however be in touch with you as soon as this process has reached its conclusion, so you are fully aware of the outcome and the ultimate decisions reached. Thank you for your on-going interest in this case.

All best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any electronic, downloading, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error please destroy it immediately, and notify the sender.

Informa Group plc. Registered in England & Wales No. 5095671 | 5 Howick Place | London | SW1P 1WG

From: Nathan Donley [mailto:jdonley@biologicaldiversity.org]
Sent: 25 June 2018 15:22
To: Whalley, Charles ^mailto:charles.whalley@tandf.co.uk^; roger.mcclellan@tandf.co.uk
Cc: Bill Freese <^mailto:bmcclellan@centerforfoodsafety.org^>; Caroline Cox <^mailto:caroline.cox@ceh.org^>; Emily Marquez <^mailto:emily.marquez@parma.org^>; jrosenblatt@propublica.org; carey@multimedia.org; Krimsky, Sheldon <^mailto:sheldon.krimsky@tufts.edu^>; McHenry, Leemon B <^mailto:leemon@csun.edu^>; Lisa Song <^mailto:lisasong@propublica.org^>; hakim@jcrd.com
Subject: Glyphosate Review Retraction Request

Hello Charles and Roger,

I am writing to inquire a third time on the status of our request for retraction of the article entitled “An Independent Review of the Carcinogenic Potential of Glyphosate.” It has been 10 months since Dr. McClellan indicated in an interview that this investigation had begun and eight months since Taylor and Francis received our request for retraction laying out definitive evidence of ethical misconduct in the publishing of this review article. Critical Reviews in Toxicology has had similar requests for retraction by concerned scientists that have received no response and had no corrective action taken (2013 letter regarding false conflict of interest disclosures in asbestos safety review here). It is my sincere hope that this is not becoming a pattern or practice for this journal.

In response to allegations of favoritism towards industry-funded studies (here and here), Critical Reviews in Toxicology often touts its “Declaration of Interest” section as an effective and transparent cataloguing of potential conflicts that the authors possess. However, if the conflict of interest disclosure contains false
statements or significant omissions (or both, as in this case), it is no longer effective or transparent - it is meaningless.

In the last couple of weeks, two peer-reviewed papers have been published that have detailed this issue in the scientific literature. I have attached both in this email. The reason this case has received, and will continue to receive, so much attention is because these ethical violations are so blatant and so egregious.

I ask you both to please consider the standards to which you are willing to hold scientists who publish in your journal, if not for the reputation of the journal itself, then for the regard of science in general. When the public keeps reading of instances where industry manipulates “independent” scientific research, it erodes trust in the scientific process at a time when that trust is needed more than ever. Bad actions must have consequences or else those actions will keep occurring.

It is Taylor and Francis’s policy to issue retractions for misconduct “when there has been an infringement of publishing ethics.” A corrigendum is not appropriate in this instance because this was not the result of an author’s error or mistake. As outlined in our retraction request, public records show that Dr. McClellan told the corresponding author specifically what information should be included in the Declaration of Interest and at least some of the authors were aware or should have been aware that information contained in that declaration was false. Retraction is the appropriate course of action in this case.

Please let us know at your earliest convenience the status of your investigation and your plans for action regarding this matter.

Thank you,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

[biologicaldiversity.org]

---

From: Whalley, Charles [mailto:Charles.Whalley@tandf.co.uk]
Sent: Wednesday, February 28, 2018 2:27 AM
To: Nathan Donley; roger.o.mcellean@tandf.co.uk
Cc: Bill Fraser; Caroline Coss; Emily Marquez; Stecker, Tiffany; irensenblatt@tandf.co.uk; bpaulmannia@tandf.co.uk
Subject: RE: Retraction request

Dear Nathan,

Thanks for your email. I'm pleased to confirm that we are near the end of the investigation, and hope to have concluded in the coming weeks. I'll be sure to notify you and any other interested parties at that time.

Best wishes from a chilly Oxfordshire,

Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: [redacted]
Switchboard: [redacted]
www.tandfonline.com

Taylor & Francis is a trading name of Informa UK Limited.
From: Nathan Donley
Sent: 26 February 2018 19:49
To: Whalley, Charles
Cc: Bill Freese;
       Stecker, Tiffany
       (Center for Food Safety);
       Caroline Cox;
       Emily Marc (bloomberenvironment.com);
       jroesnblatt@...;
       pwaldman@...;
       rocker.o.mcclellan@...;
       Caroline Cox;
       Emily Marc (bloomberenvironment.com);
       jroesnblatt@...;
       pwaldman@...
Subject: Retraction request

Hello Charles and Roger,

I am inquiring once again about the status of the investigation into scientific misconduct that occurred in the 2016 supplemental issue of Critical Reviews in Toxicology entitled “An Independent Review of the Carcinogenic Potential of Glyphosate.”

It has been more than six months since this investigation began. I have attached the letter that was sent to you both on October 12th, 2017 by scientists from four national environmental-health organizations. I have also CC’d the 3 reporters who broke this story and whose initial inquiries sparked your investigation.

https://www.bloomberg.com/news/articles/2017-08-09/monsanto-was-its-own-ghostwriter-for-some-safety-reviews

Please let us know at your earliest convenience the status of your investigation.

Thank you,

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

From: Nathan Donley
Sent: Wednesday, November 1, 2017 9:04 AM
To: Whalley, Charles
Subject: RE: Retraction request

Great, thanks Charles

Nathan

From: Whalley, Charles
Sent: Wednesday, November 1, 2017 12:49 AM
To: Nathan Donley
Subject: RE: Retraction request

Dear Nathan,
Thanks for your email. I can confirm that we have received your letter. Our investigation into these matters is still ongoing. I’ll be happy to update you in due course.

All best wishes,
Charles

From: Nathan Donley [mailto:ndonley@biologicaldiversity.org]
Sent: 31 October 2017 23:53
To: Whalley, Charles <roger.o.mcclellan@tandf.co.uk>; roger.o.mcclellan@tandf.co.uk
Subject: Retraction request

Hello Charles and Roger,

Just checking in to make sure you got our retraction request. I want to thank you both for looking into this issue.

Nathan

From: Nathan Donley
Sent: Thursday, October 12, 2017 7:56 AM
To: Whalley, Charles
Subject: Retraction request

Hello Charles,

Please find the attached letter from scientists from four national environmental-health organizations calling for a retraction of the summary review article that was published in the 2016 supplemental issue of Critical Reviews in Toxicology entitled “An Independent Review of the Carcinogenic Potential of Glyphosate.”

Please feel free to contact me if you have any questions and please keep me updated on your investigation.

This letter was also sent to Roger McClellan and this matter forwarded to the Committee on Publication Ethics (COPE)

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

ndonley@biologicaldiversity.org
I just realized that Dr. McHenry replied-all on that last email. I'm not sure if that was intentional or by accident but it was completely unprofessional. Please accept my sincere apologies and know that it does not reflect my opinion or that of my colleagues.

I included Dr. McHenry on this email chain because of the recent paper he wrote on this subject. I will not be including him on any future correspondences.

And thank you for the work you are doing on this investigation, Charles.

Nathan Donley, Ph.D
Senior Scientist, Center for Biological Diversity

[biologicaldiversity.org]
Roger McClellan

From: Roger McClellan <Roger.McClellan@att.net>
Sent: Thursday, July 5, 2018 1:29 PM
To: Whalley, Charles
Cc: Roger McClellan, Mildred B. Morgan
Subject: Re: Letter 21 August 2017/ Special Supplement on Glyphosate

Charles;

In reviewing my files on the Glyphosate Issue I retrieved this memo from you. In the second full paragraph you make reference to a time consuming "review of all the authors connected with this matter" and concluded "we identified no serious issues for CRT".

I would appreciate receiving a copy of that report so I will have it in my files for future reference. I assume the report will describe the nature of the "review of all authors" and the results.

Related to this investigation I will relate to you a story about myself, CRT and investigations. Some time about the turn of the century my high level security clearance for providing advice to the Director of the Central Intelligence Agency on terrorism activities was being updated. After several rounds of completing paper work and investigations the individual who was conducting the review came to my home for further discussions. He noted that there was a discrepancy between my previous answers and their findings. One finding of concern was my compensation from the publisher of Critical Reviews in Toxicology. I had identified myself as a subcontractor, they noted the publisher had identified me as an employee. Hence, they needed to speak personally with my supervisor. I indicated I had no supervisor at the publisher. After much discussion, I gave them the name of my contact in Boca Raton, FL.

A few months later my contact in FL called and was quite upset. She related they were investigating me and were going to personally come to see her the next day -she asked -- "What should I tell them?" My response was tell them "Dr McClellan was a fine upstanding US citizen and the best of her knowledge never done anything to over throw the US government."

A month later the investigator came to my home for a wrap up. He said --"I think you are OK, nothing new has emerged!" But, what a waste of time. Your prior neighbors in North Carolina did not seem to know you. The lady in FL seemed to have only one response -- "I have never seen Dr McClellan, however, I know he is a fine US citizen and has never did anything to over throw the US government."

I hope your investigation of me revealed that I have been a valuable editor for CRT for 30 years and despite many allegations that I was friendly with industry you could not find a substantive basis for not trusting my scientific judgement on important scientific issues of importance to Society at large. If you go in to finances I think you will find that CRT has been a regular contributor to the series of companies that have owned CRT.

I am serious in requesting a copy of the report of the review of the 16 authors.

Best regards,
Roger
On Friday, September 1, 2017 8:23 AM, "Whatley, Charles" <whalley.charles@tandf.co.uk> wrote:

Dear Roger.

My apologies, I’m at home today but occupied some urgent meetings.

Rest assured that there is movement on our side. With the assistance of our internal publication ethics team, we have completed a review of all authors connected with this matter for all previous submissions in all related T&F journals, which was, as you’d expect, an extensive piece of work. You’ll be pleased to hear that we identified no serious issues for CRT.

Currently, we are reviewing the contractual basis of the glyphosate supplement as well as reviewing how best to approach contact to all authors connected to it. This involves our legal counsel in the UK and the US. I’m hoping to get an agreement from them soon.

Would you like me to call you on Monday 4th? I’m back in the office and things will be quieter come 4pm UK time.

Best wishes,
Charles

From: Roger McClellan [mailto:rmcclel@att.net]
Sent: 31 August 2017 15:13
To: Whalley, Charles <whalley.charles@tandf.co.uk>
Cc: Mildred B. Morgan <margray.com>; Roger McClellan <rmcclel@att.net>
Subject: Re: Letter 21 August 2017/Special Supplement on Glyphosate

Charles:
I just attempted to reach you by telephone and was not successful. I did leave you a message as to my views on how to proceed. I am eager to learn who the T and F personnel are who are involved in the investigation and their plans and schedule for proceeding. In my opinion, it is important to proceed expeditiously. Can we set up a conference call for tomorrow, September 1st or early next week?
Best regards,
Roger

On Thursday, August 31, 2017 5:43 AM, "Whalley, Charles" <whalley.charles@tandf.co.uk> wrote:

Dear Roger,

Thanks for this. I’ll discuss with colleagues.

Best wishes,
Charles

From: Roger McClellan [mailto:rmcclel@att.net]
Sent: 30 August 2017 16:20
To: Whalley, Charles <whalley.charles@tandf.co.uk>
Cc: Mildred B. Morgan <margray.com>; Roger McClellan <rmcclel@att.net>
Subject: Fw: Letter 21 August 2017/Special Supplement on Glyphosate
Hi Pat,

YES, thank you! I can open these files. Dr. McClellan is going to call Dr. Kier and see if he will send us a CV.

Mildred Morgan
Assistant to Roger McClellan
Tel: 
Fax: 
Email: @hargray.com

Hi Mildred.

Thanks for your e-mail. Could you please try opening the enclosed and let me know if you can access. If not I will have our IT people check into or send as individual files. Ashley’s c.v. has been added. Please let Dr. McClellan know we do not have Dr. Kier’s c.v. on file but can ask him for it if required.

Best regards,

Pat

Dear Patricia:

Dr. McClellan forwarded me your e-mail with the Monsanto Panel in a zip file and when I try to open the CVs, my system comes up with an error message - “Windows cannot complete extraction – destination could not be created.” I would appreciate it if you could check the zip file and make sure that I can open these CVs. I have never had a problem opening a Zip file. If I cannot do that, you might have to send each CV separately.

Also, I am missing CVs for Dr. Ashley Roberts and Dr. Larry Kier which need to be included in the list.
Thanks for your help.

Mildred Morgan
Assistant to Roger McClellan
Tel: [redacted]
Fax: [redacted]
Email: [redacted]

From: Roger McClellan [mailto:[redacted]@att.net]
Sent: Friday, July 13, 2018 2:10 PM
To: Mildred B. Morgan
Subject: Fw: Expert Panel C.V.s

Mildred:
Please retain.
Roger

On Friday, July 13, 2018 11:49 AM, Patricia Borror Intertek [mailto:[redacted]@intertek.com] wrote:

Dear Dr. McClellan,

On behalf of Dr. Roberts please find enclosed the c.v.s of the expert panelists on the Glyphosate Expert panel.

If I can be of further assistance, please do not hesitate to contact me.

Best regards,

Pat

Patricia Borror

Intertek, 2233 Argentia Rd., Suite 201, Mississauga, ON L5N 2X7
Dear Roger,

Many thanks for passing this on. Please continue to just forward these to us.

Best wishes,
Charles

From: Roger McClellan
Sent: 02 August 2017 21:20
To: Whalley, Charles
Cc: Roger McClellan; Mildred B. Morgan
Subject: Fw: Glyphosate papers/ another inquiry- I do not intend to respond

On Tuesday, August 1, 2017 4:03 PM, "Hakim, Danny" wrote:

Mr. McClellan -- I'm writing on the latest back of glyphosate papers and will mention some of the latest details regarding the CRT and Monsanto relationship. Let me know if you want to comment. Thanks

On Tue, Mar 14, 2017 at 2.45 PM, Hakim, Danny wrote:

Mr. McClellan -- I'm writing a story tonight on the unsealing of records in the Monsanto/glyphosate litigation. The documents raise questions about the disclosures made in glyphosate papers that appeared in Critical Reviews in Toxicology. The disclosures in CRT say that "expert panel members recruitment and evaluation of the data were organized and conducted by Intertek." It also says that Monsanto did not review "any of the Expert Panel's manuscripts prior to submission."

E-mail traffic released by the court show that Monsanto executives actually came up with the names of the panelists and "discussed approaches for literature and data reviews." Monsanto executives even discussed that "An option would be to add Greim and Kier or Kirkland to have their names on the publication, but we would be keeping the cost down by us doing the writing and they would just edit & sign their names so to speak. Recall that is how we handled Williams Kroes & Munro 2000."

This raises questions about the accuracy of the disclosures made in CRT.

Let me know if you'd like to comment.

Thanks
Dear Roger,

Thanks for this and your other emails. I will try to collect together the information you've mentioned for our call, along with an agenda, all of which I will send to you in advance. Please can you let me know your schedule at the earliest opportunity so I can book this call in. I'm hopeful it will be very productive.

Best wishes,
Charles

p.s. I had recalled you telling me that you'd stayed in Abingdon, but not the name of the hotel. My girlfriend and I had a drink at the Crown and Thistle (or, more properly, the pub in the courtyard attached to it) only last week. The Crown and Thistle claims a very early 'established' date, which my girlfriend idly scoffed at. I'll have to tell her that it is accurate at least up to 1962.

Charles:

Thanks for the note. I am pleased to learn you are moving to Abingdon. On my first visit to England in July 1962, my bride of one month (Kathleen) and I stayed at the Crown and Thistle. The next day my bosses boss and I headed off for a meeting with senior Harwell AEA personnel. I had prepared a talk for my bosses boss, however, as was frequently the case, he developed a sore throat so I ended up giving the talk after all.

I will check my schedule for the week of July 22nd. In the meantime, please send me your biography and Todds and those of any other people you expect to have on the call.

As I have noted I am available to fly to England to meet with you and senior T and F personnel to attempt to reach a resolution on this complex issue that is equitable to all parties (T and F, the authors, me as Editor in Chief, readers and users of the papers, and the public).

Best regards,
Roger
Dear Roger,

My colleague Todd is on holiday in the week commencing July 15th. Would the following week (commencing July 22nd) suit you?

Safe travels,
Charles

---

From: Whalley, Charles
Sent: 02 July 2018 09:25
To: 'Roger McClellan' <att.net>
Subject: RE: CRT Supplement now published Note the extensive DOI

Dear Roger,

Thanks for your email, and indeed for your voicemails. I’ve been leaving the office promptly of late as I’m moving house (from Oxford to Abingdon), so have not been around for your calls. I enjoy our chats too much to purposefully avoid them.

I do think it would be quicker to tie all this up on the phone with my colleagues Todd and Sarah. **Please can you give me an idea of which mornings this week and next you would be free?** Todd is travelling between London and New York this week, and then of course the 4th July holiday approaches, but I will do my best to get us all on the phone together as soon as possible.

I’d of course be grateful to hear any input from the Editorial Board.

Best wishes,
Charles

---

From: Roger McClellan <att.net>
Sent: 02 July 2018 01:44
To: Whalley, Charles <att.net>
Subject: Fw: CRT Supplement now published Note the extensive DOI

Charles:

I was doing some work this evening reconstructing all the events associated with the negotiations to publish, the review of the papers and the final acceptance of the papers for the special Glyphosate Supplement. I remain very proud of this issue and appreciate your assistance in bringing it to fruition. I remain impressed by the Declaration of Interest statements, including the one included with my foreword. Most importantly, the five papers are scientifically sound and it is clear the papers were prepared with financial support from Monsanto.

My position remains unchanged. Yes, there were some mistakes made along the way with these papers. Some by Taylor and Francis, some by me, some by the coordinator (Ashley Roberts) and some by the authors. However, I remain convinced that the five papers reflect the independent views of the 16 authors. They have all offered independent verification of that in their own words. Do you not give any validity to these statements and the reputations of those 16 scientists?

I urge you to agree to my recommendation to publish corrected and expanded Declaration of Interest statements and abandon the “we gotcha” approach with Retraction of the papers. I can assure that
approach likely to be viewed by many including the courts as arbitrary and capricious and will likely do great harm to the authors, Taylor and Francis, the future of Critical Reviews in Toxicology, the readership of CRT, the public and to me. I have served as Editor in Chief of CRT for 30 years reviewing over 1000 papers and bringing CRT to a leadership position in the Taylor and Francis portfolio of Journals. I have at the same time earned a solid reputation as a scientist and editor who sets high standards and deals with my scientific peers and others in a fair manner. I will not allow my well-earned reputation to be tarnished by arbitrary and capricious actions by others.

Does some one within Taylor and Francis hold a view that the only successful outcome is retraction or they will not have done their job.? If so I will remind them that successful managers operate using a "management by objectives" approach not count the beans approach. In this case, we need to collectively attempt to reach agreement on an equitable outcome that is FAIR to the authors, the publisher, CRT readers, the public and me as the Editor-in-Chief and the CRT Editorial board. We must not take an approach that determines winners and losers in legal cases based on what is allowed to appear in the peer reviewed literature. That is clearly the position of some of the critics.

As I have repeatedly noted, I am willing to fly to England at my expense to meet with you, your advisors and the senior most Taylor and Francis officials that I can be given access to during my visit. This is a very serious matter that needs to be resolved at an early date.

One question for you that was raised by one of the CRT Editorial Board members -- Has anyone within Taylor and Francis or any external parties raised any questions as to the scientific validity of the five inter-related reviews and the conclusions drawn? I HAVE HEARD NONE-- THE PAPERS ARE SCIENTIFICALLY SOUND!!

A second question to you is can you provide me any single paper or collection of papers published by Taylor and Francis that contain Declaration of Interest statements that equal or begin to approach those included with my foreword and the five papers? I take full responsibility for providing the directions for their preparation. As you know, Taylor and Francis did not then or does it provide today a set of clear directions to authors for preparation of Declarations of Interest! If you and your associates wish to be helpful to prospective authors and to me you could provide clear succinct directions to authors for preparation of DOIs. I do not want some oblique references to Conflicts of Interest, I envision explicit directions that scientific authors can follow. Please let me know if you think this is a reasonable expectation and, if it is, when would be a reasonable target date for me to receive a draft for me to review along with members of the CRT Editorial Board.

Conversations with Editorial Board members have raised other issues that I will bring to your attention in a separate e-mail. One question is the issue of dealing fairly with authors. Taylor and Francis personnel, including you, seem to have focused on dealing with the external critics and journalists. Perhaps, you assumed I would provide periodic updates to the authors. If so, I have been negligent. Should not those accused of misdeeds receive the same courtesies as those who level the accusations?

With best regards,
Roger

On Thursday, September 29, 2016 8:54 AM, Roger McClellan <rm@t.net> wrote:
Charles:
I will call at 4 PM your time. I am interested if you have any conversations with Jim Bus on the
Barbara Neal paper. Regards, Roger

On Thu, 9/29/16, Whalley, Charles <[redacted]@tandf.co.uk> wrote:

Subject: CRT Supplement now published
To: "Roger McClellan" <[redacted]att.net>, "Whittle, Jenna"
Cc: "mbmorgan@att.net" <[redacted]informa.com>, "Vasili, Temis" <[redacted]informa.com>
Date: Thursday, September 29, 2016, 12:45 AM

Dear
Roger,

I note that
the glyphosate supplement is now published online and all
showing as Open Access. The full table of contents is
accessible at the following link:
http://tandfonline.com/toc/itxc20/46/sup1?nav=tocList
This has been a considerable amount of work on all sides so
I’m delighted to see it come to fruition

I’m
in the office today if you wanted to follow up on this by
phone. Between 3:30 and 4pm UK time I shall be on the phone
(incidentally to a toxicologist at the University of New
Mexico), but
otherwise I should be available and at my desk.

Very best
wishes,
Charles

Charles Whalley
- Managing Editor, Medicine & Health Journals
Taylor & Francis Group
Dear Charles:

Dr. McClellan will be providing you the cover letter on the “Context for Decision-Making on Papers Published in Supplemental Issue on Potential Carcinogenic Hazard of Glyphosate.” This memo has 7 attachments which I will be forwarding you with this e-mail. They are:

1. Summary of Authors’ individual comments
2. Comments of Reviewers for the 5 papers

Let me know if you need anything else.

Mildred Morgan
Assistant to Roger McClellan
Tel: [Redacted]
Fax: [Redacted]
Email: [Redacted]@hargray.com
Mildred:
Please retain in Glyphosate file. Thanks, Roger

On Wednesday, June 27, 2018 1:20 AM, "Whalley, Charles" <Charles.Whalley@tandf.co.uk> wrote:

Dear Roger,

Thank you again for your detailed memo regarding the glyphosate supplement. I have now fully digested it and consulted with colleagues. You raise several points which I shall try to address.

By way of this email, I'd first like to introduce my colleague Sarah Robbie (CCed), our Head of Peer Review Policy & Research Integrity. Sarah leads our in-house team on publication ethics, and has worked together with COPE for many years. I'd also like to introduce Todd Hummel (CCed), the Editorial Director for Medicine & Health Journals. Although we have also involved legal counsel and others, both Todd and Sarah have been my main advisors on this matter. We would like to have a teleconference with you soon. Are you available either at the end of this week or early next? Please let me know your availability over the rest of this week and the next, and I'll do my best to schedule something with us all.

As you know well, this has been a complex and unusual matter, and one in which we have worked carefully to abide by industry standards. We are confident that the outcome proposed is in line with both our policies and with COPE guidelines.

To summarise, the authors of this supplement submitted their manuscripts with Declarations of Interest statements. We have since learnt, most importantly from the authors themselves, that for 3 of the manuscripts these statements were not correct. Specifically, the involvement of the ultimate sponsor and its representatives was misrepresented rather than simply omitted: the original Declarations of Interest explicitly contradicted what we now know to be the case. This can only be categorised as misconduct and a breach of publishing ethics. Taylor & Francis’ applicable policies here are quite clear: “Retractions for misconduct are made when there has been an infringement of publishing ethics or a breach of author warranties”. Similarly, COPE Guidelines on Retractions state: “Retractions are also used to alert readers to [a] failure to disclose a major competing interest likely to influence interpretations or recommendations.”

There is certainly a need to better establish a mutual understanding of the expectations around declarations of interest for CRT, amongst all involved. I would emphasise, however, that the breaches of publication ethics that we have identified in this case are clear breaches of fundamental and clearly defined standards, and not attributable to misunderstandings of detail or nuance.

Finally, I want to reassure you that another clear outcome of the investigation is that the peer review process of these manuscripts was entirely consistent with the high standards of the journal. There’s
no question over your handling of the manuscripts or the supplement as a whole. Retractions are evidence that editorial policies are working, not that they have failed.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: [redacted]
Switchboard: [redacted]
www.tandf.co.uk

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately and notify the sender.

Informa Group plc | Registered in England & Wales No. 3099067 | 5 Howick Place | London | SW1P 1WG
Dear Roger

I have carefully read the Corrigendum, and there is nothing stated that would change my view about the scientific objectivity and acceptability of the papers on glyphosate. The authors are internationally recognized experts and highly regarded in their fields, and thus, it is not surprising they have served as consultants, including for industry. And although two may have consulted for Monsanto on litigation involving glyphosate, the papers are multi-authored and represent the view of a panel, not a single individual. Also, how the authors were paid is not relevant (i.e. directly by Monsanto or by Intertek). Again this is a multi-authored effort with an extensive peer review process. Lastly, the fact that a scientist at Monsanto looked at the summary paper and provided comments of an editorial nature (vs scientific) is not atypical for a sponsor.

There is one declaration that you might want to expand on:


You might want to indicate the nature of this support (Travel, honorarium?) and confirm that Monsanto had no scientific input in the poster presentation.

Kind regards. Vicki
From: Mildred Morgan <hargray.com>
Sent: Wednesday, July 25, 2018 12:25 PM
To: roger.o.mcclellan@att.net
Subject: Personnel at T&F

Shown below is the new table for personnel at T&F. I had forgotten to include Bridget Sheppard earlier. I have rechecked every e-mail, etc. and the only time I have anything that shows Anna Treadwell is in 2013. I am not real sure I have the right year for Jenna Whittle — I know she was in there in 2015, but in 2016 Charles had written an email that had Jenna on it. Since Charles came on in 2015, I am pretty sure that was when Josie Brown came on, but again, not real sure on some of these.

### Primary Contacts with Taylor and Francis Personnel for Roger O. McClellan, Editor-in-Chief, Critical Reviews in Toxicology Over 2008-2018

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Year(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stewart Gardiner</td>
<td>Production Manager</td>
<td>2008 through 2013</td>
</tr>
<tr>
<td>Phil Garner</td>
<td>Publishing Director</td>
<td>2008 through 2011</td>
</tr>
<tr>
<td>Cleo Hall</td>
<td>Managing Editor</td>
<td>2008, 2009</td>
</tr>
<tr>
<td>Kristina Kefi Munn</td>
<td>Managing Editor</td>
<td>2008, 2009</td>
</tr>
<tr>
<td>Anna Muldoon</td>
<td>Managing Editor, US Journals</td>
<td>2008</td>
</tr>
<tr>
<td>Felicia Ruocco</td>
<td>Production Editor</td>
<td>2008</td>
</tr>
<tr>
<td>Claire Summerfield</td>
<td>Production Editor</td>
<td>2008 through 2013</td>
</tr>
<tr>
<td>Yvonne Oliver</td>
<td>Business Development Executive</td>
<td>2009, 2010</td>
</tr>
<tr>
<td>Joris Rouleau</td>
<td>Managing Editor</td>
<td>2010 through 2013</td>
</tr>
<tr>
<td>Lindsay Duncan</td>
<td>Production Editor</td>
<td>2012, 2013</td>
</tr>
<tr>
<td>Bridget Sheppard</td>
<td>Managing Editor</td>
<td>2012, 2013</td>
</tr>
<tr>
<td>Anna Treadway</td>
<td>Head of Journal Publishing Informa Health Care</td>
<td>2013</td>
</tr>
<tr>
<td>Jenna Whittle</td>
<td>Production Editor</td>
<td>2015, 2016</td>
</tr>
<tr>
<td>Charles Whalley</td>
<td>Managing Editor</td>
<td>2015-present</td>
</tr>
<tr>
<td>Josie Brown</td>
<td>Production Editor</td>
<td>2015-present</td>
</tr>
</tbody>
</table>
Dear Charles:

Attached is Dr. McClellan's memo on the "Long-Standing Issues with Declaration of Interest for CRT." Also attached is the current instructions to authors I have pulled out.

Mildred Morgan
Assistant to Roger McClellan
Tel: [redacted]
Fax: [redacted]
Email: [redacted]@hargray.com
RE: Long-Standing Issues with Declaration of Interest for Critical Reviews in Toxicology

Charles,

As I have already noted, my primary concern for Critical Reviews in Toxicology (CRT) over the past 10 months has been achieving a fair and equitable resolution of issues surrounding the Special Glyphosate Supplement in Volume 46 (2016). This was my concern in March when I read the CRT Publishing Report and continues today.

A central issue concerning the Glyphosate Special Supplement relates to CRT’s Declaration of Interest policy and its implementation. I was absolutely flabbergasted when I read on page 9 of the Publishing Report - "We have finally (and I hope successfully) ironed out issues about DOIs as comments about these have ceased." I am at a total loss to explain your basis for this completely inaccurate statement. [Before discussing the DOI issue, let me note that both Mildred and I appreciated the expression of the gratitude sentence that followed.]

The issue of Declarations of Interest for CRT is a long standing and unresolved issue! It began in about 2009, as I will relate in detail later. The current situation is not acceptable. It is rare when CRT receives a submitted review manuscript via ScholarOne that contains an adequate DOI. Almost every submitted paper requires substantial involvement by me and Milcred to create an acceptable DOI. I have attempted to involve you during the past year; however, your input has not been very effective. Indeed, your guidance usually triggers a need for more input from me and Mildred.

I am beginning to realize one of the key problems may be our mutual failure to clearly describe the situation and related terminology, specifically the distinction between Declarations of Interest and Conflicts of Interest. Moreover, it is my candid impression that you and others at
Taylor and Francis (T&F) like to fall back on the Committee on Public Ethics (COPE) guidance, especially in recent years. It is my impression that you and your T&F colleagues have not taken the time to understand that CRT, as a high-quality review journal publishing papers on high-profile and contentious issues, requires unique input. Many of these reviews are sponsored by government agencies, trade associations or private corporations. The “cookie cutter” approach used with most T&F journals has not, and is not, working.

Let me illustrate using the Glyphosate Special Supplement. An attorney friend, who is a law professor, carefully read “The Monsanto Papers” and related documents. He also read very carefully my Foreword and the five papers published in the Special Supplement. He asked me if I would be willing to discuss this complex situation with him. I indicated I would be willing to do so if he was not involved in any of the on-going litigation. He indicated he had no personal involvement with Monsanto attorneys or those representing plaintiffs in any of the cases. He was aware of the cases.

He offered the following observations:

1. He felt the Foreword, which I authored, was very clear. He felt I had appropriately set the stage for his reading of the papers. He was impressed with the detailed external review the papers had received prior to acceptance by CRT. He also felt it was clear, based only on my Foreword that Monsanto sponsored and paid for preparation of the review papers.

2. He thought the summary paper and the four supporting papers were very well written with the science clearly presented and the conclusions drawn clearly supported in language a sophisticated reader could understand.

3. He thought the Declarations of Interests were very detailed and much more extensive than what he found in most scientific review papers. He suggested it might have been sufficient to shorten the DOIs to read – “Preparation of this paper was funded by Monsanto Company.”

4. He noted with special interest my e-mail to Ashley Roberts that had been provided to William Heydens of Monsanto and released with “The Monsanto Papers.” His question to me was, “why did I need to explain to Roberts and the authors what was needed in a DOI”? I responded, “It was because the publisher’s instructions to authors for preparation of DOIs were not adequate.”
His advice to me was—"You need to hold the publisher’s feet to the fire and demand the publisher develop adequate instructions to authors for preparation of DOIs." In a later conversation, he related he had read the T&F instructions to authors. He did not recall that they even mentioned preparation of a DOI.

My legal friend is right. When I request that you provide input on these issues you provide references and cross-links to "conflicts of interest." Most of the material referenced relates to publication of the results of original research, especially related to pharmaceutical research and financial support from sponsors of the research.

Let me return to the saga of CRT and Declarations of Interest. Over my 30 years as Editor-in-Chief of CRT, I have dealt with multiple publishers as the Journal has been sold several times with personnel located in Boca Raton, FL, Philadelphia, PA, New York City, NY and most recently in England. During the first two decades, I dealt with only a few individuals as staffing was quite stable. The situation over the past decade has been quite different as shown in the table below.

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Year(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stewart Gardiner</td>
<td>Production Manager</td>
<td>2008 through 2013</td>
</tr>
<tr>
<td>Phil Garner</td>
<td>Publishing Director</td>
<td>2008 through 2011</td>
</tr>
<tr>
<td>Cleo Hall</td>
<td>Managing Editor</td>
<td>2008, 2009</td>
</tr>
<tr>
<td>Kristina Kefi Munn</td>
<td>Managing Editor</td>
<td>2008, 2009</td>
</tr>
<tr>
<td>Anna Muldoon</td>
<td>Managing Editor, US Journals</td>
<td>2008</td>
</tr>
<tr>
<td>Felicia Ruocco</td>
<td>Production Editor</td>
<td>2008</td>
</tr>
<tr>
<td>Claire Summerfield</td>
<td>Production Editor</td>
<td>2008 through 2013</td>
</tr>
<tr>
<td>Elizabeth Yepez</td>
<td>U.S. Managing Editor, Pharmaceutical &amp;</td>
<td>2008 through 2010</td>
</tr>
<tr>
<td></td>
<td>Toxicology Journal</td>
<td></td>
</tr>
<tr>
<td>Joris Rouleau</td>
<td>Managing Editor</td>
<td>2010 through 2013</td>
</tr>
<tr>
<td>Lindsay Duncan</td>
<td>Production Editor</td>
<td>2012, 2013</td>
</tr>
<tr>
<td>Bridget Sheppard</td>
<td>Managing Editor</td>
<td>2012, 2013</td>
</tr>
<tr>
<td>Anna Treadway</td>
<td>Head of Journal Publishing, Informa</td>
<td>2011 through 2014</td>
</tr>
<tr>
<td></td>
<td>Healthcare</td>
<td></td>
</tr>
<tr>
<td>Jenna Whittle</td>
<td>Production Editor</td>
<td>2015, 2016</td>
</tr>
<tr>
<td>Charles Whalley</td>
<td>Managing Editor, T&amp;F</td>
<td>2015 - present</td>
</tr>
<tr>
<td>Josie Brown</td>
<td>Production Editor, T&amp;F</td>
<td>2015 - present</td>
</tr>
</tbody>
</table>

Let me set the stage for considering the DOI issues. It has been my custom for decades to actually quickly scan all galley proofs. I do this because I was badly abused in the 1990s when I opened a hard copy issue of CRT and found a "strange paper." Yes, it had a chemical in...
the title and mentioned something about environmental effects. When I read it, I realized I had never seen it before. I was right. When I checked with the production editor for CRT, it soon became apparent the paper was intended for another journal. Yes, errors occur. The challenge is to learn from them and minimize their recurrence!

Let me illustrate the saga of DOIs for CRT with the collection of e-mails attached to this memo. As shown in the memos from 2009, the “system” automatically inserted in multiple papers the statement – “The authors declare no conflicts of interest.” At best, it could be determined if the author checked the appropriate box in ScholarOne, this statement would automatically be placed in the galley. I viewed that as an unacceptable practice. I finally reached an understanding with a series of Taylor and Francis personnel that this practice, while easy and convenient for them, was not acceptable to me. That was when I began pleading for assistance from them (and now from you) to create meaningful “Instructions to Authors” for creating Declarations of Interest unique to CRT. I am still making the same plea. You need to get the T&F DOI situation in order – action is long overdue!

Every time I see a paper, and you have sent me several papers, with a statement – “The authors declare no conflicts of interest,” I laugh! That statement is like saline eye drops if you have bacterial conjunctivitis. I will bet you with a little work I could find numerous papers published in journals published by T&F as well as other publishers that contain that statement and I will show they are bogus. I suspect no one ever checks!

One of my views is that “Conflicts of Interest” are in the eye of the beholder, not the declarer. That is why I have advocated Declarations of Interest statements. Let the reader decide if there are conflicts of interest.

One of the difficulties we are likely encountering now is that we (you, me, and your colleagues at Taylor and Francis) are expecting too much to be declared. My friend probably analyzed the situation correctly for the Glyphosate papers. A DOI that contains two sentences should have sufficed; “These papers were prepared with financial support from Monsanto Co. The authors declare the review and conclusions drawn represent their collective independent professional work products” should have sufficed. I would probably have had difficulty accepting that brevity; however, it would have avoided the “gotcha” approach you and your advisors have advocated when you were provided details by the authors. I might add I requested the revised DOIs, with your approval, anticipating their use in a positive manner by T&F, not as a basis for punitive action which, in my opinion, is not warranted. As I have said, and will
continue to repeat, -- the five papers on the potential carcinogenicity of Glyphosate published in the Special Supplement Vol. 46 of CRT are scientifically sound and there is no basis for their retraction. Yes, procedural errors have occurred; however, they are traceable as much to the publisher as they are to the authors. Let’s focus attention on the real problem rather than them punishing the publishers most valuable and limited assets – competent and highly recognized authors.

I close with this request – “Please provide me a proposed draft set of instructions to authors for preparing Acknowledgement and Declaration of Interest sections for review papers published in Critical Reviews in Toxicology. Please keep the instructions simple so they will be understandable by scientific authors around the world. Please limit the electronic linkages to other material.” For your convenience, I have attached the current instructions to authors.

I look forward to meaningful future dialogue on this critical matter with input from T&F that is long overdue.

Respectfully,

Roger O. McClellan

Attachments:
A series of e-mails on issues of Declaration of Interest
Phil Garner:

Phil:

I do hope we can get this confusion over --- Declaration of Interest: The authors declare no conflict of interest. --- straightened out soon. This issue is very confusing. I am uncertain who proposed this as a default. It is a real burden for me to have to check every manuscript to determine if it has been inserted as a default by someone associated with Informa.

Thanks for your help.

Roger

Advisor, Toxicology and Human Health Risk Analysis
Albuquerque, NM

-------------- Forwarded Message: --------------

From: roger.o.mcellean@informa.com
To: "Summerfield, Claire" <claire.s@informa.com>, "Bertram Price" <bertram.priccassociatcsinc.com>, "Mildred Morgan" <m.morgan@htimav.coin>, "Yepez, Elizabeth C." <yepez@informausa.com>, "Adam Ware (PAI)" <a.ware@priceassociatcsinc.coin.com>

Subject: RE: Proofs for Manuscript 404665 of BTXC/CHANGES
Date: Thu, 18 Jun 2009 02:17:12 +0000

Claire:

Sounds great! I just want to avoid any unpleasant situations as I have encountered in the past. I want to make certain that the only circumstances under which the statement --- Declaration of Interest: The authors declare no conflict of interest. The authors are responsible for the writing and content of the article. --- is published in CRT is when I have personally approved the statement. As of now, I cannot envision the circumstances under which I would approve its use. I would like to see any reference to the statement removed from the Instructions to Authors from CRT. It is totally confusing to prospective authors. I strongly disagree with its use by default.

I am counting on you to alert me any time it is inserted in an article either by default or by the author.

Regards,

Roger
Hi Roger,

As these e-mails come in I will upload the notes to the proof correction area on CATS. As I mark up the authors corrections I will have to check these comments to proceed.

I hope this is sufficient protocol to assure you that the amendments will be done.

Kind regards,
Claire
Bert:

I am concerned that the Acknowledgements Section and Declaration of Interest are very confusing. Unless, you have strong feelings to the contrary, I suggest that it be re-worded as follows:

Acknowledgements

The preparation of this review was funded by Price Associates, Inc. The authors are responsible for the content and writing of the paper.

I would have no problem if you wish to modify it as follows — by Price Associates, Inc., a consulting firm providing services in the field of environmental and occupational health. The authors—.

I am interested in having complete and accurate disclosure. If this is done I do not think it necessary to have a specific Declaration of Interest.

Let me know your views.

Best regards,

Roger
Hi Roger,

Thanks for this. I've spoken to Kristina and Claire, and we have agreed that this is fine for now, as I agree that the term “conflict” in this line needs to be changed. These changes to the IFAs, production process, and website have already been requested, and highlighted to you, so they should be up, available, and used shortly.

However, once these are released, when no declarations of interest are declared, we will put a note in the author queries that says: A declaration of interest statement reporting no declaration of interest has been inserted. Please confirm the statement is accurate. When the author affirms this, the line will appear. Once I have confirmation that this change has happened, I will let you know. At this point it will no longer be necessary for Claire to come to you for approval of the DOI section.

Regards,
Elizabeth

Elizabeth Yepez
US Managing Editor, Pharmaceutical Science and Toxicology Journals
informa
informa Pharmaceutical Science
www.informapharmascience.com

52 Vanderbilt Ave, 16th Floor
New York, NY 10017
Tel: [number]
Fax: [number]@informa.com

From: roger.o.mcclellan@informa.com
Sent: Wednesday, June 17, 2009 10:17 PM
To: Summerfield, Claire; Bertram Price
Cc: Mildred Morgan; Yepez, Elizabeth C.; Adam Ware (PAI)
Subject: RE: Proofs for Manuscript 404665 of BTXC/CHANGES
Importance: High

Claire:

Sounds great! I just want to avoid any unpleasant situations as I have encountered in the past. I want to make certain that the only circumstances under which the statement -- “Declaration of Interest: The authors declare no conflict of interest. The authors are responsible for the writing and content of the article.” is published in CRT is when I have personally approved the statement. As of now, I cannot envision the circumstances under which I would approve its use. I would like to see any reference to the statement removed from the Instructions to Authors for CRT. It is totally confusing to prospective authors. I strongly disagree with its use by default.

I am counting on you to alert me any time it is inserted in an article either by default or by the author.

Regards,
Roger
Please find the new instructions with regards the Acknowledgements and Declaration of interest section.

From: Yepez, Elizabeth C.
Sent: 12 January 2010 15:41
To: Avey, Nesha; Andrews, Rachel; Summerfield, Claire; Chamay, Alexa; Collard, Jonathan; Csemiczky, Emma (Linderoth)
Cc: Gardiner, Stewart; Munn, Kristina; Hall, Cleo; Yepez, Elizabeth C.
Subject: FW: A new year, a new volume...

Hi all,

At the end of last year I talked with you about the Declaration of Interest Section and the Acknowledgment section—changing how we were doing it before. This is just an FYI copy (see email string below) of the communication I’ve sent to the editors. If you have any questions let Stewart, Kris, or me know. As we discussed I know issues are completed already for the new year, so of course that’s fine, but if you could confirm that this is slated going forward, (if you’ve not already) that would be great.

As you know, the three changes as they affect you are:

1. We’re not having the copyeditor include any lines about ‘authors declare no conflict of interest’. All the papers should have this section now. If the copyeditor sees something obviously wrong, raise it as an AQ, but otherwise, they should not be inserting this line.

2. The Acknowledgements section or an Acknowledgements subheading should not
be included unless the authors have included it in the paper.

3. Formatting: The old way:

Elizabeth Yepez

US Managing Editor, Pharmaceutical Science and Toxicology Journals
informa healthcare
www.informahealthcare.com

52 Vanderbilt Ave, 16th Floor
New York, NY
Tel: 
Fax: 

 Register for free TOC alerts now at www.informahealthcare.com/alerts

---

From: Yepez, Elizabeth C.
Sent: Tuesday, January 05, 2010 4:18 PM
To: Elizabeth.
Cc: Gardiner, Stewart; Munn, Kristina
Subject: A new year, a new volume...

Editors-in-Chief,

As we start the new year, I wanted to re-cap the editorial standards we covered in the recent webinar you attended. By now, all 17 of you editors have joined me in a conversation around handling authorship, publication misconduct, open access, and transparency questions and concerns.

As promised, below I have synthesized some of the ongoing points of our discussion. These may be helpful for you to forward on to your editorial board, along with the downloadable Instructions for Authors on your individual

11
If your journal is holding a board meeting at the SOT meeting this year, we will go over the below points there as well.

- **Declaration of Interest section and Acknowledgments section**: two separate sections, as of Jan 1. The Declaration of Interest Section is mandatory; the Acknowledgments section, optional.

- **The Declaration of Interest section**: Authors need to include the information entailed in the declaration of interest section prior to submission, or if the section is lacking, prompted to fix it at review. No paper should be published without this section. Attached above is the slide reminding what belongs here—to oversimplify, anything with regards to financial support, employment, or consultancies. As you and the reviewers regularly examine the methods, results, and conclusions of submissions critically, extend that to this section.

- **The Acknowledgment section**: For special thanks, personal assistance, and dedications. Nothing related to funding belongs here.

- **NIH/Open Access Policy**: A reminder: Please be sure to send me or the production editor an email when you accept an NIH- or Wellcome-funded article. We have someone on staff who submits all these to PubMed Central. You are the first line of watching for these types of articles.

- **Letters to the Editor**: A reminder: When you receive these, make sure the original authors (specifically, the corresponding author) are aware, and offer them a opportunity with a deadline to respond. We are now holding the Letter to the Editor, if the original authors choose to respond, until it can be published alongside a Response, as one document.

Thanks for your work, and Happy New Year,

Elizabeth
For a free trial to Informa Healthcare journals, reply with the contact details of your librarian or information manager.

Register for free TOC alerts now at www.informahealthcare.com/alerts

The information contained in this email message may be confidential. If you are not the intended recipient, any use, interference with, disclosure or copying of this material is unauthorised and prohibited. Although this message and any attachments are believed to be free of viruses, no responsibility is accepted by Informa for any loss or damage arising in any way from receipt or use thereof. Messages to and from the company are monitored for operational reasons and in accordance with lawful business practices.

If you have received this message in error, please notify us by return and delete the message and any attachments. Further enquiries/returns can be sent to postmaster@informa.com
FROM: Claire Summerfield
TO: R.O. McClellan, et al.

Dear All,

Thanks for your e-mail Roger.

As you know we have been dealing with this matter for some time now and I have addressed it with both the copy editor and typesetters. I can confirm that it is not included by the copy editor and must be a repeating error by the typesetters, despite my constant messages to change the procedure for BTXC.

Please see the instructions I sent to the typesetters recently (attached).

I know that the general statement sometimes gets into the proofs, but rest assured that I always carefully check these before they go online to ensure they are correct and the statement removed. It is (mutually) frustrating to have to reinforce the fact that we do not want this statement included. I have bcc’d the typesetters in on this e-mail.

Shiv, please note this is still happening, and it is not acceptable for any BTXC papers.

We look forward to having this reoccurring issue resolved.

Kind regards,

Claire

From: Roger McClellan [mailto:Roger.McClellan@att.net]
Sent: 17 August 2010 00:49
To: Rouleau, Joris
Cc: Summerfield, Claire; Munn, Kristina; Mildred B. Morgan Ms
Subject: Re: Informa Healthcare - new managing editor/ Response

Joris:

The one thing you can do for me is to solve the problem of the entry during production of the MEANINGLESS statement—"All authors declare that they have no conflicts of interests related to this study." For example, see Volume 40, Issue 7, page 629. I am uncertain as to when this slipped in to this manuscript, however, I DID NOT approve it.

Quite frankly, I do not have the time to repeatedly go back and check and check again as to whether some person or electronic system has entered this in every paper. Other Editors are free to take this ridiculous approach, which is meaningless. However, I REFUSE to cave in on this issue. Please give me assurances that Informa will get this matter solved. This problem has gone on for much too long a period of time.
Who should I address this issue to within Informa if you, Kristina and Claire are unable to solve this issue? My patience is nearly exhausted.

Thank you in advance for your assistance.

Roger

Roger O. McClellan
Editor, Critical Reviews in Toxicology
Advisor, Toxicology and Human Health Risk Analysis
Albuquerque, NM
Tel:
Fax:
E-mail: @att.net
7/6/10

Hi Claire,

Elizabeth's e-mail is attached. it explains everything very clearly.

For BTXC specifically (and the PharmTox journals listed in Elizabeth's e-mail; I don't think this applies to other Informa journals):

If no DOI. add an AQ. DO NOT insert the generic statement.

I'm sending you a saved copy of Elizabeth's e-mail that I kept for quick reference. In a few days I'll go dig my e-mail archives for the original, in case you need to distribute it.

Please let me know if there's anything else you need.

Caroline
in close to 40C New York

----- Original Message ----- 
Received: Tue, 06 Jul 2010 07:58:17 AM EDT
From: "Summerfield, Claire" <[redacted]@informa.com>
To: "Caroline Lee"<asuna.net>
Subject: RE: BTXC Acknowledgments and DOI

Hi Caroline,
Things keep changing so fast that I am trying to verify what happens when.

All I need to clarify is... If there is no DOI statement included in the MS do you then add the generic statement of: The author reports no conflict of interest... The author alone is responsible for the writing...
Or does the typesetter do that?!

Also, do you still have the e-mail Elizabeth sent.
She has now left this journal so we are just trying to straighten everything out! THANKS IN ADVANCE FOR YOUR HELP ON THIS :O)))
C
Hi Claire,

I'm not sure if I understand your or Dr McClellan's e-mail.

I believe all the BTXC articles uploaded since Elizabeth's e-mail last year clarifying what goes into Acknowledgments and DOI have been copyedited correctly with regards to these two sections. May be you can let me know which article was a problem and I'll take a look at my files.

As for Issue 7, I don't know the rest of the line up; but the two letter/response articles mentioned were uploaded on June 23, using the DOI the authors provided (see attached).

Caroline

Hi Caroline, can you just clarify what the process is with regards the copyedit for BTXC, with regards the Acknowledgements and DOI section. Thanks,

Claire

Roger McClellan

Claire: Looks fine. The only change might be if you could get the Dement and Stayner Letter (ID 498410) and the Berman Response (ID 498411) in Issue 7 (August). It would be great to get them published at an early date. If they are not published in Issue 7, be sure to include them in Issue 8.

Best regards,

Roger

PS. I have not had the opportunity to verify that the articles for Issue 7 do NOT have the copy editor's introduction of the statement --"No conflict of interest reported." that I have objected to on several occasions. Please verify for me that this issue has been dealt with so I can quit worrying about it.

7/7/10
FROM: Claire Summerfield

TO: R.O. McClellan and M. Morgan

Cc: Kristina Munn

Dear All,

We have recently had some confusion with regards this section for BTXC. I am sending this e-mail to clarify the situation.

The Editor works hard to re-write and agree on an accurate and correct Acknowledgement and DOI section for all these papers. This revised version is then submitted and accepted into CATS for the CE to include. To date these revised sections are being transferred into the final proofs correctly.

The problem is occurring in when the author is then asked to provide further information for the Ack. and DOI sections in the Author AQ's, especially when the CE has already raised an AQ to check the given text (as in paper 494250).

Shiv, please can you instruct your team to not add any additional AQ's with regards to the Acknowledgement/DOI sections, unless there is a problem, i.e. it is missing.

If this is the case the AQ should be a PE's note at the bottom of the AQ's, followed up by an e-mail to myself to clarify. The Acknowledgement and Doi query which is automatically generated in your auto flow process should be cancelled for all future articles.

I hope this helps to sort out the process for BTXC papers from here in.

Kind regards,
Claire

Claire Summerfield - Production Editor
Informa Healthcare
Dear All,

Thanks for your e-mail Roger.

As you know we have been dealing with this matter for some time now and I have addressed it with both the copy editor and typesetters. I can confirm that it is not included by the copy editor and must be a repeating error by the typesetters, despite my constant messages to change the procedure for BTXC.

Please see the instructions I sent to the typesetters recently (attached).

I know that the general statement sometimes gets into the proofs, but rest assured that I always carefully check these before they go online to ensure they are correct and the statement removed. It is (mutually) frustrating to have to reinforce the fact that we do not want this statement included. I have bcc'd the typesetters in on this e-mail.

Shiv, please note this is still happening, and it is not acceptable for any BTXC papers.

We look forward to having this reoccurring issue resolved.

Kind regards,

Claire
Thank you in advance for your assistance.

Roger

Roger O. McClellan

Editor, Critical Reviews in Toxicology
Disclosure statement
Please include a disclosure of interest statement, using the subheading "Disclosure of interest." If you have no interests to declare, please state this (suggested wording: The authors report no conflicts of interest). For all NIH/Wellcome funded papers, the grant number(s) must be included in the disclosure of interest statement.

What is a conflict of interest?
A conflict of interest can occur when you (or your employer or sponsor) have a financial, commercial, legal, or professional relationship with other organizations, or with the people working with them, that could influence your research.

Full disclosure is required when you submit your paper to a journal. The journal editor will use this information to inform his or her editorial decisions, and may publish such disclosures to assist readers in evaluating the article. The editor may decide not to publish your article on the basis of any declared conflict. The conflict of interest can be declared on your cover letter or on the manuscript submission form in the journal’s online peer-review system.

Personal conflicts of interest
Potential conflicts of interest in relation to your submitted manuscript could include:

- Consultancies
- Employment
- Advocacy groups
- Grants
- Fees and honoraria
- Patents
- Royalties
- Stock or share ownership

If necessary, please describe any potential conflicts of interest in a covering letter. All funding sources supporting the work should also be fully acknowledged.

Institutional conflicts of interest
If you are aware of your employer having any financial interest in, or conflict with, the subject matter or materials discussed in your manuscript, please provide additional detail in your covering letter to the editor.

Disclosure statement
You should also include a relevant disclosure statement with the text of your article, in conjunction with any acknowledgments and details of funders.

Conflict of interest: sample disclosure statements

In accordance with Taylor & Francis policy and my ethical obligation as a researcher, I am reporting that I [have a financial and/or business interests in] [am a consultant to] [receive funding from] (delete as appropriate) a company that may be affected by the research reported in the enclosed paper. I have disclosed those interests fully to Taylor & Francis, and I have in place an approved plan for managing any potential conflicts arising from [that involvement].

In accordance with Taylor & Francis policy and my ethical obligation as a researcher, I am reporting that I [have a financial and/or business interests in] [am a consultant to] [receive funding from] (delete as appropriate) a company that may be affected by the research reported in the enclosed paper. I have disclosed those interests fully to Taylor & Francis, and I have in place an approved plan for managing any potential conflicts arising from [that involvement].

or

This research is sponsored by [company A] and may lead to the development of products which may be licensed to [company B], in which I have a business and/or financial interest. I have disclosed those interests fully to Taylor & Francis, and have in place an approved plan for managing any potential conflicts arising from this arrangement.

If there is no disclosure, we will publish the following statement: “No potential conflict of interest was reported by the authors.”
Charles:

I have received numerous favorable comments concerning the scientific quality of the five papers published in the Special Glyphosate Supplement of CRT (2016). Many have commented on the extensive review the papers were given by CRT. The favorable comments are not surprising in view of the extraordinary scientific expertise of the authors drawn from around the world (10 from the USA, 2 from England, 2 from Canada, 1 from Brazil and 1 from Germany). Attached are CVs or biographies for 15 of the scientists/authors. The CV for Larry Kier is missing, the last time I spoke to him early in the year both he and his wife were quite ill.

I am proud of the fact that CRT attracts authors like these to prepare high quality review papers on contentious topics of broad importance to Society.

As you will recall the 2 complaints concerning the Glyphosate papers came from two sets of parties that had a special interest in having these papers removed from public access. It is noteworthy that both of the parties argued for retraction of the papers on procedural grounds and neither challenged the scientific validity of the five papers.

Let me close by emphasizing that any arbitrary and capricious actions taken by Taylor and Francis that damages the reputation of the authors will likely be challenged by the authors including their taking potential legal action against T and F to recover damages.

The bottom line is that we need to continue to seek ways to resolve this complex set of issues in a way that is fair and equitable to all parties (the authors, the publisher, you as the Managing Editor, me as the Editor in Chief and readers of the Journal and those who use scientific analyses and conclusions published in papers in Critical Reviews in Toxicology). I for one do not think it appropriate to take any action that will restrict public access to these valuable papers reporting important analyses and conclusions.

Please share these CVs/biographies with others at T and F. I look forward to further dialogue on these important matters.

Best regards,
Roger
Dear Roger,

I'm glad you felt our conversation useful. I did too.

With legal counsel we have discussed how the timings of any actions might relate to the ongoing trial, and how best to manage that. This element will certainly form part of our discussions when we meet. Ideally I would like to ensure that either our counsel is available on the phone should we need to call them during our meeting, or that we can have some prepared advice from them beforehand to review in our meeting.

These discussions around the supplement have certainly occupied the time we would normally be using discussing other issues and moving the journal forwards. I suppose we have previously had an ad hoc schedule of regular calls to discuss the journal. I agree that it may make sense to set a formal schedule, so that we don't lose momentum on anything.

As I said, I will try to confirm a date for a visit asap early next week, as well as attendees and a draft agenda. I appreciate it is coming up very soon and you will want to make arrangements.

Best wishes,
Charles

Private and confidential
Charles:
Thanks for taking time from your busy schedule for our private conversation earlier today. I think it was useful in rebuilding mutual trust and respect in dealing with complex decisions.

In retrospect, we should have never undertaken the investigation without at least a brief written protocol and identification of those involved in making the final decision. Ad hoc decision making can be a disaster. It would also have been useful to having had a schedule for regular updates on the process.

Indeed, it may be useful for you and I to schedule a periodic update on activities, perhaps, quarterly.

For now with regard to the Special Glyphosate Issue I hope we are agreed it will not be appropriate to announce any decision until after a decision is announced by the Court in the Johnson vs Monsanto trial in San Francisco.

Warm regards,
Dear Roger,

Thank you for your email. I know that you're working with Charles and other Taylor & Francis colleagues on the current issues regarding CRT, but I wanted to verify that Charles has been keeping me informed on all issues and I'm up-to-date with all that is ongoing at the moment for the journal.

Best wishes

Ellie

Charles:

As has been the case since 2009, it would be very helpful if the Instructions to Authors for CRT contained clear instructions to Authors on what should be included in the Declaration of Interest. Who at Taylor and Francis has responsibility for providing this material? It is approaching a decade since I first requested this assistance with no progress. I feel very uncomfortable with vague statements - "The authors have no conflicts to report." That may be acceptable to you, it is not acceptable to me! As I hope you are beginning to appreciate it is the lack of clear guidance by Taylor and Francis that contributed to the Glyphosate Supplement controversy.

When can I expect to see some draft Instructions to Authors that addresses what is needed in a Declaration of Interest. I want to minimize the possibility that other authors will have to take a "hit" for internal T and F short-comings. If I am off base let me know.

I have included Ellie Gilroy on this e-mail since I understand she is your immediate supervisor. She needs to understand the nature of this long standing deficiency. I sense some individuals in T and F feel it is OK to charge authors with short-comings and potentially tarnish the reputation of authors and deflect attention from core failings at T and F. I do not deal that way. That is totally contrary to my life long treatment of people in a fair manner.

Who knows-- without attention NOW this paper could be the next Glyphosate disaster. This is exactly how the Glyphosate case started!

Thanks for your attention to this matter. I assume that by now you have shared my detailed memo on the "Declaration of Interest" statements and lack of guidance with Ellie. Please verify.
I appreciate your attention to this critical issue.

Best regards,
Roger

On Friday, July 27, 2018 11:28 AM, Critical Reviews in Toxicology <onbehalfof@manuscriptcentral.com> wrote:

27-Jul-2018

BTXC-2018-0043 - Systematic review and quality ranking of studies of two phthalate metabolites and anogenital distance, bone health, inflammation, and oxidative stress

Dear Dr Herman Gibb:

Before proceeding with review of your manuscript please provide me some additional information.

Please provide a more complete Declaration of Interest. You may wish to review the Declaration of Interest statements for recent papers published in Critical Reviews in Toxicology. At a minimum, it should disclose that the employment affiliation of the authors is as shown on the cover sheet. It should also clearly describe how preparation of preparation of the work was funded and if the sponsor had any role in preparing or reviewing the paper. It should also clearly state that the review and conclusions drawn are the exclusive professional work product of the authors, if that is true. It should also note if the authors have or have not appeared during the past five years in any legal or regulatory proceedings related to the contents of the review paper. Anticipate what your most strident critics will want disclosed.

I also provide you the opportunity to nominate 10 individuals as potential reviewers. For each nominee, please provide me their name, affiliation, e-mail address, a few sentences on their expertise and note if their work has been cited in your review. As always, as Editor I retain the responsibility to select reviewers.

Thank you for your assistance.

Sincerely,
Dr Roger McClellan
Critical Reviews in Toxicology

Visit www.tandfonline.com and sign up for free eTOC alerts to all Informa Pharmaceutical Science journals
Roger McClellan

Charles and others:

I appreciate that our meeting on Thursday, August 9th is intended to focus on concluding our investigation of the issues related to how the five papers in the Special Supplement to Volume 46 were prepared, reviewed editorially and published. Nonetheless, I think it is critical that we consider the context of how the issues concerning the five papers arose.

Thus, I have quickly scanned the 31 papers published in the core issues of Volume 46 directing special attention to the published Declarations of Interest for each of the papers. A review of the papers focusing on the topics addressed, the authors, the affiliation of the authors, and sponsors of the papers provides some useful insights into the publishing niche occupied by Critical Reviews in Toxicology. It is clear that the Journal publishes on topics at the interface of science and public policy and of interest to Society at Large. I am certainly proud that the authors come from a cross section of the scientific community including academic institutions, private companies, consulting firms, trade associations and some individuals working as independent consultants. The topics covered, the high quality of our authors and the rigorous review process used by Critical Reviews in Toxicology are what support are consistently high citation index ratings.

A review of the Declaration of Interest sections of each paper in Volume 46 clearly reveals how different CRT is from most journals published by Taylor and Francis and other publishers with the emphasis given by CRT to the Declarations of Interest provided for each paper. I believe you are aware this emphasis grew out of my personal dissatisfaction with how the publisher handled conflict of issue statements in 2009 -2010 and going forward. From then until now, I have repeatedly asked the publisher, through a series of staff members in various roles, to prepare written instructions to Authors that include how to prepare Declarations of Interest. That call from 2009 through 2016 and on to the present has gone unaddressed.

By default, in my role as Editor in Chief, I have had to on an ad hoc basis provide guidance to authors on how to prepare Declarations of Interest. This is a matter at the core of the controversy over the five papers in the Glyphosate Special Supplement. My letter to Ashley Roberts that appears in "The Monsanto Papers" would never have been written if the publisher had provided the appropriate written instructions for preparation of Declaration of Interests that should have been in place long ago.

The point I hope we can discuss next Thursday is the shared responsibility for creating the issues surrounding the five papers. I feel strongly that we need to seek a resolution that is fair and equitable to all parties; the scientist/ authors, the Editor in Chief, the publisher and the readers. I do not think a resolution that places fault exclusively on the scientist/ authors is fair and equitable. Quite frankly, that approach if implemented would slander and defame our most important asset -- the distinguished scientist/ authors we depend on to provide high quality review manuscripts for publication in Critical Reviews in Toxicology.

I urge all of the prospective attendees at next weeks meeting to quickly scan the papers in Volume 46. It was easy for me to do the old-fashioned way since I had a hard copy at hand. I was disappointed that it did not include my foreword and the five Glyphosate papers, a secondary issue that deserves discussion in the future.
I look forward to meeting with you and your colleagues next week for a productive meeting.

Best regards,

Roger
Beyond informing you, we have not yet notified anyone, and would be grateful if you could wait further notice before discussing this with anyone other than me. After you and I have discussed any points or issues you might have, the next steps (in order) would be:

- To inform the authors of our decision. This can be sent by you, on behalf of the both of us. I will send you the wording for this communication.
- To inform Ashley Roberts of the implications of this for him as commercial sponsor of the supplement. I will send this. He will of course have already received the above notification, due to him being corresponding author on the summary article.
- To inform the Editorial Board of what has occurred. This can be sent by you. It is important to emphasise that, should any journalists contact them about this, we'd kindly ask them to refer the question to me.
- To publish the retraction and expression of concern notices. As mentioned, these will be signed on behalf of us both. As such, I will send them to you before publication.
- To notify Retraction Watch, a widely-read blog that reports upon retractions and ethical misconduct in scientific journals. This will be done by my colleagues.
- To notify Drs Donley and Guyton, who have expressed concern to the journal. I will do this, CCing you.

There will necessarily be a lot of press interest in this. My colleagues believe that a proactive update on the situation to Retraction Watch should pre-empt most, but it’s possible you may be contacted for comment. If so, I’d ask you to notify me so we can talk about how best for you to respond.

I hope this all makes sense! Let’s aim to speak next Thursday. Have a safe flight and enjoy San Diego.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: -
Switchboard: -
www.tandfonline.com
RM 000732
Roger McClellan

From: Roger McClellan <redacted@att.net>
Sent: Sunday, August 5, 2018 1:11 PM
To: Kathleen McClellan, Mildred B. Morgan
Subject: Fw. CONFIDENTIAL Glyphosate supplement

On Friday, May 18, 2018 9:26 AM, "Whalley, Charles" <redacted@landf.co.uk> wrote:

Dear Roger,

I'm sorry we didn't get much of a chance to speak. Let me summarise my points by email, and then we can hopefully catch up on the phone on Thursday. I think 8am Albuquerque will be 5pm Bucharest, so I should be free to speak.

In reviewing the results of our investigation, how we will communicate this externally, and how it relates to our policies, we have decided that the only tenable outcome is to retract 3 of the articles; specifically, the summary, epidemiology and genotoxicity papers. In the investigation, John Acquavella and Larry Kier made us aware they were on contract with Monsanto when the manuscripts were prepared, and we were informed that Monsanto staff (either William Heydens or other clerical staff) were involved in drafting or editing the manuscripts in some form. This directly contradicts both parts of the following key statement from the initial Declaration of Interest:

The Expert Panelists were engaged by, and acted as consultants to, Intertek, and were not directly contacted by the Monsanto Company. [...] Neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel’s manuscripts prior to submission to the journal.

In our earlier discussions, I had thought that, as these concerns are with how the authorship rather than with the content, we would be able to resolve them by publishing corrections; however, in considering what would be consistent with the policies of the journal, the only appropriate response is retraction. Failing to disclose the contractual status of two of the authors, or the involvement of Monsanto staff in drafting the manuscripts, represents a breach of publishing ethics; the journal would be remiss not to notify its readers of this, for which purpose publishing corrigenda would not be sufficient.

For the remaining 2 articles, the exposure and carcinogenicity papers, we don’t have the same evidence of misconduct, so instead we will publish ‘expressions of concern’ to notify readers of those articles about the broader context. This is to protect against a future when readers may come to the single articles directly, without being aware of the situation with the other papers.

After (very lengthy) consultation, I believe that this is the correct response, and is necessary to demonstrate how seriously CRT takes these matters. Any communications to authors, and the notices of retraction themselves, would be on behalf of the publisher and you, so I'm grateful for your support, as ever, in this. As such, please let me know if you have any concerns or questions about the above.
On Thursday May 24, 2018 1:08 AM, "Whalley, Charles"<tandf.co.uk> wrote:

Dear Roger,

I’m glad you enjoyed the ATS meeting. Your recognition there is certainly well-deserved.

You’re right that I’ve changed my view. I’m not, I hope, too proud to do so. All of this is a complex matter, and has required quite a few detailed meetings with colleagues, the most recent of which being after we met at SOT. There’s no additional information that has changed my mind, only a broader perspective. I was a little too focussed I think on trying to ‘fix’ the supplement, when the correct response, per our policies and industry guidelines, is clear. I regret that I’ve wasted a little time heading towards the wrong resolution, although in the end our investigation would have been the same regardless.

As I explain below, failing to disclose conflicts of interest on the journal constitutes a breach of publishing ethics. Regardless of what we think of intent, the facts here are unequivocal on this point. The evidence for this is what we’ve been told by the authors themselves, completely aside from any newspaper reports. I don’t agree that retractions would harm the reputation of the journal; we need to uphold the standards expected of us, and this is the only way of doing so. I’m only eager now to get this wrapped up.

Our corrections policy is here; the section on ‘Retractions’ applies in this case: https://authorservices.taylorandfrancis.com/wp-content/uploads/2016/01/Author-services-correction-policy.pdf

“Retractions for misconduct are made when there has been an infringement of publishing ethics or a breach of author warranties, which can include breaches of third party copyright.”

Our guidance to authors on ethics is here: https://authorservices.taylorandfrancis.com/ethics-for-authors

“If a conflict of interest is not declared to the journal upon submission, or during review, and it affects the actual or potential interpretation of the results, the paper may be rejected or retracted.”

I look forward to discussing this with you later.

Best wishes,

Charles
Charles:
I am back in Albuquerque. The American Thoracic Society meeting was excellent, however, with about
18,000 participants it was a bit overwhelming. I was delighted to be recognized along with 3 former colleagues
of mine from the Lovelace Inhalation Toxicology Research Institute as one of 178 inaugural ATS Fellows. My
primary involvement has been with the Assembly on Occupational and Environmental Exposures and
Population studies. The Assembly meeting lasted 3 hours and was rather political. The Assembly has a definite
tilt to the liberal side with concern that air quality is not adequately regulated around the world. Many
Assembly members do not support the call for more open access to data for replication and extended analyses
by other scientists.

I will call on Thursday. I will be interested in learning of the basis for your major change in position on the
Glyphosate papers. At the SOT meeting you were supportive of having corrected Acknowledgements and
Declarations of Interest published for the several papers. This was also my position after very detailed
analysis of the substantial record of correspondence with the authors. Indeed, at the Editorial Advisory Board
meeting and in our private conversations you indicated you had a few details to wrap up and would be
providing proposed corrections to me very soon.

I am at a loss as to why there was a long delay. Now two months later you are suggesting retraction. What
changed your position? Can you share with me any detailed analyses including e-mails from others at T and F
that influenced your position? I have not changed my view. In my opinion, to retract any of the papers would do
irreparable harm to the authors, to the Journal, to the Publisher, to your reputation as a Managing Editor and to
my scientific and editorial reputation. I will be reviewing all my extensive correspondence to see if I have
missed anything in my detailed analysis. There is no question that some matters might have been handled
differently under ideal circumstances. However, the issues do not warrant retraction of any of the papers. It is
especially important to not use reports in the media as facts. Some of those reports are very misleading.

I look forward to speaking with you on again on this complex matter and moving to resolution at an early date.

Best regards,
Roger

Roger O. McClellan

On Tuesday, May 22, 2018 11:27 AM, "Whalley, Charles" wrote:

Dear Roger,

I hope all is going well in San Diego.

Please see below the dial-in details for our call on Thursday May 24th, 8:30am Albuquerque. Let me know if
this time doesn’t suit.

CRT Editorial Call, May 24
Thu, May 24, 2018 3:30 PM - 4:30 PM BST

Please join my meeting from your computer, tablet or smartphone.
https://global.gotomeeting.com/join/302877829
You can also dial in using your phone.
United States (Toll Free): 1
Access Code:

More phone numbers
Romania (Toll Free): 0
United Kingdom (Toll Free): 0
First GoToMeeting? Let’s do a quick system check: https://link.gotoineetinu.com/system-check

Best wishes from Bucharest,
Charles

Dear Roger,

I’m sorry we didn’t get much of a chance to speak. Let me summarise my points by email, and then we can hopefully catch up on the phone on Thursday. I think 8am Albuquerque will be 5pm Bucharest, so I should be free to speak.

In reviewing the results of our investigation, how we will communicate this externally, and how it relates to our policies, we have decided that the only tenable outcome is to retract 3 of the articles; specifically, the summary, epidemiology and genotoxicity papers. In the investigation, John Acquavella and Larry Kier made us aware they were on contract with Monsanto when the manuscripts were prepared, and we were informed that Monsanto staff (either William Heydens or other clerical staff) were involved in drafting or editing the manuscripts in some form. This directly contradicts both parts of the following key statement from the initial Declaration of Interest:

The Expert Panelists were engaged by, and acted as consultants to, Intertek, and were not directly contacted by the Monsanto Company. [...] Neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel’s manuscripts prior to submission to the journal.

In our earlier discussions, I had thought that, as these concerns are with how the authorship rather than with the content, we would be able to resolve them by publishing corrections; however, in considering what would be consistent with the policies of the journal, the only appropriate response is retraction. Failing to disclose the contractual status of two of the authors, or the involvement of Monsanto staff in drafting the manuscripts, represents a breach of publishing ethics; the journal would be remiss not to notify its readers of this, for which purpose publishing corrigenda would not be sufficient.

For the remaining 2 articles, the exposure and carcinogenicity papers, we don’t have the same evidence of misconduct, so instead we will publish ‘expressions of concern’ to notify readers of those articles about the broader context. This is to protect against a future when readers may come to the single articles directly, without being aware of the situation with the other papers.

After (very lengthy) consultation, I believe that this is the correct response, and is necessary to demonstrate how seriously CRT takes these matters. Any communications to authors, and the notices of retractions themselves, would be on behalf of the publisher and you, so I’m grateful for your support, as ever, in this. As such, please let me know if you have any concerns or questions about the above.
Beyond informing you, we have not yet notified anyone, and would be grateful if you could wait further notice before discussing this with anyone other than me. After you and I have discussed any points or issues you might have, the next steps (in order) would be:

- To inform the authors of our decision. This can be sent by you, on behalf of both of us. I will send you the wording for this communication.
- To inform Ashley Roberts of the implications of this for him as commercial sponsor of the supplement. I will send this. He will of course have already received the above notification, due to him being corresponding author on the summary article.
- To inform the Editorial Board of what has occurred. This can be sent by you. It is important to emphasise that, should any journalists contact them about this, we’d kindly ask them to refer the question to me.
- To publish the retraction and expression of concern notices. As mentioned, these will be signed on behalf of us both. As such, I will send them to you before publication.
- To notify Retraction Watch, a widely-read blog that reports upon retractions and ethical misconduct in scientific journals. This will be done by my colleagues.
- To notify Drs Donley and Guyton, who have expressed concern to the journal. I will do this, CCing you.

There will necessarily be a lot of press interest in this. My colleagues believe that a proactive update on the situation to Retraction Watch should pre-empt most, but it’s possible you may be contacted for comment. If so, I’d ask you to notify me so we can talk about how best for you to respond.

I hope this all makes sense! Let’s aim to speak next Thursday. Have a safe flight and enjoy San Diego.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RX, UK
Direct line: [Redacted]
Switchboard: [Redacted]
www.tandfonline.com

Taylor & Francis is a trading name of Informa UK Limited,
registered in England under no. 1072954
PLEASE DO NOT SHARE WITH ANYONE

Attached is a briefing document I have prepared as background for a meeting I will have in England with Taylor and Francis personnel on the controversy over the Five Glyphosate papers. They are pushing for RETRACTION. I am arguing for publication of corrigendum with revised Declaration of Interest for each paper. My approach avoids defaming the reputation of the 18 distinguished scientists/authors and keeps the papers in the public arena. I think retraction will have a serious negative impact on the journal, they argue it will bolster the journal’s reputation.

I leave for England tomorrow. The meeting will be held on Thursday at 1 PM, London time. I will be checking my e-mails and welcome any insights you may have to offer me.

With best regards,
Roger

On Sunday, August 5, 2018 4:43 PM, Mildred Morgan <morga@hargray.com> wrote:

Attached is the Briefing memo as well as the 4 attachments.
Dear Roger,

Further to this, unfortunately Claire is off work on Thursday so regrets that she won't be able to see you. She sends on her very best wishes. Josie, however, will be in the office and so able to say hello. I will see when is best to fit this in, depending on your timings.

All best wishes,
Charles

From: Whalley, Charles
Sent: 06 August 2018 13:37
To: Whalley, Charles
Cc: Gilroy, Ellie; Hummel, Todd
Subject: RE: Further Discussions Re Glyphosate Papers

Dear Roger,

Thank you first of all for sending on the additional material yesterday, which covers much of what I wanted to collect together. I will add some policies and information from our side and send along with the agenda.

Although Ellie is fully aware of this matter, she has deferred to Todd and me in handling it. She'll be in the office and pleased to meet you on Thursday, even so.

I will find out if Josie and Claire are available. I think Claire told me that she'd never met you in person, so I'm sure she'll enjoy the opportunity if she is around.

I wasn't intending on having anyone from our Communications team in the meeting; I only think that it would valuable to review our plans in that area. I will send you a list of attendees and agenda shortly.

My cell is although I shall be more easily reachable at my desk Most trains from London Paddington to Didcot Parkway take 40 minutes. Our office is less than 10 minutes' drive from the station. If you can tell me which train you intend to take, I'll arrange for a taxi to meet you at Didcot. There's one that arrives at 12:16. There is a taxi rank at Didcot so we needn't book if you're unsure of your timings.

Best wishes,
Charles

From: Roger McClellan
Sent: 06 August 2018 12:16
To: Whalley, Charles
Cc: Gilroy, Ellie; Hummel, Todd
Subject: Re: Further Discussions Re Glyphosate Papers
Charles

Thanks for the update on the meeting. I was surprised that Ellie Gilroy, as your supervisor, was not on the list of attendees. If she will not be participating and will be available on Thursday I would like to have the opportunity to meet with her.

In addition, if Josie Brown and Claire Summerfield are available I would like to briefly meet them. As you know, Claire was a key contributor to the success of CRT for a number of years. And Josie is currently a key contributor.

I was a bit surprised at the suggestion of including PR personnel in the meeting. Is that getting the cart before the horse? I remain optimistic we can agree on the wisdom of publication of corrigendum which will minimize the need for a lot of PR.

If you and others insist on the retraction approach there is a lot of ground to be covered with regard to giving the 16 scientist/authors their day "in court". Our last formal interaction with the scientist/authors, done with your approval, was focused on publishing corrigendum. I am sure they will be as shocked as I was to learn you are considering retraction of the papers. It is important that you and others know I am an old fashioned western US guy who believes in fair play and equity. Each of the authors has a well-earned and distinguished reputation which they do not want to see tarnished. I want to deal with the authors in a fair and equitable manner.

I will be staying at the St Ermin's Hotel in London and plan to catch a morning train to Dicott. I will check in with you by phone on Wednesday. What is your cell phone number? My cell phone number is 001-505-850-9190. I will also be regularly checking my e-mail account for messages.

Best regards, Roger

On Friday, August 3, 2018 5:38 AM, "Whalley, Charles" <whalley@tanof.co.uk> wrote:

Dear Roger.

I'm very pleased you're able to come on Thursday. I'm sure it will be very productive.

Thank you for suggestions for points of discussion. There will certainly be an opportunity for you to provide background on the supplement's broader context as well as then your detailed view on the matter at hand. I'm not sure if I will be able to schedule a full 45 minutes for this, but I will see when I send you an agenda soon. Your general idea makes sense: I thought that it would be best for us to review the material together, to 'make the case' on both sides, and then review the next steps. I also wanted to talk through a few other aspects of this, such as PR. I will also confirm the attendees for the meeting soon, but I anticipate (other than you and me): Todd Hummel (via videoconference) and Deborah Kahn.

As I mentioned, the meeting will start at 1 pm, and I hope conclude by 4. We can arrange for a taxi to collect you (or I may be able to drive over) from Dicott Parkway. Let me know if you'd like any further suggestions or assistance with travel or accommodation. I'll you could also let me know your plans thus far.

All best wishes,
Charles
Subject: Re: Further Discussions Re Glyphosate Papers

Charles:

Thanks for the note. I look forward to meeting with you and others, including Todd by teleconference on Thursday, August 9th.

I propose, after introductions, that I be given about 45 minutes to cover the following:

CRT's early years with Leon Golberg as Editor in Chief (1971 to 1987)
CRT with McClellan as Editor in Chief (1988 to present)
Emergence of risk analysis as complement to toxicology
Emergence of concern for Conflicts of Interest
CRT's shift from Acknowledgements to Declaration of Interests (2009 to present)
IARC Glyphosate Cancer Hazard Characterization Meeting and publications
Monsanto Interest in publication of Special Supplement with five papers
Review of five papers included in Supplement published 2015
Release on August 1, 2017 of “The Monsanto Papers” related to litigation pre-trial discovery
Two Requests for Retraction based on “The Monsanto Papers”
Cooperative investigation by McClellan and Whalley beginning in fall 2017
Independent affirmation by 16 scientists/authors that publications are independent professional work product
Initial proposal for resolution using Corrigendum. I would anticipate indicating my continued support for this approach as being fair and equitable to multiple parties including the 16 scientists/authors, Editor-in-Chief, publisher and readers.

I think I can cover this critical material in about 45 minutes. Of course, it could take longer dependent upon questions and discussion. I anticipate providing you and others a briefing paper covering these points in advance of the Thursday PM meeting.

At that juncture in the meeting, I would anticipate you or some one else from T and F would advance the proposal that emerged later for Retraction of the papers (Post Society of Toxicology meeting in March 2018).

Does this overall approach seem reasonable to you? I look forward to your response.

As an aside, I will plan to travel on Thursday to Milton Park by train from London to Didcott and cab arriving late in the AM at your offices.

Best regards,

Roger

On Monday, July 30, 2018 3:15 AM, "Whalley, Charles" wrote:

Dear Roger,

Thanks for your most recent email and your offer to reschedule later in the month. Although it would be helpful to have Sarah’s attendance, she is by no means a single ‘advocate’ for a view amongst us
here. We could always have an additional teleconference with Sarah once she has returned from holiday, if we need additional input. However, I know we are all eager to progress, so I'd prefer to proceed with your initial dates if at all possible.

Would you be able to meet at our Milton Park office on Thursday 9th August? I anticipate starting no earlier than 1pm UK time, to allow participation from New York. We should be able to videoconference so it will be almost as good as having Todd in the room.

I know this is short notice to be arranging travel; I hope it is not too inconvenient for you. Let me know if I can help with any of the logistics.

Looking forward to hearing from you.

Best wishes,
Charles

From: Roger McClellan <rmc@att.net>
Sent: 29 July 2018 23:42
To: Whalley, Charles <cwhalley@tandf.co.uk>
Cc: Mildred B. Morgan <mhargray.com>; Roger McClellan <rmc@att.net>
Subject: Re: Further Discussions Re Glyphosate Papers

Follow up Proposed dates for Conference

Charles:

As I recall from our last conversation, Sarah Robbie, is away on holiday all four of the days (August 8, 9 10 or 13) I proposed in early August for us to meet face to face in England.

On reflection, since I assume Robbie is a major advocate of retracting the papers, it would probably not be useful for us to meet without her participation. Hence, I suggest we abandon those dates. As an alternative, I propose August 23, 24, 27 or 28. I can not re-arrange my calendar to be in England on those dates so it would have to be a teleconference. Alternatively, I might be able to arrange to be in New York on the latter 3 days so I could participate from Todd Hummel's office.

So you will be aware, I intend to provide you prior to the meeting a document summarizing my position on the matter. Specifically, it is my professional opinion that a fair and equitable resolution will be to publish a Corrigendum for each paper including a revised Declaration of Interest.

Separately, for internal use and as an agreement between T and F and me as Editor-in-Chief, T and F would commit to drafting at an early date proposed Instructions to Authors including preparation of Declarations of Interest. This would acknowledge that since 2009 the publisher has not posted adequate Instructions to Authors specifying the need to prepare Declarations of Interest instead relying on the Editor-in-Chief to provide such advice by default and on an ad hoc basis. That is the sole basis for my letter to Ashley Roberts that was released in "The Monsanto Papers".

This approach would keep these valuable and extensively reviewed papers in the public domain where they can continue to be used and widely cited. This is appropriate since I am not aware that any parties have challenged the scientific credibility of any of the five papers. Most importantly, it would avoid punishing the 16 scientist/authors for a situation beyond their control and doing irreparable harm to their reputations. As significantly, my recommended approach would not blemish
and harm my reputation as a scientist, Editor, and public servant nor harm the excellent reputation of Critical Reviews in Toxicology.

Please let me know if any of those dates are agreeable.

Best regards,
Roger

---

On Monday, July 23, 2018 7:43 AM, "Whalley, Charles" <@tandf.co.uk> wrote:

Dear Roger,

Thanks for your memo. Todd, our Editorial Director, is based in New York, so your travel to the UK would only bring 3 of us together. For expediency and convenience, a teleconference would very much be easiest to achieve for now. Would you mind if we started with that? It’s not that I’m trying to put you off visiting, which you’re always welcome to do; I’m just trying to ensure we move forward as quickly as possible. We can always retain the option for an in-person meeting if needed afterwards.

Best wishes,
Charles

---

From: Roger McClellan <mailto:Roger.McClellan@att.net>
Sent: 22 July 2018 22:39
To: Whalley, Charles <@tandf.co.uk>
Cc: Roger McClellan <@att.net>; Mildred B. Morgan <hargray.com>
Subject: Further Discussions Re Glyphosate Papers

Charles,

See attached memo.

Roger
Charles:

Please call me (______) as soon as possible concerning the attached inquiry. I will be available on Sunday at my home in New Mexico. I suggest I call the reporter and indicate that the extensive DOIs accompanying each article have been accepted as being complete and accurate.

Roger

On Saturday, August 5, 2017 7:56 PM, Peter Waldman (BLOOMBERG/ NEWSROOM.)<bloomberg.net> wrote:

Dr. McClellan,

I am a reporter for Bloomberg Businessweek magazine and I’m working on an article about possible publication improprieties by Monsanto and Intertek in the series of papers on glyphosate that you published last year. I have several questions for you that I would like to ask, based on some emails that were recently released by plaintiffs’ lawyers in a lawsuit against Monsanto in San Francisco. Is there a time tomorrow or Monday that we can speak? My deadline is roughly mid-afternoon on Monday. Your name and journal are very likely to appear in this article, based on the emails, so it is important for us to talk.

Thank you!

Peter Waldman
Bloomberg Businessweek
Telephone:_______
Dear Mildred and Roger,

I've attached the agenda as a Word document. I will also paste it beneath my signature here. The other attachments were copies of documents found online; the addresses are below:


https://authorservices.taylorandfrancis.com/what-is-a-conflict-of-interest/

https://authorservices.taylorandfrancis.com/defining-authorship/


Best wishes,

Charles

---

**Critical Reviews in Toxicology (ITXC) Glyphosate Supplement Meeting**

*Simon Franklin Room, Taylor & Francis - Thursday 9th August, 1pm*

**Agenda**

1. Introductions
2. Supplement and proposed resolution
   a. Background to supplement, including journal history and supplement context (McClellan)
   b. Review of materials and applicable policies
   c. Discussion of proposed resolution
3. PR plans
4. Taylor & Francis corrections policy and suggested changes

**Attendees (+ short bios for T&F staff)**

- *Roger McClellan, Editor-in-Chief of Critical Reviews in Toxicology*
- *Charles Whalley, Managing Editor, Medicine & Health Journals*
  
  Charles has managed Critical Reviews in Toxicology, as well as most of Taylor & Francis' other journals in toxicology, since November 2014.

- *Todd Hummel, Editorial Director, Medicine & Health Journals*
  
  Todd moved to Taylor & Francis as Editorial Director for Medicine & Health Journals in 2017, prior to which he has held positions at J. B. Lippincott Company, W. B. Saunders/Elsevier, Wolters Kluwer, Oxford
University Press, and BioMed Central/Springer Nature. He is responsible for leading editorial teams in London, Abingdon and Philadelphia, and is the most senior person working solely on medical journals at Taylor & Francis. In this capacity he has been advising on this matter throughout. Todd works in the Philadelphia office and lives in New York.

- **Deborah Kahn, Publishing Director, Medicine & Open Access -- optional**
  Deborah became Publishing Director at Taylor & Francis in 2016, prior to which she was Executive Vice President BioMed Central at Springer Nature. At Taylor & Francis she leads our publishing in Medicine as well the Open Access programme across all subject areas. She also chairs our internal Ethics Committee. Outside of Taylor & Francis, Deborah sits on Council for the Committee on Publication Ethics. Deborah has been involved in consultations around the supplement since the manuscripts were submitted to the journal.

- **Leon Heward Mills, Global Publishing Director -- optional**
  Leon is Global Publishing Director for Taylor & Francis Journals, reporting to the CEO, Annie Callanan. He is responsible for all T&F’s publishing in journals, currently over 2,600 titles. Leon was previously Chief Executive at the Society for Endocrinology and Head of Publishing at the Institution of Civil Engineers.

Abridged Organisation Chart
Including only either those attending or involved in discussions around the supplement.

---

**From:** Mildred Morgan <m.morgan@hargray.com>
**Sent:** 07 August 2018 22:37
**To:** Whalley, Charles <C.Whalley@tandf.co.uk>
**Cc:** roger.o.mcclellan@tandf.co.uk
**Subject:** Meeting Agenda

Hi Charles,

Dr. McClellan asked me to send him the 5 attachments relating to the meeting on Thursday as he could not open a couple of them. He wanted me to embed them in an email, however, I cannot do that as they are all pdf files. I re-sent all the rest of the attachments to Dr. McClellan except for the meeting agenda and I am hoping he can open them.
When I try to open the agenda, an error message comes up "Adobe could not open file because it is either not a supported file type or because file has been damaged and wasn't correctly decoded." Could you send this agenda to Dr. McClellan in an embedded e-mail. I would appreciate it if you would send it to me too.

Thanks.

Mildred
BUSINESS CONFIDENTIAL

Briefing Paper on Issues Related to the Authorship, Editorial Review and Publication of Special Supplement on Potential Carcinogenic Hazard of Exposure to Glyphosate,
Critical Reviews in Toxicology, Volume 46, 2016

Roger O. McClellan, DVM, MMS, DSc (Honorary)
Diplomate-ABT and ABVT
Fellow-ATS, SRA, AAAR, IARA, HPS, ATS and AAAS
Member-National Academy of Medicine
Editor, Critical Reviews in Toxicology
Advisor, Toxicology and Human Health Risk Analysis

Albuquerque, NM 87111-7168
Tel:  ; Cell:  ; Fax:  
E-mail:  @att.net

August 5, 2018
Executive Summary

"An Independent Review of the Carcinogenic Potential of Glyphosate," a Special Supplement to Volume 46 (2016) of Critical Reviews in Toxicology (CRT) was published online on September 28, 2016. The Supplement contained a Foreword (McClellan, 2016), a summary paper (Williams et al., 2016) and four detailed papers with evaluations undergirding the summary paper. The detailed papers addressed exposure evidence (Solomon, 2016), genotoxicity evidence (Brusick et al., 2016), animal carcinogenicity evidence (Williams et al., 2016), and epidemiological evidence (Acquavella, et al., 2016). The five inter-related papers were prepared by an advisory team of 16 internationally-recognized scientists/authors whose efforts were coordinated by Ashley Roberts of Intertek, a Canadian Consulting firm. The project was funded by Monsanto Company, a producer and marketer of products containing Glyphosate. Monsanto also produces and markets seeds for plants that are resistant to Glyphosate.

The five papers were given the most rigorous external review of any papers ever published in CRT since its first issue was published in 1971. This included 36 sets of review comments prepared by 27 highly-qualified scientists from around the world whose comments were solicited by the Editor-in-Chief and identity was anonymous to the authors. Since 2010, each paper published in CRT has included a Declaration of Interest (DOI). In the absence of published Instructions to Authors with guidance on preparation of Declarations of Interest prepared by Taylor and Francis, it has been necessary, by default, for the CRT Editor-in-Chief to provide such guidance, on an ad hoc basis, to authors of papers submitted to CRT. This was done for the 31 papers included in regular issues of Volume 46 and the five papers in the Special Supplement on the potential carcinogenicity of Glyphosate. It is clear from the Foreword to the Special Supplement, as well as the DOIs in the five papers, that preparation of the five review papers was funded by the Monsanto Company.

Convening of the Panel of 16 experts by Monsanto Company was prompted by publication of an International Agency for Research on Cancer (IARC) Monograph in 2015 that reviewed the potential carcinogenic hazard of a group of herbicides, including Glyphosate. The IARC Panel (IARC, 2015; Guyton, et al., 2015) concluded that Glyphosate was a probable human carcinogen (Class 2A). The five papers authored by the 16 person Advisory Group and published in Critical Reviews in Toxicology, Supplemental Issue 1, Volume 46 (2016) concluded that Glyphosate exposure did not pose a carcinogenic risk to humans.

The five papers published in the CRT Special Supplement have received substantial attention around the world. The summary paper by Williams et al. (2016) has been accessed more than 13,000 times. Interest in the papers has come from the scientific, regulatory and legal communities.

The IARC Report (2015), categorizing Glyphosate as a probable human carcinogen, has stimulated the filing of thousands of law suits alleging that exposure to Glyphosate caused the plaintiff's cancer. The law firm of Baum Hedlund Aristei Goldman, representing plaintiffs in a number of the law suits obtained a Court Order requiring the Monsanto Company to release certain internal documents on the health hazards of Glyphosate exposure during the discovery phase of one of the law suits. The released documents frequently identified as "The Monsanto
Papers,” include correspondence related to papers published by Taylor and Francis in various journals, including CRT. One of the disclosures is an e-mail from Roger McClellan, as Editor-in-Chief of CRT, to Ashley Roberts, in his role as Coordinator of preparation of the five papers, providing guidance on preparation of Declaration of Interest for the papers published in the CRT Special Supplement. The letter was written of necessity; statements by McClellan because the publisher has not provided specific written guidance to CRT authors on preparation of DOIs. Roberts forwarded the McClellan e-mail to Monsanto, hence, its appearance in “The Monsanto Papers.”

The on-line release to the public of the contents of “The Monsanto Papers” triggered in August and September 2017, requests to the Editor-in-Chief of CRT and the publisher for “retraction” of the papers in the Special Supplement of CRT. The two requests, built on the contents of “The Monsanto Papers,” requested retraction of the papers based on procedural issues. It is of special note that neither complaint notes any scientific flaws or inaccuracies in any of the five papers.

An investigation into these complaints was initiated jointly in the fall of 2017 by McClellan, in his role as Editor-in-Chief of CRT, and Charles Whalley, in his role as Managing Editor of CRT. That investigation yielded individual statements from each of the 16 scientists/authors attesting to the fact that the five papers were the independent professional work product of the scientists/authors and the contents had not been influenced by Monsanto Company. A copy of those statements and biographical information on the scientists/authors (with the exception of Larry Kier, who I believe is seriously ill) is attached.

With encouragement from McClellan and Whalley, the authors also provided proposed corrigendum for each of the papers, including revised and extended Declarations of Interest. Copies of the proposed corrigendum are attached.

At the March 2018 meeting of the CRT Editorial Advisory Board, Whalley presented a progress report on the investigation. He specifically indicated he thought the Corrigendum approach would be followed to resolve the controversy. He indicated he needed input from several other individuals at Taylor and Francis to bring closure to the matter.

On May 24, 2018, much to his surprise, McClellan received an e-mail from Whalley indicating his position had changed and that several of the papers should be retracted. In a subsequent telephone call, he indicated the retraction approach, in contrast to the approach using published corrigendum, was a “close call that could have gone either way.” In my opinion, this is what may be deemed as an “arbitrary and capricious decision” based on my more than 50 years of experience in decision-making in business and at high levels in government.

In my opinion, a fair and equitable resolution of the controversy would be to publish corrigendum for each of the papers. The corrigendum approach would allow the papers, which are scientifically sound, to remain in the public view while acknowledging that procedural errors were made during the preparation of the papers and their editorial review and publication. Equally as important, the corrigendum approach does not defame or tarnish the reputation of the 16 internationally-recognized, distinguished scientists who authored the five papers published in
the Special Supplement to CRT. Scientists/authors like these 16 individuals are a core asset that CRT depends on to author and submit highly credible critical reviews on contemporary issues at the interface of science and public policy.

Concurrently, it is important that Taylor and Francis prepare, with the advice and consent of the Editor-in-Chief, written Instructions to Authors (for CRT) that provides clear guidance for preparation of DOIs in the future. Based on my extensive managerial experience, I also urge Taylor & Francis to prepare written internal guidance for resolving disputes of this nature in the future, including the role of the publisher, the Editor-in-Chief and authors to minimize future misunderstandings.

**Introduction**

“An Independent Review of the Carcinogenic Potential of Glyphosate,” a Special Supplement to Volume 46 (2016) of Critical Reviews in Toxicology (CRT) was published online on September 28, 2016. The Supplement contained a Foreword (McClellan, 2016), a summary paper (Williams et al., 2016) and four detailed papers with evaluations undergirding the summary paper. The detailed papers addressed exposure evidence (Solomon, 2016), genotoxicity evidence (Brusick et al., 2016), animal carcinogenicity evidence (Williams et al., 2016), and epidemiological evidence (Acquavella et al., 2016). The five inter-related papers were prepared by an advisory team of 16 internationally-recognized scientists/authors whose efforts were coordinated by Ashley Roberts of Intertek, a Canadian Consulting firm. Biological information on the 16 experts is attached. The project was funded by Monsanto Company, a producer and marketer of products containing Glyphosate. Monsanto also produces and markets seeds for plants that are resistant to Glyphosate.

Convening of the Expert Panel was prompted by publication of an International Agency for Research on Cancer (IARC) Monograph in 2015 that reviewed the potential carcinogenic hazard of a group of herbicides, including Glyphosate. The IARC Panel (IARC, 2015; Guyton, et al., 2015) concluded that Glyphosate was a probable human carcinogen (Class 2A). The five papers authored by the 16 person Advisory Group and published in Critical Reviews in Toxicology, Supplemental Issue 1, Volume 46 (2016) concluded that Glyphosate exposure did not pose a carcinogenic risk to humans.

The five papers were given the most rigorous external review ever given to papers submitted to CRT and, very likely, to any papers ever submitted to any Taylor & Francis Journal. Thirty-six sets of review comments were submitted by 27 different internationally-recognized scientists from around the world whose comments were solicited by the Editor-in-Chief of CRT and whose identity was anonymous to the authors. The summary paper (Williams et al., 2016) was reviewed by 10 scientists as external reviewers and the Editor-in-Chief of CRT.

In the absence of written instructions to authors prepared by Taylor and Francis on preparation of “Declarations of Interest” statements, it was necessary for the Editor-in-Chief of CRT to provide, by default, guidance for the preparation of DOIs. This e-mail, from McClellan to Roberts, ultimately appeared in “The Monsanto Papers.” To state the obvious, this e-mail
would never have had to be written if Taylor & Francis had fulfilled its responsibilities for providing such guidance.

The conclusions drawn in the five papers by the Scientific Advisory Team funded by Monsanto have received widespread attention, including substantial media coverage. The controversy over the human carcinogenic potential for Glyphosate exposure has also been stimulated by regulatory debates around the world over continued use of Glyphosate and Glyphosate-ready seeds and litigation in the United States over the role of Glyphosate exposure in causing specific cases of human cancer. More recently, the U.S. Congress has expressed interest in the activities of IARC and funding of IARC by U.S. Agencies.

Papers Widely Accessed

As an aside, the five papers have been widely accessed. The summary paper by Williams et al. (2016) has been accessed over 13,000 times; a level of interest associated with only a few papers ever published in CRT or other Taylor and Francis journals. There have been no concerns expressed to the Editor-in-Chief of CRT as to the scientific content of the five papers.

The Monsanto Papers

The Judge presiding over one of the law suits filed in California as part of the pre-trial discovery process ordered Monsanto to release a number of internal documents related to the health effects of Glyphosate. The documents released have been referred to as “The Monsanto Papers” and posted on the website of the Baum Hedlund Aristei Goldman PC law firm. “The Monsanto Papers” include references to papers published by Taylor and Francis prepared both before and after the IARC cancer hazard classification meeting. This includes e-mails referencing papers published in CRT. Of special note is an e-mail from McClellan to Ashley Roberts providing guidance on preparation of Declarations of Interest for the five papers published in CRT. This guidance was necessary since Taylor and Francis has never published such guidance despite requests made since 2009 by the CRT Editor-in-Chief that such guidance be prepared.

Request for Retraction

Public availability of “The Monsanto Papers” stimulated two complaints to Taylor and Francis and the Editor-in-Chief of CRT requesting retraction of the papers published in the Special Supplement to CRT. The first retraction request dated August 21, 2017 was from Kathryn Z. Guyton of IARC. Guyton was the IARC staff member who organized the review that concluded Glyphosate exposure was a probable human carcinogen. Although not revealed in her letter, it is apparent she has a vested interest in the Volume 46 CRT papers because they reach the conclusion that Glyphosate exposure does not pose a carcinogenic risk to humans, a position counter to that of the IARC Panel Guyton organized.

A second retraction request in September 2017 came from Nathan Donley, on behalf of four environmental health activist organizations [Center for Biological Diversity; Center for Food Safety, Pesticide Action Network North America and Center for Environmental Health].
This request, written in the style of a legal brief, draws heavily on “The Monsanto Papers.” This retraction request was posted on the Internet and widely distributed to media representatives and, very likely, to representatives of plaintiffs in the numerous pending legal cases alleging exposure to Glyphosate caused the plaintiffs’ cancer. These individuals have a clear interest in destroying the credibility of the five papers in the Volume 46 Supplement.

Of special note, neither of the two retraction requests takes exception to the scientific content and credibility of the five papers in Volume 46. The requests for retraction are based on procedural issues related to the authorship of the papers.

Investigation of Complaints

In the late summer of 2017, Taylor & Francis, the publisher of Critical Reviews in Toxicology, in response to the two retraction requests, initiated an investigation into the circumstances related to the preparation, review and publication of the five papers included in the Special Supplement to Volume 46. The investigation has specifically involved Roger O. McClellan, Editor-in-Chief of CRT, Charles Whalley, Managing Editor of CRT and other Taylor & Francis personnel. A range of actions to conclude the Taylor & Francis review have been discussed, focusing on the potential for (a) publishing Corrigendum with corrected and expanded Declarations of Interest for the five articles, or (b) retraction of one or more of the articles published on-line on September 28, 2016 as a Special Supplement to Volume 46.

Independence of Authors

At an early stage in the investigation each of the 16 scientists/authors, serving as Advisors to and funded by Monsanto, offered individual testimonial statements on their role in preparation of the five manuscripts in the Supplement to Volume 46. In their own words, they testified that the papers were the work product of their independent professional review and analysis without any influence by Monsanto. These independent statements are attached. These statements totally counter the charges of Guyton and Donley based on “hearsay evidence” contained in “The Monsanto Papers” that the content of the papers was inappropriately influenced by Monsanto Company personnel.

Especially compelling is the statement of Sir Colin Berry, Emeritus Professor Pathology, Queen Mary, University of London. He was named a Knight Bachelor in the Queen’s Birthday Honours List in 1993 for his services to Medicine and Science. Sir Colin Berry stated ---

"As a former Chairman of the UK Advisory Committee on Pesticides and as Chairman of Section for Committee of the Medicines Act, I have, for many years, dealt with information concerning toxicity of xenobiotics in a consistent manner. Since retirement from those duties I have seen no reason to change my procedures. Information may come from any source but is used to provide the basis of my independent opinion. In this instance, the members of the panel dealing with carcinogenicity produced text on the various issues before us in this field and considered the database identified in the document. We then met, or discussed electronically the various sections, about which we harmonized our views. At no stage was anyone from Monsanto involved in any of the
Preparation of Corrigendum

The 16 scientists/authors also prepared, under the leadership of the lead author of each of the five papers, a proposed Corrigendum for each paper, including a proposed revised “Acknowledgments” and “Declaration of Interest” sections. [These proposed Corrigendum are attached.]

Conflicts of Interest Versus Declarations of Interest Statements

It is useful to provide some historical background for the Declaration of Interest statements in the five Glyphosate papers. In the early 2000s, the issue of Conflicts of Interest for publications began to receive more attention, including for Taylor & Francis Journals. As best I can determine, Taylor & Francis attempted to deal with Conflicts of Interest with a “one-size fits all” approach. This was not appropriate for CRT which is a critical review journal, not a journal for publication of original research as is typical of most Taylor & Francis Journals.

As I have detailed in a separate memo to Charles Whalley (July 25, 2018), this was a very challenging time to edit CRT. It was further complicated as Informa management “force fit” CRT into a short-lived venture, Informa HealthCare. This was also a period of major turnover in personnel at Informa/Taylor and Francis as shown in the attached table. Bright spots were having Claire Summerfield as Production Editor (2008-2013) and Joris Roulleau as Managing Editor (2010-2013) for relatively long periods of time. I am optimistic that the assignment of Charles Whalley as Managing Editor (2015 to present) and Josie Brown as Production Editor (2015 to present) represents a return to stability of a much earlier time period.

The difficulty with documentation of Conflicts of Interest versus Declaration of Interest statements is clearly apparent in a series of e-mail exchanges from 2009-2010. A plea was made then by the CRT Editor-in-Chief for Taylor & Francis to prepare clear instructions to authors, including preparation of “Declarations of Interest.” That request has never been answered. I have never been given an explanation for the lack of action. I can only speculate that some individuals at Taylor & Francis consider it adequate to describe Conflicts of Interest. It is NOT! Authors require clear instructions on how to prepare Declarations of Interest. In the absence of clear written instructions prepared and posted by Taylor & Francis personnel, it has been necessary for the Editor-in-Chief, by default, to provide guidance on preparation of Declarations of Interest to individual corresponding authors on an ad hoc basis. Hence, the memo from McClellan to Roberts that was forwarded to Monsanto Company and appears in “The Monsanto Papers” and becomes a source of “hear-say evidence” used by the two complaints, one calling for retraction of the papers in the Special Supplement to CRT containing the five Glyphosate papers.

In considering the “Declaration of Interest” issue, it is useful to consider these sections in the 31 papers published in the regular issues of Volume 46. It is clear that the DOIs for the
regular papers and those for the five papers in the Special Supplement are remarkably similar in format and general content. A careful review will reveal that the 31 papers dealt with a wide range of scientific topics. It is especially noteworthy that the scientists/authors have a wide range of affiliations, including academic, institutions, private corporations, trade associations, consulting firms and some functioning as independent consultants. A careful review also identifies a number of papers in which explicit reference is made to employees of organizations sponsoring reviews serving as members of the advisory teams authoring papers. In other cases, there is acknowledgement of review of draft papers by the financial sponsor of the review. These are common practices and are not illegal or unethical.

The Donley retraction request, written in the style of a legal brief, uses the “hearsay evidence” in “The Monsanto Papers” to advance the notation that the participation of two former Monsanto employees on the Advisory team and/or review by Monsanto Company personnel of draft material prepared by the Advisory team were inappropriate and serve as a basis for retracting the five articles. These are not unusual practices. In retrospect, it is apparent the specifics of the functioning of the Advisory Team might have been more clearly portrayed in the “Declarations of Interest” for each paper. That can be readily accomplished with corrigendum.

Editor-in-Chief's Recommendation: Publish Corrigendum

The Editor-in-Chief recommended resolution of this matter is based on two central findings. First, the five papers are scientifically valid critical reviews by highly respected scientists/authors and the five papers should remain available to the public. Second, I give great weight to the testimonials of the 16 internationally-recognized scientists/authors that the five papers are their independent professional work product without influence from the Monsanto Company. Third, the confusion that has arisen over the papers arose from errors on the part of both the scientists/authors and the publisher. Moreover, the failure of the Editor-in-Chief to more vehemently insist on written guidance to authors on preparation of “Declarations of Interest” was a contributing factor.

The publication of corrigendum for public view to resolve this complex matter is fair and equitable to the multiple parties in the dispute; the 16 scientists/authors, the Editor-in-Chief, the publisher and the readers of CRT. It is also important that the publisher immediately commit to preparation of written instructions to authors that include provision of guidance for preparation of “Declarations of Interest.” This should be done with the advice and consent of the Editor-in-Chief of CRT. Moreover, I urge the publisher to develop for internal use, written guidance for resolving disputes like this when they occur in the future. This leadership will minimize the potential for such misunderstandings to occur in the future.

Respectfully,

Roger O. McClellan
Scientific Editor, Critical Reviews in Toxicology
Attachments:
1. Biographical material on scientists/authors
2. Authors’ individual testimonies
3. Corrigendum on Authors’ Revised Acknowledgments and DOIs
4. Primary Contacts with Informa/Taylor & Francis Personnel

References


Testimonials from Authors and Co-Authors on 5 Glyphosate Papers

Marilyn Aardema

9/17/17

Roger-I am not aware of any writing by anyone not listed as a coauthor on the papers I was involved in. I did not have any contact or relationship with Monsanto, or any influence from them during the writing of these papers. We undertook an independent review following scientific and professional standards.

Marilyn
Marilyn Aardema Consulting

John Acquavella

9/15/17

Roger:

Thank you for the chance to respond. The epidemiology manuscript was authored jointly by the 5 listed (epidemiologist/biostatistician) authors and each author met every one of the ICJME authorship guidelines. No one from Monsanto had any role in the writing of the epidemiology manuscript, nor did anyone from Monsanto attend our in person expert panel meeting where the approach to our systematic review was decided and each article was critiqued according to standard criteria. The epidemiology section of the summary article also had no input from Monsanto.

Regards,

John

John Acquavella, PhD FACE FISPE
Professor, Dept Clinical Epidemiology
Aarhus University, Denmark
(office)
(mobile)
Aarhus University email @clin.au.dk

9/20/17
Thank you Roger for the chance to provide additional information. I’ll begin by drawing a distinction between the epidemiology paper per se, the epidemiology sections of the summary paper, and the other sections of summary paper. Bill Heydans didn’t offer any input on the epidemiology paper or the epidemiology section of the summary paper. With regard to other sections of the summary paper, the gist of the suggested edits by the epidemiologists concerned the tone toward IARC, not the scientific assessment re exposure, genotox or chronic tox. We epidemiologists pushed for sticking to a scientific assessment of the available evidence with very limited explicit or implied criticism of IARC. We left it to Gary Williams, the primary author, to adjudicate where there were differing suggestions re tone and I didn’t keep track of whose comments prevailed where there was disagreement. However, we 5 epidemiologists all read the final version of the summary paper and were satisfied with the tone. As far as I know, the edits in question concerned tone only.

Regards,
John

9/20/17

Roger:

Thank you again for the chance to respond. I’ve included the published DOI below for reference.

I did not receive any compensation from Intertek. I already had a consulting contract in place with Monsanto prior to the initiation of the review, so there was no need for a contract with Intertek or payment from Intertek for my efforts on the review article. I charged Monsanto my usual hourly rate for my time spent on the review, just as the other panelists charged Intertek their usual hourly rate (for them, paid by Monsanto through Intertek). I thought that the important issue regarding compensation for the DOI was that we were all paid by Monsanto, not the contracting or invoicing/payment details.

I believe the DOI is very comprehensive. It notes: that Monsanto funded our work, my previous employment with Monsanto more than 10 years ago, and even the fact that I consulted on a legal case unrelated to glyphosate involving a former Monsanto chemical plant. I tried to include everything possible in the DOI that you might want to be disclosed.
As I noted in my previous email, the glyphosate epidemiology review was conducted according to the highest standards of my profession. The work was conducted totally independent of the sponsor. All five authors contributed actual written sections to the manuscript and met every one of the ICJME authorship criteria. Monsanto did not contribute to or influence the writing at all. I and my co-authors had sole responsibility for the content of the paper, and the interpretations and opinions expressed in the paper were ours.

Regards,
John

Sir Colin Berry

On Sunday, September 17, 2017 2:21 AM, Colin Berry <sircolinberry.co.uk> wrote:

Dear Mr. McClelland,
Thank you for your mail.
As a former Chairman of the UK Advisory Committee on Pesticides and a Chairman of Section four Committee of the Medicines Act, I have, for many years, dealt with information concerning toxicity of xenobiotics in a consistent manner. Since retirement from those duties I have seen no reason to change my procedures. Information may come from any source but is used to provide the basis of my independent opinion.

In this instance, the members of the panel dealing with carcinogenicity produced text on the various issues before us in this field and considered the database identified in the document. We then met, or discussed electronically the various sections, about which we harmonised our views. At no stage was anyone from Monsanto involved in any of the discussions. Our opinion and the resultant document was arrived at in the manner which has been used by many regulatory authorities, as for example, the WHO/FAO joint panels.

Drafting was carried out by regular exchanges by members of the panel alone.

Your sincerely,
Professor Sir Colin Berry
David Brusiek

9/15/17

Roger

These questions have been asked of me on more than one occasion. As the individual who assembled the manuscript describing the genetic toxicology results and interpretation, I can assure you that the entire manuscript content was drafted, reviewed, and finalized only by the members of the genetic toxicology panel. I can assure Critical Reviews in Toxicology that there were no other authors directly or indirectly involved in preparing its content.

David Brusiek

Michele M. Burns

From: Burns, Michele [mailto:burns.michele@childrens.harvard.edu]
Sent: 16 September 2017 13:07
To: Roger McClellan
Subject: RE: Glyphosateae Papers Published in CRT [EXTERNAL]

Dear Roger,

I had no communication with Monsanto staff about the content of the papers listed below, nor know of anyone who did. The meetings and scientific discussions were conducted in a highly professional, ethical manner.


Thanks,
Michele

Michele M. Burns, MD, MPH
Dear Dr. McClellan,

I am not aware of any contribution to the manuscripts by someone not listed as coauthor of the published papers. I understand that the section on animal tumors – in which I did participate – was drafted and finalized solely by the panel members. I believe that the declaration of interests that appeared at the end of the articles accurately reflects my participation. During the panel activities and writing of these papers I did not have contact with anyone from Monsanto regarding the contents of the manuscripts. The published papers convey my own independent expert opinion.

J.L.V. de Camargo, MD, PhD, FIATP
Professor of Pathology
Botucatu Medical School
18618-000 Botucatu SP Brazil
@uol.com.br
@fmb.unesp.br

PS – A copy of this email was sent to the other coauthors.

David Garabrant
9/22/17

Dear Dr. McClellan,


As far as I am aware, no employees of Monsanto were involved in the drafting of the two articles that I co-authored. I had no contact with any employees of Monsanto at any time during the drafting of these articles. As far as I am aware, no one other than the listed authors was involved in the drafting of the two articles that I co-authored.

The Declarations of Interest (DOI) that I provided for the two articles that I co-authored were accurate to the best of my knowledge at the time I wrote them. In both articles I wrote, “DG serves on a scientific advisory board to Dow Agro Sciences, which markets pesticides including
glyphosate. and has consulted on behalf of Bayer Corp. on litigation matters concerning glyphosate and leukemia.”

In November 2016 after the publication of the five papers, in the course of responding to subpoenas from the plaintiffs’ attorneys in the California litigation, two events occurred:

1. I was reminded by the attorney for Bayer Corporation, who retained me to act as an expert in that litigation, that I was also retained to act as a joint expert for several defendants in the *Walsh v BASF Corp, et al.*, case. Those defendants are: Bayer Corporation; Bayer CropScience LP; Bayer CropScience Holding, Inc.; Dow AgroSciences, L.L.C.; BASF Corporation; Syngenta Crop Protection, Inc.; Deere & Company; Lesco, Inc.; and Monsanto. My point of contact for the group of *Walsh* defendants was the attorney for Bayer, which led to the statement I made in the DOI that I had consulted on behalf of Bayer Corporation on litigation matters concerning glyphosate and leukemia. When I wrote my DOI, I did not list the other defendants in that litigation because I did not recall (or did not know at that time) that they had jointly retained me.

2. I reviewed my consulting engagements and found that in February 2016 I had been retained by a law firm on behalf of Pharmacia LLC (formerly known as Monsanto) regarding litigation involving leukemia and benzene exposure, but not involving glyphosate. I spent a total of 0.3 hours on that case on 2/16/2016 and never did any further work. My company, EpidStat Institute, Inc., was paid $187.50 for my work. I did not recall this engagement at the time I wrote my DOI later in 2016.

To the best of my knowledge, I have had no other relationships with Monsanto at any time prior to co-authoring the two articles, and I have never spoken with any Monsanto scientist about glyphosate or any other scientific issue. Subsequent to the publication of the two glyphosate reviews I have had contact with attorneys representing Monsanto, for the purposes of responding to subpoenas from the plaintiffs’ attorneys in the California litigation.

I hope these clarifications assist you in your inquiry. I will be pleased to provide any further assistance you may need.

Sincerely,

David H. Garabrant, MD. MPH

Ann Arbor, MI
e-mail: [redacted]
phone: [redacted]
Dear Roger,
in my response to you and all other participantsof our exercise the mail
to you bounced back.
I am sending my statement to you separately.
Best
Helmut

Dear Roger,
I only can support all the previous statements. There was no interaction
or interference with Monsanto people before, during or after the
meeting, the evaluation of data or preparation of the manuscripts I have
been involved.
Best regress
Helmut Greim

Larry D. Kier

9/22/17

Dear Dr. McClellan:

Thank you for your communication providing the opportunity to respond to concerns.

With respect to the specific question of authorship I fully concur with my fellow authors that the
genotoxicity expert panel report was the product of the listed authors. Neither Monsanto employees
nor attorneys were “ghost-writers.”

I was initially hired by Monsanto to serve as a consultant to support the Intertek genotoxicity expert
panel. In this capacity I was in contact with Monsanto to facilitate providing the panel members with
complete and accurate information, including supplemental information on regulatory genetic
toxicology studies.

Subsequent to development of the genotoxicity expert panel manuscript I agreed to be added as a co­
author subject to the approval of the panel members.

Please note that my employment with Monsanto began in 1974 and not 1979.

Thanks.

Larry Kier
Dear Dr McClellan,

I am aware of the accusations of “ghostwriting” by Monsanto employees, and I can appreciate the need for an investigation. Because my name was mentioned in one or more of the released emails, I have been contacted on this issue by several journalists, and have given them the same assurance as I will now give you. As far as I am aware, there was no “ghostwriting”, and the papers of which I was co-author were written entirely by the authors. Certainly from my side there was no contact with or influence by Monsanto, and I believe that to be the case for the other co-authors. I would never let my name be used on an article ghostwritten by others.

I hope this is helpful.

Kind regards,

David Kirkland.

Gary Marsh

On Tuesday, September 19, 2017 3:22 PM, "Marsh, Gary M" wrote:

Dear Roger,

In response to your email of September 15, 2017, this is to confirm that I had no contact whatsoever with Monsanto staff about the contents of the glyphosate review articles. The members of the epidemiology panel on which I served had absolute control, at all stages of the effort, over the contents of the epidemiology review article as well as the epidemiology section of the comprehensive review article. The opinions and conclusions expressed in these epidemiology components of the project were exclusively those of the panel members.

Sincerely,

Gary
Ashley Roberts

9/27/17

Dear Roger:

In response to your enquiries, I can confirm that Monsanto did not participate in the preparation of the 4 critical subject evaluations. The summary paper required clarification on the history and regulatory processes for glyphosate and I shared that summary with Dr. Heydens to ensure the accuracy of this information once the underlying evaluations had been finalized. Dr. Heydens’ comments on the summary had no impact on the viewpoints/interpretation or the independent conclusions that had already been reached and set out by the 4 expert panel groups in their evaluations. As such, Monsanto was not involved in the drafting of any of the evaluations and did not have any input into the evaluations or conclusions regarding the safety of glyphosate that was provided to the journal.

Ashley

Ashley Roberts, Ph.D.

Keith R. Solomon

9/21/17

Dear Dr. McClellan et al.,

I have finally received computer (back from repair). I have checked the paper and the DOI. The DOI is completely correct in the statement that “Neither any Monsanto company employees nor any attorney reviewed any of the Expert Panel’s manuscripts prior to submission to the journal.”

As noted in the Acknowledgments “I thank Monsanto Inc. for providing access to reports from exposure studies for glyphosate in applicators”. Obviously, to obtain those reports, I communicated with people at Monsanto and might have asked for clarification of material in the reports. The data from the reports that were used are part of the paper and are reported in the supplemental information.

The opinions expressed in this paper and mine only.

Keith
Dear Roger, I had no communications with Monsanto staff about the content of the reviews. Tom Sorahan

Douglas L. Weed

9/19/17

Dr. McClellan,

I appreciate the opportunity to respond to your questions. I can assure you that the manuscript on epidemiology was authored only by those listed as the co-authors, including myself. Similarly, the epidemiology section in the summary article was authored only by the co-authors. Monsanto had no role in writing either of these manuscripts. Furthermore, no one from Monsanto attended the meetings prior to submission of these manuscripts. Finally, my declaration of interests was correct.

Sincerely,

Doug Weed

Douglas L. Weed, M.D., M.P.H., Ph.D.
Founder and Managing Member
DLW Consulting Services, LLC
Salt Lake City, UT

Gary Williams

9/20/17

Dear Roger,

I will respond to your request at this time because the College is closed for the next two days by which you requested a response. I would have wanted to discuss some items with Dr. Roberts, but he is travelling.

My responses cover the three sections of the publication of which I am a co-author.

For the carcinogenicity section, I was assisted in pathology review by my colleague Dr. Michael Latropoulos. He confirms that all materials provided to us came from Intertek.

Likewise, for other sections, source documents came from Intertek.

Any materials provided to one member of a working group were provided to all members.
In the many exchanges of drafts I saw no material changes that did not come from a member of the Panel. In other words, I saw no changes that could have come from Monsanto.

From the time of my recruitment to the Panel up to the present, I have had no contact with any Monsanto representative.

In summary, the DOI accurately reflects the absence of input from Monsanto.

In reviewing the DOI, however, I have found a couple of inaccuracies. In referring to the previous review of glyphosate supported by Monsanto (Williams et al, 2000), acknowledgement is made to the contribution of Barry Lynch of Cantox. In the paper, we actually thank Douglas W. Bryant. Also, in several places it is stated that I consulted for Monsanto on litigation matters involving glyphosate. I have consulted for Monsanto on other matters, but I have no recollection of consulting on glyphosate.

I hope that these responses are helpful.

Yours sincerely,

Gary M. Williams, MD
Professor of Pathology
This Corrigendum is provided for five papers published in the Special Supplement noted above. For convenience, the Editor's original commentary that introduced the five papers is also included. The five papers were prepared by 16 independent scientists who worked together to review the relevant literature on the potential carcinogenic hazard of glyphosate, a widely used agricultural chemical. Preparation of the papers and their publication were stimulated by publication of the International Agency for Research on Cancer Monograph 112, Monograph on the Evaluation of Carcinogenesis Risks to Humans: Some Organophosphate Insecticides and Herbicides (IARC, 2015) (Guyton et al, 2015). The papers in this Special Supplement have attracted substantial interest with more than 10,000 individuals having read the summary paper on-line.

As noted in the Editor’s Commentary, the papers in this Supplement were rigorously reviewed by 27 internationally-recognized experts selected by the Editor and anonymous to the authors. It was also noted that each paper was accompanied by an extensive Declaration of Interest statement, a published statement that was beyond the norm for scientific publishing. Some individuals have raised questions as to the accuracy and completeness of the Declaration of Interest statements. In response to this interest the Managing Editor, Charles Whalley, representing the Publisher, Taylor and Francis, a subsidiary of Informa, Inc. and the Editor-in-Chief of Critical Reviews in Toxicology, Roger O. McClellan, have conducted an independent review of the process by which the papers were prepared under the direction of Ashley Roberts, Intertek Scientific and Regulatory Consulting (Intertek), with funding provided by Monsanto, a producer and marketer of Glyphosate.

The review involved communication with each of the senior authors of the five papers and their co-authors. All of the authors expressed the view that the original papers clearly communicated the role of Intertek in managing the process by which the papers were prepared with funding provided by Monsanto Co. Moreover, each of the authors emphasized that the contents of the papers and the conclusions drawn represented the independent professional views of the authors and were not influenced by either Intertek or Monsanto.

However, the review process did identify areas in which the Acknowledgments and Declaration of Interest sections of the papers were not totally accurate or as complete as desired.
Thus, the lead author on each of the five papers has developed, in collaboration with the co-authors on the paper, a Revised Acknowledgment and Revised Declaration of Interest section. These reviewed statements are shown below for each of the five papers. To provide context, the original Acknowledgments and Declaration of Interest statements of the Editor's Commentary introducing the five papers has been provided. It is our opinion that these revised sections, when published, go beyond the norm of the scientific publishing field. Some Publishers and Journals may require authors to provide this level of detail, however, it is rarely published nor easy to obtain. In our opinion, the contents of these papers are of vital importance to the scientific and regulatory committees and society-at-large. Thus, we are pleased to communicate these revised statements so readers can form their own opinions as to any potential conflicts of interest.

Managing Editor
Charles Whalley

Editor-in-Chief
Roger O. McClellan

Original Acknowledgements

The Editor gratefully acknowledges the extensive review comments offered by the 27 external reviewers. Those comments enhanced the quality and completeness of the five papers.

Original Declaration of Interest

Roger O. McClellan, the Editor-in-Chief of Critical Reviews in Toxicology (CRT), since 1987, currently serves as an independent advisor to private and public entities on environmental and occupational health issues. Early in his career, his research focused on the health effects of radiation and internally-deposited radionuclides as an employee of General Electric Company and the U.S. Atomic Energy Commission (AEC). Later he provided leadership for the Lovelace Inhalation Toxicology Research Institute’s extensive research program on airborne radionuclides and other toxicants with primary financial support from the AEC and the U.S. Department of Energy. From 1988 to 1999, he was the President and Chief Executive Officer of the Chemical Industry Institute of Toxicology (CIIT), a not-for-profit research institute whose extensive research program, focusing on mechanisms of action of chemicals, was supported by dues payments from member companies. The Monsanto Company was a founding member of the CIIT. The CIIT did not conduct any research on glyphosate. McClellan, during his career, has served on over 100 major advisory committees for private firms, academic institutions and U.S. government and international agencies, including the International Agency for Research on Cancer (IARC). None of these advisory assignments has directly involved review of the health hazards of glyphosate. McClellan, in his role as Editor-in-Chief of CRT, selected the 27 individuals who reviewed the five papers published in this Special Supplement. The reviewers represented a cross-section of scientists from around the globe employed by academic, government and private entities or working as sole proprietors. The review comments they provided were considered to represent their independent professional views. This article is part of a supplement, sponsored and supported by Intertek Scientific & Regulatory Consultancy (Intertek). Funding for the sponsorship of this supplement was provided to Intertek by the Monsanto Company, which is a primary producer of glyphosate and products containing this active ingredient.

Revised Acknowledgments

The authors gratefully acknowledge the extensive comments received from nine independent reviewers selected by the Editor and who were anonymous to the authors. These comments were very helpful in revising the manuscript. Ashley Roberts would like to thank his colleague at Intertek, Barry Lynch, for assistance in the preparation of the manuscript and William Heydens of Monsanto for providing a regulatory history overview for use by the authors in the preparation of this summary paper and his review of a preliminary draft of the summary manuscript and the final manuscript. The authors welcome the opportunity to correct the failure of not acknowledging the contributions of Barry Lynch, Intertek, and William Heydens, Monsanto, in the original Acknowledgments. These individuals were not considered for authorship because they did not participate in the deliberations of the Panel and did not contribute to the conclusions drawn by the Panel. The conclusions were independently formulated by each of four Panel Sub-Groups as detailed in the individual papers.

Revised Declaration of Interest

This paper (Summary Paper) is part of a supplement, the preparation of which was coordinated by Intertek Scientific & Regulatory Consultancy (Intertek) under the leadership of Ashley Roberts. It was prepared as a summary of, and subsequent to preparation of four manuscripts produced by and containing the opinions and conclusions of four groups of an expert panel. The expert panel members' recruitment was organized and conducted by Intertek. Funding for this project was provided to Intertek by the Monsanto Company which is a primary producer and marketer of glyphosate and products containing this active ingredient. All of the expert panelists other than John Acquavella and Larry D. Kirk were engaged by, and acted as consultants to Intertek, and were not directly contracted by the Monsanto Company. John Acquavella and Larry D. Kirk served as independent consultants to Intertek for this project, however, they were compensated directly by the Monsanto Company through existing consulting contracts.

The employment affiliations of the authors are as shown on the cover page. Everyone participated in the review process and preparation of this Summary Paper as an independent professional and not as representative of their employer.

William Heydens of Monsanto reviewed a draft of this Summary Paper and suggested wording changes but did not comment on the opinions and conclusions of the expert panel. The opinions expressed and final conclusions set out in this Summary Paper and in the individual papers by the four groups were those of the listed authors and no one else.

While Intertek (formerly Cantox) has not previously worked on glyphosate-related matters for the Monsanto Company, previous employees (Ian Munro and Douglass Bryant) of Cantox, have worked in this capacity. Ian Munro and Gary Williams, with the assistance of Douglass Bryant, prepared a safety and risk assessment of Roundup herbicide (glyphosate), which was supported by Monsanto (Williams et al, 2000).

Gary Williams, Sir Colin Berry, David Brusick, Joao Lauro Viana de Camargo, Helmut A. Greim, David J. Kirkland, and Tom Sorahan have previously served as independent consultants for the Monsanto Company, some serving on the European Glyphosate Task Force. Keith R. Solomon previously served as an independent consultant for the Monsanto Company on the deregulation of RR alfalfa in the US (2012-2014). In collaboration with Cantox, Dr. Solomon contributed to an ecotoxicological risk assessment for Roundup® herbicide, which was published (Giesy et al, 2000). In addition, between 2014 and 2016, he served on a scientific advisory board to Dow AgroSciences, which markets pesticides, including glyphosate. John Acquavella and Larry D. Kier have also served as independent consultants and were previously employees of the Monsanto Company. John Acquavella was employed by Monsanto between the years 1989 and 2004. He is a consultant on a legal case unrelated to glyphosate that involved a former Monsanto industrial chemical plant. Larry D. Kier was employed by Monsanto between 1974 and 2000.

Helmut Greim has previously reviewed the available long-term studies in rodents and has published a paper (Greim et al., 2015) together with three coauthors. One of them, an employee
of Monsanto, provided the original data from the studies conducted by Monsanto, the other two authors were independent consultants, one of them a member of the glyphosate task force.

David Garabrant serves on a scientific advisory board to Dow Agro Sciences, which markets pesticides including glyphosate. He was jointly retained by Bayer Corporation; Bayer CropScience LP; Bayer CropScience Holding, Inc.; Dow AgroSciences, L.L.C.; BASF Corporation; Syngenta Crop Protection, Inc., Deere & Company, Lesco, Inc.; and Monsanto in litigation matters concerning glyphosate and leukemia. He also provided consultation in February 2016 to an attorney representing Pharmacia (formerly Monsanto) in litigation that did not involve glyphosate. Tom Sorahan has consulted for Monsanto on litigation matters involving glyphosate. Tom Sorahan has received consultancy fees and travel grants from Monsanto Europe SA/NV as a member of the European Glyphosate Toxicology Advisory Panel and participated in the IARC Monograph Meeting for volume 112, as an Observer for the Monsanto Company.

Douglas L. Weed has consulted on litigation matters for Monsanto that did not involve glyphosate.

Other than David Garabrant and Tom Sorahan, none of the aforementioned authors had previously been involved in any litigation procedures involving Monsanto and glyphosate.

Marilyn Aardema, Michele M. Burns, Gary Marsh and Ashley Roberts had not been previously involved in any activity involving glyphosate and as such declare no potential conflicts of interest.

Revised Acknowledgments

The author gratefully acknowledges the extensive comments offered by five reviewers selected by the Editor and presented anonymously to the author. These comments were useful in revising the paper. I thank Monsanto Inc. for providing access to reports from exposure studies for glyphosate in applicators and for providing clarification of the methods used in these studies. I wish to thank the authors of the other papers in this series for their constructive suggestions and comments on the exposure paper.

Revised Declaration of Interest

The employment affiliation of the author is shown on the cover page. However, it should be recognized that the author participated in the review process and preparation of this paper as an independent professional and not as a representative of his employer. Keith R. Solomon previously served as an independent consultant for the Monsanto Company on the deregulation of RR alfalfa in the US (2012-2014). In collaboration with Cantox, the predecessor company to Intertek Scientific and Regulatory Consultancy (Intertek) KRS contributed to an ecotoxicological risk assessment for Roundup® herbicide, which was published (Giesy et al., 2000). In addition, between 2014 and 2016, he served on a scientific advisory board to Dow AgroSciences, which markets pesticides including glyphosate. KRS has not been involved in any litigation procedures involving Monsanto Company and glyphosate. KRS’s recruitment and evaluation of the data was organized and conducted by Intertek. Intertek is a consultancy firm that provides scientific and regulatory advice, as well as safety and efficacy evaluations for the chemical, food and pharmaceutical industries.

While Intertek Scientific & Regulatory Consultancy (Intertek) has not previously worked on glyphosate related matters for the Monsanto Company, previous employees of Cantox, the predecessor company to Intertek, had worked in this capacity. Funding for this evaluation was provided to Intertek by the Monsanto Company which is a primary producer of glyphosate and products containing this active ingredient.

Revised Acknowledgment

The authors gratefully acknowledge the very useful comments provided by seven reviewers who were selected by the Editor and anonymous to the authors. These comments helped improve the manuscript. The authors gratefully acknowledge the comments of William Heyden of Monsanto for his comments on the section of analytic selection bias comments which led to a revision that was more understandable to a general scientific audience.

Revised Draft Declaration of Interest

The employment affiliation of the authors is as shown on the cover page. However, it should be recognized that each individual participated in the review process and preparation of this paper as an independent professional and not as a representative of their employer. This expert panel evaluation was organized and conducted by Intertek Scientific & Regulatory Consultancy. Funding for this evaluation was provided by Monsanto Company, which is a primary producer of glyphosate and products containing this active ingredient. The authors had sole responsibility for the content of the paper, and the interpretations and opinions expressed in the paper are those of the authors.

JA worked for Monsanto from 1989 through 2004. He is currently a consultant on a legal case unrelated to glyphosate that involves a former Monsanto industrial chemical plant. DG serves on a scientific advisory board to Dow AgroSciences, which markets pesticides including glyphosate. He was jointly retained by Bayer Corporation; Bayer CropScience LP; Bayer CropScience Holding, Inc.; Dow AgroSciences, L.L.C.; BASF Corporation; Syngenta Crop Protection, Inc., Deere & Company, Lesco, Inc.; and Monsanto in litigation matters concerning glyphosate and leukemia. He also provided consultation in February 2016 to an attorney representing Pharmacia (formerly Monsanto) in litigation that did not involve glyphosate. That consultation consisted of 0.3 hours of professional services, after which he did no further work on the litigation. GM has no additional declarations. TS has received consultancy fees and travel grants from Monsanto Europe SA/NV as a member of the European Glyphosate Toxicology Advisory Panel and participated in the IARC Monograph Meeting for volume 112 which
reviewed the literature and provided a carcinogenic hazard assessment for glyphosate as an Observer for the Monsanto Company. In addition, TS has consulted for Monsanto on litigation matters involving glyphosate. DW has consulted on litigation matters concerning Monsanto that did not involve glyphosate. This article is part of a supplement, sponsored and supported by Intertek Scientific & Regulatory Consultancy. Funding for the sponsorship of this supplement was provided to Intertek by the Monsanto Company, which is a primary producer of glyphosate and products containing this active ingredient. IA was paid directly by Monsanto for his work on this expert panel. The other authors (DG, GM, TS, DW) were paid by Intertek, which was funded by Monsanto.
Revised Acknowledgement

The authors gratefully acknowledge the extensive comments received from nine independent reviewers selected by the Editor and who were anonymous to the authors. These comments were very helpful in revising the manuscript. Materials for consideration for use in the preparation of this paper were provided by Intertek. The authors thank Barry Lynch of Intertek for writing the Introduction to the paper. Dr. Williams thanks his colleague, Dr. Michael J. Iatropoulos for assistance in writing the section on mouse kidney tumors, and Ms. Sharon Brana for typing the manuscript.

Revised Declaration of Interest

This paper is part of a series on glyphosate, which was sponsored and supported by Intertek Scientific & Regulatory Consultancy (Intertek) under the leadership of Ashley Roberts. Funding for preparation of this supplement was provided to Intertek by the Monsanto Company, which is a primary producer of glyphosate and products containing this active ingredient.

The employment affiliations of the authors of the carcinogenicity group of the expert panel are as shown on the cover page. Each individual participated in the review process and preparation of this paper as an independent professional and not as a representative of their employer.

The carcinogenicity group members recruitment and the evaluation of the data was organized and conducted by Intertek Scientific & Regulatory Consultancy (Intertek). The group panelists were engaged by Intertek, and acted as consultants to Intertek and were not directly contacted by the Monsanto Company. Neither any Monsanto company employee nor any attorney reviewed the group’s manuscript prior to submission to the journal. Intertek (previously Cantox) is a consultancy firm that provides scientific and regulatory advice, as well as safety and efficacy evaluations for the chemical, food, and pharmaceutical industries. While Intertek has not previously worked on glyphosate-related matters for the Monsanto Company, previous employees (Ian Munro, Douglass W. Bryant, Barry Lynch) of Cantox, have worked in this capacity. These employees of Cantox, and Gary Williams, prepared a safety and risk assessment, including the carcinogenicity, of Roundup herbicide (glyphosate) supported by Monsanto.
Gary Williams, Sir Colin Berry, João Lauro Viana de Camargo, and Helmut Greim have previously served as independent consultants for the Monsanto Company, some on the European Glyphosate Task Force. Helmut Greim has previously reviewed the available long-term studies in rodents and has published a paper (Greim et al., 2015) together with three coauthors. One of them, an employee of Monsanto, provided the original data of the Monsanto studies, the other two were independent consultants, one of them a member of the glyphosate task force. Michele Burns has not previously been involved in any activity involving glyphosate and as such declares no potential conflict of interest. None of the aforementioned authors have been involved in any litigation procedures concerning glyphosate.
Acknowledgment

The authors gratefully acknowledge the extensive comments received from seven independent reviewers selected by the Editor and who were anonymous to the authors. These comments were very helpful in revising the original submitted manuscript. The authors also gratefully acknowledge the clerical assistance of Anna Bickel, a Monsanto employee, in formatting the final paper prior to submission to the journal.

Revised Declaration of Interest

The employment affiliation of the authors is as shown on the cover page. Each individual participated in the review process and preparation of this paper as an independent professional. No individuals other than the cited authors were involved in developing the analysis and conclusions of the manuscript prior to its submission to the journal.

The Expert Panel Member recruitment was organized and conducted by Intertek Scientific & Regulatory Consultancy (Intertek) and the initial Expert Panelists worked under individual consulting contracts with Intertek. Intertek (previously Cantox) is a consultancy firm that provides scientific and regulatory advice, as well as safety and efficacy evaluations for the chemical, food, and pharmaceutical industries. While Intertek Scientific & Regulatory Consultancy has not previously worked on glyphosate related matters for the Monsanto Company, previous employees of Cantox had worked in this capacity.

Larry Kier did not have a consulting contract with Intertek; he was employed as a consultant by Monsanto to provide support for the Glyphosate Expert Panel in the areas of genotoxicity and oxidative stress. LK did review the report as it was being written and provided his expertise when requested by the panel members. After the final draft of the report was written Larry was added as a co-author and genotoxicity Expert Panel member based on a unanimous decision of the original genotoxicity Expert Panel Members.

Gary Williams, David Brusick, and David Kirkland have previously served as independent consultants for the Monsanto Company, some serving on the European Glyphosate Task Force.
Larry Kier was previously an employee of the Monsanto Company (1994-2000) has also served as an independent consultant for Monsanto Company. As a consultant to Monsanto, LK prepared and published a review on the genotoxicity of glyphosate-based formulations (Kier, 2013).

Marilyn Aardema has not previously been employed in the Monsanto Company or previously been involved in any activity involving glyphosate and as such declares no potential conflicts of interest. Ian Munro, Douglass W. Bryant, and Gary Williams prepared a safety and risk assessment paper of Roundup herbicide (glyphosate) (Williams G.M. et al., 2000).

Except for assistance with final formatting, neither any Monsanto company employees nor any attorney provided any review of the Expert Panel’s manuscript analysis and conclusions prior to submission to the journal. This article is part of a supplement, sponsored and supported by Intertek Scientific & Regulatory Consultancy. Funding for the sponsorship of this supplement was provided to Intertek by the Monsanto Company, which is a primary producer of glyphosate and products containing this active ingredient.
Primary Contacts with Informa/Taylor and Francis Personnel for Roger O. McClellan, Editor-in-Chief, Critical Reviews in Toxicology Over 2008-2018

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Year(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stewart Gardiner</td>
<td>Production Manager</td>
<td>2008</td>
</tr>
<tr>
<td>Phil Garner</td>
<td>Publishing Director</td>
<td>2008, 2009</td>
</tr>
<tr>
<td>Cleo Hall</td>
<td>Managing Editor</td>
<td>2008</td>
</tr>
<tr>
<td>Kristina Kefi Munn</td>
<td>Managing Editor</td>
<td>2008, 2009</td>
</tr>
<tr>
<td>Anna Muldoon</td>
<td>Managing Editor, US Journals</td>
<td>2008</td>
</tr>
<tr>
<td>Felicia Ruocco</td>
<td>Production Editor</td>
<td>2008</td>
</tr>
<tr>
<td>Claire Summerfield</td>
<td>Production Editor</td>
<td>2008 through 2013</td>
</tr>
<tr>
<td>Yvonne Oliver</td>
<td>Business Development Executive</td>
<td>2009, 2010</td>
</tr>
<tr>
<td>Lindsay Duncan</td>
<td>Production Editor</td>
<td>2012, 2013</td>
</tr>
<tr>
<td>Anna Treadway</td>
<td>Head of Journal Publishing, Informa Health Care</td>
<td>2013-2014</td>
</tr>
<tr>
<td>Jenna Whittle</td>
<td>Production Editor</td>
<td>2014</td>
</tr>
<tr>
<td>Charles Whalley</td>
<td>Managing Editor</td>
<td>2015-present</td>
</tr>
<tr>
<td>Josie Brown</td>
<td>Production Editor</td>
<td>2015-present</td>
</tr>
</tbody>
</table>
Dear Roger,

If you're not already in bed, I'm available this morning at my usual number: +44 20 3377 3946. I've a few meetings but I'll be at my desk for most of the day.

I'll try giving you a call in my late afternoon (your morning).

I'll need to consult on this, but our advice remains the same. Please don't comment to journalists and refer all queries to us.

All best wishes,
Charles

Charles:
I would like to discuss this as early on Monday as possible. I will call you. Please let me know if you will be available, time and best number to call.
Best regards, Roger

On Sunday, August 6, 2017 6:27 PM, Peter Waldman (BLOOMBERG/NEWSROOM:<bloomberg.net>) wrote:

Dr. McClellan,
In the interest of time, let me ask you in this email to respond to the main assertion in our article about the glyphosate papers you published. There are numerous emails that show senior Monsanto employees reviewed, edited, and had extensive contact with authors of the papers, and even was paying at least two of them at the time. Monsanto appears to have been orchestrating the whole process behind the scenes. All of that apparently took place behind your back, given your conscientious efforts at full disclosure in the Declaration of Interest section of the articles. In one of your attached emails, you told Dr. Roberts of Intertek, "The DOIs should start something like -"The employment affiliation of the authors is as shown on the cover page. However, it should be recognized that each individual participated in the review process and preparation of this paper as an independent professional and not as a representative of their employer. The remainder of the DOI should make clear how individuals were engaged, ie by Intertek. If you can say without consultation with Monsanto that would be great. If there was any review of the reports by Monsanto or their legal representatives that needs to be disclosed."
Biographical Material on the Scientists/Authors of the Five Papers in the Glyphosate Supplement (Volume 46, 2016)
As you know, the published Declaration of Interest stated, "Neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel's manuscripts prior to submission to the journal."

My question is what happens now that we know that that Declaration of Interest was false and that Intertek and Monsanto were well aware they were publishing fabricated statements about the purported independence of the panelists? How serious is this violation of scientific publishing canon? Are you reviewing the papers for possible retraction?

Please give me a call tomorrow or reply with your response to this email.
Thanks so much!
Peter Waldman
Bloomberg Businessweek
Telephone [redacted]
Dr. McClellan,

Thank you for your prompt reply.

Mr. Whalley,

Do you or Taylor and Francis have a response for our article to this situation? Specifically, are you reviewing the glyphosate papers for possible retraction due to false Declaration of Interest statements? FYI I'm in San Francisco so you can call me any time this evening.

Thank you!
Peter Waldman
Bloomberg Businessweek
Tel. 1

From: roger.o.mcclellan@bloomberg.net
To: Peter Waldman
Cc: Charles.whalley@bloomberg.net
Subject: Inquiry on Glyphosate Papers

Peter Waldman:

I am pleased to respond to your e-mail of August 6, 2017 concerning the five papers on Glyphosate published in Critical Reviews in Toxicology, Volume 46, 2017. In your e-mail you noted my conscientious efforts to have documented in the Declaration of Interest for each article full disclosures as to the preparation of each article. You have called to my attention recent disclosures in legal proceedings, disclosures I have not previously seen, that question the accuracy and completeness of the published Declarations of Interest for the papers. These are serious accusations relative to scientific publishing canons and deserve very careful investigation.

Accordingly, I have forwarded your communication to Taylor and Francis in the United Kingdom, the publisher of Critical Reviews in Toxicology. I can assure you that Taylor and Francis, as the Publisher, and I, as the Scientific Editor, of Critical Reviews in Toxicology will carefully investigate the matter and take appropriate action with regard to these five specific papers. Until all the facts are in hard, it would be premature for me and/or Taylor and Francis to identify a specific future course of action with regard to these papers.

Sincerely,
Roger O. McClellan, DVM, MMS, DSc (Honorary)
Diplomate- ABVT and ABT; Fellow- ATS, SRA, HPS, AAAR, IARA, and AAAS; Member-National Academy of Medicine
Advisor, Inhalation Toxicology and Human Health Risk Analysis
Editor, Critical Reviews in Toxicology
Albuquerque, NM 87111
Dear Roger,

This is interesting. Thanks for passing on.

All best wishes,
Charles
The attached communication is quite straightforward and is quite sensitive since the Johnson vs. Monsanto trial is underway in San Francisco. Please do not share this material with anyone or discuss with anyone. If contacted by the media, tell them to contact me. Do not share your response to me with anyone at Taylor and Francis.

I appreciate your help on this very complex matter.

Roger
From: Whalley, Charles <whalley.charles@tandf.co.uk>
Sent: Wednesday, August 8, 2018 7:09 AM
To: Roger McClellan
Subject: RE: ITXC Glyphosate Supplement -- Agenda for meeting on Thursday

Dear Roger,

We will need to postpone the start of our meeting by 1 hour, to 2pm, as Deborah needs to have some emergency dental work! If you are still aiming to arrive at Milton Park around 12 to 12:30, I wonder if you and I could go for lunch for an hour before our 2pm start. Due to time, we will need to go to the restaurant in our business park, which I'm afraid is of a middling standard...

Before this change of plans, I was also hoping that we would have time to go for dinner. There are some nice country pubs in the villages nearby. Anyway, we can discuss this tomorrow.

All best wishes,
Charles

From: Whalley, Charles
Sent: 07 August 2018 17:10
To: Roger McClellan
Cc: Hummel, Todd <taylorandfrancis.com>; Kahn, Deborah <tandf.co.uk>; Heward Mills, Leon <informa.com>
Subject: ITXC Glyphosate Supplement -- Agenda for meeting on Thursday

Dear Roger,

Please find attached the agenda for our meeting on Thursday, also pasted below. The attendees will be you, me and Todd (on videoconferencing), with either Deborah and/or Leon possibly present for some or all of the meeting, depending on their availability and our progress on the day. The attachment has more information as to each of us. As mentioned in other emails, you will also have the opportunity to meet separately with Ellie and Josie.

In addition to the materials you sent earlier, I have also attached a copy of Taylor & Francis' Corrections Policy, a copy of COPE's Retraction Guidelines, and copies of our Author Services guidance on authorship and conflicts of interest.

I look forward to seeing you. I'm optimistic for a productive meeting. Please keep me updated as to your movements.

Agenda

1. Introductions
2. Supplement and proposed resolution
   a. Background to supplement, including journal history and supplement context (McClellan)
   b. Review of materials and applicable policies
   c. Discussion of proposed resolution
3. PR plans
Safe travels,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon. OX14 4RN, UK
Direct line:  
Switchboard:  
www.tandfonline.com

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately and notify the sender.

Informa Group plc. | Registered in England & Wales No. 3039067 | 8 Harewood Place, London, SW1P 1WG
| From: | Roger McClellan <RogerMcClellan@att.net> |
| Sent: | Sunday, August 6, 2017 7:36 PM |
| To: | Ashley Roberts Intertek |
| Cc: | Roger McClellan; Mildred B. Morgan; Charles Whalley |
| Subject: | Fw: Main Question/ Urgent |
| Attachments: | 19-Editor-of-Journal-That-Published-Expert-Panel-Manuscript-St...5987B3F40201051EO0AB0079.pdf; Untitled.txt |

Ashley:
Were the papers you and your colleagues submitted to CRT reviewed by Monsanto prior to submission to CRT? If so, this would contradict the DOIs you and the other senior authors submitted. Please advise me ASAP by e-mail. Regards, Roger

Dr. McClellan,
in the interest of time, let me ask you in this email to respond to the main assertion in our article about the glyphosate papers you published. There are numerous emails that show senior Monsanto employees reviewed, edited, and had extensive contact with authors of the papers, and even was paying at least two of them at the time. Monsanto appears to have been orchestrating the whole process behind the scenes. All of that apparently took place behind your back, given your conscientious efforts at full disclosure in the Declaration of Interest section of the articles. In one of your attached emails, you told Dr. Roberts of Intertek, "The DOIs should start something like "The employment affiliation of the authors is as shown on the cover page. However, it should be recognized that each individual participated in the review process and preparation of this paper as an independent professional and not as a representative of their employer. The remainder of the DOI should make clear how individuals were engaged, ie by Intertek. If you can say without consultation with Monsanto that would be great. If there was any review of the reports by Monsanto or their legal representatives that needs to be disclosed."

As you know, the published Declaration of Interest stated, "Neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel's manuscripts prior to submission to the journal."

My question is what happens now that we know that that Declaration of Interest was false and that Intertek and Monsanto were well aware they were publishing fabricated statements about the purported independence of the panelists? How serious is this violation of scientific publishing canon? Are you reviewing the papers for possible retraction?

Please give me a call tomorrow or reply with your response to this email.
Thanks so much!
Peter Waldman
Bloomberg Businessweek
Telephone [redacted]

On Sunday, August 6, 2017 6:27 PM, Peter Waldman (BLOOMBERG/ NEWSROOM:) <[redacted]@bloomberg.net> wrote:
Roger McClellan

From: Ashley Roberts Intertek <@intertek.com>
Sent: Wednesday, January 3, 2018 1:10 PM
To: Roger McClellan
Subject: Automatic reply: Responses

Thank you for your e-mail. I will be returning on Monday, January 8 and will have limited access to e-mail. If this is an urgent matter please contact my assistant Ms. Patricia Borror; phone: [redacted], patricia.borror@intertek.com.

Ashley Roberts
On Thursday, August 9, 2018 1:53 PM, "Whalley, Charles" wrote:

Dear Roger,

Thanks for taking the time to visit us in Milton Park. I hope you found the meeting as constructive as we did, as well as enjoying seeing the office, meeting the other members of our team, and learning more about how T&F operates.

First, I've attached the corrigenda and expression of concern that we agreed in the meeting. Assuming approval from our legal counsel, we will aim to have these published online asap. I will update you on timelines when I have them.

Second, I will send you our final communications plan very soon. This will include FAQs etc., as well as form the basis of our updates to the Editorial Board, authors and then Ashley Roberts. I will work with you to draft the first of these messages. I will handle the correspondence with Ashley separately.

The communications plan will include the various steps in the process. Once we have a date set for publication of the corrigenda and expression of concern, ideally before the end of next week, all will happen very quickly.

Third, we will have a separate call with you soon, perhaps with you, me and Sarah, to talk through our proposed changes to our corrections policy and guidance on declarations of interest. It may be that we need some specific guidance for CRT authors, which could be incorporated in the submission system.

I hope your other business in London is as useful as today, and safe travels for your return to the US.

All best wishes,
Charles
Dear Roger,

Now that we have reached agreement for our next steps, we will need to brief the Editorial Board. I know that they are aware of the investigation and developments. We need to advise them that we are publishing corrigenda and an expression of concern, and that, if they receive any communications from journalists, they should direct them to us. Would you be willing to send this out asap?

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: 07778 243390
Switchboard: 020 3176 6600
Email: taylorandfrancis.co.uk
WWW.taylorandfrancis.com

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately and notify the sender.
Dear Ms. Morgan,

Thank you very much for getting in touch.

I did also hear from Dr. McClellan directly, and that he was traveling.

Tomorrow is good but I would like to set up a specific time so that I can be ready to talk to him, ie, have my MacBook open ready to take notes and be sure that I am in my office. Would that be possible? As I said to Dr. McClellan, I am pretty free all day tomorrow, and I am on the East Coast so two hours ahead of ABQ. My number is 718 751-6473 but I am also happy to call him at a specific time to be arranged.

Thanks also for the papers which I will be sure to look at.

best, Michael

On Tue, Aug 14, 2018 at 3:29 PM Mildred Morgan <hargray.com> wrote:

Dear Mr. Balter:

Dr. Roger McClellan asked me to send you an email to let you know that he has been traveling and just returned to the USA today and will be at his home in Albuquerque this evening. He will be able to speak to you tomorrow (Wednesday, August 15th) if you will provide him a telephone number. His e-mail address is att.net.

I am attaching two papers that Dr. McClellan authored that he thought you might find useful on his background. They are:

1. Role of Science and Judgment in Setting National Ambient Air Quality Standards: How Low is Low Enough?
2. Human Health Risk Assessment: A Historical Overview and Alternative Paths Forward

Mildred Morgan
Assistant to Roger McClellan
A:
F:
E: hargray.com
Writer/reporter
Adjunct Professor of Journalism "emeritus"
New York University

Email: redacted@gmail.com
Tweet: @redacted
Web: michaelbalter.com
Book: http://tinyurl.com/13np9st

"Lying is done with words and also with silence." --Adrienne Rich

---

Michael Balter
Writer/reporter
Adjunct Professor of Journalism "emeritus"
New York University

Email: redacted@gmail.com
Tweet: @redacted
Web: michaelbalter.com
Book: http://tinyurl.com/13np9st

"Lying is done with words and also with silence." --Adrienne Rich

---

Michael Balter
Writer/reporter
Adjunct Professor of Journalism "emeritus"
New York University

Email: redacted@gmail.com
Tweet: @redacted
Web: michaelbalter.com
Book: http://tinyurl.com/13np9st

"Lying is done with words and also with silence." --Adrienne Rich

---
"Lying is done with words and also with silence." — Adrienne Rich
Charles:

PLEASE RESPOND BY e-mail or text as to how I can reach you. I feel I need to respond to Michael Balter. I do not understand the slow, slow pace of activity at T and F.

Regards, Roger

On Thursday, August 30, 2018 4:40 AM, Michael Balter <Michael.Balter@gmail.com> wrote:

Hello again Roger,

We are just getting ready to finalize the story, and so I wanted to come back to you again for comment on this article. The article claims, based on discovery documents in the Monsanto Roundup litigation, that Monsanto was heavily involved in the review and editing of the five papers published in CRT and thus the COI declaration was inaccurate.

In all fairness I would urge you to comment, because otherwise I will be obliged to write that you did not respond to requests for you to do so.

I hope Mildred can help facilitate this process by the end of this week.

thanks again,

Michael Balter
Undark

On Wed, Aug 22, 2018 at 9:22 AM Michael Balter <Michael.Balter@gmail.com> wrote:

Hello Roger,

I hope you are having a good week.

I need to ask you to read this latest article by Carey Gillam and Nathan Donley which is specifically about the CRT special review and Monsanto’s alleged involvement in it, based on documents from the court case.

https://www.ehn.org/monsanto-science-ghostwriting-259/869694.html

We discussed some of these issues in our telephone interview but these allegations are very specific in nature. I think you can understand why I would be required as a reporter to ask you about them, and for any comment you care to make about the accuracy (or not) of this story and the validity of its interpretations.

Many thanks,

Michael

On Wed, Aug 15, 2018 at 1:24 PM Roger McClellan <Roger.McClellan@att.net> wrote:

Michael:

I will be available for the next couple of hours if you wish to call. I have attached a copy of my biography with contact info.
On Wednesday, August 15, 2018 4:17 AM, Michael Balter <mailto:mm@hargray.com> wrote:

Dear Mildred,

Thanks for this. I'm sure Dr. McClellan is very tired from all that traveling, so it's no problem. I will hope to hear from him sometime today to arrange a good time to talk. I am also on the East Coast.

Best wishes, Michael

On Tue, Aug 14, 2018 at 8:42 PM Mildred Morgan <mailto:mmm@hargray.com> wrote:

Dear Michael,

Dr. McClellan didn't call me from Dallas so I couldn't talk to him about this. He doesn't get to Albuquerque until 8:20 PM which is 10:20 PM my time as I live on the East Coast and I am sure he won't call me that late. So I am forwarding this message to him and hopefully he will respond to you directly. I have no idea what his schedule is tomorrow, but I am sure he will be in touch with you. His telephone number

Mildred Morgan
Assistant to Roger McClellan
Tel: [Tel.]
Fax: [Fax.]
Email: [Email @hargray.com]

From: Michael Balter [mailto:mm@hargray.com]
Sent: Tuesday, August 14, 2018 3:48 PM
To: mm@hargray.com
Subject: Re: Roger McClellan Reply

Okay, excellent, and it really can be at his convenience on Weds as long as I know the time.

thanks again, Michael

On Tue, Aug 14, 2018 at 3:46 PM Midred Morgan <mailto:mmm@hargray.com> wrote:

Dear Mr. Balter:

I am sure Dr. McClellan will probably see your e-mail below, but he told me that he would call me when he lands and changes planes at the Dallas/Fort Worth airport this evening, so I will see if he can answer your question about the time of the call and one of us will let you know.

Midred Morgan
Assistant to Roger McClellan
Tel: [Tel.]
Fax: [Fax.]
Email: [Email @hargray.com]
From: Mildred Morgan <morgan@hargray.com>
Sent: Thursday, August 30, 2018 12:25 PM
To: roger.o.mcclellan
Subject: FW: CRT reviews of glyphosate -- COI allegations

FYI

From: Michael Balter [mailto: mibanter@gmail.com]
Sent: Thursday, August 30, 2018 1:23 PM
To: Mildred Morgan
Subject: Fwd: CRT reviews of glyphosate -- COI allegations

Hi Mildred, for your records and to make sure Roger sees this.

dest, Michael

Forwarded Conversation
Subject: CRT reviews of glyphosate -- COI allegations

Dear Dr. Whalley,

I am a science writer for Undark, the online magazine published by MIT's Knight Science Journalism Program. I am contacting you at the suggestion of Roger McClellan.

As you know, some journalists and activists have raised issues about the declarations of interest in CRT's 2016 series of papers on glyphosate. The allegations are that these declarations were incorrect and possibly misleading because they did not reveal Monsanto's direct involvement in the review and editing of the papers. That involvement was revealed in discovery documents from the Roundup litigation in California and elsewhere. Some of the key documents are here, which make the interactions between Intertek and Monsanto very clear:


In addition the journalists/advocates Nathan Donley and Carey Gillam have published at least two articles in the past week or so on this subject.
I understand that Taylor & Francis has been investigating this matter. Could you tell me what conclusions have been arrived at, what action you intend to take, and when those decisions or actions will be taken?

We are on a tight deadline with this and so I will need a response no later than Monday of next week.

With thanks and best wishes,

Michael Balter
Undark

My colleague, Charles Whalley, has passed your query on to me regarding Critical Reviews in Toxicology. I am replying on his behalf.

We are still working on an ongoing investigation process into the articles included in this supplement which is in line with industry-standard best practice, and will be taking all necessary steps once this investigation has concluded. As that is the case, we will be making no further comment until this process is complete.

With best wishes,
Jennifer McMillan
Director of Marketing, Content & Communications

From: Michael Balter <michael.balter@gmail.com>
Sent: 30 August 2018 14:06
To: Whalley, Charles <charles.whalley@tandf.co.uk>
Subject: CRT reviews of glyphosate -- COI allegations

Dear Jennifer,

Many thanks for getting back to me with this update on the investigation.

I will be sure to send you a link to our story when it goes online, I expect within a couple of weeks.

best regards,

Michael

Dear Roger,

Thanks for your call today.

This is all T&F are willing to say at this point, so your press statement would be very helpful. I look forward to getting it if that is still your plan.

best wishes,

Michael
"Lying is done with words and also with silence." — Adrienne Rich
Thank you for forwarding this update to me, Roger.

Alison

From: Roger McClellan [mailto:roger.o.mcclellan@urmc.rochester.edu]
Sent: Tuesday, August 21, 2018 11:43 AM
To: Elder, Alison
Cc: Roger McClellan; Mildred B. Morgan
Subject: Fw: Path Forward re glyphosate supplement

Alison:
I apologize for inadvertently leaving your name off the original distribution of the attached e-mail. As I send
this e-mail I can not help but recall my first visit to the U of Rochester in August 1961 in conjunction with my
participating in an Am Soc for Pharm and Exp Ther meeting. Harold Hodge invited me to attend a special
meeting he chaired — that became the SOT. It has been interesting to remain connected with the U of R faculty
over the years. You are now my primary connection to full time staff.
Best regards, Roger

On Monday, August 20, 2018 8:43 PM, Roger McClellan <roger.o.mcclellan@urmc.rochester.edu> wrote:

To: CRT Editorial Advisory Board

I am pleased to provide you an update on resolution of issues related to five papers on the potential
carcinogenic hazard of glyphosate published as a special supplement to Volume 46 (2016). On August 9, 2018
I met with Charles Whalley and two senior Taylor and Francis officials at the Abingdon, UK offices of T and
F. The two senior individuals were Deborah Kahn, in person, and Todd Hummel, via teleconference linkage
from his USA office. Both are experienced in the publishing business, however, are relatively new to Taylor

The meeting was productive and interactive. I briefly reviewed the material I have previously shared with you
concerning the five papers. It was agreed by all four participants in the meeting that the appropriate path
forward would involve publishing corrigenda prepared by the authors for each of the five papers and an
expression of concern authored by Charles and me. You have previously seen draft corrigenda prepared by the
authors. The authors will be given the opportunity to review and, as necessary, update the earlier drafts so they
are as complete and accurate as possible at the time the papers were published online in 2016. The specific time
line for publication of the corrigenda is still being developed. I have expressed my personal view that this
should be done as expeditiously as possible.

Ironically, the Jury in the Thompson vs Monsanto case in San Francisco rendered its verdict on August 10th the
day after our meeting in the UK. The tempo of media coverage of the controversy over the carcinogenic hazard
of glyphosate exposure has been ceaseless and, in my opinion, is likely to continue for a long time.
If you have any questions on this matter please contact Charles or me. If you receive any inquiries from the media or others related to this matter please refer the individuals to Charles or me.

With best regards and appreciation for your interest in this matter.

Roger O. McClellan, DVM, MMS, DSc (Honorary)  
Diplomate, ABVT and ABT. Fellow, ATS, AAAR, SRA, HPS, ATS, and AAAS  
Member, National Academy of Medicine  
Independent Consultant, Toxicology and Human Risk Analysis  
Editor-in-Chief, Critical Reviews in Toxicology  
Albuquerque, NM  
Telephone:  
E-mail: roger.o.mcclellan@  

On Friday, August 10, 2018 8:05 AM, “Whalley, Charles” wrote:

Dear Roger,

Now that we have reached agreement for our next steps, we will need to brief the Editorial Board. I know that they are aware of the investigation and developments. We need to advise them that we are publishing corrigenda and an expression of concern, and that, if they receive any communications from journalists, they should direct them to us. Would you be willing to send this out asap?

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals  
Taylor & Francis Group  
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN UK  
Direct Line  
Switchboard  
www.tandfonline.com

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately and notify the sender.

Informa Group plc | Registered in England & Wales No 3099017 | 5 Hico Wick Place | London | SW1P 1WG

733

RM 001088
Roger McClellan

Charles:
I attempted to call you just now with no response, hence, this e-mail.

Thanks for acknowledging receipt of my e-mails. I am rather surprised and disappointed that I have not been included in the loop on the message to be sent to the authors. This is especially the case since I was involved in the original communication to the authors concerning preparation of draft corrigendum nearly a year ago.

Perhaps you can provide an explanation.

I would appreciate your keeping me fully informed as to the activities underway as we move to resolve this complex matter with far reaching consequences in an expeditious manner.

Regards.
Roger

On Thursday, August 23, 2018 9:38 AM, "Whalley, Charles" <tandf.co.uk> wrote:

Dear Roger,

I've received your emails. The wording for the messages to the authors and to the sponsor is still being worked on. Todd and Sarah had some changes before we can pass to legal counsel. As for the email from Michael Balter, we don't have anything to tell him as yet. If he would like a comment on the investigation, it would be best if this was answered by us. Would you like to acknowledge his query and direct him to me?

Best wishes,
Charles

---

From: Roger McClellan <att.net>
Sent: 23 August 2018 14:39
To: Whalley, Charles <tandf.co.uk>
Cc: Roger McClellan <att.net>; Mildred B. Morgan <hargray.com>
Subject: Fw: Plan of action PLEASE CONFIRM RECEIPT

Charles:
Please confirm receipt of the attached e-mails as well as the e-mail exchange with Michael Balter.
Regards, Roger

On Thursday, August 23, 2018 3:42 AM, Roger McClellan <att.net> wrote:

Charles:
Please verify receipt of my e-mail. Can you share with me later today a draft of the e-mail you propose to send to the 16 authors of the five papers? It has been two weeks since we met at the Taylor and Francis offices in Oxfordshire. That seems to be more than adequate time to draft the various communications that are needed. Why the stone-walling? I think we need to pick up the pace!

Let me know what I can do to assist you. If you were in my position what would you tell those who inquire of me as to progress in this year long investigation?

Regards,
Roger

On Wednesday, August 22, 2018 9:37 PM, Roger McClellan wrote:

Charles:

Please bring me up to date on progress made yesterday. Please share with me at your earliest convenience a draft of your memo to the authors, perhaps by end of day on Thursday. Do you plan to have a separate memo to Ashley Roberts? If so, I would like to review a draft. As soon as possible I suggest you give a call to Roberts indicate the importance of the Corrigendum addressing the various charges that have been made relative to "The Monsanto Papers". This might best be done with a telephone call rather than an e-mail. I suggest the contact with him since he had a special role in coordinating the preparation of the Special Supplement and he had a special role in interactions with Monsanto.

Please let me know if I can do anything to assist you in moving these activities forward in an expeditious manner. I am very concerned with the slow pace post our August 9th meeting. I thought agreement was reached at that meeting with senior Taylor and Francis personnel as to the path forward. Have I over-interpreted what was agreed to at the August 9th meeting and the commitment of senior Taylor and Francis personnel? Do I need to return to England to meet with the CEOs to impress on them the importance of timely action. Quite frankly, I am beginning to feel like I was not dealt with fairly in leaving England without meeting with the CEOs seeing a specific plan of action.

There is really no excuse for taking nearly a year to deal with this matter which is now becoming a crisis. You have a key role in finalizing the actions that must be taken to resolve this matter in the manner agreed to at the August 9th meeting. Do you have the support of Ellie Gilroy? I am prepared to spend as much time as necessary on this matter to bring it to resolution. I have already done that for a number of months and can make further changes if necessary including returning to England. I hope your doing the same. This can not be a back burner issue. Every day of delay makes it more difficult to convince reasonable observers that this matter was ,and is, being dealt with in a professional and business-like manner. I am eager to see a written plan for activities that must be accomplished with responsible parties and target dates identified to bring resolution. The absence of such a plan is an invitation to disaster.

I am beginning to receive increased queries from senior folks in industry and government as to whether "we" know what we are doing in dealing with this matter since it has gone on for so long.

I do hope you understand my high level of concern. I expect for the near term we should plan on daily updates between the two of us. Would it be useful for me to express my concern to Todd Hummel?
Again, let me know what I can do to assist you in moving to resolution of this complex issue in an expeditious manner.

Best regards,
Roger

On Wednesday, August 22, 2018 3:55 AM, "Whalley, Charles" wrote:

Dear Roger,

We are awaiting a final legal review of some of the communications around this, after briefings to the CEOs of T&F and of Informa. We’ll then be ready to proceed with contacting authors once I have that, likely by the end of this week. I have not contacted the authors until this is done; I’d ask if you could do the same.

As for your two interviews, please can you provide more information as to what was discussed? Presumably the authors asked about the papers; what did you tell them about the investigation and any possible next steps? Do you have any email correspondence you’d be willing to forward to me? Please can you notify us in advance of any media queries you receive. It’s important that we share a clear and consistent message in all public comments on this.

Thanks and best wishes,
Charles

From: Roger McClellan <-----atnet>  
Sent: 22 August 2018 03:56  
To: Whalley, Charles <-----@tandf.co.uk>  
Cc: Mildred B. Morgan <-----@chargray.com>, Roger McClellan <-----@at.net>  
Subject: Plan of action

Charles:

Please share with me our plan of action for implementing the publication of corrigendum and expression of concern we agreed to at our meeting on August 9th. I am envisioning a list of required activities/ actions, who is responsible for each and projected date of activity/ action. This plan document will help ensure that we are all working in a coordinated fashion. As I have previously noted, I think it is important that we move forward as expeditiously as possible in taking the actions agreed upon and, secondarily, make known these actions to the media. Any further delays will not reflect well on Taylor and Francis, you, as the Managing Editor or me, as the Editor-in-Chief. Indeed, our competence will be called in to question.

Have you contacted the lead authors of the five papers and requested updated corrigendum? Or do you want me to take this action since I obtained the corrigendum we currently have in hand? I would be pleased to request updated versions if you agree. I do think it is important that at an early date we need to share with all the authors what has been agreed to as a path forward.

I have had two requests for interviews with reporters on the glyphosate issue. One was with a reporter Michael Balter) associated with an MIT publication. The other was with a reporter for Australian News (Stephanie March) who is preparing a documentary video. I spoke to both of them. I
thought both interviews went well and I avoided indicating specifics on dealing with the retraction requests. However, as noted above, I do not think we can continue to "stone wall" on our path forward. In my opinion, the coverage of the Glyphosate issues is going to be in the news for an extended period of time because of the many ramifications of what has happened to date and legal trials extending for years.

Best regards,
Roger
Roger McClellan

From: Roger McClellan @att.net>
Sent: Thursday, August 23, 2018 10:21 AM
To: Charles Whalley
Cc: Mildred B. Morgan; Roger McClellan
Subject: Fw: Implications of Roundup Case

Charles:
The attached article provides an excellent review of the importance of the controversy over the potential human carcinogenicity of glyphosate. The consequences are not restricted to Glyphosate.
Best regards, Roger

Monsanto's Roundup Case: What's at Stake from a Legal and Policy Perspective
JD Supra
to see if the case should have been disallowed in the first place under FIFRA preemption, which limits failure to warn claims that are in READ MORE
Charles:

Thanks for the progress report. As I recall the letter to the authors was to be a joint letter from you and me. Since it was to be a joint letter it would seem appropriate that I review a draft of the letter prior to the draft being sent to legal counsel for review. The approach you have taken puts me in a position of accepting the reviewed draft and lumping it or insisting on further changes which will necessitate a second review by legal counsel and further delay.

I think I may have some useful input on the issue of how robust with censure of the authors should be since I have authored over 400 papers, reviewed thousands of papers, served on numerous senior advisory groups and edited CRT for over 3 decades. In my opinion, no one has identified any scientific flaws in the papers. The issues that have been raised have been procedural in nature and the long delay in dealing with the matter has allowed outside parties to control events and create a "kangaroo court" atmosphere for discrediting the papers to minimize their value in any legal proceedings. In my opinion, care needs to be taken to avoid Taylor and Francis becoming a party to discrediting the papers with an inappropriate expression of concern. In short, I favor a very terse statement and I do not think it necessary to censure the 16 authors. The corrigendum should stand on their own without further elaboration.

To be very clear, at the August 9th meeting I did NOT agree to publishing corrigendum and then "damming" the papers and authors in the expression of concern and censureship such that the published papers would be of limited value. That would be the equivalent of retraction thorough the expression of concern. If that is the approach some one envisions I will feel duped and mis-used.

Please feel free to contact me at any time. I am typically available 24/7.

Best regards,
Roger
I intend on giving the authors 1 week to provide any amendments to the corrections or to ask any questions. I was hoping to have the letters ready to send by the end of today, but I can't proceed without the legal review. I imagine this may now take until Tuesday of next week, as next Monday is a public holiday in the UK.

I will still be in Switzerland next week. I will be available on email and telephone if needed whilst at the conference. I am attending with a colleague, who can cover for me at the meeting if I need to take calls at my hotel. As the people involved in this area in Abingdon, London and New York/Philadelphia, excluding yourself, it makes little difference whether I'm in Abingdon or Basel.

Please bear with us on this. I'll update you as soon as I can.

Best wishes,
Charles

---

From: Roger McClellan <att.net>
Sent: 24 August 2018 03:44
To: Whalley, Charles <tandf.co.uk>
Cc: Mildred B. Morgan <hargray.com>; Roger McClellan <att.net>
Subject: Plan and Progress to implementing August 9th agreement

Charles:

Please provide me an update as soon on Friday as possible on plans and progress for implementing August 9th agreement. I have several appointments scheduled for Friday, however, I am giving high priority to working with you on this crucial matter. Are you still planning to be away from your office next week? Have you considered the possibility or re-arranging your schedule so you can focus on the Glyphosate issue?

Do you have a draft of the proposed communication to the authors you can share with me for my review and input. I was hoping it would be possible to get this to the authors this Friday, August 23rd? How soon do you expect them to respond?

As I have emphasized we are dealing with a crisis and need to be moving forward in an expeditious manner. Do you think it possible to have the corrigendum and expression of concern published on-line by September 1st? If you have a redraft of the expression of concern I would like the opportunity to review it as soon as possible.

In my opinion, as time goes by the media is going to cut us (Taylor and Francis, you and I) less slack and things could become even more ugly. We need to be prepared for another salvo from Donley and Carey and others.

Would it be useful to schedule a teleconference with Todd Hummel, you and me for early next week?

Best regards,
Roger
Roger McClellan

From: Roger McClellan <removed@att.net>
Sent: Monday, August 27, 2018 10:10 AM
To: Kathleen McClellan
Cc: Mildred B. Morgan
Subject: Fw: CONFIDENTIAL Glyphosate Supplement -- Agreed next steps
Attachments:

ITXC 46 s1 corrigendum 1214680.docx; ITXC 46 s1 corrigendum 1214679.docx; ITXC 46 s1 corrigendum 1214678.docx; ITXC 46 s1 corrigendum 1214677.docx; ITXC 46 s1 expression of concern.docx

On Monday, August 27, 2018 1:27 AM, "Whalley, Charles" <removed@tandf.co.uk> wrote:

Dear Roger,

I’ve received your emails, now here in Basel. The wording that is being discussed is for the emails to be sent to authors, not the corrigenda or expressions of concern. I attach the wording for these, as reviewed in our meeting in Milton Park. These will not be changed. There is a public holiday at home today, so I won’t have the approval on the emails until tomorrow. Rest assured we have not put any words into your mouth. I’ll send you the emails once all agreed here. There is little in them that isn’t already in the expressions of concern, corrigenda or emails previously sent to the authors earlier this year and last.

Best wishes from Switzerland,
Charles

From: Roger McClellan <removed@att.net>
Sent: 27 August 2018 04:28
To: Whalley, Charles <removed@tandf.co.uk>
Cc: Mildred B. Morgan <removed@hargray.com>; Roger McClellan <removed@att.net>
Subject: Fw: CONFIDENTIAL Glyphosate Supplement -- Agreed next steps

Charles:
Please acknowledge receipt.
Best regards and safe travels.
Roger

On Sunday, August 26, 2018 5:45 PM, Roger McClellan <removed@att.net> wrote:

PERSONAL AND BUSINESS CONFIDENTIAL
Charles:
I have searched my files and this is my last e-mail form you that contains proposed Corrigendum (sent by the authors to us months ago) and a draft Statement of Concern to be signed by you and me. Is this the material you propose to send to T and F Legal Counsel? If so, this meets with my approval.

741
In a more recent e-mail you note consideration of how robust the statements of censure (ie defined as a judgement involving condemnation) should be. Are you proposing censure statements to be added to the Statement of Concern? If so, I have not seen these proposed censure added to the Statement of Concern? Indeed, I do not recall any previous conversations or communications concerning censure. If these are to be added to any statement over my signature it is essential I see and approve them BEFORE they are submitted for legal review. Any statements attributed to me must be authored and approved by me. I have not authorized you or any other T and F personnel to ghost write for me. I am quite capable of writing for myself! Indeed, I think what we previously agreed to was and is quite adequate. I do not think it necessary to censure the authors, they have already had a year of water torture related to our collective inability to get this matter resolved.

I am finding the saga of the Special Glyphosate Supplement and Taylor and Francis more confusing as time goes by. I think it imperative that you and I have a personal conversation soon to allow you to communicate to me the games going on and the role of the various players. Can we speak on Monday, August 27th?

Best regards,
Roger

PS. I still refer to the 16 authors as Distinguished Scientists/Authors and I am pleased to have them as contributors, past and future, to CRT. I have not met anyone from T and F who I view as qualified to challenge my statement!

On Thursday, August 9, 2018 11:53 AM, “Whalley, Charles”<tandf.co.uk> wrote:

Dear Roger,

Thanks for taking the time to visit us in Milton Park. I hope you found the meeting as constructive as we did, as well as enjoying seeing the office, meeting the other members of our team, and learning more about how T&F operates.

First, I’ve attached the corrigenda and expression of concern that we agreed in the meeting.
Assuming approval from our legal counsel, we will aim to have these published online asap. I will update you on timelines when I have them.

Second, I will send you our final communications plan very soon. This will include FAQs etc, as well as form the basis of our updates to the Editorial Board, authors and then Ashley Roberts. I will work with you to draft the first of these messages; I will handle the correspondence with Ashley separately.

The communications plan will include the various steps in the process. Once we have a date set for publication of the corrigenda and expression of concern, ideally before the end of next week, all will happen very quickly.

Third, we will have a separate call with you soon, perhaps with you, me and Sarah, to talk through our proposed changes to our corrections policy and guidance on declarations of interest. It may be that we need some specific guidance for CRT authors, which could be incorporated in the submission system.

I hope your other business in London is as useful as today, and safe travels for your return to the US.
All best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line
Switchboard
www.tandf.co.uk

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately and notify the sender.

Informa Group plc | Registered in England & Wales No. 3099067 | 5 Howick Place | London | SW1P 1WG
Charles,

I trust your meeting in Basel has gone well.

Please provide me a progress report update on the legal review. Since it is now Wednesday PM in Europe and the UK I had expected to receive feed back from you by now. When do you return to the UK? Will you be in your Abingdon office on Friday, August 31st?

I am traveling to St Louis, MO for the International Aerosol Conference (combined with the annual meeting of the American Association for Aerosol Research) on Sunday, September 2 and returning to my home in Albuquerque on September.

I am traveling to the Kansas University Medical Center on September 12 to give a lecture in memory of my long time friend, John Douil, and returning to Albuquerque on September 14

I will have access to my e-mail. Please keep me posted on ANY developments on bringing the Special Glyphosate Supplemental Issue matter to an orderly and fair resolution. I am eager to see the proposed Q and A, especially how to respond to the question - “Why has it taken over a year to complete your investigation?”

Safe travels and best regards,

Roger

On Tuesday, August 28, 2018 5:21 AM, "Whaley, Charles" <whaley.co.uk@tandf.co.uk> wrote:

Dear Roger,

The material currently in legal review is the letters to the authors and the supplement sponsor. As I mentioned in my last email to you, there is little in them that isn’t already in the expressions of concern, corrigeenda or emails previously sent to the authors earlier this year and last.

Best wishes,

Charles

---

Roger McClellan

From: Roger McClellan <roger.mcclellan@att.net>
Sent: Wednesday, August 29, 2018 6:04 PM
To: Whalley, Charles
Cc: Mildred B. Morgan, Roger McClellan
Subject: Re: Plan and Progress to implementing August 9th agreement
Subject: Re: Plan and Progress to implementing August 9th agreement

PERSONAL AND CONFIDENTIAL

Charles

My primary concern at this juncture relates to the third sentence in the first paragraph of your e-mail —"The specific point to be settled is how robust it is appropriate to be in our censure to the authors in the letter.......

My concern relates to our August 9th meeting and the very clear and strong disdain exhibited by Deborah Kahn for the 16 distinguished scientists/authors of the five papers. I am sure you will recall that portion of the meeting. It was difficult for me to not call her out on the matter, however, I did not at the time because I did not want to disrupt our discussions and, most importantly, disrupt progress toward a greater goal. At this stage I do not want to depart from what was mutually agreed to at that meeting by allowing insertion of any language that censures the authors beyond the issuance of the corrigendum and the terse statement agreed to at the meeting. Indeed, I did not want to debate it at the meeting but I felt some of the language in the statement seemed unnecessary in view of the comprehensive corrigendum.

Would you prefer to speak by phone after the legal review of the material you provided me. If I understand you correctly the legal folks have only been provided the corrigendum and statement for review, no other material.

Best regards,
Roger

On Friday, August 24, 2018 6:24 AM, "Whatley, Charles" <iam@jnl.co.uk> wrote:

Dear Roger,

The letters to authors and supplement sponsor are currently with legal counsel for review. There’s little point me sending drafts to you before we’re all agreed on T&F’s side, otherwise you may end up wanting to make changes to parts of a draft that end up being removed anyway. The specific point to be settled is how robust it is appropriate to be in our censure to the authors in the letter, and the terms in which we can express to Ashley Roberts that we aren’t willing to accept future supplements from Intertek.

I intend on giving the authors 1 week to provide any amendments to the corrections or to ask any questions. I was hoping to have the letters ready to send by the end of today, but I can’t proceed without the legal review. I imagine this may now take until Tuesday of next week, as next Monday is a public holiday in the UK.

I will still be in Switzerland next week. I will be available on email and telephone if needed whilst at the conference. I am attending with a colleague, who can cover for me at the meeting if I need to take calls at my hotel. As the people involved in this area in Abingdon, London and New York/Philadelphia, excluding yourself, it makes little difference whether I’m in Abingdon or Basel.

Please bear with us on this. I’ll update you as soon as I can.

Best wishes,
Charles
Charles,

Please provide me an update as soon on Friday as possible on plans and progress for implementing August 9th agreement. I have several appointments scheduled for Friday, however, I am giving high priority to working with you on this crucial matter. Are you still planning to be away from your office next week? Have you considered the possibility of re-arranging your schedule so you can focus on the Glyphosate issue?

Do you have a draft of the proposed communication to the authors you can share with me for my review and input. I was hoping it would be possible to get this to the authors this Friday, August 23rd? How soon do you expect them to respond?

As I have emphasized we are dealing with a crisis and need to be moving forward in an expeditious manner. Do you think it possible to have the corrigendum and expression of concern published online by September 1st? If you have a redraft of the expression of concern I would like the opportunity to review it as soon as possible.

In my opinion, as time goes by the media is going to cut us (Taylor and Francis, you and I) less slack and things could become even more ugly. We need to be prepared for another salvo from Donley and Carey and others.

Would it be useful to schedule a teleconference with Todd Hummel, you and me for early next week?

Best regards,
Roger
Charles:
I am eager to speak to you. Please give me a call at 505-296-7083.
Roger

On Thursday, August 30, 2018 10:36 AM, Roger McClellan wrote:

Charles:
Please give me a call ASAP at 001-505-296-7083 so we can discuss.
Roger

On Thursday, August 30, 2018 10:24 AM, Whalley, Charles wrote:

Dear Roger,

Regarding the query from Michael Balter, we ask that you respond as follows:

Apologies for not responding to you sooner on this query. With respect to the articles in the supplement, I have been working alongside the journal’s publisher, Taylor & Francis, on an investigation into these which is in line with industry-standard best practice. This has included reviewing the submission process for these articles to ensure the standards the publishers and I expect all papers to adhere to were followed. As this investigation is ongoing, I have no further comment to make until it has concluded.

Mr Balter has also contacted me directly; our press team will respond much the same as the above. As you have here, I’d ask you to refer all other queries or contact from the media to me. It will be quicker and easier if we are able to manage all press enquiries through us.

The messages to authors and sponsor are still awaiting review from legal counsel. This will be complete soon.

I am working from home today and tomorrow.

Best wishes,
Charles

From: Roger McClellan
Sent: 30 August 2018 12:08
To: Whalley, Charles
Cc: Mildred B. Morgan, Roger McClellan
Subject: Fw: Roger McClellan Reply

RM 001102
Charles:
It is imperative that I speak to you directly very soon. Are you available for a telephone call tomorrow, Friday August 31. I can probably schedule one as early as 8 AM your time.

As You are aware, it was about one year ago we started to cooperatively investigate the issues associated with the five papers published in the Special Supplement on the potential carcinogenicity of glyphosate in 2016. That year has been filled with periodic action and months with no apparent action.

I flew to England specifically to meet face to face on August 9, 2018 with you and other Taylor and Francis personnel of your choosing to achieve a fair and equitable resolution of this matter. I thought that meeting concluded with agreement that corrigendum would be published for each of the five papers and a joint statement published over my signature as Editor-in-Chief and yours as Managing Editor of CRT. Three weeks have passed and there has been essentially no evidence of any progress. I have called for a plan of action and none has been provided. A week ago I was told material I had previously seen was being reviewed by legal personnel. A week has passed and nothing has been provided to me.

I am compelled to ask, was I bamboozled in the August 9th meeting? As a person of the western USA I believe in dealing directly, honestly and fairly with people. A hand shake is a good as a 100 page legal document. I thought we had a handshake agreement at the end of the August 9th meeting or was my recollection wrong?

This lack of communication is totally baffling for a "communication's company", Taylor and Francis as a component of Informa PLC. Your CEO, Annie Callahan, has a distinguished record of achievement dating to her dynamic activities as a Combat Medic in the Israeli War with Lebanon. It appears she is a decisive person of action.

Do I need to initiate communications with Mrs Callahan to substantially increase the pace of resolution of the issues surrounding the Special Supplement of Critical Reviews in Toxicology?

Please plan for a call with me yet today (Thursday) or tomorrow (Friday) or at a minimum send me an e-mail explaining what in the hell is going on, who is involved or blocking action and why the on-going delay.

With best regards and a call for improved communications.

Roger
Charles:

I am going to bed and hope that when I check my e-mails in the morning I will find one from you indicating when we can have a CANDID telephone conversation early my time on Friday. I definitely want some feedback on the legal review and if not completed, why not.

I am wondering if your "all knowing colleague" has decided when the sweet spot in time will emerge for bringing the investigation to a conclusion and having maximum favorable media coverage. I am also compelled to ask favorable coverage for who? Did you or others brief the CEOs of Taylor and Francis and Informa PLC on this grand strategy for dealing with the media. That is not very professional. Has T and F given you any training for dealing with the media? If not, I urge you to request it. You will find it very useful.

Regards and looking forward to our conversation.

Roger
Charles: Great news!! I have pushed aside my draft letter to Mrs Callanan and focused on this material.

I concur with what has been proposed with one change. I think a due date of September 7th is more appropriate for return of the proposed Corrigendum. One week is more than adequate for the requested review and potential revisions. We need to bring this protracted investigation to closure at the earliest possible date!!!

As an aside, Mildred has reviewed the e-mail addresses and they are consistent with our records.

I am OK with having the material returned to you, however, I would like to have it specifically noted that copies should be sent to me.

Since many of the authors have probably not seen the articles by Carey and Donley I suggest that I send them, without comments, linkages to the articles. This should stimulate their careful review of the proposed revised Acknowledgements and Declaration of Interest.

During the next several days I would like for you to draft a "proposed plan of action" detailing all anticipated future actions, the anticipated dates, the responsible individuals for the action and any reviewers for actions through publication online and related releases to the media.

I am approving our going forward plan with the understanding that the corrigendum will be published online at the earliest possible date without any consideration as to media impact. Further, the plan should not give a favored position to the individual proposed earlier as offering good coverage to Taylor and Francis. Events of the past several weeks have demonstrated how foolhardy that approach has been.

Please let me know if we can plan to speak by telephone yet today after 1130 MDT, 1830 your time.

I really appreciate your special effort to get these out today, August 31, 2018.

Best regards,
Roger

---

On Friday, August 31, 2018 7:16 AM, "Whalley, Charles" wrote:

Dear Roger,

I've spoken with legal counsel this morning and this afternoon. I've attached our wording for the emails to the authors and to Ashley Roberts notifying them of the outcome of our investigation. In this
email, I will send them the draft corrigenda and expression of concern for their review. I will also invite
them to ask any questions or provide any changes to the material before it is published. I will also
inform Ashley Roberts separately that we will not accept any additional supplements from Intertek in
CRT. I recall this was something you proposed quite a few months ago, and I believe is appropriate in
this case.

My intention is to send both of these emails from my address, on behalf of both of you and the
publisher. It would make sense for responses to come to me as I anticipate some further
correspondence needed around the technical part of publishing the corrections (e.g. copyright forms).

Please review these emails as soon as you can and let me know if you see any major issues. I would
like to send these out today, if possible. If you are able to confirm today, I will make time to send out
the email to the authors this evening.

I have a dentist's appointment this afternoon, following some surgery earlier in the summer, so won't
be available to speak to you at 8am your time.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line:  
Switchboard:  
www.tandfonline.com

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately and notify the sender.

Informa Group plc | Registered in England & Wales No. 3099067 | 5 Howick Place | London | SW1P 1WG
Charles:
What a relief to see the e-mails sent to the 16 authors.

Unless you have a strong objection based on sound reasoning, I would like to very soon, perhaps on Monday, September 2, to send an e-mail to the authors letting them know the sooner complete and accurate material is returned the faster the process can move forward with publication of the Corrigendum. In short, September 14 is an absolute deadline not a target date. I would also like a commitment from you that the activities to be carried out by Taylor and Francis will be carried out as expeditiously as possible. I would personally be pleased if the Corrigendum could be published by September 14, 2018 or soon after. As I recall that is about the one year anniversary of our initiation of the investigation. The sooner the Corrigendum are published the sooner a shift in the nature of the media coverage.

Who is drafting the media release to announce publication of the Corrigendum. I am eager to see a draft so I can spend some time reviewing and approving it. I am also eager to review a list of the media contacts that will receive the media release. It is important that the list include a number of professional organizations such as the American Chemical Society, Society of Toxicology, American Medical Association, American Association for Advancement of Science, American Bar Association and the like as well as trade associations such as the American Chemistry Council and Crop Life.

I am also eager to review a list of anticipated Questions and Answers prepared for use by you, me and others who are likely to be contacted by the media. One key question will be -- why did it take a year for T and F working with the CRT Editor-in-Chief to complete this investigation and announce its findings?

You and I also need to draft and have approved very soon letters to the two individuals who requested the papers in the Supplements be retracted. My advice is these letters be very concise. They will need to be sent electronically at the time the Corrigenda are published.

Thanks for your superb work. Best regards. I still need to speak to you soon.
Roger

On Friday, August 31, 2018 4:39 PM, "Whalley, Charles" <[redacted]@tanf.co.uk> wrote:

Dear Roger,

I will send the emails to authors now. I will add a reminder to the authors to include you on responses. I think 2 weeks is best for a deadline, as it is likely to take that long to move the corrections through Production in any case, never mind the authors' availability.

Thank you (to you and to Mildred) for checking the emails; I had meant to ask you about that, so I appreciate you thinking of it.
Dear Ashley,

I'm emailing regarding the supplement entitled “An Independent Review of the Carcinogenic Potential of Glyphosate”, in volume 46 of Critical Reviews in Toxicology. In your capacity as a named author, you will have received a separate email from me about the conclusion to our investigation on this. To summarise, we will publish corrections to the articles to update their respective Acknowledgements and Declaration of Interest statements. We will also publish an expression of concern regarding the supplement as a whole. In this email, I would like to address this with regard to your role as coordinator of the supplement’s sponsorship on behalf of Intertek.

Our Publishing Agreement with Intertek for the publication of the supplement included obligations around requiring full disclosure of any relevant conflicting interests to the journal - in particular, the contractual obligation in clause 2.7.1 requiring Intertek to ensure that all content to be published in the supplement provides full disclosure in the form of a declaration of all sources of commercial assistance or financial sponsorship received, or of any affiliation, organization or entity which is relevant to the content. The corrections required to these articles represent a breach of these obligations on Intertek’s part. In light of Intertek’s coordinating role in putting the Declaration of Interest statements together, and given that we have not received an adequate explanation from the authors as to why the necessary level of transparency was not met on first submission, we will not be accepting future supplement proposals from Intertek for Critical Reviews in Toxicology.

Please let me know if you have any questions.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct Line: [Redacted]
Switchboard: [Redacted]
www.tandfonline.com

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error please destroy it immediately and notify the sender.
On Saturday, September 1, 2018 2:19 PM, Kathleen McClellan wrote:

On Saturday, September 1, 2018 12:41 PM, Mildred Morgan wrote:

Check this over before I send out. I am pretty sure that your system will not pick up your signature.
Dear Roger,

please explain what is meant with Whalley's statement that the declaration
"Neither any Monsanto company employees nor any attorneys reviewed any
of the Expert Panel’s manuscripts prior to submission to the journal."
for our glyphosate paper in CRT has not been correct.
From my side it is correct and I do not understand what this is all about.
Best
Helmut
Dear Roger and Mildred,

Thanks for tracking me down with this information. I will review and send comments/corrections on the corrigendi I received from Dr. Whalley separately. My initial reading indicates there are definitely some corrections needed (e.g., my employment dates with Monsanto and whether I was under contract to Intertek).

With regards to my relocation and email change Kathi and I were planning on moving to St. Louis to be with our family. I’m so very sorry to tell you that Kathi passed away in April and I subsequently completed the move without her living presence but as my granddaughter wrote she has been watching from a higher vantage point.

My new contact information is below.

Best regards,

Larry Kier
12440 Bennett

On Mon, Sep 3, 2018 at 10:20 AM Mildred Morgan <mich_morgan@att.net> wrote:

Dear Dr. Kier:

I am glad that we received your correct e-mail address. Dr. McClellan would like to have your telephone number which you can send to him <mich_morgan@att.net> and me so I can include it in my records.

Thanks.

Mildred Morgan
Assistant to Roger McClellan
Tel: [redacted]
I received the email.

Thank you.

Larry Kier

On Sun, Sep 2, 2018 at 7:46 PM Mildred Morgan <harerav.com> wrote:

Dear Dr. Kier:

I am attaching a memo from Dr. Roger O. McClellan regarding background material related to issues over glyphosate papers. This e-mail was sent to you by Dr. McClellan yesterday, however, the e-mail bounced. I hope I have your correct e-mail address and you will receive this document.

I would appreciate it if you would confirm receipt of this e-mail. Thank you.

Mildred Morgan
Assistant to Roger McClellan
Roger McClellan

From: David Brusick <1 l@aol.com>
Sent: Monday, September 3, 2018 3:26 PM
To: roger.o.mcdellan@acquajohn
Ce: jdecam@uol.com.br; root@uol.com.br; TM.Sorahan@uol.com.br; charles.whalley@t.hargray.com
Subject: Re: Background Material Related to Issues over Glyphosate Papers

I acknowledge the receipt of the two e-mails regarding "Background Material Related to Issues over Glyphosate Papers"

David Brusick

-----Original Message-----
From: Roger McClellan <roger.o mcclellan@yahoo.com>
To: gary_williams@acquajohn; mjaardema@acquajohn; acquajohn
<acquajohn@acquajohn.com>; colin@acquajohn.com; brusick41<brusick41@uol.com.br>; Michele.Burns<brichele.burns@acquajohn.com>; helmut.greim<helmut.greim@uol.com.br>; dhg3<dhg3@uol.com.br>; gmarsh911@gmarsh911.com; ashley.roberts@ashleyroberts.com; douglas.wedd<douglas.wedd@uol.com.br>; Charles Whalley <charles.whalley@t.hargray.com>; Roger McClellan <roger.o. mcclellan@yahoo.com>; Mildred B. Morgan <mmbmorgan@att.net>
Cc: Charles Whalley <charles@landr.co.uk>
Sent: Sat, Sep 1, 2018 5:05 pm
Subject: Background Material Related to Issues over Glyphosate Papers

TO: Authors of Papers in Special CRT Supplement on Glyphosate
FROM: Roger O. McClellan
Xc: Charles Whalley
RE: Background Material Related to Issues over Glyphosate Papers

TO ALL:

You should have all received an e-mail from Charles Whalley, Managing Editor of Critical Reviews in Toxicology (CRT) and me, as Editor-in-Chief of CRT, requesting careful review and return of material for Corrigendum for the five papers published on-line as a Special Supplement to Volume 46 (2016), Critical Reviews in Toxicology. Please acknowledge to me and Charles that you have received his e-mail as well as this e-mail.
Several of you have contacted me asking for additional information related to this matter. Apparently some of you are not aware that Monsanto, as part of litigation in California, was ordered to release certain internal documents on glyphosate. The released documents have become widely known as “The Monsanto Papers.” The link below will reveal some of the contents of “The Monsanto Papers” related to your work as an expert panel.


I hope this additional information is helpful to you. If you have any further questions please do not hesitate to contact Charles or me by e-mail or phone.

With best regards,

Roger O. McClellan
Editor-in-Chief, Critical Reviews in Toxicology
E-mail: [redacted]@att.net
Home/office telephone: [redacted]
Cell Phone: [redacted]
I am forwarding this to you since all the e-mails Dr. Kirkland sends to you bounces.

I am comfortable with Larry’s changes to the documents.

Larry's revisions to 2 of the corrigenda (1214680 and 1214667) cover the issues that I raised, but Larry's wording is more precise. I am happy to agree to the changes suggested by Larry.

Kind regards,

David Kirkland.

Please find attached my comments/corrections on two of the corrigenda (genotoxicity and summary corrigenda) which were attached to your email. I am copying members of the genotoxicity expert panel and Dr. McClellan and Mildred Morgan so they can please review my comments.
Please forward as appropriate my comments on the summary corrigenda.

I have moved to St. Louis and my current contact information is below.

With regards,

Larry Kier
12440 Bennett Springs Ct.
St. Louis, MO 63121
larrydkier@gmail.com

On Mon, Sep 3, 2018 at 4:42 AM Whalley, Charles <Charles.Whalley@...> wrote:

Dear Dr. Kier,

I'm unsure if you received the below. Apologies if I am sending this to you twice.

Best wishes,
Charles

From: Whalley, Charles
Sent: 31 August 2018 23:49
To: gary.williams@....; miaardema@....; colin@....; Michele.Burns@....; idecam@....; dian3@....; helmut.ereime@....; ldkier@....; root@....; emarsh911@....; ksolomon@....; ashley.roberts@....; douglasweedio@....
Cc: Roger.McClellan@....
Subject: CONFIDENTIAL Critical Reviews in Toxicology vol 46 s1 -- conclusion to investigation
Importance: High

Dear Authors:

I'm emailing on behalf of Taylor & Francis and Dr. Roger McClellan regarding your articles published in the supplement entitled “An Independent Review of the Carcinogenic Potential of Glyphosate”, in volume 46 of Critical Reviews in Toxicology, for which you have provided responses to our questions regarding the authorship of those articles and provided revised Acknowledgements and Declarations of Interest statements. We have now concluded our investigation regarding the accuracy of the information provided to the journal on submission.

We note that, despite requests for full disclosure, the original Acknowledgements and Declaration of Interest statements did not fully represent the involvement of Monsanto or its employees or contractors in the authorship of the articles. As referred to in our previous memos to you, this specifically relates to the statements that:

```
771
```
"Neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel's manuscripts prior to submission to the journal."

and that.

"The Expert Panelists were engaged by, and acted as consultants to, Intertek, and were not directly contacted by the Monsanto Company."

From information you have provided to us, we now believe that neither of these statements was accurate at time of submission. This is in contradiction to declarations you made on submission and to warranties you made in the Author Publishing Agreements regarding your compliance with Taylor & Francis' policies.

To provide the necessary transparency to our readers, we will publish corrections to your articles to update their respective Acknowledgements and Declaration of Interest statements as per the material you have provided. I have attached the text for each of these, in line with standard policy. Please let me know as soon as possible should you wish to make any further amendments. As a formality, so that we may publish these corrections without delay, I'd ask you to process the additional Author Publishing Agreements promptly once received.

We will also publish an expression of concern regarding the supplement (attached). In this, we will provide the necessary context to the corrections, again with the aim of achieving transparency around this matter.

Please let me know if you have any questions. Please ensure you include Dr McClellan and me on any emails on this matter. If I don’t receive any questions or amendments to the corrections by September 14th, we will proceed as indicated.

Best wishes,
Charles

Charles Whatley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: [redacted]
Switchboard: [redacted]@tandf.co.uk
www.tandfonline.com

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender.

Informa Group plc | Registered in England & Wales No. 3095067 | 5 Howick Place | London | SW1P 1WG

_________ ESET NOD32 Antivirus _________

772

RM 001117
This email was scanned, no threats were found.

Detection engine version: 18011 (20180907)

http://www.eset.com
I am in agreement with the changes Larry has made.

Marilyn Aardema, Ph.D.

Marilyn Aardema Consulting LLC

http://www.linkedin.com/in/marilynaardema

-----Original Message-----
From: David Kirkland
To: 'Larry Kier' 'Aardema Marilyn' Williams Gary
Cc: 'McClellan Roger' 'Brusick David' Mildred B. Morgan
Sent: Fri, Sep 7, 2018 4:33 am
Subject: RE: FW: CONFIDENTIAL Critical Reviews in Toxicology vol 46 s1 -- conclusion to investigation

Dear Charles and Roger,

Larry’s revisions to 2 of the corrigenda (1214680 and 1214667) cover the issues that I raised, but Larry’s wording is more precise. I am happy to agree to the changes suggested by Larry.

Kind regards,

David Kirkland.
Dear Mr. Whalley,

Please find attached my comments/corrections on two of the corrigenda (genotoxicity and summary corrigenda) which were attached to your email. I am copying members of the genotoxicity expert panel and Dr. McClellan and Mildred Morgan so they can please review my comments.

Please forward as appropriate my comments on the summary corrigenda.

I have moved to St. Louis and my current contact information is below.

With regards,

Larry Kier
12440 Bennett Springs Ct.
St. Louis, MO

larrydkier@gmail.com

On Mon, Sep 3, 2018 at 4:42 AM Whalley, Charles <Charles.Whalley@<redacted>> wrote:

Dear Dr Kier,

I'm unsure if you received the below. Apologies if I am sending this to you twice.

Best wishes,
Charles

From: Whalley, Charles
Sent: 31 August 2018 23:49
To: 'gary williams<gary.williams@<redacted>>'; 'miaardema@<redacted>'
'acquaiohn@<redacted>'; 'colin@<redacted>'
'Michele.Burns@<redacted>'
'decam@<redacted>'
'kelmut.greim@<redacted>'
'root@<redacted>'
'emarsh911@<redacted>'
'T.M.Sorahan@<redacted>
'ashley.roberts@<redacted>'
'douglaslweed@<redacted>'
Cc: 'Roger McClellan' <roger.o.mcclellan@<redacted>>
Subject: CONFIDENTIAL Critical Reviews in Toxicology vol 46 s1 -- conclusion to investigation
Importance: High

Dear Authors:

I'm emailing on behalf of Taylor & Francis and Dr. Roger McClellan regarding your articles published in the supplement entitled “An Independent Review of the Carcinogenic Potential of Glyphosate”, in volume 46 of Critical Reviews in Toxicology, for which you have provided responses to our questions regarding the authorship of these articles and provided revised Acknowledgements and Declarations of Interest statements. We have now concluded our investigation regarding the accuracy of the information provided to the journal on submission.
We note that, despite requests for full disclosure, the original Acknowledgements and Declaration of Interest statements did not fully represent the involvement of Monsanto or its employees or contractors in the authorship of the articles. As referred to in our previous memos to you, this specifically relates to the statements that:

"Neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel’s manuscripts prior to submission to the journal."

and that:

"The Expert Panelists were engaged by, and acted as consultants to, Intertek, and were not directly contacted by the Monsanto Company."

From information you have provided to us, we now believe that neither of these statements was accurate at time of submission. This is in contradiction to declarations you made on submission and to warranties you made in the Author Publishing Agreements regarding your compliance with Taylor & Francis policies.

To provide the necessary transparency to our readers, we will publish corrections to your articles to update their respective Acknowledgements and Declaration of Interest statements as per the material you have provided. I have attached the text for each of these, in line with standard policy. Please let me know as soon as possible should you wish to make any further amendments. As a formality, so that we may publish these corrections without delay, I’d ask you to process the additional Author Publishing Agreements promptly once received.

We will also publish an expression of concern regarding the supplement (attached). In this, we will provide the necessary context to the corrections, again with the aim of achieving transparency around this matter.

Please let me know if you have any questions. Please ensure you include Dr McClellan and me on any emails on this matter. If I don’t receive any questions or amendments to the corrections by September 14th, we will proceed as indicated.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon. OX14 4RN, UK
Direct line
Switchboard
www.tandfonline.com

This email was scanned, no threats were found.

Detection engine version: 18011 (20180907)
On Friday, September 7, 2018 5:29 PM, Keith Solomon <@uoguelph.ca> wrote:

Dear all.,

I have some suggested edits for the corrigendum for the exposure paper (attached). I have added comments to those to David G (attached) I did check the PDF of the email from William Heydens and this was the first time I had seen it. If these comments were used by Intertek, I was not aware of that and, in addition, the text of the email was badly corrupted, making it difficult to read and even find the substance of the comment. However, if any edits were made, they did not change the conclusions or the data upon which they were based. These data are from the open literature and a compilation of the data from the unpublished Monsanto Exposure Studies was provided in the SI to the paper.

I did add thanks to Marian Blecke for providing clarification of the methods used in the Monsanto Exposure Studies to the acknowledgments, my omission.

I believe that it would have been helpful to have an SOP for declarations to clarify what exactly was required, how far back these needed to go, and what they should include.

--
Keith R Solomon, Fellow ATS, Fellow SETAC, Prof. Emeritus (U of G)  
Centre for Toxicology, School of Environmental Sciences  
University of Guelph, 2120 Bovey Building  
Gordon Street, Guelph, ON, N1G 2W1, Canada  
Skype:  
Fax: @uoguelph.ca

Centre for Toxicology  
University of Guelph  
Protecting health of humans and the environment with quality science  

RM 001123
Roger McClellan

From: David Garabrant <comcast.net>
Sent: Thursday, September 13, 2018 8:08 AM
To: Roger McClellan
Cc: John Acquavella; Thomas Sorahan; Doug Weed; Gary M. Marsh
Subject: Glyphosate papers
Attachments: ITXC 46 s1 expression of concern-revised by epid panel 9-13-2018.docx

Roger,

I have attached a revised version of 'ITXC 46 s1 expression of concern'. This version was created by the authors of the epidemiology panel (Acquavella, Garabrant, Marsh, Sorahan, and Weed) and it was agreed to by all members of the panel.

I would like to have a brief telephone conversation with you to express our thanks to you personally for your efforts to bring the revised disclosures to conclusion. What is your availability today 9/13 and tomorrow 9/14? I will make myself available at whatever time works for you.

Thank you.

David H. Garabrant, MD, MPH

www.epidstat.com

CONFIDENTIALITY NOTE: The information transmitted in this electronic communication, including attachments, is intended only for the person(s) or entity to which it is addressed and may contain confidential and/or privileged materials. Any review, transmission, dissemination or other use of this information, or taking any action in reliance upon this information, by person or entities other than the intended recipient is strictly prohibited. If you have received this message in error, please contact the sender and destroy any copies of this information.
Hello Roger,

Have you received the proof for the carcinogenicity paper corrigendum? As far as I know, no author proposed a change.

Once you have reviewed the corrigenda for the four subgroup papers, please provide to Ashley and me and we will incorporate into the Summary corrigendum anything not presently covered.

Thanks, Gary

Charles and Josie:

I have received proofs of Corrigendum of three Glyphosate papers for review (Summary - Williams et al., Genotoxicity - Brusick et al., and Epidemiology - Aquavella et al.). I have not yet received the proofs for the other two glyphosate articles (Exposure - Solomon and Animal evidence - Williams).

I would like assurance that Ashley Roberts has reviewed and approved the three Corrigendum in hand and certifies they are accurate and complete including any review of the papers by Monsanto personnel. Perhaps he can send me an e-mail attesting that the Corrigendum are completely accurate and complete before I sign off on them. He should recall that "The Monsanto Papers" released under court order contained reference to the CRT Glyphosate papers. In addition, I have been told that in Heydens video testimony in the San Francisco court case he refers to the CRT papers. The corrigendum must be consistent with all that occurred and has been revealed.

I will be carrying out my review of the proofs of the corrigendum of the Williams et al Summary Paper AFTER I have reviewed and approved the corrigendum for the four papers (Exposure, Genotoxicity, Animal Evidence and Epidemiology) that under-gird the summary paper. In this way I can be assured that the corrigendum of the summary paper is consistent with the contents of four papers providing under-girding input to the summary.

I am pleased that we are on the threshold of publishing the Corrigendum. I appreciate the assistance and input of everyone.

Best regards,
Roger
PS Josie, make certain the final published versions of the corrigendum list ALL the authors for each paper, do NOT use etal in the versions to be published. This is a time when it is appropriate to ignore the general rules on listing of authors and use of etal.

On Monday, September 10, 2018 9:30 AM, Mildred Morgan <mmorgan@hargray.com> wrote:

fyi

From: tandlco.uk [mailto@taylorandfrancis.com]
Sent: Monday, September 10, 2018 11:01 AM
To: mmorgan@hargray.com
Subject: Proofs for Manuscript 1522175 of ITXC

10 Sep 2018
Dear Mildred Morgan,
The following proofs for ITXC, Critical Reviews in Toxicology, have been placed on our Editor Electronic Proof site for you to review.
MS ID: 1522175 Williams, 'Corrigendum'
Please approve these proofs or return any corrections by 19 Sep 2018 to avoid delay to publication. Corrections must be limited to answers to queries, typographical and essential corrections only.
1. Click on 'Review Proofs'.
2. Retrieve your PDF proof by selecting 'Download PDF'.
3. Follow the guidance on the proof cover sheet to return your corrections. Please check your proofs thoroughly before submitting your corrections, as further corrections cannot be accepted. If you have any queries, please email me.
https://cats.informa.com/PTS/in?url=exedprl
• Your User Name is: [REDACTED]
• If you do not know your password, you may reset it here:
http://cats.informa.com/PTS/forgottenPassword.do
If this link does not work for you please copy it into the location bar of your browser to access your articles.
PLEASE NOTE: The CATS system only supports Internet Explorer 6 (and later), or Firefox 3 (and later) browser software. Popup blockers should be disabled. If you have any difficulty using CATS, please contact me.
Thank you,
Josie Brown
Taylor & Francis
4 Park Square
Milton Park
Abingdon
Oxfordshire
OX14 4RN
UNITED KINGDOM
Dear Roger & Charles:

Thank you for the opportunity to review and revise the disclosure for the glyphosate epidemiology review article. The epidemiology authors conferred on September 11 to review the materials forwarded to us on August 31 by Charles Walley and the September 1 email from Roger McClellan. Please find attached our unanimously agreed revisions for the disclosure statement for our epidemiology review article. I’ll elaborate briefly on one of the changes:

1. We revised the text about Bill Heyden’s feedback on the draft manuscript to be factually accurate with regard to his feedback and our related independent actions. In our experience, it is highly unusual to acknowledge someone from the sponsoring entity who provided such inconsequential feedback (viz., he didn’t understand a section of the paper and had no specific suggestions with regard to revisions). Nonetheless, we agree to acknowledge him, but feel it is important to be accurate and not to overstate his contributions or make it seem that we feel he made meaningful contributions to the paper.

Roger, you mentioned the “Monsanto papers” in your September 1 email. The 4 of us who reside in the US have been subpoenaed or deposed by the plaintiffs’ law firm responsible for that website. We are very familiar with the content. It seems that the law firm stimulated various reporters to make related enquiries of those involved in the reviews. I was contacted by 5 reporters asking questions that were some variation of questions asked during my deposition. I’m sure you appreciate that the website hosting the Monsanto papers is part of a legal strategy related to ongoing glyphosate toxic tort litigation from which the lawyers stand to benefit financially. Part of that strategy is to discredit scientists who have done reviews supported by Monsanto. We think it very important to emphasize to you that there is no content on that website that would indicate any role other than financial sponsorship for Monsanto in the development or finalization of the glyphosate epidemiology review article. Rather, we worked with total independence. We shared our draft manuscript with the sponsor as is usual for virtually any research sponsored by private industry or government. The feedback we received was so limited and general that it had essentially no influence on the actual scientific content and conclusions of our review. We all feel very strongly that our original disclosure was composed in good faith and with our best efforts to conform with your initial guidance about complete disclosure — viz. mentioning all consequential factors that might be expected to be disclosed.

We thank you and Charles for your consideration related to the epidemiology review article and our revised disclosure.

Sincerely,

John Acquavella for the epidemiology authors
Dear Roger,

I had a mail just as I was leaving for the USA on the 6th Sept. from a man at France 2 TV called Tristan Waleckx. He wanted to talk about the “Monsanto papers” and I suspect this may be the issue he is interested in.

I cannot comment on the declarations of others, only that mine was complete in terms of the information I was asked for at the time. Should I refer him to you? I am happy to talk to him if you are content with that.

Regards
Colin

Gary:

Based on the e-mail exchanges I have seen it appears that some corrections in the Declarations of Interest and the Acknowledgements should be made to the originals published online so the Corrigendum will be complete and accurate as of the time the papers were published in 2016. At the final stage all of the authors of each of the papers will have to certify that the Corrigendum for each paper is accurate and complete and sign the accompanying copyright forms since the Corrigendum for each paper will be published online.

I suggest you start with the animal evidence paper on which you are the first author making certain you and all your co-authors are in agreement as to the final proposed Corrigendum for that paper. This should also include input from Ashley Roberts with regard to any interactions concerning this paper he may have had with any Monsanto personnel.

At a next step you can proceed to deal with the Corrigendum for the summary paper on which you are the first author. The Corrigendum for that paper should be fully consistent with the Corrigendum for the under-girding papers (Exposure - Solomon, Gen Tox-Brusick etal, Epi - Acquavella etal, and Animal Evidence - Williams etal.) Moreover, the Corrigendum for the summary paper must reflect any interactions Ashley Roberts, you, or any of the other authors may have had with Monsanto personnel up until the time the paper was published online in 2016.

Several versions of the various Corrigendum may be developed over time as input is provided from different authors. Thus, I suggest each specific version of a Corrigendum be dated so the latest draft version can be distinguished from earlier versions.

I hope this matter can be wrapped up soon. I do appreciate that some of you are traveling and not readily available. Charles Whalley and I are available to assist all of you and address questions.
However, the final Corrigendum for each paper will be the responsibility and work product of all the authors of each particular paper.

Best regards,
Roger

On Friday, September 7, 2018 9:20 AM, "Williams, Gary" <redacted@NYMC.EDU> wrote:

Dear Charles and Rodger,
I have no changes to make to the documents.
Yours sincerely,
Gary Williams
Dear John,

Thank you for your email. I understand the reasons for removing Keith Solomon's name, which was a mistake on our part.

The lines on William Heydens' input are properly placed in the Acknowledgements section. The Declaration of Interest section is for the authors to disclose relevant information about their own financial and personal relationships (such as contractual status). Dr. Heydens is not an author so should be Acknowledged as a 'non-author contributor' (see: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html). His feedback on the manuscript is a contribution to it that should be acknowledged, not a relationship to an author that should be disclosed. Your initial correction is appropriate. I realise that this may be different from how you discussed this with Dr. McClellan. This is somewhat of a technical distinction, but it's important we get this right.

As for the first paragraph, the original wording characterises the need for the correction accurately, as per my previous emails to you. This will remain as it is. Similarly, the final sentence will remain as "The authors apologize for these errors." for consistency with the other corrections to the supplement, and our template for corrections more broadly.

Best wishes,
Charles

Charles:

Roger McClellan called me today to discuss the revised corrigendum for the epidemiology review article. He asked me to explain to you that we deleted Keith Solomon's name from the list of authors you sent to us because Keith was not an author on the original publication. Please see the attached screen shot of the epidemiology authors as published initially. In addition, Roger suggested that we move mention of Bill Heydens' comments from the acknowledgements section to the disclosure section because his comments were few and so general and do not merit an acknowledgment, just a disclosure. I have done as he suggested in the attached. Lastly, I edited the introductory sentence in the attached because there were no
additional contributions as was stated in the draft you sent to us, only a couple of additional disclosures identified by the authors (viz. Bill Heydens’ comments, Dr. Garabrant’s 18 minutes of consulting for the parent company of Monsanto on a non-glyphosate issue, and my direct contractual status). We think it suffices to say that:

Since this article was published on 28 September 2016, additional competing interests were identified by the authors. The Acknowledgements and Declaration of interests should read as follows:

We thank you and Roger for your consideration.

Regards,

John

John Acquavella, PhD FACE FISPE
Professor, Dept Clinical Epidemiology
Aarhus University, Denmark
+1 (office)
+1 (mobile)
Aarhus University email: john@clin.au.dk
To all:

The last paragraph of my e-mail contains a typographical error. It should read -- "I do not want to inaccurately relate Heyden's involvement in review of the manuscript. I am concerned that placing reference in the Acknowledgements to his having received the manuscript implies he had a scientific role in review of the manuscript. As I understand the facts that was not the case. Moreover, there was certainly no question with regard to his receipt of the paper implying a decision had to be made as to his being identified as an author. Thus, I am uncertain as to the relevance of the electronic reference cited by Charles. It is important to accurately recount Heyden's involvement because the issue may be raised in legal proceedings."

Respectfully,

Roger

On Monday, September 17, 2018 12:28 PM, John Acquavella <acquajohn@gmail.com> wrote:

Roger:

I sent the draft of the epidemiology manuscript to Ashley (as coordinator) and Bill Heydens (as a courtesy) on the same day.

Regards,

John

John Acquavella, PhD FACE FISPE
Professor, Dept Clinical Epidemiology
Aarhus University, Denmark
+1-555-000-0000 (office)
+1-555-000-0000 (mobile)
Aarhus University email: joac@clin.au.dk

From: Roger McClellan <mc@mc.com>
Reply-To: Roger McClellan <mc@mc.com>
Date: Monday, September 17, 2018 at 10:53 AM
To: "Whalley, Charles" <charleswhalley@earthlink.net>, John Acquavella <acquajohn@gmail.com>
Cc: Thomas Sorahan <t.sorahan@cam.ac.uk>, David Garabrant <dgarabrant@comcast.net>, Gary Marsh <dmmarsh@pitt.edu>, "douglasweeds@verizon.net", "acquajohn@verizon.net", "acquajohn@comcast.net", Ashley Roberts Intertek <ashley.roberts@intertek.com>, "Mildred B. Morgan"
Charles:

I respectfully disagree with you. However, I will agree to however the authors wish to reveal that the manuscript was shared with William Heyden, Monsanto Corp if you will agree with what the author's propose. As I understand it the paper was shared by Ashley Roberts, as coordinator of the project, with William Heyden as Monsanto's representative funding the project.

It is not apparent that William Heyden had ANY scientific input in to the content of the paper. Hence, their is nothing to acknowledge. Apparently, Roberts shared the manuscript with Heyden as a representative of the financial sponsor of the Advisory Panel and the paper. Let me note this is not unusual. I always assume that review manuscripts prepared with financial support from either a private or government entity have been shared with some personnel in the sponsoring organization. This is the norm. If a manuscript is submitted from an academic institution without outside support or with grant and/or contract support I expect that to be revealed. Moreover, I hope the authors have availed themselves of the opportunity to have the paper critically reviewed by their colleagues.

My advice to reveal in the Declaration of Interest that the paper was reviewed by Heydens was based on the assumption he provided NO scientific input to the content of the paper.

As you and I provide advice to the authors on the content of the Corrigendum it is important for us to remember the Corrigendum is an extension of the paper and authored by the authors of the paper. Our role is not that of authors but advisors.

Perhaps, we can revisit this issue when the proposed final Corrigendum for all five papers are in hand and shared with all the authors including Ashley Roberts. For some of the papers the input of Heyden may warrant Acknowledgement. In other cases, his role need only be revealed in the Declaration of Interest when he had NO scientific input.

I remain eager to bring this matter to closure at the earliest possible date, however, I do not want to accurately reveal Heyden's involvement. This may become a critical issue if the papers are cited in legal proceedings.

Respectfully,
Roger

On Monday, September 17, 2018 4:13 AM, "Whatley, Charles" <phanumeric@tandf.co.uk> wrote:

Dear John,

Thank you for your email. I understand the reasons for removing Keith Solomon's name, which was a mistake on our part.

The lines on William Heydens' input are properly placed in the Acknowledgements section. The Declaration of Interest section is for the authors to disclose relevant information about their own financial and personal relationships (such as contractual status). Dr Heydens is not an author so should be Acknowledged as a 'non-author contributor' (see: http://www.icmje.org/Recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html). His feedback on the manuscript is a contribution to it that should be acknowledged, not a relationship to an author that should be disclosed. Your initial correction is appropriate. I
realise that this may be different from how you discussed this with Dr McClellan. This is somewhat of a technical distinction, but it's important we get this right.

As for the first paragraph, the original wording characterises the need for the correction accurately, as per my previous emails to you. This will remain as it is. Similarly, the final sentence will remain as “The authors apologize for these errors.” for consistency with the other corrections to the supplement, and our template for corrections more broadly.

Best wishes,
Charles

Charles:

Roger McClellan called me today to discuss the revised corrigendum for the epidemiology review article. He asked me to explain to you that we deleted Keith Solomon's name from the list of authors you sent to us because Keith was not an author on the original publication. Please see the attached screen shot of the epidemiology authors as published initially. In addition, Roger suggested that we move mention of Bill Heydens' comments from the acknowledgements section to the disclosure section because his comments were few and so general and do not merit an acknowledgment, just a disclosure. I have done as he suggested in the attached. Lastly, I edited the introductory sentence in the attached because there were no additional contributions as was stated in the draft you sent to us, only a couple of additional disclosures identified by the authors (viz. Bill Heydens' comments, Dr. Garabrant's 18 minutes of consulting for the parent company of Monsanto on a non-glyphosate issue, and my direct contractual status). We think it suffices to say that:

Since this article was published on 28 September 2016, additional competing interests were identified by the authors. The Acknowledgements and Declaration of interests should read as follows:

We thank you and Roger for your consideration.

Regards,
John

John Acquavella, PhD FACE FISPE
Professor, Dept Clinical Epidemiology
Aarhus University, Denmark
+1 (office)
+1 (mobile)
Roger McClellan

From: Keith Solomon <[redacted]@uoguelph.ca>
Sent: Tuesday, September 18, 2018 6:24 AM
To: Roger McClellan
Subject: Re: Review of proposed last Corrigendum for five papers in Supplement.

Roger,

Just a quick observation on the emails from William Heydens on the paper. The emails are addressed to Ashley Roberts and one or more redacted people so I would assume that the draft(s) of the papers was provided by Ashley. I checked my files on the paper and did not locate any document referring to Heydens. Unfortunately, my email records do not go that far back as there was a change in the email system at the university but I am sure that I was not copied on any of those emails.

Keith

On 2018-09-17 12:45 PM, Roger McClellan wrote:

Ashley:
As noted in an earlier e-mail to Charles and all the authors of the five papers in the special Glyphosate Supplement I want to make certain you have reviewed the proposed last Corrigendum for all five papers that were in the Special Supplement to Volume 46 (2016) and offered any proposed changes to ensure that the Corrigendum to all five papers, individually and collectively, are accurate and complete.

I especially want to make certain that if you or any of the authors shared any of the papers with Monsanto for review that fact is revealed in the Corrigendum. For example, the Corrigendum for the Solomon paper does not indicate it was shared with Monsanto personnel by either Keith or you. Verify this is correct.

We are aware that Taylor and Francis incorrectly entered Solomon as an author on the Epidemiology paper in both the Corrigendum for that paper and in the Expression of Concern. I am certain Charles and / or Josie will correct that error.

Please verify you have in hand the proposed final Corrigendum for all five papers and the Expression Of Concern. We are eager to receive any proposed changes to those Corrigendum as soon as possible.

Best regards,
Roger

58
Dear all,

Further to the below, copies of the final amended corrections are attached. Copyright forms are sent to corresponding authors. The corresponding authors on the corrections follow those on the original articles.

Best wishes,
Charles

From: Whalley, Charles
Sent: 17 September 2018 15:24
To: gary_williams@...; 'mjaardema@...; 'acquajohn@...; 'colin@...; 'brusick41@...; 'helmut.greim@...; 'root@...; gmarsh911@...; ksolomon@...; T.M.Sorahan@...; ashley.roberts@...; douglaslweed@...; larrydkierler@...;
Cc: 'Roger McClellan' <roger.o.mcclellan@...>
Subject: RE: CONFIDENTIAL Critical Reviews in Toxicology vol 46 s1 -- conclusion to investigation

Dear all,

Thank you for your responses to this and our other emails. I've incorporated your provided amendments to the corrections, in some cases as per our separate conversations. These will be published online within the next 10 days. Thank you for those of your who have returned your copyright forms. If you have yet to do so, please return these asap.

The expression of concern that I circulated in my below email will not be amended. This is a statement on behalf of the publisher and Editor-in-Chief, not on behalf of the authors. The wording there will remain as initially shared with you. My apologies if this was not clear.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: 794-7948260

RM 001140
From: Whalley, Charles  
Sent: 31 August 2018 23:49 
To: ‘gary_williams@aol.com’; ‘mjaardema@taylorandfrancis.com’; ‘colin@taylorandfrancis.com’; ‘brusick41@taylorandfrancis.com’; ‘michele.burns@taylorandfrancis.com’; ‘jdecam@taylorandfrancis.com’; ‘dhg3@taylorandfrancis.com’; ‘helmut.greim@taylorandfrancis.com’; ‘idkier@taylorandfrancis.com’; ‘root@taylorandfrancis.com’; ‘smarsh911@comcast.net’; ‘ksolomon@taylorandfrancis.com’; ‘tmsorahan@taylorandfrancis.com’; ‘ashley.roberts@taylorandfrancis.com’; ‘douglasweed@taylorandfrancis.com’  
Cc: ‘Roger McClellan’ <roger.mcclellan@taylorandfrancis.com>  
Subject: CONFIDENTIAL Critical Reviews in Toxicology vol 46 s1 -- conclusion to investigation  
Importance: High 

Dear Authors:

I'm emailing on behalf of Taylor & Francis and Dr. Roger McClellan regarding your articles published in the supplement entitled “An Independent Review of the Carcinogenic Potential of Glyphosate”, in volume 46 of Critical Reviews in Toxicology, for which you have provided responses to our questions regarding the authorship of these articles and provided revised Acknowledgements and Declarations of Interest statements. We have now concluded our investigation regarding the accuracy of the information provided to the journal on submission.

We note that, despite requests for full disclosure, the original Acknowledgements and Declaration of Interest statements did not fully represent the involvement of Monsanto or its employees or contractors in the authorship of the articles. As referred to in our previous memos to you, this specifically relates to the statements that:

"Neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel's manuscripts prior to submission to the journal."

and that:

"The Expert Panelists were engaged by, and acted as consultants to, Intertek, and were not directly contacted by the Monsanto Company."

From information you have provided to us, we now believe that neither of these statements was accurate at time of submission. This is in contradiction to declarations you made on submission and to warranties you made in the Author Publishing Agreements regarding your compliance with Taylor & Francis' policies.

To provide the necessary transparency to our readers, we will publish corrections to your articles to update their respective Acknowledgements and Declaration of Interest statements as per the material you have provided. I have attached the text for each of these, in line with standard policy. Please let me know as soon as possible should you wish to make any further amendments. As a formality, that we may publish these.
corrections without delay, I'd ask you to process the additional Author Publishing Agreements promptly once received.

We will also publish an expression of concern regarding the supplement (attached). In this, we will provide the necessary context to the corrections, again with the aim of achieving transparency around this matter.

Please let me know if you have any questions. Please ensure you include Dr McClellan and me on any emails on this matter. If I don't receive any questions or amendments to the corrections by September 14th, we will proceed as indicated.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: 4
Switchboard: 2
www.tandf.co.uk

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the intended recipient. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately and notify the sender.

Informa Group plc | Registered in England & Wales No. 3099667 | 5 Howick Place | London | SW1P 1WG
Roger McClellan

From: Williams, Gary <[redacted]@NYMC.EDU>
Sent: Tuesday, September 18, 2018 8:34 AM
To: Roger McClellan
Subject: RE: Review of proposed last Corrigendum for five papers in Supplement.

Roger,

I will be out of the country until the 29th.

I have been working with Ashley to complete the Corrigenda which will be forthcoming.

I believe that it would be useful to circulate the final drafts for one last time.

Best regards, Gary

---

From: Roger McClellan <[redacted]@att.net]
Sent: Monday, September 17, 2018 12:45 PM
To: Ashley Roberts intertek
Cc: Mildred B. Morgan; Charles Whalley; Josie Brown; Roger McClellan; Williams, Gary; David Brusick; John Acquavella; Keith Solomon
Subject: Review of proposed last Corrigendum for five papers in Supplement.

Ashley:

As noted in an earlier e-mail to Charles and all the authors of the five papers in the special Glyphosate Supplement I want to make certain you have reviewed the proposed last Corrigendum for all five papers that were in the Special Supplement to Volume 46 (2016) and offered any proposed changes to ensure that the Corrigendum to all five papers, individually and collectively, are accurate and complete.

I especially want to make certain that if you or any of the authors shared any of the papers with Monsanto for review that fact is revealed in the Corrigendum. For example, the Corrigendum for the Solomon paper does not indicate it was shared with Monsanto personnel by either Keith or you. Verify this is correct.

We are aware that Taylor and Francis incorrectly entered Solomon as an author on the Epidemiology paper in both the Corrigendum for that paper and in the Expression of Concern. I am certain Charles and / or Josie will correct that error.

Please verify you have in hand the proposed final Corrigendum for all five papers and the Expression Of Concern. We are eager to receive any proposed changes to those Corrigendum as soon as possible.

Best regards,

Roger
I'm in agreement

Marilyn
Marilyn Aardema Consulting

On Sep 24, 2018, at 4:25 PM, Ashley Roberts Intertek wrote:

Dear Charles,

I have just spoken to Roger regarding the publication of the revised corrigendum. I would like to inform you that a revised summary and carcinogenicity corrigendum was sent to the panel on behalf of Dr. Williams, which has resulted in some further changes. These changes have not been agreed to by everybody as yet. The complicating factor is that Dr. Williams is currently on vacation and does not have internet access and won't return until next week. I am also unsure at this stage if any further changes were made to the genetox or epidemiology corrigendum that might need to be incorporated into the summary.

As a result, I would like to request that we wait until all of the latest changes have been ratified by everybody before publication.

Kind Regards

Ashley Roberts, Ph.D.

Direct +1  
Office +1  
Skype  
www.intertek.com

<image001.png>

Intertek, 2333 Argentia Rd., Suite 201, Mississauga, ON L5N 2X7
Ashley et al.,

I have suggest some editorial changes as well as changes to wording. Not critical but one sentence was a bit has to follow.

Keith

On 2018-09-20 7:28 AM, Ashley Roberts Intertek wrote:

Dear All,

Dr. Williams has asked me to send you some minor revisions to the summary corrigendum as he is currently travelling in Europe and does not have access to the internet.

Please find attached the revised version. As you will see, these minor changes relate to the poster presentation on glyphosate that you were all involved with and to a section regarding Dr. Kier that was taken from the genetox DOI. I hope that all of the typographical errors and date changes have also been captured accurately?

Please could you let Dr. Williams know and copy myself if you are in agreement with these changes and the overall content of this corrigendum before Gary forwards to the journal.

Thanking you all in advance.

Best Wishes

Ashley

Ashley Roberts, Ph.D.

Intertek, 2233 Argentia Rd., Suite 201 West, Mississauga, ON L5N 2X7
Dear Authors:

I'm emailing on behalf of Taylor & Francis and Dr. Roger McClellan regarding your articles published in the supplement entitled "An Independent Review of the Carcinogenic Potential of Glyphosate", in volume 46 of Critical Reviews in Toxicology, for which you have provided responses to our questions regarding the authorship of these articles and provided revised Acknowledgements and Declarations of Interest statements. We have now concluded our investigation regarding the accuracy of the information provided to the journal on submission.

We note that, despite requests for full disclosure, the original Acknowledgements and Declaration of Interest statements did not fully represent the involvement of Monsanto or its employees or contractors in the authorship of the articles. As referred to in our previous memos to you, this specifically relates to the statements that:

"Neither any Monsanto company employees nor any attorneys reviewed any of the Expert Panel's manuscripts prior to submission to the journal."

and that:

"The Expert Panelists were engaged by, and acted as consultants to, Intertek, and were not directly contacted by the Monsanto Company."

From information you have provided to us, we now believe that neither of these statements was accurate at time of submission. This is in contradiction to declarations you made on submission and to warranties you made in the Author Publishing Agreements regarding your compliance with Taylor & Francis' policies.

To provide the necessary transparency to our readers, we will publish corrections to your articles to update their respective Acknowledgements and Declaration of Interest statements as per the material you have provided. I have attached the text for each of these, in line with standard policy. Please let me know as soon as possible should you wish to make any further amendments. As a formality, so that we may publish these corrections without delay, I'd ask you to process the additional Author Publishing Agreements promptly once received.
We will also publish an expression of concern regarding the supplement (attached). In this, we will provide the necessary context to the corrections, again with the aim of achieving transparency around this matter.

Please let me know if you have any questions. Please ensure you include Dr. McClellan and me on any emails on this matter. If I don’t receive any questions or amendments to the corrections by September 14th, we will proceed as indicated.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon. OX14 4RN, UK
Direct line: +44 1234 567890
Switchboard: +44 1234 567890

This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error please destroy it immediately and notify the sender.
Charles:

Roger McClellan called me today to discuss the revised corrigendum for the epidemiology review article. He asked me to explain to you that we deleted Keith Solomon's name from the list of authors you sent to us because Keith was not an author on the original publication. Please see the attached screen shot of the epidemiology authors as published initially. In addition, Roger suggested that we move mention of Bill Heydens’ comments from the acknowledgements section to the disclosure section because his comments were few and so general and do not merit an acknowledgment, just a disclosure. I have done as he suggested in the attached. Lastly, I edited the introductory sentence in the attached because there were no additional contributions as was stated in the draft you sent to us, only a couple of additional disclosures identified by the authors (viz. Bill Heydens’ comments, Dr. Garabrant’s 18 minutes of consulting for the parent company of Monsanto on a non-glyphosate issue, and my direct contractual status). We think it suffices to say that:

Since this article was published on 28 September 2016, additional competing interests were identified by the authors. The Acknowledgements and Declaration of interests should read as follows:

We thank you and Roger for your consideration.

Regards,

John

John Acquavella, PhD FACE FISPE
Professor, Dept Clinical Epidemiology
Aarhus University, Denmark
+1 (office)
+1 (mobile)
Aarhus University email: @clin.au.dk
Dear Roger,

Further to the below, as you will have seen from Ashley Roberts' email, there are still some delays on their side. This is far beyond the deadline provided. As such, we will publish the confirmed corrections we have already in the pipeline tomorrow. The remaining corrigenda will be published as soon as they are agreed by the authors. This should meet both needs of moving quickly towards resolving this whilst allowing the authors to approve wording that goes out.

I know you are still travelling but let me know asap if you have any questions. As ever, please can you forward any media enquiries to us. As soon as these go online, we are likely to have media interest.

Best wishes,
Charles

From: Whalley, Charles
Sent: 25 September 2018 08:39
To: roger.o.mcclellan@att.net
Subject: RE: CONFIDENTIAL Glyphosate supplement corrections

Dear Roger,

Please find attached. The corresponding authors on each manuscript have confirmed their changes and/or signed copyright agreements confirming the same. With Waldman, we are balancing the need to show transparency versus our desire to limit coverage of this as much as possible. Waldman has asked us questions about this, so we have committed to respond to him; other journalists haven't had the same discussions with us. If they do contact us after the event, we will answer their questions as accurately and openly as we can.

Best wishes,
Charles

From: Roger McClellan
Sent: 24 September 2018 19:23
To: Whalley, Charles <whalley.charles@tandf.co.uk>
Cc: Roger McClellan <roger.mcclellan@att.net>
Subject: Re: CONFIDENTIAL Glyphosate supplement corrections

Charles, I am traveling this week in state of WA. Please send current and final, I hope, versions of Corrigendum. Have these been approved by ALL authors and Roberts? I remain uncertain why Waldman gets special treatment. Why give him specialized treatment? He certainly did us no favors.

Keep me posted on any new developments. Best regards. Roger

Sent from Yahoo Mail on Android

On Mon, Sep 24, 2018 at 9:33 AM Whalley, Charles <whalley.charles@tandf.co.uk> wrote:
Dear Roger,

I hope this finds you well. I tried calling you just now but perhaps you are out.

The corrigenda and expression of concern are due to be published at 10am UK time this Wednesday (26th). As per the communications plan we discussed when you visited Milton Park, our press team will contact Peter Waldman at Bloomberg in advance, but will be making no other proactive announcements. Similarly, I will email Kate Guyton and Nathan Donley, in response to their emails, once the corrections have been published to alert them to the fact. Beyond that, our objective will be to minimise coverage whilst answering any queries as quickly and factually as possible. With that in mind, can I ask you to forward any media enquiries you receive to me?

Please can you confirm when you’ve received this? I’m travelling now until Thursday but am contactable via email.

All best wishes,

Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line
Switchboard:
@tandf.co.uk
www.tandfonline.com
Dear Roger,


It seems a fair and balanced assessment of the situation to me.

Let me know if you have any questions, and if anyone contacts you for comment.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line -
Switchboard -
www.tandfonline.com
Dear Roger,

Sorry, I didn't answer your other question. I don’t have any press release as such to share with you from our conversation with Peter Waldman. Our Communications team sent him an update when the Expression of Concern was due to be published, which he has incorporated with some answers to other questions. As below, these have been very limited in nature. Unless anything changes, we intend on leaving it there.

Best wishes,
Charles

---

Roger McClellan

From: Whalley, Charles  <[redacted]@tandf.co.uk>
Sent: Friday, September 28, 2018 7:43 AM
To: Roger McClellan
Cc: Mildred B. Morgan
Subject: RE: Bloomberg article on the corrections

Dear Roger,

I’m glad you and your wife have had pleasant travels! The weather has been unexpectedly warm and clear here too this week.

Our priority in this is in limiting coverage, as we’ve discussed before. Any responses to the media will be short and factual. The corrections and the expression of concern are out there for our readers to make their own judgement.

You may have seen the recent article on this matter in Retraction Watch:

Best wishes,
Charles

---

From: Roger McClellan  <[redacted]@att.net>
Sent: 27 September 2018 17:18
To: Whalley, Charles  <[redacted]@tandf.co.uk>
Cc: Mildred B. Morgan  <[redacted]@hargray.com>, Roger McClellan  <[redacted]@att.net>
Subject: Re: Bloomberg article on the corrections

Charles,

Thanks for the update. I have just returned from a visit to the San Juan Islands in Puget Sound in the state of WA. I did not have phone or e-mail service for several days. The good news is the weather was perfect and it was great visiting a beautiful area my wife and I had not visited for a decade and she had spent her first year of life. I am now back on the main land and headed to
Seattle and then on Friday morning driving across the state to Washington State University, Pullman, WA and then on Sunday to Pasco, WA, part of the Tri-Cities and home to the Hanford Nuclear project where I began my scientific career. Next Monday, I give the kick off lecture for a three day conference on Radiation Dose-Response issues.

Keep me posted on any developments. Please be assured I will refer any queries to you. I urge all Taylor and Francis personnel to be very guarded in any responses to the media. We all have a responsibility to protect the credibility of both T and F AND the authors. They, the authors, should not be tossed overboard.

I am absolutely convinced none of the content of the 5 articles was ghost written by Monsanto. Hence, my defense of the authors and my urging of the use of the Corrigenda. From the beginning of discussion of publication of these papers it was clear they were sponsored by Monsanto and it was fully anticipated the draft papers would be shared with Monsanto. Quite frankly, it is standard practice for draft review papers to be shared with either private or government sponsors. Obviously, the media and some lawyers are trying to create a contrary image. In my opinion, I would tone down the references to COPE. The COPE material is strongly oriented to original research papers and, in my opinion, has limited relevance to review papers.

Let me know if you would like me to call you on Friday before I leave Seattle.

Please send me a copy of the press release you sent Waldman. Also send to ALL authors of all five papers.

Best regards,
Roger

Cell: [redacted]

On Thursday, September 27, 2018 8:06 AM, "Whalley, Charles" <[redacted]@tandf.co.uk> wrote:

Dear Roger,

Waldman at Bloomberg has published on the corrections:

It seems a fair and balanced assessment of the situation to me.

Let me know if you have any questions, and if anyone contacts you for comment.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN, UK
Direct line: [redacted]
Switchboard: [redacted]
www.tandfonline.com
This electronic message and all contents transmitted with it are confidential and may be privileged. They are intended solely for the addressee. If you are not the intended recipient, you are hereby notified that any disclosure, distribution, copying or use of this message or taking any action in reliance on the contents of it is strictly prohibited. If you have received this electronic message in error, please destroy it immediately, and notify the sender.

Informa Group plc | Registered in England & Wales No. 3099067 | 5 Howick Place | London | SW1P 1WG
Dear Roger,

We are still processing the glyphosate article, and making edits and editions.

Now that the investigation is officially over and an expression of concern has been published, I want to go back to the questions I originally asked you, in full fairness.

My question was: When did you first know that the COI disclosures were not accurate? When did you find out that William Heydens at Monsanto had reviewed and edited at least some of the manuscripts eventually published in CRT? Did you know that before they were published? How did you find out?

Also, when did you first learn that the financial arrangements for some of the authors, including their relationships with Monsanto, were inaccurately stated in the COI disclosures? Did you find out before or after the papers were published, how did you find out, and when?

I would appreciate full and frank responses given that your role in this situation will be discussed in my article.

Thanks again,

Michael

On Thu, Sep 6, 2018 at 1:25 PM Roger McClellan <mcclellan@att.net> wrote:

Michael:

I apologize for my tardiness. I am attending the 10th International Aerosol Conference this week. I do appreciate your interest in the papers on glyphosate published in a Special Supplement (Vol 46, 2016) to Critical Reviews in Toxicology. As the Editor-in-Chief of CRT, I am working cooperatively with Charles Whalley of Taylor and Francis who is Managing Editor of CRT to investigate the preparation, review and sponsorship of these papers. We expect that investigation to be concluded soon. However, until the investigation is complete, it is not appropriate for Charles or I to comment on the investigation.

Thank you for your interest.

Sincerely,

Roger

On Thursday, September 6, 2018 7:39 AM, Michael Balter <mbalter@gmail.com> wrote:

Dear Mildred,

Could you please confirm that Roger has received my last emails? I am trying to be fair and he can still provide me with a statement or the press release he mentioned he was thinking of writing, but I must have it by end of today at the latest.
many thanks, Michael

On Mon, Sep 3, 2018 at 9:42 AM Michael Balter <michael@mbalter.com> wrote:

Dear Roger,

I hope you have some nice plans for Labor Day.

However, I just wanted to remind you of our agreement that you would supply me with some comments on the issues we discussed (Monsanto editing and reviewing the CRT manuscripts, especially when exactly you found out about it and what you think should be done about it) by tonight, Sept 3.

I hope that is still the plan.

best wishes,

Michael

--

***************************
Michael Balter
Writer/reporter
Adjunct Professor of Journalism "emeritus"
New York University

Email: mbalter@gmail.com
Tweet: @mbalter
Web: michaelbalter.com
Book: http://tinyurl.com/13np9st

***************************

"Lying is done with words and also with silence." ---Adrienne Rich

--

***************************
Michael Balter
Writer/reporter
Adjunct Professor of Journalism "emeritus"
New York University

Email: mbalter@gmail.com
Tweet: @mbalter
Web: michaelbalter.com
Book: http://tinyurl.com/13np9st

***************************
"Lying is done with words and also with silence." — Adrienne Rich
Dear Roger,

It might be best that you respond to Michael Balter, as he has directed the questions to you to follow on from your previous conversations. Our suggested responses are as below. You’re welcome to adapt these into your own words, but I’d be grateful if you could keep with the basic message, as this is consistent with what we have been saying elsewhere.

Best wishes as ever,
Charles

1. When did you first know that the COI disclosures were not accurate?
The ethical investigation into this supplement began in August 2017, with confirmation from the authors that the declarations of interest weren’t accurate by late September 2017.

2. When did you find out that William Heydens at Monsanto had reviewed and edited at least some of the manuscripts eventually published in CRT? Did you know that before they were published? How did you find out?
The ethical investigation has specifically looked at the contributions, contractual status and potential competing interests of all contributors. William Heydens was not declared as a contributor to the supplement by the authors on submission so, when this supplement was published, we did not know he had reviewed a manuscript draft (as now stated in the corrections). He is now acknowledged, following full disclosure by the authors on three of the five papers published.

3. Also, when did you first learn that the financial arrangements for some of the authors, including their relationships with Monsanto, were inaccurately stated in the COI disclosures? Did you find out before or after the papers were published, how did you find out, and when?
After the papers were published (which was September 2016). As answered above, our investigation began in August 2017 and we had confirmation from the authors that the declarations of interest weren’t accurate by late September 2017.

Dear Roger,

We are still processing the glyphosate article, and making edits and editions.

Now that the investigation is officially over and an expression of concern has been published, I want to go back to the questions I originally asked you, in full fairness.

Best wishes,
Charles
My question was: When did you first know that the COI disclosures were not accurate? When did you find out that William Heydens at Monsanto had reviewed and edited at least some of the manuscripts eventually published in CRT? Did you know that before they were published? How did you find out?

Also, when did you first learn that the financial arrangements for some of the authors, including their relationships with Monsanto, were inaccurately stated in the COI disclosures? Did you find out before or after the papers were published, how did you find out, and when?

I would appreciate full and frank responses given that your role in this situation will be discussed in my article.

Thanks again,

Michael

On Thu, Sep 6, 2018 at 1:25 PM Roger McClellan <[redacted]@att.net> wrote:

Michael:
I apologize for my tardiness. I am attending the 10th International Aerosol Conference this week. I do appreciate your interest in the papers on glyphosate published in a Special Supplement (Vol 46, 2016) to Critical Reviews in Toxicology. As the Editor-in Chief of CRT, I am working cooperatively with Charles Whalley of Taylor and Francis who is Managing Editor of CRT to investigate the preparation, review and sponsorship of these papers. We expect that investigation to be concluded soon. However, until the investigation is complete, it is not appropriate for Charles or I to comment on the investigation.

Thank you for your interest.

Sincerely,
Roger

On Thursday, September 6, 2018 7:39 AM, Michael Balter <[redacted]@gmail.com> wrote:

Dear Mildred,

Could you please confirm that Roger has received my last emails? I am trying to be fair and he can still provide me with a statement or the press release he mentioned he was thinking of writing, but I must have it by end of today at the latest.

many thanks, Michael

On Mon, Sep 3, 2018 at 9:42 AM Michael Balter <[redacted]@gmail.com> wrote:

Dear Roger,

I hope you have some nice plans for Labor Day.

However, I just wanted to remind you of our agreement that you would supply me with some comments on the issues we discussed (Monsanto editing and reviewing the CRT manuscripts, especially when exactly you found out about it and what you think should be done about it) by tonight, Sept 3.

I hope that is still the plan.

best wishes,
"Lying is done with words and also with silence." -- Adrienne Rich
"Lying is done with words and also with silence." — Adrienne Rich
Dear all,

Please can you send the agreed corrections for the summary paper if ready? If not, please can you advise on when I am likely to receive it? I would like to be able to publish the final 2 corrigenda as soon as possible.

Best wishes,
Charles

---

Roger McClellan

From: Whalley, Charles <redacted> @tandf.co.uk>
Sent: Thursday, October 4, 2018 8:34 AM
To: Ashley Roberts Intertek; Keith Solomon; gary_williams@uoguelph.ca; mjaardema@intertek.com; acquajohn@acquajohn.com; colin@intertek.com; brusick41@gmail.com; micheelle.burns@dermnet.org.nz; djecaman@gmail.com; dhg3@intertek.com; helmut.greim@teri.de; ldkier@teri.de; root@teri.de; gmars0911@intertek.com; T.M.Sorahan@dermnet.org.nz; douglasweedd@teri.de; larrydkier@teri.de; roger.o.mcclellan@tandf.co.uk
Cc: 
Subject: RE: Glyphosate Supplement Corrections

Dear Ashley (and authors),

I am surprised to receive these emails from you so long after our deadline. The corrigenda with amendments received by September 14th have now been typeset and are ready to publish. From your email, I take it that you do not believe the corrections to the summary paper (manuscript ID 1214677) to be agreed amongst all the authors, and you've only recently sent a new version of the corrections to the carcinogenicity paper (1215679). Accordingly, we will only publish corrections for the other 3 papers already typeset.

Please be aware that shortly we will also publish an Expression of Concern stating that we have been unable to secure all agreed corrections, to acknowledge that only 3 of 5 corrections will appear in the first group. We will not delay this update to our readers and subscribers any longer. Corrections supplied after today will be published as soon as they have been received. I will expect to receive the final wording for the remaining correction very soon.

Best wishes,
Charles

Charles Whalley - Managing Editor, Medicine & Health Journals
Taylor & Francis Group
4 Park Square, Milton Park, Abingdon. Oxon, OX14 4RN, UK
Direct line: 815
Switchboard: 815

RM 001162
Dear All,

A number of minor changes have been made to the summary corrigendum which has yet to be ratified by all of the individual experts.

I am hoping to receive feedback from everybody very shortly, which will enable finalisation.

Kind Regards

Ashley Roberts, Ph.D.
Dr. McClellan asked me to send you the attached glyphosate supplement corrections. Please double check the attached material for accuracy, completeness and consistency. If you have any problems with the material, please contact Charles Whalley by Wednesday, September 26th.

Mildred Morgan
Assistant to Roger McClellan
Tel: [redacted]
Fax: [redacted]
Email: [redacted]@hargray.com

Total Quality Assured.

CONFIDENTIALITY NOTICE

This email may contain confidential or privileged information, if you are not the intended recipient, or the person responsible for delivering the message to the intended recipient then please notify us by return email immediately. Should you have received this email in error then you should not copy this for any purpose nor disclose its contents to any other person.

http://www.intertek.com
Roger,

I have been out and Ashley is currently traveling. I expect to hear from him soon.

As far as I know, the animal data declaration is agreed to. Ashley has been receiving responses on the summary declaration.

We should be able to finish this in the coming days.

Best regards,

Gary
Gary,

OK with me and thanks very much for your good and patient work with this.

Larry Kier

On Fri, Oct 5, 2018 at 8:35 AM Williams, Gary <GARY.WILLIAMS@JDECAM> wrote:

Dear Colleagues.

Attached is the proposed final draft of the corrigendum for the summary paper.

I hope to submit this on Monday, Oct 8. Therefore, please send any essential corrections before noon Monday.

Thanks, Gary
Dear Colleagues,

Attached is the proposed final draft of the corrigendum for the summary paper.

I hope to submit this on Monday, Oct 8. Therefore, please send any essential corrections before noon Monday.

Thanks, Gary
Dear Roger,

As requested.

Again thanks for your support in this ordeal.

Best regards,

Gary
Roger McClelland

From: Keith Solomon <jones@uoguelph.ca>
Sent: Monday, October 8, 2018 3:39 PM
To: Roger McClellan
Subject: Re: Final Corrigendum

Roger,

Thanks for this email and "vote of confidence" in the science. As it should be, all the conclusions and opinions were backed up by data and it good that this is still the case. I know that you are always careful with DOIs and I value your sage advice, but I believe that a little more guidance would have been useful. I believe that there should be a time window on DOIs, just as there is on reviewers of grants. As happened in these DOIs, they should be restricted to the substance under discussion but it should be clear that all advice and papers on the substance, even for companies other than the "owner" of the substance should be included.

Keith

On 2018-10-08 12:23 PM, Roger McClellan wrote:

Gary and co-authors:  
Thank you for providing this final Corrigendum for the summary paper in the Special Supplement to the Glyphosate issue of Critical Reviews in Toxicology published in 2016. The only correction I wish to suggest is the removal of "(paper)" , a duplication, in the first line of the Declaration of Interest.

I appreciate the special efforts of all the authors of this summary paper in preparing this Corrigendum and the Corrigendum for each of the four papers that under-girded this summary paper. I also extend my appreciation to Charles Whalley and his colleagues at Taylor and Francis for their insights and assistance in resolving the issues raised by the several parties that requested that the five papers on glyphosate be retracted. I think it is noteworthy that the requests for retraction did not raise any substantive issues with regard to the scientific content of the five papers. Thus, it is important that the issues surrounding the preparation and publication of the papers have been resolved in a manner that retains these five papers, with the Corrigendum, in the published scientific literature where they will be available in perpetuity to the scientific and regulatory community and the public at large.

I know that this has been a learning experience for me, for all the authors, and for personnel at Taylor and Francis. The experience ratified the fundamental approach used by Critical Reviews in Toxicology and Taylor and Francis in publishing very comprehensive Acknowledgements statements and Declaration of Interest statements, practices and statements that set a high standard for scientific review journals. I am proud of the Journal’s past practices in this arena and pleased that the current investigation was concluded in a manner that emphasizes the approach is appropriate. However, we need to learn from the experience and be even more diligent in the future to make certain the statements originally submitted with review papers are complete and accurate.

Thank you again for your special efforts.
With best regards,
Roger

Roger O. McClellan, Editor
Critical Reviews in Toxicology

On Monday, October 8, 2018 7:47 AM, "Williams, Gary"@NYMC.EDU> wrote:

Dear Mr. Whalley,

Please find attached the final corrigendum for the summary paper.

Thank you for your assistance.

Kind regards,

Gary M. Williams, M.D.
Professor of Pathology,
New York Medical College

Keith R Solomon, Fellow ATS, Fellow SETAC, Prof. Emeritus (U of G)
Centre for Toxicology, School of Environmental Sciences
University of Guelph, 2120 Bovey Building
Gordon Street, Guelph, ON, N1G 2W1, Canada

Skype: [redacted]
Fax: [redacted]@uoguelph.ca

Centre for Toxicology
University of Guelph
SCC Recognized GLP
Protecting health of humans and the environment with quality science
Dear Roger,

We are doing some work within T&F in the next couple of weeks over what we have learnt from the glyphosate supplement, now that the matter is effectively resolved. We are looking at our policies and procedures as part of this, around guidance on conflicts of interest but also more broadly. I agree that it would be useful to have a similar conversation with you. I will speak to Todd, Sarah, Deborah and Ellie about how best to incorporate your feedback into this, and how we approach CRT-specific issues versus cross-T&F policy. This is might be delayed a little by my imminent departure but Sarah Robbie is particularly well-placed to take things forward.

Thanks for your idea about submitting a declaration of interest statement. I don't know if it will be possible to turn the submissions process into a two-stage process; however, it may make sense to improve the guidance provided when authors are asked for this statement during submission. It would then be appropriate for you to send back a submission on that basis, before review is begun on the manuscript.

If you have other suggestions for areas of improvement, either in the guidance on conflicts of interest or anything else, please send them other soonest.

All best wishes,
Charles

--

Roger McClellan

From: Roger McClellan <[redacted]@att.net>
Sent: Friday, 12 October 2018 12:07 PM
To: Whalley, Charles <[redacted]@andf.co.uk>
Cc: Gilroy, Ellie; Brown, Josie; Mildred B. Morgan
Subject: RE: Critical Reviews in Toxicology -- Need for clear instructions

Charles and Ellie:

The attached letter related to a recent submission from a very experienced researcher and author illustrates, yet again, that the Taylor and Francis developed Instructions to Authors for preparation of Declarations of Interest are GROSSLY INADEQUATE. It is apparent authors rarely read them and, even if they do, find them inadequate. In my opinion, the publisher should take the lead role in revising the current Instructions to Authors. I have made this point numerous times over the last decade to no avail. On some occasions when I raise the issue I receive electronic linkages to material prepared by COPE or T and F on conflicts of interest. I am of the impression that this must be self-satisfying to some individuals within T and F. However, I can assure you this material is of little value and is rarely read. It misses the market and suggests personnel within T and F do not really understand the issues involved.

I suggest we have a teleconference some time soon to discuss how this SERIOUS problem should be addressed. This an especially serious problem for Critical Reviews in Toxicology because the journal publishes papers on high impact topics that are frequently contentious. In today’s contentious
Society various parties with entrenched views on these topics are eager to exploit any mis-cues they can find to undermine the credibility of specific papers, the authors, the Editor and the publisher.

I can assure you that the lack of adequate Instructions to Authors on Preparation of Declaration of Interest sections contributed to the controversy over the papers in the special Glyphosate Supplement. I should not have had to write the memo I did to Ashley Roberts that was disclosed in the Monsanto Papers. I am proud to have authored the memo, however, I am disappointed it was even necessary to write.

A starting point for moving forward is to review the current Instructions to see how many times the words, "Declaration of Interests" are used. The last time I checked they were not there. I submit part of the problem is individuals talking past each other and confusing "Conflicts of Interest" with "Declarations of Interest". They are closely related but not the same. That was clear when I asked Charles to provide me input on how other T and F journals addressed Declarations of Interest and the response addressed Conflicts of Interest.

A key step in any future approach is likely to be an explicit step in the manuscript submission process where the submitting author must show the proposed "Declaration of Interest" for the paper before being allowed to proceed with the submission process. It should not be necessary for me to write time and again to authors, like in the current situation, explaining the Journal's expectations for Declarations of Interest.

I look forward to working with you on this important issue. Please let me know how you think we should proceed.

Sincerely,
Roger

On Wednesday, October 10, 2018 9:28 AM, Critical Reviews in Toxicology <onbehalfof@manuscriptcentral.com> wrote:

10-Oct-2018
BTXC-2018-0058 - Impact of changes in human reproduction on the incidence of endocrine-related diseases

Dear Dr Gerard Swaen:

I am in the final stages of reviewing your excellent manuscript. To allow me to proceed with completing the review please provide me a revised Declaration of Interest statement (to replace the Conflicts of Interest statement and, possibly, an Acknowledgements statement.

Our journal uses a Declaration of Interest statement grounded in the view that conflicts of interest are in the eye of the beholder rather than the declarer. Thus, the emphasis is on disclosure. Something like the following might be used, as long as it is complete and accurate ---- "The employment affiliation of the authors is as shown on the cover page. This critical review was conducted during the normal course of their employment using institutional funding. No outside funds were used to prepare the review. The review is the professional work product of the authors and the views expressed are not necessarily the views of their employers. None of the authors have appeared during the last five years in any regulatory or legal proceedings related to the contents of the paper."
The use of an Acknowledgements section is optional. I suggest it be included if the manuscript was critically reviewed by any of your colleagues or other parties to acknowledge their input.

Please send me electronic copies of your proposed input and my assistant, Mildred Morgan, can enter it in Scholar One. I will then proceed with completing my review.

Sincerely,
Dr Roger McClellan
Critical Reviews in Toxicology

Visit www.tandfonline.com and sign up for free eTOC alerts to all Informa Pharmaceutical Science journals.
Roger McClellan

From: Roger McClellan <mcclellan@att.net>
Sent: Friday, October 12, 2018 12:19 PM
To: Charles Whalley
Cc: Mildred B. Morgan; Roger McClellan; Josie Brown; Ellie Gilroy
Subject: Full Contents of Hard Copy Volume for 2018

Charles,

We will need to make some decisions very soon as to the contents of the hard copy printed edition of Volume 48 for 2018. Since you will have served as the Managing Editor for most, if not all, of the contents of this volume, it will be appropriate to have your input as the content of the hard copy volume.

If am specifically interested in your views as to the handling of the Expression of Concern and Corrigendum for the five papers in the Special Glyphosate issue published as part of Volume 46 in 2016. As you will recall the complete papers were not published in the year end hard copy volume, only the abstracts of the five papers were published. My Foreword to the Supplement was ignored.

In retrospect the Foreword I authored and all five papers should have been published in the hard copy volume for 2016. I understand that was not done because the financial sponsor of the Supplement did not wish to pay for publishing the hard copy. Looking to the future it is my strong recommendation that all material published on line (with the exception of electronic appendices) should be treated the same. If the main issues are published both on-line and as hard copies than all Supplements should be published both on line and as hard copy.

I provide this as background for a decision as to whether the Expression of Concern and Corrigendum for the five papers should or should not be published in the year end hard copy of Volume 48 (2018). I can be persuaded to go either way. Since the Acknowledgements and Declaration of Interest and complete text were not published previously it can be argued that nothing further should be published in Volume 48. Alternatively, it can be argued that the high level of interest in these papers requires publication of the Corrigendum. If this approach is taken it can be argued that, at a minimum, the abstracts of all five papers should be published in the hard copy volume to provide context for the Corrigendum. Indeed, it can be argued that the complete text of the five papers and my Foreword should be published to give even more complete context.

It would be great to have your input on this matter before you leave Taylor and Francis. My desire is to bring closure to the matter of the contents of the hard copy Volume 48 in as orderly a manner as possible.

Best regards,
Roger
Dear both,

Further to the below, I wanted to let you know that my Publisher Ellie Gilroy (CCed) will be responsible for managing the journal until my successor is appointed. Roger, you will recall you met with Ellie on your visit to Milton Park earlier this year. I have handed the journal over to her today.

I will respond to your other queries separately.

Best wishes,
Charles

---

Dear Roger and Mildred,

I hope this finds you well today.

I have some news for you! I am leaving Taylor & Francis at the end of this month to take up a job at the British Pharmacological Society, developing their two wholly-owned journals. I have been at Taylor & Francis for almost 7 years and will be sad to leave, but the position at the BPS is a very exciting one and too good for me to pass up. It is primarily based in London but I will mostly be working from home in Abingdon, so won't be spending too much time commuting.

I will miss all of my current journals, editors and societies. I'll be sad to leave CRT, after spending the last 4 years working with you on it. I know we've had some difficult times this year. I was reflecting on the whole business earlier this week, and I think that although we've had some similar situations on CRT – such as with asbestos – the pressures and the implications around the glyphosate supplement are effectively unprecedented. The ethical issues that normally arise are typically at much lower stakes than what we've had to deal with on this. I don't think there's any way we could have avoided that. Like you always say, this is just the atmosphere the journal is working in.

I am working on clearing up the last things on my plate. In the next week or so I will be handing the journal over to another member of my team, who will be responsible for the journal until my permanent successor is appointed. I'll introduce you when this happens. I will be sure to update them on all the journal's goings-on. I should also say that the rest of the people at T&F involved in CRT remain the same.

Please let me know if you have any questions or concerns for me. I'm around for another couple of weeks if you'd like to speak on the phone.

Very best wishes,
Charles
Dear Roger,

The remaining corrections as well as a second Expression of Concern, summarising the final situation, will be published early next week. I look forward to seeing the end of the matter then! They should then be assigned to the next available issue. It doesn't matter if we go over a few pages in doing so. I don't think there's a need to republish anything else from the supplement. I'd rather keep it as low-key as possible.

As for the pages, it would be best if we could publish as close to 1,100 as possible. This budget was set back in summer 2017. I appreciate that evidently our communication over this wasn't up to scratch. That's my responsibility and I apologise. We are now working on the basis of 1,100 pages, so the closer we can get to that number the better. I understand that we may not have that amount of pages in the pipeline at present, but I'm sure we can move in that direction.

I think that answers everything you need from me, but please let me know if I've missed anything.

All best wishes,
Charles

Josie and Charles:

I suggest you proceed with the following content in Issue 7:

<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schenk</td>
<td>9</td>
</tr>
<tr>
<td>Lison</td>
<td>18</td>
</tr>
<tr>
<td>Hall</td>
<td>15</td>
</tr>
<tr>
<td>Rannug</td>
<td>20</td>
</tr>
<tr>
<td>Hard</td>
<td>21</td>
</tr>
<tr>
<td>Landsdown</td>
<td>20</td>
</tr>
<tr>
<td>Total</td>
<td>103</td>
</tr>
</tbody>
</table>

I suggest you include the following content in Issue 8:

<table>
<thead>
<tr>
<th>Author</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rusch</td>
<td>51</td>
</tr>
<tr>
<td>Reitjens</td>
<td>16</td>
</tr>
<tr>
<td>Cox</td>
<td>32</td>
</tr>
<tr>
<td>Total</td>
<td>99</td>
</tr>
</tbody>
</table>

I am confused as to how the Expression of Concern and the 5 Corrigendum are being handled. I note the Expression of Concern and 3 Corrigendum (Brusick et al., Acquavella et al. and Solomon) have been published on

826
line. I note that 2 Corrigendum (Williams et al. [animal evidence] and Williams et al. [summary]) have not been published on line. However, these are included on your list as being ready for publication.

I need for Charles or you to explain the situation for me. I do think it is very important to have all 5 Corrigendum published on line at the earliest possible date. I do not understand the basis for the delay on the 2 Corrigendum related to the Williams et al. papers. Is anything further needed from me?

I would prefer that the Expression of Concern and all 5 Corrigendum appear together in the same issue. However, with all the issues published in a single hard copy volume at year end I am not certain of the significance any longer of designating publication in a particular issue. Each of these items bears its own date of on line publication. Unless there are rules covering how it should be done, it would be my preference to have the Expression of Concern and all 5 Corrigendum appear at the end of the hard copy for Volume 48 (2018). I have previously raised the issue of providing context for the Expression of Concern and the 5 Corrigendum. You may recall I suggested the possibility of republishing the abstracts for each of the papers. I could prepare a brief abstract for my Foreword for the Special Issue since it was never published in hard copy. Recall the 5 papers in the Special Supplement were not included in the hard copy for Volume 46, only the abstracts of the 5 papers were included.

I think it is important to have these matters to be resolved as soon as possible and, if at all possible, prior to Charles leaving Taylor and Francis.

I also need to have a discussion with Charles as to whether Volume 48 (2018) is intended to have 920 pages as in recent years or 1100 pages. To the best of my knowledge this substantial increase in page target was not discussed with me. As I recall I saw it for the first time in the Publisher's report for 2017. Perhaps, Charles can review the history of this change with me in a private conversation.

Thanks again to both of you for your assistance with the Journal. This past year has been, as we say in the West, quite a wild ride!

Best regards,
Roger

On Wednesday, October 3, 2018 5:13 AM, "Brown, Josie" <jbrown@informa.com> wrote:

Hi Roger,

I hope all is well with you. I am attaching a backlog report of the current articles we have in production. We are ready to fill issues 7 upwards. 110 pages budgeted.

Please let me know if you need any further details.

Many thanks,
Josie

Josie Brown
Production Editor
Taylor & Francis
Hi Roger,

Myself and the production team are still currently working with the typesetters to fix this issue, as this did not occur during the publication of the first 3 corrigenda and Expression of Concern. We are actually trying to republish the whole issue so everything links but there seems to be an issue in the system that the team are trying to fix. This is now our top priority to have fixed at the earliest.

I will immediately send you an update as soon as the teams have discovered and resolved the issue.

All best wishes,

Josie Brown
Production Editor
Taylor & Francis

Josie Brown
Production Editor
Taylor & Francis

From: Roger McClellan <rogemcc@aol.com>
Sent: 20 November 2018 17:10
To: Gilroy, Ellie <elgill@tanfi.co.uk>; Brown, Josie <josi@informa.com>
Cc: roger.o.mcclellan@mbmorgan.com
Subject: Fw: RE: Final Corrigendum/ Update

Josie and Ellie:
Attached is the latest inquiry from authors of the papers in the Glyphosate Supplement asking about the status of publishing the Corrigendum for all five papers. Members of my Editorial Advisory Board are also asking, I want to send a single e-mail to the Editorial Advisory Board explaining the situation and also relating Charles Whalley’s leaving for other opportunities. I am hesitant to send anything out until all actions are complete. Please provide me an update.
Perhaps we the entire Glyphosate Supplement should be republished along with the Expression of Concern and the five Corrigendum if the production crew can not determine how to link the several items. In any event, I think that the Expression of Concern and all five Corrigendum should be placed in the same issue of Volume 48 (2018) on line and when published as a hard copy volume. It is imperative that all five Corrigendum should appear together.

Thanks for your assistance with this difficult matter.

Best regards,
Roger

--- On Tue, 11/20/18, jdecam <jdecam@uol.com.br> wrote:

> From: jdecam <jdecam@uol.com.br>
> Subject: RE: Final Corrigendum
> To: "David Kirkland" <david.kirkland@genetoxconsulting.co.uk>, "Roger McClellan" <rmcclellan@att.net>, "Williams, Gary" <gwilliams@nyu.edu>, Charles.Whalley@nyu.edu, "Williams, G. R." <gwhalley@nyu.edu>, "Williams, Gary" <gwilliams@nyu.edu>, Charles.Whalley@nyu.edu
> Cc: "Ashley Roberts Intertek" <a.roberts@intertek.com>, "Keith Solomon" <ksolomon@entomology.ucdavis.edu>, mjaardema@genetoxconsulting.co.uk, acqaujohn@uoguelph.ca, colin@genetoxconsulting.co.uk, brusick41@uoguelph.ca, Michele.Burns@ntu.edu.sg, dhagar@genetoxconsulting.co.uk, idkier@genetoxconsulting.co.uk, jdecam@uol.com.br, root@gmmarsh911.com, T.M.Sorahan@hargray.com, douglasweede@uml.edu, larrykier@genetoxconsulting.co.uk, "Mildred B. Morgan" <MBMorgan@hargray.com>
> Date: Tuesday, November 20, 2018, 8:45 AM
> Nice to remember! I would appreciate receiving a pdf copy of that publication.
> Thanks in advance!
> João Lauro de Camargo
> Enviado do meu smartphone Samsung Galaxy.
> ------ Mensagem
> original --------De : David Kirkland
> <dskirkland@genetoxconsulting.co.uk> Data 20/11/2018 13:12 (GMT-03:00) Para: Roger McClellan <rmcclellan@att.net>, "Williams, Gary" <gwilliams@nyu.edu>, Charles.Whalley@nyu.edu, "Williams, G. R." <gwhalley@nyu.edu>, "Williams, Gary" <gwilliams@nyu.edu>, Charles.Whalley@nyu.edu
> Cc: "Ashley Roberts Intertek" <a.roberts@intertek.com>, "Keith Solomon" <ksolomon@entomology.ucdavis.edu>, mjaardema@genetoxconsulting.co.uk, acqaujohn@uoguelph.ca, colin@genetoxconsulting.co.uk, brusick41@uoguelph.ca, Michele.Burns@ntu.edu.sg, dhagar@genetoxconsulting.co.uk, idkier@genetoxconsulting.co.uk, jdecam@uol.com.br, root@gmmarsh911.com, T.M.Sorahan@hargray.com, douglasweede@uml.edu, larrykier@genetoxconsulting.co.uk, "Mildred B. Morgan" <MBMorgan@hargray.com>
> Assunto: RE: Final Corrigendum
> Does anyone know when the Corrigendum for the summary paper will be published? Many
> thanks, David
> Kirkland. From: Roger
> McClellan @att.net>
> > Sent: 08 October 2018 17:24
> > To: Williams, Gary
> > 'Charles.Whalley@tandf.co.uk' <Charles.Whalley@tandf.co.uk>
> > 'Keith Solomon' <ubiquleah.ca>
> > 'mjaardemai <mjaardemai>
> > 'acquaiojohn <acquaiojohn>
> > 'coline <coline>
> > 'brusick41 <brusick41>
> > 'Michele.Burns@children <Michele.Burns@children>
> > 'idecam@uol.com.br <idecam@uol.com.br>
> > 'dhe3 <dhe3>
> > 'helmut.greim <helmut.greim>
> > 'ldkier <ldkier>
> > 'root <root>
> > 'gmarsh911<gmarsh911>
> > 'T.M.Sorahan <T.M.Sorahan>
> > 'douglas@wee <douglas@wee>
> > 'larrydkier <larrydkier>
> > Mildred B. Morgan <hararay.com>
> > Roger McClellan <compare@att.net>
> > Subject: Re: Final
> > Corrigendum Gary
> > and co-authors:
> > Thank you for providing this final Corrigendum for the
> > summary paper in the Special Supplement to the Glyphosate
> > The only correction I wish to suggest is the removal of
> > " (paper)" , a duplication, in the first line of
> > the Declaration of Interest.
> > I appreciate the special efforts of all the authors of
> > this summary paper in preparing this
> > Corrigendum and the Corrigendum for each of the four
> > papers that under-girded this summary paper. I also extend
> > my appreciation to Charles Whalley and his colleagues at
> > Taylor and Francis for their insights and assistance in
> > resolving the issues raised by the several parties that
> > requested that the five papers on glyphosate be retracted. I
> > think it is noteworthy that the requests for retraction did
> > not raise any substantive issues with regard to the
> > scientific content of the five papers. Thus, it is important
> > that the issues surrounding the preparation and publication
> > of the papers have been resolved in a manner
> > that retains these five papers, with the Corrigendum,
> > in the published scientific literature where they will be
> > available in perpetuity to the scientific and regulatory
> > community and the public at large.
I know that this has been a learning experience for me, for all the authors, and for personnel at Taylor and Francis. The experience ratified the fundamental approach used by Critical Reviews in Toxicology and Taylor and Francis in publishing very comprehensive Acknowledgements statements and Declaration of interest statements, practices and statements that set a high standard for scientific review journals. I am proud of the Journal's past practices in this arena and pleased that the current investigation was concluded in a manner that emphasizes the approach is appropriate. However, we need to learn from the experience and be even more diligent in the future to make certain the statements originally submitted with review papers are complete and accurate. Thank you again for your special efforts.

With best regards,
Roger O. McClellan, Editor
Critical Reviews in Toxicology

On Monday, October 8, 2018 7:47 AM, "Williams, Gary"
<@nymc.edu> wrote:
Dear Mr. Whalley, Please find attached the final corrigendum for the summary paper. Thank you for your assistance. Kind regards, Gary M. Williams, M.D., Professor of Pathology, New York Medical College

This email was scanned, no threats were found.

Detection engine version: 18177 (20181008)
http://www.eset.com
This email was scanned, no threats were found.
Josie and Ellie:

Attached is the latest inquiry from authors of the papers in the Glyphosate Supplement asking about the status of publishing the Corrigendum for all five papers. Members of my Editorial Advisory Board are also asking. I want to send a single e-mail to the Editorial Advisory Board explaining the situation and also relating Charles Whalley's leaving for other opportunities. I am hesitant to send anything out until all actions are complete. Please provide me an update.

Perhaps we the entire Glyphosate Supplement should be republished along with the Expression of Concern and the five Corrigendum if the production crew can not determine how to link the several items. In any event, I think that the Expression of Concern and all five Corrigendum should be placed in the same issue of Volume 48 (2018) online and when published as a hard copy volume. It is imperative that all five Corrigendum should appear together.

Thanks for your assistance with this difficult matter.

Best regards,

Roger
> Subject: RE: Final Corrigendum

> To: "David Kirkland" <genetoxconsulting.co.uk>,
"Roger McClellan" <att.net>, "Williams, Gary" <NYMC.EDU>,
Charles.Whalley@

> Cc: "Ashley Roberts Intertek"

"Keith Solomon" <joguelph.ca>, mjaardema@
acquajohn@<> colin@<> brusick41@
Michele.Burns@<> dhg3@<> helmut.greim@
ldkier@<> root@<> gmarshal911@
T.M.Sorahan@<> douglasweed@<> larrydkier@<> "Mildred B. Morgan"
<>

> Date: Tuesday, November 20, 2018, 8:45 AM

> Nice to

> remember! I would appreciate receiving a pdf copy of that

> publication.

> Thanks in advance!

> João Lauro de Camargo

> Enviado do meu

> smartphone Samsung Galaxy.

> -------- Mensagem

> original --------De : David Kirkland

><genetoxconsulting.co.uk>

Data:

> 20/11/2018 13:12 (GMT-03:00) Para: 'Roger

> McClellan' <att.net>,

> "Williams, Gary"

> <NYMC.EDU>,

Charles.Whalley@...
> Cc: 'Ashley Roberts Intertek'
> 'Keith Solomon'
> <mjaardema@uoguelph.ca>,
> acquajohn@#
> colin@#
> brusick41@#
> Michele.Burns@#
> jdecam@#
> dhg3@
> helmut.greim@#
> Idkler@
> root@gmarsh911@
> T.M.Sorahan@#
> douglaslweed@#
> larrydkier@
> "Mildred B.
> Morgan" <morg@hargray.com>
> Assunto: RE: Final Corrigendum
> Does anyone
> know when the Corrigendum for the summary paper will be
> published? Many
> thanks, David
> Kirkland. From: Roger
> McClellan <roger.o.mccellan@>
Subject: Re: Final

Corrigendum Gary

and co-authors:

Thank you for providing this final Corrigendum for the
> summary paper in the Special Supplement to the Glyphosate
> The only correction I wish to suggest is the removal of
> "(paper)", a duplication, in the first line of
> the Declaration of interest.
>
> I appreciate the special efforts of all the authors of
> this summary paper in preparing this
> Corrigendum and the Corrigendum for each of the four
> papers that under-girded this summary paper. I also extend
> my appreciation to Charles Whalley and his colleagues at
> Taylor and Francis for their insights and assistance in
> resolving the issues raised by the several parties that
> requested that the five papers on glyphosate be retracted. I
> think it is noteworthy that the requests for retraction did
> not raise any substantive issues with regard to the
> scientific content of the five papers. Thus, it is important
> that the issues surrounding the preparation and publication
> of the papers have been resolved in a manner
> that retains these five papers, with the Corrigendum,
> in the published scientific literature where they will be
> available in perpetuity to the scientific and regulatory
> community and the public at large.
>
> I know that this has been a learning experience for me, for
> all the authors, and for personnel at Taylor and Francis.
The experience ratified the fundamental approach used by Critical Reviews in Toxicology and Taylor and Francis in publishing very comprehensive Acknowledgements statements and Declaration of Interest statements, practices and statements that set a high standard for scientific review journals. I am proud of the Journal’s past practices in this arena and pleased that the current investigation was concluded in a manner that emphasizes the approach is appropriate. However, we need to learn from the experience and be even more diligent in the future to make certain the statements originally submitted with review papers are complete and accurate.

Thank you again for your special efforts.

With best regards,

Roger O. McClellan, Editor

Critical Reviews in Toxicology

On Monday, October 8, 2018 7:47 AM, "Williams, Gary" wrote:

Dear

Dear
> Mr. Whalley, Please
> find attached the final corrigendum for the summary
> paper. Thank
> you for your assistance. Kind
> regards, Gary
> M. Williams, M.D., Professor
> of Pathology, New
> York Medical College
> 
> ________ESET NOD32 Antivirus ________
> 
> This email was scanned, no threats were found.
> 
> Detection engine version: 18177 (20181008)
> 
> http://www.eset.com
> 
> ________ESET NOD32 Antivirus ________
> 
> This email was scanned, no threats were found.